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Abstract 
Pharmacists have been identified to address the increasing workload in United Kingdom 
(UK) general practice. A pilot has been commissioned by National Health Service England 
(NHSE) to upskill pharmacists for this purpose. Evaluation is underway and early reports 
indicate that there have been integration issues.  
The value of pharmacists working in general practice and the level of training required for the 
role are not fully understood. The research reported in this thesis was started before the 
NHSE pilot. It was conducted to understand the background of Clinical Commissioning 
Group (CCG) practice pharmacists (PPs), and their interactions with stakeholders. The 
rationale was to provide an insight into their working relationships and to generate 
recommendations to support the integration of pharmacists into general practice. The project 
was conducted in four CCGs in the West Midlands in 2014 using an interpretive/collective 
case study approach incorporating mixed methods for data collection. Quantitative data was 
collected on the background, employment and activities of PPs. Qualitative data was 
collected on stakeholders’ views of the CCG PP role from commissioners, general 
practitioners (GPs), and patients. Different commissioning models for PPs were studied to 
provide a deeper understanding of PPs’ interactions. The workload problems in general 
practice subsequently modified the focus of this thesis to determine the value of PPs to 
general practice, the level of training required and to propose a model for the integration of 
pharmacists into UK general practice. 
The thesis study identified some determinants of integration found in previously published 
studies but also discovered new areas specific to the integration of pharmacists into UK 
general practice. These areas can be grouped into three elements - the pharmacist’s skills 
and attributes, practice level facilitation and national level support. They are presented as a 
unique Model for the Successful Integration of Pharmacists into General Practice Teams.  
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Preface 
This thesis comprises nine chapters. Chapter one introduces the thesis project and describes 
the current situation in primary care and how this has stimulated interest in the development 
of more pharmacists to work closely with general practitioners. This overview is followed by a 
brief description and analysis of the National Health Service England (NHSE) initiative to 
train and part-fund pharmacists to work in general practice and indicates some of the 
remaining issues with this initiative that will be addressed in this thesis project. The Chapter 
includes a working definition of the term Practice Pharmacist (PP) and concludes with a 
review of the literature relevant to the research project. 
 
Chapter two begins with my background and experience and describes how and why I 
became a PP and my initial investigations into the role. This is followed by a summary of the 
Initial Study that I undertook to support my DPharm research and to begin to understand 
some of the questions I had about the PP’s role within Clinical Commissioning Groups (CCG) 
after the 2013 changes. The chapter concludes with the derivation of my thesis research 
questions and the relevance of these to current developments and the necessity for scientific 
investigation. 
 
Chapter three begins with a reminder of the project aims and research questions followed by 
a detailed description of the methods chosen to carry out the thesis project including how the 
data was analysed. This is followed by an outline of my perspective, the methodological 
approach and a discussion of the methods chosen and why others were rejected. The 
chapter concludes with a statement of the ethical approval obtained before the project 
commenced. 
 
Chapter four begins by describing the selection of the four thesis project CCGs. It goes on to 
introduce the case study project teams by respondent group and describes who they were. 
Descriptive data is reported for all the respondent groups, but in the case of the PPs this is 
 xxi 
more detailed and includes their professional background, levels of education and 
employment status within the CCG. Qualitative data is also included on the reasons why 
pharmacists take on the PP role and why some maintain a portfolio career. This overview of 
the PP participants, within the case CCGs, will indicate if they are typical of primary care 
pharmacists studied elsewhere. 
 
Chapter five describes the effects of the NHS change from the point of view of the 
stakeholders as Primary Care Trusts (PCTs) transitioned to CCGs in 2013. It begins by 
outlining why the PP Teams could no longer be directly employed by the CCGs and then 
goes on to describe the structure and commissioned functions of the CCG PP teams and 
how these functions were perceived by the stakeholders. There follows a brief discussion on 
how the PP role was assessed by the commissioners and the stakeholders’ views on the 
work plans agreed by the commissioners. The chapter continues with the effects of the 
transition on the relationships between the professional stakeholders, how the PP role 
changed and concludes with a discussion on the current training of PPs. 
 
Chapter six begins with the importance of the PP role, including the value of PP prescribing, 
from the stakeholders’ point of view. The stakeholders’ aspirations for the future of the 
pharmacist’s role within general practice are then described. The Chapter continues by 
defining the drivers for the integration of pharmacists into primary care that have been 
identified during the thesis project and draws attention to some remaining perceived 
obstacles. 
 
Chapter seven discusses the results of the thesis project related to the research questions. It 
includes the background of the PPs, their attributes and the effects of the 2013 NHS changes 
on them and their teams. The stakeholder perceptions of the PP role are discussed, 
including the value of the PP including pharmacist prescribing. These perceptions are 
followed by a discussion about the future of the role PP role and the opportunities and 
 xxii 
perceived barriers. The chapter concludes by discussing the transferability and limitations of 
the thesis study. 
 
Chapter eight summarises the thesis study results related to integration and postulates a 
Model for the Successful Integration of Pharmacists into General Practice Teams 
based on my findings from the Initial Study and the thesis project. I present a unique model, 
the elements of which may be generalisable to facilitate the integration of clinical pharmacists 
into general practice in a UK setting.  
 
Chapter nine, the Conclusion, summarises the background to the thesis project, and the 
similarities with other studies. This summary is followed by a brief description of the Model 
for the Successful Integration of Pharmacists into General Practice Teams and how it might 
benefit integration in the NHSE Pilot and elsewhere in the UK. The chapter continues by 
describing the implementation of the Model and ends with recommendations for further 
research.
 1 
Chapter 1: Introduction and Review of the Literature 
Currently, there is a workforce crisis in primary care that has come about because of 
inadequate workforce planning and increasing workload (Dayan et al., 2014). This situation 
has coincided with increasing numbers of registered pharmacists in the workplace (Centre 
for Workforce Intelligence, 2013) creating one obvious solution. The professional bodies for 
Medicine and Pharmacy have promoted the use of pharmacists to fill some of the gaps in the 
primary care workforce (RCGP and RPS, 2015). This is supported by existing research into 
the role of pharmacists in general practice, and by the activities of PPs that been working in 
general practitioner (GP) surgeries since the 1990s (Blenkinsopp et al., 2001).  Nevertheless, 
there are concerns that the value of pharmacists working in general practice and the level of 
training they required still needs to be defined (NHS Alliance and Royal Pharmaceutical 
Society, 2014). The Government, via NHSE, has promised a substantial sum of money, £143 
million by 2020 (NHS England, 2016a), to increase the numbers of pharmacists working 
closely with GPs, and has set up a National Training Pathway (Centre for Pharmacy 
Postgraduate Education, 2016). The initial funding was to train, and part-fund the salaries of, 
250 more pharmacists to work in GP practices in pilot sites in England (NHS England, 
2015a). A further two waves have been authorized with the intention to have a further 1500 
pharmacists in general practices by 2010. 
There are several outstanding issues, besides the level of training and the value of 
pharmacists in general practice being unclear. The second wave of pilot sites have been 
recruited (NHS England, 2017) before formal evaluation of the pilot due in February 2018. It 
is unknown if the pilot is fit for purpose or addresses the issues around training and 
subsequent value. The National Training Pathway may be incomplete in the area of critical 
practical and human issues that arise when new individuals join established teams, although 
Primary Care Commissioning (PCC) are supporting pilot practices to embed pharmacists into 
their teams (Primary Care Commissioning, 2016). Nationally, there is some urgency to recruit 
 2 
pharmacists to GP practices. The demand for the pilot has been high and places limited, and 
there is evidence that some GP practices have hired inexperienced pharmacists outside the 
pilot (Mills, 2016) where the processes for recruiting are unclear. In addition, the Government 
plans to improve GP recruitment and retention (NHS England, 2016a), potentially filling the 
workforce gap in the future, questioning the long-term future of pharmacists working with 
GPs. 
The research reported in this thesis addresses these important issues by identifying the 
value of pharmacists to stakeholders and the level of training that pharmacists need to work 
in general practice. Also, a model for the integration of pharmacists into existing teams will 
be promulgated along with some of the long-term roles that pharmacists are specifically 
suited to undertake now and in the future. There is a lot at stake for patients, the credibility of 
primary care, the pharmacy profession and the Government, including the substantial human 
and financial investment in this pilot. 
The origins of pharmacists working closely with GPs in primary care goes back to the 
introduction of fundholding in 1991 that created an internal market (Wilkin, 2002), and 
provided financial incentives for cost-effective purchasing and drug use (Shortt, 2003). 
Pharmacists were utilised by a small number of Health Authorities in the early 1990s 
(Blenkinsopp et al., 2001) to help realise savings from improved prescribing. The role 
developed quickly, and by 1994 at least one practice employed a pharmacist full-time, in a 
non–dispensing role, and had already given the pharmacist a wider remit beyond cost control 
(Wells, 1997). By 2005, 8.2% of registered pharmacists were working a proportion of their 
time in primary care (Seston and Hassell, 2009), but numbers appear to have subsequently 
fallen (Phelps et al., 2014). It is likely the numbers of pharmacists working in primary care will 
now begin to rise again. 
Pharmacists that work closely with GPs have been defined as Primary Care Pharmacists 
(Marinker M and Reilly P, 1994, p.107). In 2000, the National Prescribing Centre (NPC) 
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further described their mode of working as “pharmacists working either full-time, part-time, or 
on a sessional basis for PCTs, Primary care Groups (PCGs) or GP practices” (National 
Prescribing Centre and NHS Executive, 2000, p. 2). Blenkinsopp et al. (2001), p. 684 further 
defined the role as “a pharmacist who works with primary care physicians and patients to 
enhance the quality of prescribing and use of medicines, and to contribute to resource 
management of medicines”. Mullen (2003) differentiated between pharmacists that work for 
NHS Authorities and those that work wholly or part of their time in GP practices, calling the 
latter Practice Pharmacists. For this thesis, a PP is defined as “a pharmacist, that is 
dedicated wholly or part of their time, to working in a GP practice with practice staff and 
patients to ensure the safe and effective use of medicines.”  
This thesis project investigated the role and relationships of West Midlands pharmacists, that 
were commissioned by four CCGs to work in primary care, after the NHS changes in 2013. 
The implementation of the Health and Social Care Act 2012 radically changed NHS 
structures in primary care including the abolition of PCTs and the creation of CCGs (NHS 
England, 2015b). The project PPs were previously employed in established teams 
commissioned by PCTs, but it was unclear how these pharmacists fared during this 
restructuring and how their work and relationships with stakeholders were affected. 
Determining changes in these relationships formed the original basis for this thesis.  
 
The 2013 NHS changes were identified as an “instance” (Bell, 2010, p. 8) prompting a 
change in how the PP teams were commissioned and potentially creating new ways of 
working and an interruption in the PP and stakeholder relationships. I identified an 
opportunity to examine this change, and its effects on PP relationships, in a case study as a 
result of the pre-project questionnaire where several models of commissioning of PP teams 
were outlined. An interpretive/collective case study approach was appropriate because the 
PPs worked in discreet groups and their relationships could be examined in the context of 
each of the commissioning models to provide a deeper understanding of their interactions.  
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A mixed methods approach was adopted with a descriptive survey to establish the 
background, levels of postgraduate education, and employment status of the CCG 
commissioned pharmacists, thereby providing quantitative data for comparison and analysis. 
Qualitative semi-structured interviews with commissioners, general practitioners (GPs) and 
patients, and focus groups with CCG commissioned pharmacists, were used to ascertain the 
working relationships with stakeholders. The qualitative data sets were analysed using the 
principles of grounded theory. 
 
The literature review that follows details and analyses the evidence relevant to the thesis 
project reported here and how this evidence relates to and supports the project research 
questions. Each section begins with a brief explanation of why this literature is relevant. 
 
1.1 National Health Service organisational change 
It is important to understand the background to previous and current iterations of the NHS as 
they form the backdrop to the project, and more significantly the genesis of the PP role and 
its subsequent development over the last twenty years.  Analysis of the literature also 
explains why the commissioning of PP teams had to change from 2013 onwards.  
 
1.1.1 General practice fundholding  
The last twenty-five years have seen unprecedented changes in the structure of the NHS 
and particularly primary care, although it has been said by some that the NHS has been in a 
continuous state of reorganisation since 1974 (Socialist Health Association, 2015). The 
National Health Service Reorganisation Act 1973 established Regional and Area Health 
Authorities and Family Practitioner Committees (FPC) (“National Health Service 
Reorganisation Act, 1973). The latter replaced Local Executive Councils and took over the 
management of primary care.  The FPCs were themselves replaced by Family Health 
Services Authorities (FHSA) as a result of the National Health Service and Community Care 
Act 1990 (“National Health Service and Community Care Act,” 1990), after which the 
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government introduced a range of National Health Service (NHS) reforms in April 1991 (Kay, 
2001). These reforms were radical, and changes were made to the GP contract (Wilkin, 
2002), and for the first time the British Medical Association (BMA) and the Royal Colleges 
were not part of the review group developing the policy and as such the medical profession 
was excluded from medical policy making (Kay, 2001). 
A major factor in these reforms was the introduction of the internal market into healthcare 
including fundholding (Petchey, 1995; Kay, 2001; Wilkin, 2002; Shortt, 2003; Smith et al., 
2010.). This separated the purchasing (commissioning), and provider functions (Kay, 2001; 
Wilkin, 2002). The principal idea behind fundholding was to improve incentives for local 
hospitals and to encourage GPs to control costs. Fundholding was based on a model of 
healthcare suggested by two academics Professor Alain Enthoven of Stanford University 
Business School and Professor Alan Maynard from the University of York (Kay, 2001). 
Fundholding was driven by the new purchasing power of GPs, allowing them to stimulate 
innovation in services (Kay, 2002). The reforms and expected outcomes were not supported 
by any evidence for effectiveness (Petchey, 1995: Kay, 2001), and were opposed by both the 
BMA and by the parliamentary opposition party, the latter proposing to abolish the scheme if 
they were elected (Kay, 2001). The government decided against any evaluation or piloting of 
the scheme as they were, arguably, afraid of any criticism (Kay, 2001, 2002).  
 
Nevertheless, the Public Accounts Committee and some academics did produce reports on 
the effects of fundholding. They suggested that fundholding practices did improve access to 
services, improved the range of available services and reduced waiting times (Kay, 2002). 
Other benefits were in reduced prescribing costs, at least in the short-term, and providers 
that were more responsive to their patients need for services (Coulter, 1995). Negative 
issues raised were an increase in administrative costs, a concern that benefits were at the 
expense of non-fundholding practices and that some evaluations were inconclusive (Kay, 
2001, 2002; Wilkin, 2002; Shortt, 2003;). These issues were partly due to the selection 
criteria for fundholding practices that tended to attract innovative and well-organised 
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practices with affluent patients, rather than inner city practices with more deprived patients 
(Petchey, 1995; Kay, 2001, 2002; Wilkin, 2002). 
 
This era is significant because Pharmaceutical and Medical Advisers were appointed to 
FHSAs (Walley, 1993) and in the early 1990s the first pharmacists were introduced into GP 
practices to provide advice on medicines and prescribing (Blenkinsopp et al., 2001). Initially, 
this was in an attempt to assist GPs in saving money (Britten, 2001), but the role developed 
more widely into medicines education, efficacy, and safety (Wells, 1997; National Prescribing 
Centre and NHS Executive, 1998; Fish et al., 2002). By 1996, PP numbers were increasing 
with support from Pharmaceutical Advisers and funding from prescribing budgets, with some 
thirty Health Authorities supporting PP schemes (Blenkinsopp et al., 2001). 
 
1.1.2 Primary Care Organisations 
In 1997 the Labour party was elected to government and suspended entry into the 
fundholding scheme (Kay, 2001, 2002). The abolition of fundholding, however, did allow the 
adoption of any aspects of fundholding that were beneficial, but the lack of good evidence 
and evaluation meant that these were unclear (Kay, 2001). The new government published 
The New NHS: modern. dependable in 1997 (Department of Health, 1997), and established 
PCGs throughout England in 1999 (Smith et al., 2000; Bindman et al., 2001; Bojke et al., 
2001; Britten, 2001; Kay, 2001, 2002; Wilkin, 2002). While legislation was going through 
Parliament, forty GP commissioning pilots were initiated in 1998 to trial some aspects of the 
PCGs and to provide some evaluation (Smith et al., 2000).  
The aims of PCGs included developing primary care and community health services, 
improving the quality of care in the NHS, and taking responsibility for commissioning services 
for their population; in short developing primary care-led health delivery (Bindman et al., 
2001; Bojke et al., 2001). The PCGs also had the responsibility to improve the quality of care 
given by primary care health professionals via clinical governance (Bindman et al., 2001; 
Wilkin, 2002). While fundholding was voluntary, all GP practices had to belong to a PCG 
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within the coterminous health authority and local authority boundary (Bindman et al., 2001), 
so GPs had to be involved in the organisation (Smith et al., 2000).  
 
Other early goals for the PCGs included, building structure and process and multidisciplinary 
team working to manage local services (Smith et al., 2000; Wilkin, 2002), resolving IT system 
incompatibilities ( Smith et al., 2000; Bindman et al., 2001) and financial management (Smith 
et al., 2000; Bindman et al., 2001; Britten, 2001; Kay, 2001, 2002; Wilkin, 2002). Financial 
management involved managing the budget for hospital and community services (Smith et 
al., 2000; Britten, 2001; Kay, 2001; Wilkin, 2002), indicative budgets for all practices (Smith 
et al., 2000; Kay, 2001; Bojke et al., 2001; Bindman et al., 2001; Kay, 2002) and controlling 
prescribing costs (Smith et al., 2000; Britten, 2001; Kay, 2001). Prescribing costs were seen 
as a major risk and, in response, PCGs were recruiting pharmaceutical advisers over 
medical advisers (Britten, 2001) with the numbers of pharmacists reporting that they worked 
in primary care rising from 6% in 2002 to 8% in 2003 (Hassell et al., 2004).   
 
The NHS Plan 2000 (Department of Health, 2000) indicated the government’s intention that 
by April 2004, all PCGs would become PCTs and also the joining of PCTs with health and 
social care to form Care Trusts. The plan also called for the expansion of Personal Medical 
Services contracts as an alternative to the standard General Medical Services contract and 
the expansion of the numbers of salaried GPs. There were also changes in the GP 
relationship with the NHS during the following years. The practice or firm held the contract 
instead of the GP and by March 2007 about thirty companies had contracts; medical services 
could be commissioned from any capable provider, so effectively GPs lost control of services 
(Pollock et al., 2007). GPs became responsible for standards across the PCT instead of just 
for their practice (Wilkin, 2002).  
 
Soon after PCTs were created concerns were raised regarding their commissioning abilities 
(Smith and Mays, 2005), effectiveness, capacity to negotiate with acute trusts and to manage 
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public health. There was a dilemma, whereby, smaller PCTs lacked negotiating powers and 
larger PCTs would find clinician engagement more difficult (Walshe et al., 2004). All PCTs 
had limited autonomy and weaker clinical leadership than the NHS Trusts (e.g. hospitals), 
with whom they had to negotiate (Smith et al., 2010) and it was not long before Strategic 
Health Authorities effectively “clustered” some PCTs together (Walshe et al., 2004). These 
mergers reduced PCTs to around 100-150, the same number of health authorities that they 
replaced, despite no evidence of benefit in doing this. 
 
While GP Principles and Partners with ownership of the general practice business appeared 
to lose both autonomy and the right to practice in a “closed shop” environment, the new 
organisations effectively expanded the opportunities for healthcare professionals to enhance 
their roles and to work as part of the larger organisation (Wilkin, 2002). For pharmacists, this 
was facilitated by the PCGs, and PCTs commissioning PPs, to deliver a provider function. 
This created a dilemma because policy dictated that commissioning should be separated 
from any provider provision (Smith et al., 2010). However, PCTs did commission pharmacists 
to work in their GP practices. 
 
1.1.3 Clinical Commissioning Groups 
The election of the coalition government in 2010 brought with it promises to reduce 
bureaucracy, strengthen monitoring, secure health funding and to end top-down NHS 
reorganisations (Travis, 2010). The new Secretary of State for Health had spent six years in 
opposition preparing for the reorganisation, with access to the evidence that government 
NHS reorganisations were poorly managed, with limited benefits and an adverse effect on 
performance (Walshe, 2010). Despite this and including the promise to end top-down 
reorganisations, the plans went ahead. There was a brief “pause” in April 2011 for further 
consultation and some changes (Gerada, 2013), but shadow CCGs signed up as Pathfinders 
and began to consider how they would function (Checkland et al., 2013). The wide-reaching 
reforms abolished Regional Strategic Health Authorities and PCTs, transferred 
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commissioning responsibilities to GPs and moved Public Health to Local Authorities. It also 
created Public Health England and the National Commissioning Board (NHS England) and 
established Local Authority-based Health and Wellbeing Boards (Checkland et al., 2013). 
The former National Prescribing Centre was also absorbed into NICE (National Institute for 
Health and Care Excellence, 2011), resulting in a significant reduction in training 
opportunities for PPs that will be discussed later in this thesis. 
 
During the period between the election and April 2013, there was much uncertainty amongst 
PCT staff with many experienced managers aware of the likelihood of cuts in the numbers of 
personnel. Some with transferrable skills left the NHS and others retired as predicted by Ham 
(2012), thereby compromising organisational memory. The CCGs had much smaller staff 
allocations and were encouraged to use the services of the newly formed Commissioning 
Support Units (CSU) to aid their workload. There was a lack of constraints on how CCGs 
were structured that led to a difference in size, structure and GP involvement in the new 
organisations (Checkland et al., 2016).  
 
Figure 1.1 shows the structure of the NHS after 2013 and shows CCGs as commissioning 
organisations (NHS England, 2014a). This restriction presented a problem for CCGs who 
wanted to retain PPs teams when these were essentially a provider service.  
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Figure 1.1 The NHS in 2013 (Source: NHS England, June 2014) 
Permission to reproduce this figure is shown in Appendix 1.1 
 
 
1.2 The Pharmacy profession and pharmacists 
The status of the Pharmacy profession and pharmacists are important as dissatisfaction is a 
potential catalyst for change. The profession has had to come to terms with changes in its 
core role, and the corporatisation and increasing business focus of its largest sector, 
community pharmacy. The way that pharmacists perceive their position in healthcare, their 
traits and the way that they use their knowledge and skills are significant to their future 
development if they are to progress to more clinical roles. 
 
1.2.1 Dissatisfaction with the hospital pharmacist role  
A study of hospital pharmacists in 2001 showed that senior grades were more likely to be 
satisfied with their salaries than more junior grades, but senior grades are more likely to 
perceive their workload and hours as being excessive (Rajah et al., 2001). Hospital 
pharmacists reported less stress than their community pharmacist counterparts but agreed 
on the top three most stressing situations, namely interruptions, excessive and or increasing 
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workloads and insufficient staff (McCann et al., 2009a). Other factors that repeatedly led to 
job dissatisfaction for hospital pharmacists included poor relationships with line managers, a 
lack of career progression and a lack of trust between management and staff (Ferguson et 
al., 2011). A lack of autonomy was identified in lower grades of hospital pharmacists as well 
as dissatisfaction with both duties and salary, as contributing factors to job dissatisfaction; it 
is not known if these are interrelated, but junior grades would naturally receive more 
supervision and lower wages (Rajah et al., 2001). Historically hospital pharmacists are more 
likely to be satisfied with their careers than community pharmacists (Boardman et al. 2001). 
 
1.2.2 Dissatisfaction with the community pharmacy role 
Despite agreement with hospital pharmacists on some factors that induce stress, stress 
factors in community pharmacy were found to be higher (McCann et al., 2009a). Reasons for 
this have included role extension due to the New Pharmacy Contract in 2005, failure to use 
skill mix to release pharmacists from the dispensing role, increasing demand for 
pharmaceutical services from an ageing population, technological advances and increasing 
prescription numbers (Gidman, 2011). 
In 2001, a study of recently qualified, largely community pharmacists, identified that their role 
was not sufficiently demanding.  In the same study, two main themes for leaving the 
profession were internal factors, for example, professional satisfaction, self-image, and 
external factors-such as working conditions and career structures (Boardman et al., 2001).  
One possible reason for community pharmacists being more dissatisfied than hospital 
pharmacists is that they have less flexibility in the way that they work. Within community 
pharmacy, the level of autonomy is related to the status of the pharmacist, with pharmacy 
owners having more autonomy (Harding and Taylor, 1997) and reporting higher levels of 
satisfaction than employees (Boardman et al., 2001). The growth of multiple (chain) 
pharmacies (Bush et al., 2009) in a regulated market, has increased the proportion of 
employee pharmacists, decreasing overall autonomy and satisfaction. 
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Community pharmacy has been described as a target driven environment with pressure to 
undertake Medicines Use Reviews (MURs), sometimes with unrealistic expectations and 
insufficient numbers of staff (Eden et al., 2009). A study of community pharmacists in 
Northern Ireland identified some other issues relating to pharmacists’ stress, including 
inadequately trained staff, interruptions interfering with workflow, lack of breaks, open plan 
dispensaries, professional isolation, new services and demands of the public (McCann et al., 
2009b). Public expectation regarding the time taken to dispense prescriptions and dealing 
with customer complaints were a source of stress, but positive interactions with the public 
were a source of job satisfaction. 
The new contractual framework for community pharmacy, introduced in 2005 (Bradley et al., 
2008) has not altered the fact that community pharmacists continue to spend the majority of 
their time on activities related to dispensing. Eden et al. (2009) postulated that the routine 
and intensive nature of this work was a cause for resentment and has had a resultant 
negative effect on job satisfaction and frustration at the lack of opportunity to use clinical 
skills. Community pharmacy has to manage healthcare policy in a business environment, 
and it has been suggested by Jacobs et al. (2011) that dispensing takes precedence over 
patient outcomes. Prescription numbers have continued to increase and there is an 
incomplete understanding of how pharmacists cope with the increasing dispensing pressures 
and the new services (Hassell et al., 2011). A systematic review in 2012 (Lea et al., 2012) 
concluded that community pharmacists have some difficulty with work-life balance due to 
increasing workloads leading to increasing stress levels. This has resulted in community 
pharmacists working longer hours to meet job demands. More recently, Davies et al. (2014) 
confirmed that community pharmacists spent about 25% of their time in activities related to 
dispensing, 10% of their time on clinical checking of prescriptions and only 3.2% on 
pharmaceutical services. The community pharmacist’s role remains dominated by dispensing 
and checking prescriptions, with a high workload and a lack of adequate breaks and trained 
staff. Individuals’ dissatisfaction with work has long been associated with stress and anxiety 
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and can affect decisions about leaving a job (Seston et al., 2009), and may affect the ability 
to practise safely and effectively (McCann et al., 2009b). 
 
1.2.3 Drivers for pharmacists to become Practice Pharmacists and to maintain a portfolio 
role. 
Blenkinsopp et al. (2001) found that the PP role used pharmacists’ skills appropriately and 
that those interested in the role wanted to work more closely with other healthcare 
professional (HCPs). Mullen et al. (2005) found that PPs with a community pharmacy 
background took on the role because they wanted to use their knowledge and have more 
interesting work. Flexible working has been identified in the literature as an advantage of the 
PP role and of working as a locum (Mullen et al., 2005; Shann and Hassell, 2006). 
Blenkinsopp et al. (2001) suggested that there are cross-sector benefits to community 
pharmacy where PPs continue to work in both sectors as part of a portfolio career. 
 
1.2.4 Part-time working 
Part-time working, within the profession, had remained static at 32.5% in 2003, and 33.3% in 
2008 while the proportion in primary care had risen from 36% in 2005 to 39.5% in 2008 
(Hassell et al., 2004; Seston and Hassell, 2009). The proportion of pharmacists working part-
time in the latest survey was 27% for pharmacists overall and 42% for pharmacists working 
in a primary care setting (Phelps et al., 2014). In the profession as a whole more female than 
male pharmacists work part-time (Blenkinsopp et al., 1999; Hassell, 2000; Hassell et al., 
2004, 2006; Seston and Hassell, 2009). In 2016 Mills found that 56.3% of the PPs studied 
worked full-time in the role [personal communication from author]. This compares favourably 
with the 2013 survey where 58% of PPs worked ≥30 hours a week in the PP role (Phelps et 
al., 2014).  
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1.2.5 Pharmacy workforce issues 
Historically, there has been a shortage of available pharmacists (Hassell et al., 2004) leading 
to recruitment issues in both hospital and community pharmacy. Demand has outstripped 
supply and from the early 1990s practice pharmacy was added as an additional career option 
(Blenkinsopp et al., 2001, 1999, Boardman et al., 2001, 2000; Hassell, 2000; Mullen et al., 
2005). Overall, pharmacists could, therefore, demand higher remuneration (Blenkinsopp et 
al., 1999), have more career choices and the flexibility to work where and when they liked 
(Shann and Hassell, 2006). Some believe that there is now an oversupply of pharmacists 
(Wright, 2013). An oversupply is likely to have a negative effect on all pharmacists related to 
income as remuneration, particularly in community pharmacy, is thought to be sensitive to 
the supply and demand of pharmacists (Smith and Sukkar, 2014). The latest plans to employ 
more pharmacists in GP practices are predicated on the increasing availability of the 
pharmacy workforce (NHS Alliance and Royal Pharmaceutical Society, 2014). 
 
1.2.6 Pharmacy as a profession 
There are theories as to what constitutes a profession dating back to the 1940s (Traulsen 
and Bissell, 2004). A profession is a special kind of occupation and has been described as 
having some traits that include specialised training and education, formal examination of its 
members and a service based on altruism rather than just profit. The professional service is 
linked to and supports the maintenance of the social system (Harding and Taylor, 1997). 
Professionals support the social system by putting service before self-interest and by 
applying scientific and rational knowledge to individual cases based on an objective view of 
illness. In this way, professionals maintain their authority to exercise their function and 
determine the relationship between the patient and the professional (Harding and Taylor, 
1997; Traulsen and Bissell, 2004). These traits confer professional authority over the patient 
and establish confidentiality in the interaction (Traulsen and Bissell, 2004). The definition of a 
profession has been further expanded to include additional common characteristics such as 
a shared ideology, a binding ethic, a unique body of knowledge, a set of technical skills, a 
 15 
guild of those entitled to practice with licensure or certification and a recognised setting for 
practice (Agomo, 2012). 
 
The business focus of community pharmacy has been considered in the literature in the 
context of the potential conflict of interest and a barrier to inter-professional working (Hughes 
and McCann, 2003; Bereznicki et al., 2011; Rubio-Valera et al., 2012). The commercial 
interests of community pharmacy can be viewed as unprofessional because they may 
conflict with the trait of putting service ahead of self-interest (Traulsen and Bissell, 2004).  
 
According to Harding and Taylor (1997), the social object of pharmacy has changed from 
compounding to the symbolic act of transformation, namely dispensing. Traditionally 
pharmacy was science-based with an emphasis on technical skills; however, of the technical 
skills, only dispensing remains since raw drug procurement, storage and compounding have 
largely been taken over by the pharmaceutical industry (Edmunds and Calnan, 2001; 
Traulsen and Bissell, 2004). It has been argued that doctors maintain control of medicines as 
a social object (Traulsen and Bissell, 2004) and that this reinforces the distinction between 
doctors as autonomous prescribers, and pharmacists as dispensers, supporting a differential 
status (McDonald et al., 2010). Harding and Taylor (1997) pointed out that Medicine has also 
potentially lost some control of medicines as a social object as pharmacists have become 
more involved in the production of formularies. Non-medical prescribing might also constitute 
a further loss of medicines control and challenge medical control (Weiss and Sutton, 2009).  
 
Waterfield (2010) has suggested that community pharmacists use more technical knowledge 
than judgment and that this leads to low expectation from the public. If pharmacists used 
more judgment, indeterminate knowledge, than technical knowledge, and moved away from 
dispensing towards “know how” then this may improve the public perception of community 
pharmacy. There is also a public image of community pharmacists as shopkeepers. This 
“shopkeeper image” is a recurring theme in the literature from the UK (Chen and Britten, 
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2000; Rutter et al., 2000; Agomo, 2012; Elvey et al., 2013), Northern Ireland (Hughes and 
McCann, 2003), The Republic of Ireland (Grimes et al., 2009), Canada (Motulsky et al., 
2008), Australia (Tan et al., 2014a), and New Zealand (Bryant et al., 2010).  
 
If some pharmacists’ altruism is in dispute and they no longer need their technical skills, then 
their professionalism relies on their training and knowledge. Pharmacists undergo unique 
training and examination that is different from any other HCP. Nevertheless, there is 
confusion in the minds of the public and other HCPs as to the role of the pharmacist in the 
modern NHS. According to Waterfield (2010), one of the key challenges for the Pharmacy 
profession today is to demonstrate the benefit of pharmacists using their knowledge in 
primary care. Waterfield (2010) also identified two key ideas associated with knowledge and 
professionalism; the inaccessible nature of professional work without appropriate training, 
and that the knowledge related to a profession cannot be standardised, rationalized or 
commodified. Waterfield (2010) went on to argue that dispensing and checking are technical 
tasks that can be undertaken by trained technicians and that the only part of the process that 
needs a pharmacist is the clinical check.  
 
Differentiating between information and knowledge is important. Information is detailed 
specifics, for example, facts, figures and data, whereas knowledge requires the complex 
assimilation, cross-referencing and analysis of different types of information (Waterfield, 
2010). In the modern world, information is freely available, but information only becomes 
knowledge when it is assimilated, analysed and cross-referenced. The use of knowledge is a 
key professional attribute. 
 
1.2.7 Pharmacists’ self-perceptions 
A few studies have looked at the way pharmacists see themselves. Social groupings of 
Danish pharmacists, influential in the development of the role of the community pharmacist, 
were studied in 2001(Nørgaard et al., 2001). More recently Elvey et al. (2013) studied the 
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perceptions of UK community, hospital and primary care pharmacists, and Salim and Elgizoli 
(2016) interviewed community pharmacists in Sudan. These studies were undertaken in 
different countries, health care systems and at different times, but similar identities were 
described. 
 
The Danish study identified pharmacists as technical drug experts providing traditional 
dispensing and standardised advice on how to take medicines, and as drug experts co-
operating with other HCPs without personally assessing individual patients. Also, the study 
identified a leadership and training role and responsibility for providing tailored information for 
individual patients. 
 
The UK qualitative study involving forty-three community, hospital and primary care 
pharmacists identified an additional six identities and acknowledged the need for 
pharmacists to have good social and communication skills. Additional roles identified 
included “the scientist”, acknowledging the training and background of pharmacists, “the 
social carer”, communication and relationship building with patients. Two other roles 
identified were “being a manager” and “business person”, although these were related to a 
community pharmacy background. The “medicines maker” was another role that was 
nostalgically viewed as an historical activity. There was also a perception that pharmacists 
were “unremarkable characters” due the hidden nature of their work, and a lack of 
recognition. The authors suggested that pharmacists do not appear to have regained as 
clear or strong identity as that of a traditional medicines maker, although the scientist was the 
strongest of the identities to emerge. The study undertaken in the Sudan identified similar 
themes but included “a monitor of medicines”, health promotion and a family practice identity 
as roles. 
 
1.2.8 Pharmacists’ personality traits 
Research into pharmacists’ personality traits was initially related to role expansion and the 
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relationship between US pharmacists and physicians (Lambert, 1996). Lambert found that 
older pharmacists and hospital pharmacists were more likely to make recommendations to 
physicians, and he postulated that experience might engender confidence. Lambert suggests 
that the setting was significant as community pharmacists more positively identified the 
physician as having power and expertise. Rosenthal et al. (2010) in Canada studied 
pharmacy culture and detailed five personality traits of pharmacists related to patient care; a 
lack of confidence, fear of new responsibilities, paralysis in the face of ambiguity, need for 
approval and aversion to risk. They concluded that pharmacists were thoughtful, careful, 
attentive and compliant and more like scientists than traditional health care practitioners, 
these traits being valuable in traditional pharmacists’ roles.  
 
Frankel and Austin (2013) investigated barriers to practice change in Canadian pharmacists 
and identified medical hierarchy, poor pharmacist role definition, a lack of preparedness to 
take on patient responsibilities, and need to develop clinical reasoning and confidence as 
barriers. The same study identified a difference in pharmacy and medical students at the 
beginning of their respective courses.  A later study comparing the personality of pharmacy 
and medical students throughout their course supported a difference in traits of the two 
groups at baseline and suggested that traits were modified or enhanced by their courses 
(Cordina et al., 2015).  
 
Published evidence shows that pharmacists appear to be closely aligned to their scientific 
background and that this is associated with a need for “certainty” rather than ambiguity and 
risk. They have been shown to have a deep desire to follow the rules and to conform. Not 
surprisingly these traits make any change and risk-taking uncomfortable. Some groups of 
pharmacists appear to be more innovative confident and ambitious and wish to be different 
from their colleagues. Innovative pharmacists take on new roles, but still retain a cautious 
approach to patient care linked to their personality (Frankel and Austin, 2013; Hughes et al., 
2014; Rosenthal et al., 2010), pharmacy education (Frankel and Austin, 2013; Rosenthal et 
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al., 2010), and the culture in healthcare (Austin et al., 2007; Rosenthal et al., 2010; Hughes 
et al., 2014).  
 
1.3 Pharmacists’ roles in primary care 
The clinical roles that pharmacists have undertaken, and subsequent outcomes, are 
important to inform the role of PPs in CCGs and elsewhere in primary care. They provide the 
evidence for the effectiveness of pharmacist interventions to inform the roles that they might 
undertake and outline the potential value of pharmacists to general practice that still needs to 
be defined (NHS Alliance and Royal Pharmaceutical Society, 2014). 
 
1.3.1 Chronic disease management 
There are relatively few studies conducted in the UK that document the effectiveness of 
pharmacist-led chronic disease management (CDM). Those that have been published 
(Macgregor et al.,1996; McDermott, 2005; Reid et al., 2005; Jamieson et al., 2010; Lowrie et 
al., 2012; Chlid et al. 2012) broadly show that pharmacists can manage those chronic 
illnesses studied and that, where patients opinion is sought (Macgregor et al., 1996; 
McDermott, 2005; Reid et al., 2005; Jamieson et al., 2010), pharmacist management is 
acceptable. 
One evaluation of a pharmacist-led anticoagulant clinic in a GP practice (Macgregor et al., 
1996) demonstrated that the international normalised ratio control (within range) significantly 
improved after transfer to the clinic and that patient knowledge was improved along with 
access and reduced waiting times. Two studies were based around a pharmacist reviewing 
treatment for a specific disease. McDermott (2005) studied chronic pain, using patient 
questionnaires, relating to pain control and general well-being before and after a pharmacist 
review. The pharmacist made recommendations in >85% of patients, and 77% of these 
recommendations had all been carried out after six months. The authors confirmed the 
potential value of a pharmacist-led review of pain management in primary care but called for 
more research. A further study into a review of antipsychotic prescribing in dementia (Child et 
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al., 2012) used a team of primary care pharmacists to review patients in one PCT; 
pharmacist interventions were shown to limit the prescribing of antipsychotics in these 
vulnerable patients. 
Despite the seemingly positive results of these evaluations, only small numbers of patients 
(n<100) were included in the final analysis (Macgregor et al.,1996; McDermott, 2005; Child et 
al., 2012) and in all cases the reviews were protocol driven and only limited attempts were 
made to compare pharmacist interventions with those of other HCPs, for example, nurses. 
 
Where patients were randomised to the care of a pharmacist or usual (GP) care, two studies 
on hypertension (Reid et al., 2005; Jamieson et al., 2010) reported statistically significant 
reductions in blood pressure. However, a third study (Lowrie et al., 2012) looking at patients 
with left ventricular systolic dysfunction showed improved prescribing with no effect on 
outcomes, but patients were described as being “relatively well treated” at baseline. There 
are, however, methodological problems with these trials regarding design. Patients were 
aware of which HCP was providing their care, and in all cases, the control was “usual care” 
that was not well described. Where documented, pharmacist clinic appointment times were 
fifteen (Reid et al., 2005) and thirty minutes (Lowrie et al., 2012), and frequency of visits 
every two weeks to two months (Reid et al., 2005) monthly or weekly (Jamieson et al., 2010) 
or two weekly (Lowrie et al., 2012). Also, the pharmacist provided additional information to 
the patients in the study groups in all three studies. It is unlikely that “usual care” by a GP 
would allow for these levels of interventions (Jamieson et al., 2010), and the novelty of a 
pharmacist-led clinic may have affected patient uptake and engagement (Reid et al., 2005). It 
is, therefore, not known if the apparent effectiveness of pharmacist-led clinics is a function of 
the pharmacist’s skills and knowledge or is because of unfair comparisons between study 
and control groups. 
 
1.3.2 Educational outreach 
Educational outreach (EO), sometimes known as academic detailing, has been described as 
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“a personal visit by a trained person to health professionals in their practice own settings” 
(O’Brien et al., 1997, p. 2). Two early US studies using “clinical pharmacists” to provide EO 
established that pharmacists could affect changes in physicians’ prescribing of vasodilators, 
an antibiotic, propoxyphene (Avorn and Soumerai, 1983) and psychoactive drugs in nursing 
homes (Avorn et al., 1992). A later study in South Africa demonstrated that pharmacists 
could deliver a statistical improvement in asthma symptoms in children (Zwarenstein et al., 
2007), as part of an EO programme, although no subjective improvements in asthma severity 
or school activities were identified. 
 
Educational outreach has been evaluated in the UK as a method of supporting guideline 
awareness among GPs across a range of therapeutic areas. These areas include non-
steroidal anti-inflammatory drugs, ulcer-like dyspepsia and Helicobacter pylori eradication, 
antiplatelet therapy, angiotensin-converting enzyme (ACE) inhibitors in heart failure and the 
use of antidepressants. Three studies used community pharmacists (Hall et al., 2001; 
Watson et al., 2001; Freemantle et al., 2002), one used primary care pharmacists [with or 
without a mental health HCP] (Patel and Afghan, 2009), and one used pharmaceutical 
advisers (Eccles et al., 2007). The details of the training received by the pharmacists, where 
stated, ranged from one (Patel and Afghan, 2009) to three days (Freemantle et al., 2002). 
It is difficult to compare the effectiveness of the pharmacists in delivering educational 
outreach in these studies, given that the baseline experiential status and post-training 
education and communication competencies of the pharmacists involved are unclear. In one 
case, additional support from a specialist practitioner was available during some of the visits 
(Patel and Afghan, 2009). Four studies were described as randomised controlled trials 
(RCTs) (Hall et al., 2001; Watson et al., 2001; Freemantle et al., 2002; Eccles et al., 2007). 
Of these, three used the educational outreach as the intervention, and one included a third 
“guideline only” group (Watson et al., 2001). Only one of these trials obtained evidence of a 
modest improvement in guideline adherence, due to educational outreach, which was due to 
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a marked improvement in guideline uptake in smaller practices only (Freemantle et al., 
2002). The remaining three trials found no significant difference.  
 
The non-randomised study (Patel and Afghan, 2009), that used educational visits to support 
guideline adherence, was unique in concluding that this intervention successfully influenced 
prescribing behaviour across a Primary Care Trust (PCT) that included both smaller and 
larger practices. Although this conclusion looks positive, the study design provided a lower 
level of evidence than an RCT and was also conducted in a PCT that is used to receiving 
similar pharmacist-led campaigns in the past. 
 
Only one of the five studies used patients’ notes to verify changes in prescribing (Freemantle 
et al., 2002), which is likely to be a more accurate method of data collecting than electronic 
prescribing analyses and cost (ePACT) used by the other studies to monitor prescribing. 
ePACT collects information on all NHS prescriptions issued by general practitioners that are 
dispensed by contractors (Majeed et al., 1997). One of the limitations of ePACT is that it 
records all dispensing, but no therapeutic or patient detail and therefore cannot be directly 
linked to a specific intervention. Dispensing is a reflection of all prescribing that occurs, within 
any selected time frame, so the drug choice must be made carefully, as many have more 
than one indication, affecting the sensitivity of the drug as a marker (Hall et al., 2001; Eccles 
et al., 2007). 
 
More recent studies have had more positive results. A study of EO to prevent adverse drug 
interactions (ADRs) used pharmacists to provide targeted interventions to identify and 
address ADRs within seventy-two GP practices (Avery et al., 2012). The pharmacists 
received training on the evidence-base, EO techniques and the study outcomes and 
interacted with the practice for a twelve-week period using a variety of interventions. Control 
practices received computerised reports of potential ADRs and supporting information. The 
intervention was more effective and clinically relevant than computerised reports and 
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information and was also cost-effective. The authors suggested that the overall effects were 
probably greater as the control was likely to be better than usual care. 
 
Lowrie et al. (2014) used pharmacists to deliver EO to increase statin prescribing in patients 
with vascular disease in thirty-one GP practices. The pharmacists had not delivered the 
intervention before but had over forty hours of clinical and academic detailing training by 
consultants, HCPs and the research team. The pharmacists worked for one day a week in 
their allocated practices for one year supporting them to improve statin prescribing. Patients 
from practices with the pharmacist support were significantly more likely to have their 
cholesterol to target due to improved prescribing. 
 
The studies discussed above used surrogate markers, so the true effect on patient outcomes 
remains unclear. The equivocal nature of some of the results suggests that the most effective 
methods of providing pharmacist-led EO are still being refined. The latest studies, which 
used pharmacists to provide both education and follow up, look promising and support the 
role of a pharmacist as an agent for change working within the primary care team. 
 
1.3.3 Medication review 
Clinical medication review has been described as “the process where a health professional 
reviews the patient, the illness, and the drug treatment during a consultation” (Zermansky et 
al., 2001, p. 2). It has been suggested that pharmacists can identify and resolve medicines-
related issues (Furniss, 2000; Krska et al., 2001; Lowe et al., 2000; Krska and Ross, 2002; 
Zermansky et al., 2001, 2002, 2006; Silcock and Petty, 2008; Desborough et al., 2012), and 
that despite incentives for (at least) annual medication review to be carried out by GPs, it is 
unlikely that this is achieved in practice (Krska et al., 2006), even for older people with 
multiple co-morbidities (Blenkinsopp et al., 2012). 
Several RCTs have reported benefits from pharmacist-led medication review including a 
reduction in the number of inappropriate drugs prescribed (Furniss, 2000), significant 
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changes in patients’ drugs (Zermansky et al., 2001), resolution of pharmaceutical care issues 
(Krska et al., 2001), and appropriate suggestions for clinically acceptable changes in care 
home patients’ medication (Zermansky et al., 2006).  
 
There is little hard evidence to support patient orientated outcomes from these trials, such as 
a reduction in hospitalisation (Furniss, 2000; Zermansky et al., 2006), improvement in quality 
of life (Krska et al., 2001; Holland, 2005;) or mortality (Holland, 2005; Zermansky et al., 
2006). Holland et al reported no effect on hospital admission after pharmacist-led medication 
review. Zermansky et al. (2006) did show a significant reduction in falls as a result of 
pharmacist review of patients in care homes, but the authors failed to recruit sufficient 
patients to detect significant changes in other secondary outcomes. 
 
A systematic review, including UK trials, concluded that there was no clear effect on 
outcomes and that this was not related to the type of pharmacist conducting the review or the 
intensity of the review. But, there were methodological weaknesses including difficulty in the 
comparison between studies (Holland et al., 2008). The results of cost analyses within RCTs 
have also yielded equivocal results, some showing savings (Furniss, 2000; Zermansky et al., 
2001), and others being cost-neutral (Krska et al., 2001; Zermansky et al., 2006). 
 
A more recent study (Desborough et al., 2012), of an established team of pharmacists 
reviewing medication as part of a service to support patients in their homes, demonstrated 
cost-savings and a reduction in hospital admissions. Although there was no control group, it 
supports the argument that established inter-professional relationships are possibly key to 
improved outcomes (Furniss, 2000; Holland et al., 2006). One study in Australia concluded 
that integrating a pharmacist into a GP practice increased the frequency and rate of 
medication review (Freeman et al., 2012a). Another Australian study comparing medication 
reviews completed by integrated and non-integrated pharmacists found that both groups of 
pharmacists made similar recommendations (Freeman et al., 2013). The integrated 
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pharmacists identified fewer drug-related problems, which was rationalised by the authors to 
be due to the pharmacist having access to the patient notes, thereby allowing the pharmacist 
to have more insight to drug choices and rationale. The uptake of recommendations by GPs 
was greater in the integrated pharmacist’s group compared to non-integrated pharmacists. 
 
The process of medication review can lead to improved patient understanding, changes to 
more appropriate formulations and better compliance; the lack of evidence of positive patient 
orientated outcomes may be due to inappropriate measures (Krska et al., 2007) or the lack of 
suitably designed large-scale trials (Blenkinsopp et al., 2012). A recent systematic review of 
pharmacist medication review in the community included 31 studies (Jokanovic et al., 2016). 
The review, of what appears to be suitably chosen studies, supported the value of 
pharmacist-led medication review related to surrogate outcomes in blood pressure, 
cholesterol and diabetic control, but not for prevention of hospitalisation. The authors called 
for more research on cost-effectiveness, patient satisfaction and medicines taking. 
 
1.3.4 Prescribing advice 
Some studies have looked at the pharmacist’s role in the prescribing process in helping to 
prevent adverse drug reactions (Shulman et al., 1981; Gray et al., 2008; Cresswell et al., 
2012) and hospital admissions (Royal, 2006). Also, at their contribution to formulary 
development (Green, 1985; Hamley et al., 1997), clinical audit (Panton and Fitzpatrick, 1996; 
Rodgers et al., 1999), prescribing cost control (Rodgers et al., 1999; Hamley et al., 1997; 
Ragubeer and Patel, 2011), medicines adherence (Chen and Britten, 2000) and safety 
(Avery et al., 2002; Petty, 2003; Cresswell et al., 2012). There is no strong evidence of 
improved patient outcomes, but some trials have indicated that potential adverse patient 
outcomes have been prevented (Gray et al., 2008; Shulman et al., 1981; Avery et al., 2012), 
that the pharmacists were probably cost-effective (Rodgers et al., 1999; Chen and Britten, 
2000; Teal et al., 2002; Avery et al., 2012), and that no patient harm from the pharmacists’ 
intervention were identified (Teal et al., 2002). Outcome measures of the effectiveness of 
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pharmacist activities in primary care have included analysis of PACT data (Green, 1985; 
Rodgers et al., 1999; Teal et al., 2002) and a reduction in hospital admissions (Royal, 2006). 
The limitations of PACT data have been discussed in section 1.3.2.  
 
Single interventions in primary care appear to have limited impact (Rodgers et al., 1999; Fish 
et al., 2001; Cresswell et al., 2012) and can lead to professional isolation (Avery et al., 2012), 
but the research has shown that pharmacists are seen as agents of change and as a 
credible solution to prescribing and monitoring issues in primary care. Therefore, there is an 
argument for a wider integration of pharmacists into general practice teams (Cresswell et al., 
2012) to work on these issues, possibly using a mixture of interventions (Avery et al., 2012). 
Other practice pharmacist activities that have been suggested as possibly beneficial are 
generic substitution (Hamley et al., 1997; Rodgers et al., 1999; Williams et al., 2000), 
medicines consultation and patient education (Chen and Britten, 2000; Teal et al., 2002), 
post hospital discharge support, professional education and drug information (Williams et al., 
2000). These suggestions were made some time ago, and it is likely that most (if not all) 
have become accepted practice. It is problematic to find suitable outcome measures for 
some of these activities, therefore, any attempt at a full cost-effective analysis is likely to be 
complex and potentially incomplete. 
 
1.3.5 Non-medical prescribing 
Pharmacists have been able to counter prescribe an increasing but restricted list of 
medicines in the community for many years. Changes in legislation in 2003 and then in 2006 
allowed pharmacists with at least two years’ experience to train as supplementary and 
independent prescribers respectively (Guillaume et al., 2008; Stewart et al., 2009a; Cooper 
et al., 2012; Gerard et al., 2012). The numbers of qualified pharmacist prescribers have 
increased steadily from zero to around 1600 in 2010 (Stewart et al., 2010) by which time 
71% were actively prescribing (Latter et al., 2010). The numbers of registered independent 
pharmacist prescribers are currently 3743 for England, 266 for Wales and 612 for Scotland 
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(General Pharmaceutical Council, 2017). National data in 2013 indicated that only 61% of 
prescribing pharmacists had prescribed in the last 12 months; male pharmacists were more 
likely to prescribe than female ones, and younger pharmacists were more likely to prescribe 
than older ones (Phelps et al., 2014). A more recent survey (General Pharmaceutical 
Council, 2016) of a smaller sample (651) of pharmacist prescribers suggested that the 
numbers of pharmacists that had ever prescribed since qualifying have increased to 74%, 
with 41% prescribing every working day and 18% prescribing more than 50 items a week. 
Most respondents (57 %) reported that they found it either easy or very easy to find 
opportunities to prescribe, although it was more difficult to find opportunities to prescribe in 
community pharmacy. This is potentially encouraging, as in 2013 the levels of prescribing in 
a primary care setting were modest with 58% of pharmacist prescribers issuing 10 or fewer 
items a week and only 10% issuing more than 50 items a week (Phelps et al., 2014).  
 
Published studies show that pharmacist prescribers were confident in the prescribing role 
(Guillaume et al., 2008), that their prescribing was appropriate ( Stewart et al., 2009a; Latter 
et al., 2010). Their patients found the service, which prescribing pharmacists provided, was 
acceptable (Latter et al., 2010; Stewart et al., 2009a, 2011; Cooper et al., 2012; Gerard et al., 
2012). Despite patients being positive about the experience, some reported being initially 
unsure of what to expect from their encounter with a pharmacist prescriber (Stewart et al., 
2009a). One large study (n=451) has identified that female patients and patients of both 
genders with long-term conditions, actually preferred prescribing pharmacist services to 
those provided by GPs; appointment length was not a factor for patient preference in this 
case (Gerard et al., 2012). Other studies have suggested that appointment length may be 
significant (Smalley, 2006; Stewart et al., 2009a), and that increased appointment times 
provided by prescribing pharmacists allowed for a more comprehensive medication review 
than that provided by doctors, and reduced patients’ medication burden (McCann et al., 
2012). It has also been suggested by Bruhn et al. (2011, 2013) that medication review by a 
pharmacist prescriber confers an additional benefit to that of medication review alone or GP 
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usual care, in chronic pain at least. It has been reported by Courtenay et al. (2012) that 
levels of prescribing by non-medical prescribers (NMP) are influenced by a number of 
organisational factors; employer, the level of experience before becoming an NMP, and 
existence of governance procedures and support for the prescribing role. A recent Cochrane 
review of predominantly RCTs from mostly high-income countries supported the view that 
non-medical prescribing, by nurses and pharmacists, is acceptable to patients and delivers 
comparable outcomes to usual medical care, at least as far as surrogate outcome measures 
and adherence are concerned (Weeks et al., 2016). 
 
Training for prescribing pharmacists appears to be fit for purpose, although some concerns 
have been raised, for example, around diagnostic skills (Latter et al., 2010) and ruling out 
conditions outside the pharmacist’s competency (Stewart et al., 2010). Latter et al. (2010) 
reported that the implementation of non-medical prescribing was not entirely supported by 
policy in about half of all NHS Trusts, but most Trusts did have governance arrangements in 
place at the time. Other researchers have shown that pharmacist prescribing appears to 
reduce GP workload (Lloyd et al., 2010) and improve patient access to medicines (Smalley, 
2006; Stewart et al., 2009a), although one systematic review could not find any evidence of 
health economic analysis or impact of non-medical prescribing on health services (Bhanbhro 
et al., 2011). Latter et al. (2010) have argued that there is a need to provide data on patient 
outcomes, both clinical and financial, and McCann et al. (2012) have argued for further 
research into the integration of pharmacist prescribers into multidisciplinary primary care 
teams to maximise patient benefit. 
 
1.3.6 Repeat prescription management 
Repeat prescriptions, described by Zermansky (1996), p. 643 as “those issued without a 
consultation to patients on long-term treatment”, then represented at least 66% of all GP 
prescriptions and 80% of drug costs. Harris and Dajda (1996) obtained a similar figure of 
81% of all drug costs from 1993 data related to 500 GP practices, but the proportion of 
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repeat prescriptions was higher at 75%. Petty et al. (2014) looked at repeat prescribing and 
found that 77% of all primary care prescriptions were repeat prescriptions but, while the 
proportion was the same, the volume of prescriptions has doubled in the last 20 years. 
 
One CCG has published a report on a pharmacist-led repeat prescription management 
service that utilises pharmacists to assess the appropriateness of repeat prescription 
requests before issuing a prescription (Walsall Clinical Commissioning Group, 2014). The 
service is designed to deliver both patient safety and cost effectiveness and runs in 52 out of 
62 GP practices. For 2013/14, the service delivered net savings of £610,270, equivalent to 
£3.05 savings for every £1 invested in pharmacist time. This figure does not include any 
savings that may have been made on GP time or any from avoiding negative patient 
outcomes such as adverse drug reactions. The potential for preventing adverse drug 
reactions from medication errors from repeat medicines was demonstrated by Avery et al. 
(2012).  
1.3.7 Practice Pharmacists demographic background 
The demographic background of PPs in published studies is important for comparison with 
those in the thesis project reported here to indicate if the PPs were similar. The outcomes of 
the project are more likely to be meaningful to a wider sample of pharmacists if the PPs in 
the thesis project are similar to PPs studied elsewhere.   
 
Several studies in the UK and Australia have studied multiple aspects of individual groups of 
PPs regarding demographic and working practices in any detail. The Australian studies 
(Freeman et al., 2014; Tan et al., 2014a) were undertaken in a different health care system. 
Three UK studies, all over ten years old, were undertaken in previous iterations of the NHS 
(Martin et al., 1998; Blenkinsopp et al., 2001; Mullen et al., 2005), but there is one recent 
study of PPs working in London and the South-East (Mills, 2016).  
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Martin et al. (1998) identified 414 pharmacists working in GP practices in 1996, of which 174 
(42%) responded to their structured postal questionnaire. Some pharmacists worked in more 
than one practice, so the total number of practices covered by the 174 pharmacists was 200 
from 10 regions of the UK, excluding Northern Ireland. There were fewer male (39%) than 
female respondents and they were, overall, more likely to have been pharmacists for over 20 
years, with 89.1% having more than one role. The most common portfolio roles were 
community pharmacy manager (n=68), community pharmacy locum (n=48), a smaller 
proportion were hospital pharmacists (n=30) and academics (n=12). Postgraduate 
qualifications, usually a diploma, were held by 36.2%. The majority were funded by the FHSA 
or directly by the medical practice and worked between one and ten hours a week. The roles 
reported were somewhat dependent on the funding source but included analysis of 
prescribing data, prescribing advice, formulary, guideline and protocol development and 
liaison with the FHSA pharmaceutical adviser. Thirty-two pharmacists ran CDM clinics, and 
more of the PPs funded by the surgeries felt “highly involved” with the practice. Despite a low 
response rate, the study represents an early example of the profile of PPs in Scotland, Wales 
and England. 
 
Blenkinsopp et al. (2001) studied PPs in the West Midlands by sending a questionnaire to all 
working registered pharmacists. Questions explored the sectors in which they worked and 
might consider working, and the hours worked in each. They achieved an overall sample of 
1767 pharmacists of which 53% were female. There was a high level of interest in the PP 
role amongst the pharmacists surveyed at the time. The authors also carried out a postal 
survey of sixty-six PPs and 30 newly employed PPs and showed that 98% worked part-time 
with 82% of these working eight or fewer hours a week as a PP. Twenty respondent also 
took part in semi-structured telephone interviews that included ten PPs and ten aspiring PPs. 
Of the twenty pharmacists interviewed on the telephone, their background role was largely 
community pharmacy (n=14) with the majority being female (n=14), aged between 21 and 40 
years (n=18), and having been qualified for 0-20 years. Four of the ten pharmacists working 
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as PPs spent 1-4 hours a week in the role, three worked 5-8 hours a week, and a further 
three worked over thirteen hours a week. Two-thirds of the PPs were under forty years of 
age, and 60% were female. The authors concluded that PPs found high levels of satisfaction 
in their work and that the overall level of interest in the PP role was related to pharmacists’ 
dissatisfaction with other roles. 
 
The tasks undertaken by the telephone interviewees that were PPs included prescribing data 
analysis, repeat prescribing support, medicines reconciliation and prescribing advice. Several 
PPs mentioned further qualifications as a way of achieving and maintaining appropriate 
levels of service, even though they had received some training before starting in the role. 
None of the PPs in the telephone interviews had face-to-face contact with patients, but they 
found their work professionally satisfying and intellectually challenging.  
 
Mullen et al. (2005) used a structured questionnaire and in-depth semi-structured telephone 
interviews to investigate the motivations for pharmacists to move into primary care in 
England. The structured questionnaire was completed by 432 pharmacists, and twelve were 
interviewed by telephone. Of the PPs who completed the survey, 73% were female 
representing a greater proportion than in the 2002 census. There was little difference 
between the male and female age ranges, and overall 43.2% were in the 30-39 age group 
with 32.7% in the 40-49 age group. In this study, 52% of pharmacists had migrated into the 
role completely, and most of these (28%) were former hospital pharmacists compared with 
19% former community pharmacists. Community pharmacists were more likely to be portfolio 
workers (31.5%) than hospital pharmacists (9.3%). Motivations for moving into the PP role 
included more interesting work, better use of knowledge, increased professional status, a 
more clinical environment, flexible hours, increased autonomy and responsibility. Drivers 
from previous employment included the converse of the motivators and needing a change, 
being undervalued, poor working conditions, and isolation. Hospital pharmacists were less 
likely than their community pharmacist counterparts to consider that primary care had more 
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interesting work, made better use of their knowledge, increased their professional status, or 
was a more clinical environment. They were, however, more likely to refer to flexible hours, 
better remuneration, increased autonomy and responsibility as factors driving them to the PP 
role. 
 
More recently, Mills (2016) looked at the training needs of PPs who were not participating in 
the NHSE Pilot. The thirty-two PPs who were recruited to the study self-disclosed as working 
at a senior (n=16) or junior level (n=16). The junior PPs were statistically more likely to be 
younger and had been registered as pharmacists for less time than the senior PPs. The PPs 
had worked in this role for a mean of 5.3 years (range 0-19 years). The number of PPs in 
each age range was as follows: 
21-30 years (n=8); 31-40 years (n=12); 41-50 years (n=8); 51-60 years (n=3); 61-70 years 
(n=1). The proportion of time spent in face-to-face consultation with patients was: less than 
20% (n=11); 21-40%(n=10); 41-60% (n=3); 61-80% (n=6); 81-100% (n=2). Most of the PPs, 
(n=20) were directly employed by a GP surgery with eleven being employed by a CCG.  
 
Three PPs had more than one employer for their PP role, and eighteen worked full-time; they 
all had previous experience in community (n=22) and hospital pharmacy (n=14) with smaller 
numbers in the pharmaceutical industry (n=2), academia (n=2). Other pharmacy role (n=6) 
and other non-pharmacy related role (n=1). Twenty-two PPs also continued to work in 
another sector of pharmacy, community (n=13) and hospital pharmacy (n=3) with two PPs 
working each of the following: academia, other pharmacy role and other non-pharmacy 
related role. Senior pharmacists were statistically more likely to work in a wide variety of 
sectors. Nine PPs had no postgraduate qualifications at all, and senior PPs were significantly 
more likely to hold a diploma or prescribing qualification. Ten PPs had a postgraduate 
certificate, fifteen a postgraduate diploma, twelve were prescribers and five had higher 
degrees. Of the twelve prescribers, nine prescribed less than 50 items a month and the 
remaining three prescribed less than 100, less than 200 and more than 200 items a month 
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respectively.  
 
The training needs identified by Mills were dependent on the length of experience of the 
pharmacists but overall were related to clinical examination and assessment, monitoring, 
long-term conditions, minor ailments, leadership and management. Mills recommended that, 
to work in general practices, pharmacists should have a postgraduate diploma and a 
prescribing qualification (possibly delivered via distance learning) and that the pharmacist’s 
role needs further examination. 
 
Tan et al. (2014a) explored stakeholders’ views on pharmacist integration into general 
practices in Victoria, Australia in 2010-11. They used qualitative sampling techniques to 
identify a sample of GPs (n=11) and pharmacists (n=16). The respondents were interviewed 
via the telephone or face-to-face. Eleven of the pharmacists were female, and five were 
male. Eleven of the pharmacists came from a community pharmacy background; overall their 
average age was 39.6 years (range 25-65 years) with an average of 11 years of experience 
(range 3-45 years) as a pharmacist. Three pharmacists had previous experience as a PP. 
This study focused on integration, and only a few PP roles were reported, such as 
prescribing advice. There was no intention to provide robust quantitative data, and many of 
the pharmacists were not fully integrated into practices.  
 
Freeman et al. (2014) recruited 26 Australian PPs to a mixed-methods study that looked at 
the PP role, their attributes and the impact of working in a general practice setting. Most of 
the respondents were female (58%) and were in the 30-49 age group (62%). The PPs had 
been qualified for between 1 and 45 years with 6 in the 6-10 years band and 4 in each of the 
11-15 and 16-20 years band. The average length of time that they had worked as a PP was 
1.2 years (range 0-16 years). Over half of the PPs (58%) had postgraduate qualifications, 
with 27% having a coursework masters, 23% a graduate diploma and 15% a research 
doctorate. Fifty-eight percent continued to work in other areas such as independent 
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consultancies (27%), academia (23%), and in community pharmacy (23%). The qualitative 
results showed that the respondents gained professional satisfaction from the role and felt 
valued by GPs. 
 
The common limitation in all the studies is that there is no national register of PPs in the UK 
(Jesson, 2001) or Australia (Freeman et al., 2014) from which to obtain a definitive list. 
Sampling frames are, therefore, uncertain and vary with the method of respondent 
recruitment and may not identify representative respondents.  
 
Formal national workforce surveys were undertaken in the UK in 2002 and 2003 (Hassell et 
al., 2004), 2005 (Hassell et al., 2006), 2008 (Seston and Hassell, 2009), 2011 (Hassell, 
2012), and most recently in 2013 (Phelps et al., 2014). Care must be taken when comparing 
figures from these surveys as the methods used to collect data in each survey were different 
(Phelps et al., 2014), not all pharmacists took part, and there were biases regarding gender 
and age with female and older pharmacists more likely to respond (Hassell et al., 2006, 
2004; Phelps et al., 2014; Seston and Hassell, 2009). Nevertheless, the surveys provide 
national data for comparison.  
 
Part-time working has become more prevalent, and the numbers of pharmacists working in 
primary care appear to have grown steadily until 2005 but have declined since then. The 
NatCen Social Research Registrant Survey for the General Pharmaceutical Council (GPhC) 
(Phelps et al., 2014) was carried out after the NHS changes in 2013, which may have 
contributed to the lower reported figures as PP teams were realigning into new NHS 
organisational structures during this time. This 2014 survey also reported data on 
postgraduate education and indicated that prescribing pharmacists were more likely to have 
postgraduate qualifications than non-prescribing pharmacists. 
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1.4 Pharmacist integration into primary care 
From my personal experience as a practitioner, to maximise the pharmacist’s input to 
general practice, the process of integration must be as efficient as possible. The pharmacist 
must be able to make their contribution to the workload of the practice, while avoiding any 
conflict with the existing team associated with their employment. The process of integration is 
examined in the literature. 
 
According to Pettinger (2002), barriers to effective change in a managerial sense can be 
classed as either operational or behavioural, as shown in table 1.1.  
Table 1.1 Barriers to effective change (Pettinger, 2002). 
Operational Behavioural 
Location 
-need to relocate staff 
“It cannot be done” 
-lack of information 
Tradition-moving from successful traditional 
roles 
 
 
“There is no alternative” 
-loss of influence of staff or representative 
bodies.  
 
Success and perceived success-similar to 
tradition. “why change something that works.” 
Failure 
-changes in the status quo 
  
Lack of clarity 
-poor organisational information 
 
Technology 
-it’s effect on work patterns 
Vested interest 
-change resisted by those it affects negatively 
 
 Fear and anxiety 
-natural response to change and uncertainty 
 
Managerial 
-divorcing ownership from control 
Bureaucracy 
-order and control 
 
Perfection 
-there is nothing wrong with the current 
model 
 
Redundancy 
-change producing redundancy and 
employment 
 
Technology is changing the way that pharmacy is practised; robotic dispensing in hospitals, 
the electronic transfer of prescriptions and remote dispensing in community pharmacy are all 
likely to change work patterns and create uncertainty. Those pharmacists that wish to 
become PPs may need to re-locate and leave previously secure positions in large 
organisations (e.g. hospitals and national pharmacy chains), change work patterns and be 
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freed from large bureaucracies. 
Pettinger’s managerial barriers may apply to GP practices. Practice staff may feel that there 
is no need to introduce a pharmacist as the existing team has traditionally performed well, 
and the existing way of working does not need changing. Some staff may feel threatened by 
the introduction of a pharmacist. This suggests that GP practices should be open and clear in 
their planning and supply accurate information to existing staff, e.g. explain increasing 
workload, inability to recruit a partner or salaried GP.  
Several studies have looked at the determinants of integration. Axelsson and Axelsson 
(2006) based their conceptual model (See figure 1.2) in the context of public health, but their 
model does offer insights into the way that organisations or organisational units can work 
together through vertical integration and horizontal integration. Vertical integration takes 
place between units on different levels in the hierarchical structure, and horizontal integration 
takes place between units on the same hierarchical level. A common management hierarchy 
can encourage vertical integration through co-ordination.  Applying this model to the thesis 
project PP teams, that are commissioned by the CCG to which the GPs also belong, should 
facilitate integration. This conceptual model suggests that the highest form of integration is 
co-operation, where there is a common management hierarchy, but there is built-in flexibility 
to allow for informal arrangements between “organisations”.  
 
Recently, a French study reviewed four pre-existing conceptual models of doctor/community 
pharmacist collaboration (Bardet et al., 2015).  McDonough and Douchette (2001) 
considered the collaborative working relationship (CWR) between pharmacists and 
physicians and synthesised the model shown in Figure 1.3.  
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Figure 1.2 A Conceptual scheme of different forms of integration (Axelsson and Axelsson, 
2006). 
 Horizontal integration  
Higher degrees of integration require more horizontal 
integration 
 
Vertical integration  
Lower degrees of differentiation 
can be managed by vertical 
integration  
 - + 
+ Co-ordination Co-operation 
- Contracting Collaboration 
 
Figure 1.3 Staged approach to developing a pharmacist-physician collaborative working 
relationship. (McDonough and Doucette, 2001)  
  
This model suggests that as the relationship progresses through the stages, efforts to 
maintain it become more bilateral. Individual characteristics affect the willingness to change 
and accept collaboration, “socialised” professionals are more likely to accept collaboration.  
Context characteristics are driven by proximity and coterminous patient groups that 
encourage collaboration and information sharing. Exchange characteristics relate to the 
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value of the collaboration to the parties involved which is enhanced by increasing trust and 
respect over time. Once practitioners reach Stage 4, commitment to the CWR has been 
achieved, and those involved have an interest in sustaining the relationship, communication 
is bilateral, and mutual trust and respect have been established.  
 
Bradley et al. (2012) considered collaboration between GPs and community pharmacists in 
Local Pharmaceutical Service pilots and Repeat Dispensing Arrangements and proposed a 
model comprising seven factors and three levels. Collaboration occurred when the 
pharmacist and GPs were co-located, had a formal and historical working relationship and 
there was interdependency. Mutual trust and respect was gained over time and the parties in 
the relationship had been “socialised” to working with each other, were comfortable 
communicating with each other and shared the goal of patient care which was valued above 
professional difference.   
 
Van et al. (2012, 2013) suggested theoretical models of inter-professional collaboration in 
Australian GPs and community pharmacists determined by interactional and environmental 
determinants. See Table 1.2. The pharmacist’s role in medicines management was found to 
be a strong predictor of interactional determinants, confirming that role recognition shapes 
interactions. 
 
Bardet et al. (2015) postulated a meta-model of physician/community pharmacist 
collaboration (PCPC Meta-model) that recognises the core determinants of trust and 
interdependence that requires four processes to develop perceptions, expectations, skills 
and interest for collaborative practice. These processual determinants characterise the move 
from independent to shared practice, from a strong individual professional identity to 
collaboration.  
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Table 1.2 Interactional and environmental determinants of GP/pharmacists collaborative 
behaviour. 
Interactional determinants 
 
Environmental determinants 
• Communication 
• Trust in the pharmacist 
• Mutual respect 
• Willingness to work together 
• Clear roles in patient care 
• GP expectations of the pharmacist 
• Pharmacists location (relative to GP) 
• Participation in Home Medication 
Reviews* 
• Contact with pharmacists in GPs 
formative years.  
 
Role for pharmacists in medicines 
management  
 
*specific to Australia 
 
The development of collaboration is also facilitated by two development tools, i.e. role 
definition and communication. Role definition is important as it defines the sharing of 
responsibility within the relationship, avoiding conflict over overlapping responsibilities. 
Communication supports the pharmacist’s contribution, mutual respect and other attitudes. 
The authors suggested that it is, therefore, crucial to determining the roles of each 
professional and that patient expectation should be included in any collaborative model. They 
go on to conclude that the collaboration of community pharmacists and physicians is a 
voluntary, complex and dynamic process.  
 
Several recent non-UK studies have looked specifically at the integration of pharmacists into 
primary care teams. In Australia, (Freeman et al., 2012b) used qualitative techniques (focus 
groups and semi-structured interviews) to ascertain the views of patients, GPs, pharmacists 
and practice managers on integration. Tan et al. (2014a) used semi-structured interviews 
with GPs and pharmacists to explore their views on integration. 
Both studies found that funding was a barrier and proposed that additional training facilitated 
integration. Freeman found that larger practices were more likely to have a PP and the PP 
respondents felt that training for PPs should be to an advanced practitioner level, although 
no competency framework was available at the time to support this. Tan found that GPs who 
were familiar with PPs were more supportive of the role, but the need for a PP was not well 
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defined and lacked the evidence-base to drive it forward. Other barriers identified by Tan 
included poor understanding of pharmacists’ training, negative non-pharmacist practitioner 
perceptions to integration, a lack of infrastructure, and that GPs may feel threatened by the 
PP role. 
 
Two Canadian studies have attempted to provide a roadmap for the integration of 
pharmacists into an existing primary care team (Kolodziejak et al., 2010; Jorgenson et al., 
2013). Both studies agreed on several points related to the pharmacist. The PP role should 
meet the needs of the practice and be defined and clearly understood by all staff. Resources 
and space required should be defined.  The pharmacist’s credibility should be established 
with their new team and the relationship should continue to develop with regular feedback 
from the primary care team. 
 
Kolodziejak et al. aimed to provide guidance on the integration of pharmacists into primary 
care using action research to define the role of the pharmacist and provide services based 
on this for eight weeks. The service was evaluated using focus groups, and the pharmacists’ 
suggestions were used to produce a guide to integration. Additional suggestions, not 
included in the guide, were to collaborate on the role definition, decide on patient referral and 
hours of work, and to select a primary care team that is positive about taking on a 
pharmacist. Jorgenson et al. (2013) carried out a literature review of pharmacists who had 
successfully integrated into primary care to produce a draft list of eleven recommendations 
that was then circulated to a network of experienced primary care pharmacists and then 
graded. A list of recommendations for integration was drawn up, including the need to 
understand other team members’ roles, to have infrastructure that supports their clinics, and 
to keep their skills up to date.  
 
Jorgenson et al. (2014) later undertook another qualitative study using telephone interviews 
to evaluate the barriers and facilitators that were experienced by pharmacists who had been 
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integrated into primary care teams. Similar themes emerged concerning relationships, trust 
and respect, role definition, support, pharmacist personality and professional experience and 
presence and visibility, resources and funding and the value of the pharmacist role. 
In 2015-16, Campbell et al. in conjunction with NHS Education South West, developed, 
delivered and evaluated a programme of continuing professional development for registered 
pharmacists who wished to work in primary care. A training needs analysis was used to 
design the training. This project found that there was considerable local and national interest 
in the further integration of pharmacists into primary care. Pharmacists expressed concerns 
about the lack of clarity of their developing role, and in the training requirements and career 
pathway of pharmacists in general practice roles. Pharmacists also expressed concerns 
about gaining competence for extended roles in primary care and access to workplace 
support. The Authors recommended accredited and tailored training for the pharmacists 
based on their roles and needs and that a prescribing qualification helped to fully utilise the 
pharmacist’s skills. In addition, further work at a national level was identified to define the 
required standards and competencies, and on the role definition and value of pharmacists in 
general practice. They also suggested that there should be a review of pharmacy 
undergraduate and pre-registration training, given the developing clinical roles of 
pharmacists, and that commissioners, primary care teams and patients should be made 
aware of the pharmacist’s role in the practice.  
 
The General Pharmaceutical Council has recently published a report on UK pharmacist 
prescribers (General Pharmaceutical Council, 2016). A total of 651 respondents took part in 
an electronic survey of all registered prescribers with available email addresses. The 
respondents (17.4% response rate) were mostly qualified independent prescribers working in 
hospital and primary care. The survey highlighted some issues around integration of 
pharmacist prescribers in general. The lack of a national policy for pharmacist prescribing 
was an issue, although the NHSE pilot was recognised as a means to possibly increase the 
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opportunities for pharmacist prescribers. Other integration issues identified related to, 
doctors not understanding the skills of pharmacists or accepting them into their team, and 
“competition” with nurses. Some pharmacists reported that relationships and the degree of 
acceptance improved over time and that their prescribing role was enhanced by 
multidisciplinary team working. 
 
1.5 The Medical profession 
A key driver for more pharmacists to work within GP practices is the workforce shortage in 
primary care (NHS Alliance and Royal Pharmaceutical Society, 2014). It is, therefore, 
important to understand how workforce issues in Medicine have come about and, how and 
when these may be addressed in the future.  
 
1.5.1 General practitioner job satisfaction and workforce issues 
Problems with the UK general practice workforce are historical with investigations into GP job 
satisfaction going back many years. Sibbald et al. (2000) studied job satisfaction in GPs in 
1987, 1990 and 1998 and found that this declined from 1987 to 1990, improved between 
1990 to 1998, but not to pre-1987 levels. This coincided with political change and the 
introduction of fundholding by the Government in 1991 (Kay, 2001, 2002); this will be 
discussed in detail in a later chapter of this thesis. Sibbald et al. (2000) identified several 
factors that negatively affected GP satisfaction with their role including increased workload, 
undermining of clinical autonomy and increasing patient demand.  
 
Other issues affecting the GP workforce have been identified in the past. These include the 
changing composition of the workforce, with vocationally trained doctors not wanting to 
commit to full time partnerships (Young and Leese, 1999) and the feminisation of the 
workforce adding to the number of GPs that had a career break (Young and Leese, 1999; 
Jones and Fisher, 2006; Lakasing, 2009;). Also, older GPs had been encouraged to retire 
early by the NHS pension scheme changes in 1995, or to consider part-time working, as a 
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way to avoid burnout (Young and Leese, 1999) and remuneration problems. Young and 
Leese (1999) also suggested that GP salary structures remained static and did not evolve to 
match the changing aspirations of the workforce.  
 
The shortage of GPs that was predicted by Young and Leese has now materialised (Irish and 
Purvis, 2012; Peile, 2013; Dayan et al., 2014). Population drivers for the workforce crisis in 
primary care are well documented such as the ageing population (Dayan et al., 2014; Irish 
and Purvis, 2012), increasing complexity of treatments, earlier hospital discharge and more 
community-based treatments (Irish and Purvis, 2012). Other issues in general practice 
include the continuing move away from doctors wanting to be principals (Jones and Fisher, 
2006), high GP vacancy rates, doctors choosing the GP role later in life and problems 
recruiting nurses (Irish and Purvis, 2012). These are further compounded by falling GP 
remuneration with increasing demands, possible inadequate levels of support staff and the 
on-going desire for part-time working amongst GPs (Dayan et al., 2014). There is also a 
“retirement bulge” with large numbers of GPs approaching retirement, often wanting to retire 
before the usual retirement age (Dayan et al., 2014; Irish and Purvis, 2012). These factors, 
O’Dowd (2015) argues, have been exacerbated by past under-investment in primary care 
 
There is a perception that red-tape, e.g. Quality and Outcomes Framework (QoF) and Care 
Quality Commission inspections are encouraging GPs to leave the NHS (Rimmer, 2015). 
Dayan et al. (2014) have reported that insufficient GPs are being trained and the Royal 
College of General Practitioners (RCGP) have predicted that it may take until 2034 for the 
extra 5000 GPs, promised by the current Government, to be realised (Rimmer, 2015).  
According to Jones and Fisher (2006), the GP role is not seen as attractive by medical 
school graduates because the role has high workloads and poor morale. Consequently, in 
2012, only one in five medical graduates indicated a desire to be a GP. In 1999, it was 
suggested by Young and Leese (1999), that medical schools should be more positively 
inclined to general practice and that more medical students should be exposed to primary 
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care, but funding, secondary care demands and working time constraints have prevented this 
(Irish and Purvis, 2012). 
 
O’Dowd (2015) reported that NHS England’s Chief Executive had admitted that it would be 
difficult to recruit the target number of GPs within the timescale and that general practice 
needed to be more attractive to recruit despite the 2014 Five Year Forward View (FYFV) 
published by NHS England (2014b). FYFV promised a new deal for primary care and 
acknowledged past underfunding compared with secondary care. It also promised to stabilise 
funding for two years, shift investment from acute to primary care, to expand HCP training 
and increase investment in new roles and returner and retention schemes. Also, the FYFV 
intended to improve primary care infrastructure, incentivise working in deprived areas and 
encourage multidisciplinary working as a means to provide expanded services in the 
community. It was unclear how far these plans had been implemented for primary care by 
May 2015 (Rimmer, 2015). There was, however, a clear commitment to strengthen primary 
care services by investing in estates and IT to deliver the workforce plan and to also 
negotiate a new contract for GPs, by March 2016. The latter was agreed for 2016-2017 (NHS 
England, 2016b). Health Education England is, reportedly, making efforts to improve GP 
recruitment and retention (Health Education England, 2015b), and are committed to retaining 
existing GPs and to make the role more attractive to medical graduates as laid out in the 
New Deal for General Practice (RCGP et al., 2015a). This plan includes the creation of 
training hubs to upskill other HCPs. 
 
1.6 Significant developments for Practice Pharmacists 
There have been increases in the demand for PPs because of the primary care workforce 
issues as previously discussed, and two related initiatives that were not announced until after 
the data collection phase of the project reported in this thesis had been completed. The 
developments are outlined in 1.6.1 and 1.6.2 and add weight to the further integration of 
pharmacists into general practice. 
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1.6.1 Royal Pharmaceutical Society and NHS Alliance round-table meeting 
On the 30th September 2014, the Royal Pharmaceutical Society (RPS) and NHS Alliance 
held a round table discussion with general practitioners (GP) and members of the public to 
address the workforce crisis in primary care. The report, published in October 2014 (NHS 
Alliance and Royal Pharmaceutical Society, 2014), acknowledged the background to the 
crisis and proposed that suitably qualified pharmacists should be recruited to “fill the gaps” in 
primary care due to GP recruitment problems and the increasing workload. The report 
suggested that pharmacists already working in GP practices have improved both working 
patterns and the provision of care. Patient feedback has been positive and many traditional 
GP roles have been taken on by pharmacists in order to release GP time. 
The report asked a key question: “Why does employing a pharmacist in a GP practice remain 
an exception rather than the rule?” and identified a lack of understanding of the PP role and 
issues with funding and training. Some suggestions to address these barriers were provided 
in the report such as managed integration, formal business cases, education and sharing 
best practice. 
The document also stated, “There are an increasing number of highly trained and skilled 
pharmacists emerging from university, yet not doing the jobs to match their skill level”. While 
both statements may be true, the PP role requires a level of experience and postgraduate 
education that is not normally attained by recently graduated pharmacists. As previously 
stated, the report also wanted to understand the value of pharmacists working in general 
practice, what training is required and how best to integrate pharmacists into the general 
practice teams. 
 
1.6.2 National Health Service England Pilot 
In 2015, NHS England announced a £15 million pilot (NHS England, 2015a) to facilitate and 
train pharmacists to work in GP practices and address the workforce issues in primary care. 
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Further details were given in a report commissioned by the RCGP, BMA NHS England and 
Health Education England. (RCGP et al., 2015b). The scheme was oversubscribed, and a 
further £16 million investment was announced in October 2015 (NHS England, 2015a) with 
further funding of over £112 million announced in 2016 (Sukkar, 2016). The pilot is underway 
and uses senior clinical pharmacists (also prescribers) to provide clinical supervision to 
several (unspecified) other clinical pharmacists working together in clusters or federations of 
practices for clinical and peer support. The pilot will fund the PPs on a reducing scale, 60% 
for year one, 40% for year two and 20% for year 3 with a focus on medicines optimisation 
and achievement of indicative outcomes. These outcomes include freeing up GP time and 
improving access to care, communication across patient care pathways and numbers of 
medication reviews. Also, there are some disease-specific outcomes that are much more 
difficult to attribute to a single intervention in practice, such as a reduction in COPD 
admission rates and CHD risk in high-risk patients. (RCGP et al., 2015b). The scheme has 
raised the profile of, and interest in, pharmacists supporting GPs in primary care, but not all 
pharmacists employed as a result of increased interest have undertaken the Pilot training or 
had significant previous experience in primary care (Mills, 2016). The Pilot includes a 
National Learning Pathway, “Developing clinical pharmacists in general practice,” that was 
developed in 2016 by CPPE (Centre for Pharmacy Postgraduate Education, 2016). The Pilot, 
including the training pathway, has yet to be formally evaluated. Primary Care 
Commissioning has been engaged to prepare and support the pilot GP practices to embed 
the pharmacist into their teams (Primary Care Commissioning, 2016) and is using the NHS 
Sustainability Model in this regard (NHS Improvement, 2017). Primary Care Commissioning 
has recently published a series of case-studies that provides some indication of the success 
of the Pilot so far (Primary Care Commissioning, 2017). Most feedback has been positive, 
often related to saving GP time, with the pilot pharmacists involved in most of the roles 
reported in the literature, depending upon experience. Pilot pharmacists have also started to 
expand their roles into telephone consultations, polypharmacy clinics and home and care 
home visits. While acknowledging their vested interest in a favourable outcome, the PCC 
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have reported several problems which suggests that there are some integration issues that 
have not been fully addressed. This thesis project hopes to clarify these and suggest 
solutions. 
The reported problems have included intrusion or encroachment into other HCP roles and a 
lack of patient understanding due to difficulties in explaining the role and purpose of the 
pharmacist in advance of appointment to the role. Part-time working has been problematic 
for some pharmacists, and there have been recruitment and pharmacist availability issues 
leading to some practices leaving the pilot. Training needs have been underestimated with 
some pharmacists requiring training in communication and integration skills. While 
acknowledging that pharmacists are not replacing a GP, some practices felt pharmacists 
were expensive and that GP budgets were a limiting factor in pharmacist employment.  
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Chapter 2: Background to the Research  
 
2.1 Overview 
This chapter begins with my background and experience and describes how and why I 
came to be a Practice Pharmacist and my initial investigations into the role. This is 
followed by a summary of the Initial Study that I undertook to support my DPharm 
research and to begin to understand some of the questions I had about the Practice 
Pharmacist’s role within CCGs after the 2013 changes. The chapter concludes with the 
derivation of the research questions for my thesis and the relevance of these to current 
developments and the necessity for scientific investigation. 
 
2.2 My background and experience 
I qualified as a pharmacist in 1976 and worked as a hospital and community pharmacist 
before becoming a proprietor in 1985. Owning a pharmacy gave me more freedom, but after 
14 years I became disenchanted with the community pharmacy role, which had not 
appreciably changed since I qualified. One aspect of the role that remained interesting was 
building a relationship with local practices and being asked for advice about medicines. I had 
also become interested in the burgeoning role of the practice-based pharmacist but was 
concerned about my lack of knowledge about disease and therapeutics. I felt that I needed 
some formal qualification to prove that I could work at a postgraduate level and to support my 
future career as a PP, so I undertook a postgraduate diploma in 1998. In 1999, encouraged 
by my initial success, I started work as a PP for a local PCG.  
 
The PP role was a revelation to me; it was challenging because there was a steep learning 
curve; often you would have to research a problem to find a solution, but also satisfying 
because of this. There were opportunities for much more satisfying patient interaction, and it 
was also much less professionally isolating than community pharmacy had been. It was 
based on teams of pharmacists and pharmacy technicians and had excellent educational 
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support from the NPC and other organisations giving access to high-quality therapeutic 
training, further consolidating my PP skills. It was refreshing to be out of a commercial 
environment and into a more professional role. There was a significant difference in the way 
that PPs interacted with GPs and their staff, compared to interacting with a community 
pharmacist and, in most practices, I felt part of their team. I watched the genesis of 
pharmacist prescribing with interest and began considering how I might become a prescriber 
myself. I was among the first pharmacists in the UK to qualify as a supplementary prescriber 
in 2003 and then converted to an independent prescriber in 2007.  
 
I took on a more strategic role in 2007 but was still able to see patients and prescribe for 
them, while supporting the management of a large team of PPs, most of whom were 
prescribers. During this period, I worked closely with secondary care on formulary 
management and the implementation of NICE guidance across primary care. Some of the 
most rewarding work was supporting our prescribing PPs to run CDM clinics.  
 
In 2010, I started a Diploma in Advanced Professional Practice and after completion I was 
invited to undertake the new Doctor of Pharmacy (DPharm) course. I had to complete an 
Initial Study (to determine my suitability for part 2 of the course, so I chose to look at the 
activities that PPs carried out and their relationship with GPs. This was because I felt that the 
PP role was professionally fulfilling with the potential to develop into a future alternative to 
traditional pharmacist roles, but I had observed some issues with the integration of PPs into 
GP practices. Sometimes the PP/practice relationship broke down, or the PPs were reluctant 
to prescribe. I found this interesting because the practices were turning down a resource and 
I wondered why a pharmacist would take on the prescribing course and not want to 
prescribe. There were other issues that needed clarification. 
 
There was published research on the PP role, but none related to hard patient outcomes 
(e.g. a reduction in morbidity or mortality), perhaps not surprisingly due to the cost of 
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undertaking long-term research and lack of obvious funding streams. The lack of evidence 
was a little disappointing, but there was burgeoning local evidence of PPs being cost-
effective. Further background reading showed that the numbers of primary care pharmacists 
had declined in 2008 (Hassell et al., 2004, 2006; Seston and Hassell, 2009). I felt that the 
declining numbers and lack of evidence were disappointing and contrary to my personal 
experience and expectation for the future of the PP role. I was also curious about how the 
latest iteration of the NHS and changes in primary care structures had affected the PPs and 
their role. These changes provided an opportunity because CCGs were new organisations 
there was no published evidence, at the time, describing the current range of activities 
carried out by CCG PPs and the relationship between PPs and GPs within CCGs.  
 
I felt compelled to research the PP role because it changed my life. It helped rescue me from 
processing endless repeat prescriptions and made me believe that there was an alternative 
long-term future for the profession in primary care. I have witnessed the benefits of a 
pharmacist in a GP practice where PPs have used their pharmaceutical knowledge and 
judgment to problem-solve and facilitate solutions for patients around medicines taking. I 
believe there is a need for pharmaceutical input in primary care that is independent of the 
need to compensate for shortages of other HCP groups, which is reported to be a driver to 
integrate pharmacists into general practice (NHS Alliance and Royal Pharmaceutical Society, 
2014). I believe that the assumption that suitably qualified pharmacists can offset the lack of 
GPs and practice nurses in primary care is overly simplistic. While undoubtedly there is a 
role for prescribing and non-prescribing pharmacists in CDM, this must be appropriate for the 
skill mix within the individual practice. Pharmacists should be part of the primary care 
multidisciplinary team where they can flourish and deliver a truly clinical pharmaceutical role. 
I feel privileged to be practising at a time when pharmacist prescribing has emerged, and 
there has been the opportunity to work in an alternative patient-facing role to hospital and 
community pharmacy. These factors have positively transformed my outlook on my career 
and the pharmacy profession. It has given me job satisfaction, motivation and continually 
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challenged me to increase my skills and knowledge. 
 
2.3 The Initial Study  
From my understanding of the PP role, my initial survey of the literature, and discussion with 
my supervisory team, the focus of the Initial Study was around the activities of PPs and the 
GP and PP perceptions of the role. The premise was that there was a lack of understanding 
of the current role of Practice Pharmacists within CCGs and the opinions and expectations of 
the PP role by both PPs and GPs.  
 
2.3.1 Initial Study research questions 
A literature search was conducted using terms related to pharmacists, general practitioners, 
primary care, inter-professional relationships and known pharmacists’ roles (these were 
added to as other relevant terms were identified). Only UK sources were included in the 
initial search as the differing healthcare systems in other countries were initially thought to 
restrict or power the pace or direction of change of the pharmacist’s role thus making these 
less relevant to the UK model. The research aim and two objectives for the IS are listed in 
Table 2.1.  
Table 2.1 Initial Study research aim and objectives 
Research question- What is the current scope of Practice Pharmacist activities?  
Aim 
 
 To begin to develop an understanding of the current scope of Practice Pharmacist 
activities in general practice  
Objectives 
 
1 To develop an understanding of the range of Practice Pharmacist activities  
2 To develop an understanding of Practice Pharmacist and general practitioner 
perceptions of Practice Pharmacist activities 
 
Relevant references and citations of the articles found were included in the review. The 
search identified some PP activities like those suggested by the NPC in 1998 (National 
Prescribing Centre and NHS Executive, 1998). These activities  
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included CDM, MR, EO prescribing support and pharmacist prescribing. Prescribing by 
pharmacists came about after changes to legislation in 2003 and 2006 respectively 
(Guillaume et al., 2008; Stewart et al., 2009a; Gerard et al., 2012). Pharmacist prescribing 
was included in the literature review as it is likely to have a bearing on PP activities where 
the pharmacist is also a prescriber. 
 
2.3.2 Initial Study methods 
Ethical approval was sought from the study CCG’s-Research Governance Group and was 
granted on 12/4/2013. A qualitative approach was taken as the study was exploratory 
because little was known about the role of the PP and participant perceptions within CCGs. 
Focus groups were considered more convenient regarding time and ease of data collection 
for the PP respondents, but it was felt that it would be difficult to get GPs to attend a focus 
group because of the time required and the difficulty in arranging dates convenient to all 
involved. Semi-structured interviews were chosen as an alternative as they could be 
conducted within the GP practice at a time convenient to the individual GP.  
Purposive sampling was used to ensure that the participants would have sufficient 
experience working with or as a PP. A minimum of four years’ experience was feasible, in 
this established team, and allowed for relationships to develop. Contact with potential 
participants was initially made by e-mail or telephone to outline the purpose of the study and 
to obtain outline consent to take part in the IS. Follow-up contact by e-mail or telephone was 
employed to reaffirm agreement to take part and to check availability and confirm dates and 
times for the focus groups and interviews. I conducted the focus groups and interviews and 
selected the participants.  
 
Focus groups participants were PPs, with at least four years’ experience in the CCG 
Medicines Management Team. The PPs were chosen to form homogeneous groups as these 
groups are thought to be more productive when little is known about the topic (Smith, 1998a). 
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No account was taken of their age, gender, position in the team, job title or prescribing status 
during the selection process. At the beginning of the focus groups, the attending PPs were 
asked to state their age band, gender and the number of years they had worked as a PP. 
Data on educational achievement and how many hours each week the PPs worked for the 
study CCG were also collected. The focus groups took place on CCG property in the 
evening.  
 
A total of three GPs were selected for interview based on having had at least four years’ 
experience of working with a PP and being available for an interview. No account was taken 
of age, gender, seniority in the practice, or practice demographics. Each GP was asked, at 
the beginning of the interviews, to state their age band, gender, list size, the number of years 
they had been qualified and how long they had worked with a PP. They were also asked 
about their current position in the practice.  
 
The data gathering took place over four weeks (April-May 2013), which was dependent upon 
arranging the focus groups and interviews. All the focus groups and interviews were audio-
recorded, transcribed verbatim and checked by RS. All participants were informed about the 
study and what was expected of them in advance. Written consent to the study itself and for 
the use of anonymous quotes was obtained from the participants before the focus groups 
and interviews commenced. The recordings were transcribed and checked by me. The 
analysis was undertaken using Dedoose® software and the principles of grounded theory 
(Silverman, 2011).  
 
2.3.3 Initial Study results  
A total of ten participants took part in two focus groups and three semi-structured interviews 
(See Table 2.2).  
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Table 2.2 Method of data collection, participants and work profile 
 
 
Pharmacists reported several reasons for becoming a PP with many like those previously 
identified in the literature. Once in the role pharmacists felt that they had more freedom to 
contribute to patient care, were more professional and were involved in the practice. The role 
was intellectually challenging, diverse and required continuous updating of clinical knowledge 
and skills.  
 
Pharmacist prescribing was identified as a significant way of freeing up GP time since it was 
viewed as facilitating CDM. This was appreciated by GPs who saw that this allowed them to 
focus on more complex patients. Efficiencies related to cost-effective prescribing were a high 
priority for GPs who were concerned about minimising waste. 
PP Gender/ 
Participant 
No 
Age 
band 
Pharmacist 
prescriber 
Years 
in 
CCG 
Hours a 
week as 
PP 
Previous 
branch of 
the 
profession 
PG 
education 
Focus 
Group 1 
 
M/P1 25-34 Yes 5 16 Community 
Pharmacy 
MSc 
 
F/P2 35-44 Yes 4 4 Community 
Pharmacy 
Education 
Clinical 
Diploma 
F/P3 25-34 Yes 5 8 Community 
Pharmacy/
Private 
hospital 
Modules 
and 
Certificate 
in 
Diabetes 
M/P4 45-54 Yes 7 16 Community 
Pharmacy 
Industry 
MBA 
Focus 
Group 2 
 
M/P5 35-44 Yes 6 
 
40 Community 
Pharmacy 
None 
M/P6 55-64 Yes 5 40 Community 
Pharmacy 
PG 
Certificate  
M/P7 45-54 Yes 11 
 
40 Community 
Pharmacy 
Clinical 
Diploma 
GPs Gender/ 
Participant 
No 
Age 
band 
Years 
qualified 
Years 
in 
CCG 
Current 
Positio
n 
List size 
Approx. 
Years 
working 
with a PP 
Semi-
structured 
Interviews 
M/GP1 35-44 12 12 GP 
Partner  
9600 12 
M/GP2 35-44 9 9 
 
GP 
Partner  
10700 9 
 
F/GP3 Over 
65 
38 
 
38 Principle  2800 
 
17 
 55 
 
The PP and GP respondents achieved a good correlation when identifying the current roles 
undertaken by the PP, in their practices, which were broadly like those roles identified in the 
literature. The IS identified several themes for PP activities, practice educational activities, 
patient safety, freeing up GP time, efficiencies and liaison with community pharmacy. 
Educational activities in the practice included direct prescribing advice in answer to individual 
queries and educational outreach to provide an overview of a prescribing topic or specific 
disease. This kind of advice, and the PP as a resource, was valued by GPs. Activities related 
to patient safety were delivered through direct patient contact, medicines reconciliation and 
via audits and the implementation of safety alerts and drug withdrawals. 
Other roles that the IS PPs were carrying out were, efficiencies such as dose optimisation, 
switching to more cost-effective drugs and operating the repeat dispensing arrangements.  
 
The IS PPs were also involved in roles not previously reported in the literature related to 
repeat prescription management. These included the management of repeat prescribing, 
reviews of patients taking sip feeds (using Malnutrition Universal Screening Tool (MUST) 
score (Bapen, 2016)), synchronising medicines (aligning prescription items to the same 
renewal date) and monitoring non-patient prescription requests from third parties such as 
contractors and care homes. The management of repeat prescriptions by PPs has 
subsequently been shown to be cost-effective and to improve patient safety (Walsall Clinical 
Commissioning Group, 2014). Liaison with community pharmacy was seen as a role suited 
to PPs where a good relationship with community pharmacy was believed to facilitate 
cooperation. All the GPs, interviewed in the IS, acknowledged their PP’s contribution to 
reducing the GP workload. They also said that pharmacists were doing most of the work for 
the incentive scheme and were prescribing in the management of chronic disease and for 
third-party requests. 
 
When pharmacists were first introduced into GP surgeries, I would argue that there was little 
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understanding of the benefits that practice-based pharmacists could bring. This was probably 
due to a lack of familiarity with the pharmacist’s skill set, and its application to general 
practice and also a suspicion of their role. Over time this had changed, and in the IS, GPs felt 
that PPs were a resource, for not only extra work but also for their specific skills and 
contribution to the practice per se. The GPs saw PPs as part of their team and respected 
their role. This was supported by their understanding that PPs were being funded by the 
CCG, and therefore the PP’s agenda was comparable to the agenda of the GP and the 
practice, e.g. ensuring the quality of care, cost-effectiveness and patient safety. Both 
professional groups felt that PP role had changed over time from quite simple beginnings, 
such as generic substitution, to now being a complex role and a trust had been built up 
based on past evidence of benefit to the practices. Pharmacists now felt integrated into their 
practices, part of the team, and enjoyed their interactions with the GPs and the practice staff. 
This integration was linked to an improved ability to effect change resulting in a feeling of 
having made a difference and of achievement. Once change had been achieved the 
outcomes were considered more visible to the PPs and could be followed through if 
necessary.  
 
GPs felt that, aside from formal qualifications skills and knowledge, there were behavioural 
attributes that positively contributed to the value of pharmacists. For example, the ability to 
positively interact at a simple level with the practice staff was a key skill that pharmacists 
displayed, simply “joining in” social events was considered important as was good 
communication skills. The GPs thought that a community pharmacy background was also a 
positive attribute as the business skills were useful in understanding the motivation behind 
some prescription requests. 
 
Ability to fit in with different GP attitudes and practice agendas was identified in the focus 
groups as a key skill, alongside communication skills. The pharmacists agreed that no matter 
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how highly qualified a PP was, they would not be able to function effectively unless they 
could engage with the practice staff and patients. Once again community pharmacy was 
identified as a good training ground for attaining some of these necessary skills. They also 
felt that there were some benefits of being in a large team regarding peer support. 
 
Seeing patients was viewed positively by PPs, but they were cognisant of the fact that they 
had the luxury of twenty-minute appointments, compared to much shorter appointment times 
for other HCPs. The PPs also felt that patients appreciated this, being grateful for the extra 
time to discuss their medicines issues and to receive information. Positive comments from 
patients provided PPs with job satisfaction. Pharmacists also considered that they brought a 
different professional perspective to the practice that was medicines focused and they were 
more likely than other HCPs, to pick up on compliance issues or side effects of medication. 
The PPs also felt that there was a difference in patient perceptions of GPs and pharmacists; 
patients were perceived to be less threatened by the status of a PP compared to the status 
of a GP, and as a result, perhaps asked different questions.  
 
While indicating that there were similarities in the skill set required for both GPs and 
pharmacists, GPs thought that there were also significant differences. Practice pharmacists 
were thought to have better knowledge of interactions, side effects and contraindications and 
were likely to be better than GPs at conducting medication reviews.  
 
The GP respondents identified some negative perceptions about the PP role. The GPs 
wanted more PP support, particularly in larger practices, and for consistency, with the same 
PP to provide that extra support. The service consistency was also an issue with PP holiday 
and sickness when a replacement was not provided, thereby making planning difficult and 
potentially compromising the value of the PP service to the GP. This was linked to the 
current employment mode compared with direct employment. Pharmacists were aware that 
their relationship with the practice was based on a positive track record of decision-making 
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and behaviours built up over time so maintaining the same PP was considered preferable. 
The GP respondents differentiated between the role of the PP and the role of the community 
pharmacist and acknowledged a more clinical focus for the PP role. GPs were aware that 
community pharmacists had business targets to meet and that this might override their 
clinical judgment and patient focus of the community pharmacist. Doctors did express 
confidence in some community pharmacists, but this was earned from experience of working 
with them over time rather than an automatic response. Community pharmacists were not 
considered by GPs to be part of the practice team. 
 
Some negative aspects of the PP role were identified by the PPs. Professional isolation, 
especially for those that worked for only one or two sessions a week, was associated with 
the ad hoc/piecemeal provision of the service. The pharmacists also saw the lack of a 
prescribing qualification as a limiting factor regarding the effectiveness and the range of 
activities in the role. An increase in workload was thought to be restricting the time available 
for qualified PPs to prescribe and was perceived as a threat to the enhanced appointment 
times that pharmacists were allowed when seeing patients. A heavy audit workload made the 
pharmacists feel that the skill mix of the team needed reconsidering, and they suggested that 
pharmacy technicians could carry out this work more efficiently. 
 
There was some pressure from practices for PPs to carry out non-core activities, outside the 
pharmacist’s work plan for that practice, that was also linked to the piecemeal provision of 
the service. Pharmacists also felt that they were sometimes sent the “difficult patients,” 
where other practice staff had been unable to resolve issues such as a request for branded 
prescribing.  On some occasions, the pharmacist’s decision had been given as the reason 
that a GP could not supply items that patients had requested, simply to avoid confrontation. 
 
There was some speculation on the future of the PP role by both professional groups. The 
CCG appeared to be driving the work plan, and the PP team was perceived as integral to 
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delivering this. The need to adhere to the work plan was thought to be partly driving GPs to 
request more pharmacist support. Larger practices appeared to be considering direct 
employment to address the piecemeal provision of the current service and to customise the 
role to suit their requirements.  
Pharmacist’s felt that they were taking on more clinical work and expressed aspirations to 
manage more chronic diseases while acknowledging the need for appropriate training to be 
able to do so. It was suggested by both professional groups that a future model, where GPs 
would diagnose, and pharmacists would take on the responsibility of treatment, was 
ultimately feasible.  
 
2.3.4 Discussion of Initial Study results 
This Initial Study began to determine the key aspects of the PP role, within CCGs, regarding 
its constituent activities and the understanding of that role by GPs and pharmacists. The IS 
had limitations; purposive sampling yielded pharmacists and GPs with experience in working 
as, or with, a PP, but as inclusion in the study was dependent on both volunteering and 
availability, it is likely that the most interested and motivated individuals took part and 
therefore their observations and opinions may not be representative. The small sample sizes 
may also mean that the full range of activities and perceptions may not have been identified. 
The CCG PP Team was not necessarily representative of other teams. The IS was 
conducted during a period of assimilation of new responsibilities and consolidation for CCGs, 
therefore, conducting the study within this period may have affected the results. 
 
I conducted all the focus group and interviews for the IS which could have posed several 
issues regarding my position in the team. I was a senior professional within my organisation 
and part of the culture, ethos and workplace mission (Drake, 2010), I tried to ensure 
objectivity when considering the outcomes of this evaluation, but I was an early adopter of 
the PP role and had worked in GP practices for 16 years. My “insider” status conferred 
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responsibilities of loyalty, confidentiality and trust (Lytle and Zeni, 2001) to my colleagues. 
Regardless of the outcome of the evaluation, I had to continue to work with the pharmacists 
and GPs who participated in the IS. My colleagues may have felt obliged to take part in the 
evaluation and thought that it might provide unspoken benefits or have even felt threatened 
because of my position in the team and this may have discouraged frank and open 
discussions in my presence (Drake, 2010) or affected what was said. 
  
The IS pharmacist respondents reported similar reasons for becoming PPs that have 
previously been reported in the literature, related to the perceived shortcomings of 
community pharmacy and the more clinical nature of the PP role. Despite this, community 
pharmacy was considered by GPs to be a good background for PPs in helping them to 
understand the motivations for some prescription requests and to also facilitate liaison with 
community pharmacy on medicines issues. A prescribing qualification was felt to make the 
PP role more effective with pharmacist prescribing freeing up GP time for more complex 
patients which were valued by GPs. 
 
The correlation between the views of GPs and PPs of the PP role suggests that there is now 
a good understanding between the two professional groups of the activities undertaken. The 
GP respondents were easily able to differentiate between community and practice pharmacy. 
The PP role had grown over time. The IS identified several themes for PP activities, practice 
education, patient safety, freeing up GP time, efficiencies, liaison with community pharmacy 
and checking the suitability of repeat medication. This kind of advice and the PPs specific 
skills were seen as a resource and valued by GPs. The IS has identified both established 
activities and some new ones, indicating that the role continues to evolve in response to 
changes in local and national priorities. 
 
Pharmacists brought a different perspective to the consultation, more medicines focused. 
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Patients were felt to be more open about medicines with pharmacists, but this was also 
linked to PPs longer appointments. GPs wanted more support from their PP and there was 
evidence of some degree of dependence on PPs by the practice.  
 
The relationship between GPs and PPs has evolved from uncertainty, through 
acknowledgement of the role and skills required, to mutual respect and increasing 
dependence on the PPs to manage the primary care workload. The perception of this 
relationship was tempered by issues about employment based on a lack of continuity that 
was identified by both respondent groups. Both professions identified formal qualifications 
and good communication skills as important attributes. The ability of the pharmacist to 
socially interact with practice staff is also important. A prescribing qualification was felt to 
make the PP role more effective. The PPs thought that they were part of the practice team 
and had a different relationship with patients to that of the GP. 
 
The direct employment of pharmacists could be a solution to the dilemma around prioritising 
PP work. It is not clear from the IS if pharmacists would like to be employed directly by GPs 
or if this would detach them from central or peer support. The PPs identified increased job 
satisfaction, but also an increasing workload because of practice requests. Practice 
pharmacists may reduce GP workload, but there were concerns about the amount of this 
work that transferred to the pharmacist. The excessive workload may have a detrimental 
effect on the role perception and may reduce pharmacists’ appointment times that were 
perceived as advantageous to patient care. Not all the PPs work full time and will often have 
a portfolio career including community pharmacy and other roles. A preference for a portfolio 
career may limit the time that some pharmacists contribute to the PP role. Also, the trust built 
between GPs and PPs may be potentially undermined by a conflict of interest with other 
portfolio roles.  
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2.4 Development of research aims and questions. 
 
In developing the research questions for the main thesis project, I felt it would be useful to 
repeat some exploration begun in the IS to see if respondents’ opinions had been modified 
over time as CCGs became more established, and to look further into the effects of NHS 
changes on the PP teams.  
 
The IS had also collected some personal information on the respondents, particularly the 
educational status of the PP, most of whom had undertaken postgraduate education. It was 
important to consider if the PPs in the project reported in this thesis were comparable with 
other PPs nationally so that other project data collected could be framed in relation to a 
representative or non-representative PP sample.  
 
I believe that the relationship between the CCG commissioned PPs, and other stakeholders 
could potentially be a factor in the way that PPs work in practice now and in the future. The 
commissioning organisation and PP relationship, and the patient and PP relationship, were 
not investigated in the IS but were important because the CCG commissions the service and 
patients are the end-users. Patients are ultimately the judge of a service and have the right to 
comment on the quality and availability of a service and to complain if dissatisfied 
(Department of Health, 2015).  I felt that these relationships require some further research to 
understand their relevance to the PP role and establish whether or not they are driving 
change. The literature does indicate that, in general, patients are happy to consult with 
pharmacists in the general practice setting and that they also currently accept prescribing by 
a pharmacist, but I felt that this needed to be investigated further as acceptable or not under 
the new commissioning arrangements. 
 
The CCG influenced the role of the PPs that the IS indicated was sometimes at odds with the 
practice agenda. There was also an associated issue with the hours that PPs were 
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commissioned to work in practices. If there is a significant difference in the expectations of 
the PP role between the commissioner and constituent practices, then the PP/GP 
relationship may break down, and PP functions may be limited or cease altogether. I felt that 
further investigation into the aspirations of the stakeholders for the PP role in the future was 
required to help to understand where they feel it should be heading and how this might be 
achieved. This is particularly important in the case of GPs who can hire additional practice 
staff to cover GP shortages and to meet the needs of the practice.  
 
The IS suggested that the PP role in primary care continues to develop in response to 
changes in the NHS and practice workload. The aspirations of CCG employed PPs, 
therefore, needs to be considered and their fit with the current and possible future models. 
Currently, most PPs work part-time and may undertake traditional roles as well; the reasons 
for this should be explored to see if there are any significant benefits in a portfolio role to the 
pharmacists or other stakeholders. If the demand for PPs increases, then individual PPs may 
be under pressure to work more, or even all their working hours in primary care. Full-time 
working may not suit all PPs, as the IS showed that some liked the flexibility that the role 
offered. The aspirations of PP themselves are important if they are to continue to integrate 
into primary care. From the literature and the IS, we know that for some pharmacists, if the 
role becomes repetitive or ceases to be challenging and does not meet their desire to help 
patients, then they may look to change to a role that does. 
 
The NHS changes prompted me to conduct the IS, and in turn from this, my choice of topic 
for the main project reported in this thesis emerged. The IS only sampled respondents from 
one CCG, but from my initial observations, it was clear that there were examples of other 
models of commissioning in the region that presented an opportunity to investigate how 
these functioned. Overall it was initially intended that the postulation of a future model for PP 
Teams might be the main thrust of my research. However, the focus of my research changed 
because of the potential significance of relationship issues identified in the IS and the 
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national investment in pharmacists in general practice. This thesis now considers the 
development of a model for the integration of pharmacists into GP practice around which 
there appeared to have been no previous work conducted in the UK, apart from my IS.  
 
2.5 Thesis study research aims and questions 
The aim of this research was to understand the background of CCG commissioned PPs, and 
their relationships with stakeholders, to identify the elements necessary to support the 
successful integration of pharmacists into general practice teams 
The research questions were: 
1. What is the background, educational and employment status of primary care 
pharmacists working in CCGs? 
2. What is the impact of the recent NHS changes on primary care practice pharmacist 
teams? 
3. What are the key stakeholders’ perceptions of the current practice pharmacist role 
and its future, including prescribing? 
4. What are the personal and career aspirations of primary care practice pharmacists 
and the perceived opportunities and barriers to achieving these? 
5. What recommendations can be made to support the successful integration of 
pharmacists into GP practice teams?  
 
2.6 Relevance of the topic and the necessity for scientific investigation  
The PP role has developed gradually since the mid-nineties, but without definitive evidence 
of patient outcomes and in the face of NHS structural change. Nevertheless, the fact that it 
has developed in these circumstances and endured suggests that both commissioning 
organisations and GPs continue to see empirical value in the role. Public money, in the 
shape of NHS funding, is being used to provide PPs on an “invest to save” model (that the 
pharmacists will save more money than they cost) at a time when NHS funding is under 
extreme pressure. There is some recent evidence to support the “invest to save” model for 
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both direct financial savings (Walsall Clinical Commissioning Group, 2014), and indirect 
savings by reducing patient risk from adverse drug reactions (Avery et al., 2012). The way 
that CCG commissioned PPs function in primary care needs to be researched as it provides 
working models that can be investigated to understand the basis of the relationship of PPs 
and the stakeholders, what the benefits of a PP service are to those involved, and if these 
are modified by different commissioning models.  
 
This research is even more pertinent now because of the recent and substantial national 
investment for expansion in the numbers of pharmacists working with GPs, to address 
workforce problems in primary care. This expansion is being partly funded by NHS England 
as a pilot from public money but does not appear to be modelled on any existing PP service. 
Understanding of the current relationship between PPs and stakeholders and assessment of 
the acceptability and benefit to patients is essential to support the expansion of the role to 
manage the expectations of all stakeholders and to integrate pharmacists into primary care 
successfully.  
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Chapter 3 Methods and Methodology  
3.1 Overview 
This Chapter begins with a reminder of the project aims and research questions 
followed by a detailed description of the methods chosen to carry out the thesis project 
including how the data was analysed. This is followed by an outline of my perspective, 
the methodological approach and a discussion of the methods chosen and why others 
were rejected. The chapter concludes with a statement of the ethical approval obtained 
before the project commenced.  
 
3.2 Method 
3.2.1 Project aim, research questions and overview of method 
The aim of this research was to understand the background of CCG commissioned PPs, and 
their relationships with stakeholders, to identify the elements necessary to support the 
successful integration of pharmacists into general practice teams. 
 
The research questions were: 
1. What is the background, educational and employment status of primary care 
pharmacists working in CCGs? 
2. What is the impact of the recent NHS changes on primary care practice 
pharmacist teams? 
3. What are the key stakeholders’ perceptions of the current practice pharmacist role 
and its future, including prescribing? 
4. What are the personal and career aspirations of primary care practice 
pharmacists and the perceived opportunities and barriers to achieving these? 
5. What recommendations can be made to support the successful integration of 
pharmacists into GP practice teams?  
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An interpretive/collective case study incorporating mixed methods for collecting data was 
carried out. Quantitative data was collected on the educational and professional background, 
current employment and prescribing activities of PPs. Qualitative data was gathered from the 
commissioners of the service, general practitioners, and patients to ascertain stakeholder 
views of the CCG PP role.  
 
3.2.2 Recruitment challenges to be addressed 
At the time of the thesis project, CCGs had only been in existence for about a year. Although 
there was a centrally published list of CCGs, there was no published list of those that 
commissioned PP teams or how the teams were commissioned. There were similar issues 
with the identification of potential participants. There was, and still is, no central or national 
register of PPs in the UK, and the numbers of patients that have had a consultation with a 
pharmacist are relatively small compared with all consultations, making identification of 
suitable PPs and patients potentially difficult. A pre-study survey (Appendix 3.1) was devised 
to identify CCGs that had PP teams, their team structure and to assess their levels of PP 
activity. Contact was made via their commissioning manager, the Head of Medicines 
Management (HoMM), and outline permission was sought for the CCG to take part in the 
thesis project. 
A project protocol was devised (Figure 3.1). It illustrates how the participants were identified 
and the way the data was collected from the chosen CCGs, which had been identified in the 
pre-study survey. The CCG HoMM provided the contact details of the PPs working for them. 
This was needed to recruit PPs to the descriptive survey and focus groups. The HoMM also 
identified which GP practices within each CCG could be used to recruit the GPs for the 
interviews. The PPs were subsequently utilised to recruit patients to the project; this took 
place after a normal patient consultation with the PPs. By this means only professional 
participants with suitable experience of working, as or with PPs, were chosen and only 
patients who had had a consultation with a PP were selected for an interview. 
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Figure 3.1 Thesis Project Protocol 
 
  
To identify Clinical Commissioning Groups in the West Midlands that have Practice 
Pharmacist Teams and to determine their structure and levels of Practice Pharmacist activity.
To ascertain interest in taking part in the thesis study from the Heads of Medicine 
Management
Work up study protocol and apply for ethical approval 
CCG A
(Directly 
Commissioned)
HoMM A
Obtain contact details for GPs and PPs in each CCG from HoMM
GP Interviews 
CCG A
Focus Group
CCG A
Patients recruited by the PPs
Patient telephone 
interviews
CCG A
Data analysis
Send out invitations to PPs to take part in descriptive survey and focus groups
Choose Clinical Commissioning Groups with different commissioning models for PP teams
CCG B
(Acute Trust 
Commissioned)
CCG C
(Mixed 
Commissioning)
CCG D
(CSU 
Commissioned)
HoMM B HoMM C HoMM C
GP Interviews 
CCG B
GP Interviews 
CCG C
GP Interviews 
CCG D
Focus Group
CCG B
Focus Group
CCG C
Focus Group
CCG D
Patient telephone 
interviews
CCG C
Patient telephone 
interviews
CCG B
Patient telephone 
interviews
CCG D
Interview all the Heads of Medicines Management
Invite practice pharmacists to focus groups and GPs for interview
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3.2.3 Clinical Commissioning Group identification 
Being familiar with the West Midlands area for over 30 years, I was aware that there were 
significant numbers of PP teams within the region, but it was unclear how many of these 
teams had transitioned into CCGs and in what form. The pre-study survey was sent to CCGs 
in the West Midlands Area identified from a list published by NHS England on their website 
(NHS Choices, 2013). The pre-project survey was designed to identify CCGs with a 
significant number of PPs and pharmacist prescribers, to establish the PPs current roles 
including consultations with patients and prescribing, and to see if the organisations might be 
interested in taking part in the project. 
There were twenty-two CCGs in the West Midlands area at the time of the study. Eleven of 
the geographically closest CCGs, to the author’s place of work, were contacted (between 
July and August 2013) initially by e-mailing the pre-project survey to their respective HoMM. 
Selecting geographically close CCG helped minimise travel time, particularly for the GP 
interviews that were conducted during working hours. The email addresses were obtained 
from the CCG websites or by direct contact. After two reminders, seven CCGs expressed an 
interest in taking part, with patient populations ranging from 250,000 to 500,000 and between 
three and ten whole time equivalent (WTE) PPs and 0-10 WTE pharmacy technicians. Within 
these CCGs the number of prescribing PPs varied between 0-15 individuals with one CCG 
describing their prescribers as ‘not active’. Most CCGs described their PPs as being 
employed by the CCGs, with two stating that they were employed by other NHS 
organisations. Another CCG was transitioning from CCG employed PPs to commissioning 
from a provider organisation. The range of PP activities across the seven CCGs were similar, 
with one CCG having a more limited range of activities. The pre-study survey provided 
sufficient data to select four CCGs with different models of commissioning, with similar 
patient populations, PP team sizes and numbers of actively prescribing pharmacists. 
Two CCGs were rejected because they had small PP teams (< 4 pharmacists), and either 
no, or inactive, prescribing pharmacists. A third CCG had more pharmacy technicians in their 
team than PPs, and although an interesting model, was outside the scope of my research. 
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The remaining four CCGs had varying models of commissioning of PP teams that presented 
an opportunity to treat each CCG as an individual case highlighting similarities and 
differences. The participating CCGs were anonymised by randomly assigning one of the first 
four letters of the alphabet (ABC or D).  
 
3.2.4 Participant recruitment  
The commissioners (HoMM) sample size was fixed by the number of CCGs, (i.e. four), and 
all HoMMs met the inclusion criteria. Demographic data on their professional experience was 
collected for comparison along with their CCG data using a pre-interview questionnaire 
(Appendix 3.2) for comparison of replies within and between the HoMM and the CCGs.  
To select participants with sufficient experience to answer the research questions, a 
purposive sampling method was used to recruit GPs, focus group PPs and patients. Only 
those GPs and PPs that had at least one year’s experience of working with or as a PP 
respectively and patients that had at least one consultation with a PP were recruited. 
Proposed sample sizes are shown in Table 3.1. and were chosen to provide theoretical data 
saturation based on experience from the IS and by the population of each group. 
 
Table 3.1 Proposed participant sample sizes  
Heads of Medicines Management 4 
Practice Pharmacists Survey 60 
Focus Group Participants 24 
General Practitioners 12 
Patients 30 
 
Additional inclusion and exclusion criteria for all participants were: 
Inclusion Criteria-All participants will be 18 years of age or over and must be able to give 
informed consent.  
All professional participants must have at least one years’ experience of working with, or as, 
a PP. 
Exclusion Criteria-Participants over the age of 18 years that cannot give informed consent, 
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including vulnerable adults. Participants who have a poor command of English (translators 
were not available) and telephone interviewees who cannot communicate over the phone. 
The thesis project data was collected between July and December 2014, and I conducted all 
the interviews and focus groups.  
 
Informed consent was obtained from the HoMMs, GPs, and PPs by asking individuals to sign 
a generic consent letter immediately before the interview or focus group commenced. This 
letter also covered consent for the audio recording and use of quotes (Appendix 3.3). 
Consent for the descriptive survey and the patient interviews is covered in sections 3.2.6 and 
3.2.9 respectively. All participants met the inclusion criteria for the project. 
 
3.2.5 Heads of Medicines Management and Clinical Commissioning Groups  
After ethical approval had been obtained, the HoMMs were interviewed first, since each was 
key to the identification of other participants. A semi-structured interview guide was devised 
to collect data from the HoMM on aspects relevant to research questions numbers two to five 
(Appendix 3.4). An information sheet was e-mailed to each HoMM before the interview 
(Appendix 3.5). All HoMMs consented to be interviewed, and each was interviewed 
independently. The inclusion and exclusion criteria for the project were explained to the 
HoMM. Each of the four HOMMs was asked to provide contact details of the PPs that they 
commissioned and to identify some GPs from varying practice list sizes in their CCG that 
they considered would be suitable for the thesis project.  
 
3.2.6 Practice Pharmacist descriptive data  
The HoMMs reported that they commissioned a total of seventy individual PPs. The HoMM 
total was approximate as some PPs worked for more than one project CCG, so the number 
of potential individual PP respondents was less than seventy and probably nearer my initial 
estimate of sixty. The descriptive cross-sectional survey form was designed to collect data 
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relevant to research question one, around the background, educational and employment 
status of PPs. In the two CCGs that directly commissioned the service, pharmacists were 
identified by the HoMM and then sent a link via e-mail by the HoMM, to an online Google© 
Forms© descriptive survey tool (Appendix 3.6) with the second link to the descriptive survey 
information sheet (Appendix 3.7). In the case of the two indirectly managed PP team 
members, the Provider Team Leader (PTL) was identified by the HoMM, and the PTL then e-
mailed both links to their respective teams. The information sheet gave details about the 
project and stated that by completing the descriptive online survey, the PPs had given 
consent for their anonymised data to be used in this project and future research. The online 
tool was piloted for suitability and functionality by reviewing the first six respondents’ data. No 
changes were made to the collection tool. To encourage non-responders, the PPs were 
reminded to take part in the descriptive survey three months after the initial contact, via the 
HoMM or PTL. All the PPs who completed the descriptive survey had at least one year’s 
experience of working with a GP. 
 
Google© Forms© allowed respondents to alter their submitted responses, up until the tool was 
removed from the internet, and automatically presented the data in a spreadsheet format. 
The survey data was checked before it was anonymized by comparing email addresses and 
individual entries for duplicated data to ensure that each PP only contributed once to the 
online survey. One PP declared that they had completed the prescribing course but were not 
yet a prescriber and were awaiting registration. This pharmacist was treated as a non-
prescriber as they were not able to prescribe at the time of the project data collection. The 
survey was closed at the end of the data collection period. Once checked and anonymised, 
the data was analysed in SPSS©, and Microsoft Excel© to provide descriptive statistics to 
define and summarise the sample of PPs.  
 
3.2.7 Focus groups 
The focus group topic guide (Appendix 3.8) was designed to answer aspects of research 
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questions two to five; the questions were developed from the focus group questions in the IS. 
The HoMM or PTL had identified the pharmacists that wanted to take part. They were asked 
to contact me, and I arranged a mutually acceptable time and venue for the focus groups. All 
prospective PP participants were sent a copy of the focus group project information sheet 
before they attended their respective focus group (Appendix 3.9). Focus groups were 
arranged so that the PPs commissioned for each CCG were interviewed in separate focus 
groups. Not all pharmacists who had initially agreed to take part attended the individual focus 
groups, so the number of participants varied. A pragmatic approach was adopted as the time 
taken to contact and get responses from the HoMM or PTL varied greatly, and there was a 
need to obtain data within a limited data collection period. As previously discussed, two of 
the PPs in one focus group also undertook PP work in another project CCG, but only 
attended one of the focus groups. The PPs that attended each focus group were asked if 
they would be prepared to recruit patients for the thesis project, and those that agreed were 
shown the relevant paperwork and had the process explained to them.  
 
3.2.8 GP interviews 
The GP interview guide (See Appendix 3.10) was designed to collect data relevant to 
research questions two to five, and was developed from the GP interview questions in the IS. 
Using the contact details provided by the HoMM, eight GPs agreed to take part in the project. 
A GP Information Sheet (Appendix 3.11) was provided via e-mail if they expressed an 
interest and a time and date for the interview was agreed. All GPs consented to be 
interviewed and each was interviewed individually. One GP refused consent to the audio 
recording of the interview but agreed for written notes to be taken. Demographic and other 
data was collected related to the GP and their practice (Appendix 3.12). All the respondent 
GPs were asked if they would consent to have their PP recruit patients to the project. Those 
that agreed were shown the relevant paperwork and had the process explained to them. Any 
PPs that worked for the project GPs and had not attended a Focus Group had the relevant 
paperwork and had the process explained to them by me. 
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3.2.9 Patient telephone interviews 
An interview guide for the semi-structured telephone interviews (Appendix 3.13) was 
designed to collect data relevant to aspects of research questions two to five. Patients who 
met the inclusion criteria were invited to take part in the project by their PP at the end of a 
normal consultation. The PPs had either already taken part in a focus group or worked for a 
GP that had already been interviewed, therefore, facilitating permission from the practice to 
recruit patients. If the patient expressed an interest, the PP gave them an information sheet 
(Appendix 3.14), that included a provisional consent statement and requested contact details 
should the patient then wish to take part in a telephone interview. The contact details of 
patients who gave provisional consent were passed on to me by the PPs, and I contacted the 
patient by phone to arrange a date and time for the telephone interview. Before the interview 
commenced, prospective patient respondents were asked to confirm their consent for the 
interview, and this was noted in the interview guide. One patient that gave initial consent was 
not interviewed, as there were difficulties in establishing contact. All other patients met the 
inclusion criteria, and all gave verbal consent to both the interview, audio recording and use 
of quotes. Limited demographic and other data were collected as part of the interview.  
 
The respondents from the focus groups and interviews were anonymised by assigning them 
with the prefix HoMM, GP, PP or P (patient) followed by the letter assigned to the CCG they 
were associated with. A number was then assigned to distinguish between individuals within 
respondent groups in each CCG. 
 
3.2.10 Research questions addressed in the topic and interview guides  
The interview guides and focus group topic guides contained similar questions, framed to 
relate to the different respondents. This commonality allowed some measure of triangulation 
between groups of respondents to overcome some of the weaknesses of individual methods 
(Alaszewski, 2007).  
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Table 3.2 shows the common areas of questioning asked in each of the interviews and focus 
groups. 
 
Table 3.2 Research Questions in the Topic and Interview Guides 
Areas of questioning Research 
Questions 
no 
GP HoMM PP Patient 
The practice pharmacists’ role and its 
value 
1, 3, 4,  Yes Yes 
 
Yes 
 
Yes 
Role changes since GP 
Commissioning 
 
2, 3,  Yes Yes Yes - 
Practice pharmacists’ training 
 
1,3,5 Yes Yes Yes - 
Training updates for practice 
pharmacists 
1,3,4 - Yes Yes - 
The importance of a non-medical 
prescribing qualification to the PP role 
1,2,3,4 Yes Yes 
 
Yes 
 
Yes 
Use of a competency framework 
 
3, 4,5   - Yes Yes - 
The future of the practice pharmacists’ 
role 
2,3,4,5 Yes Yes 
 
Yes 
 
Yes 
 
3.2.11 Transcription 
The Interviews and focus groups were recorded and transcribed verbatim by me or by a 
professional transcription company (Transcribe Me©). All transcripts were checked by me for 
accuracy against the original recordings and then anonymised before being analysed using 
NVIVO© 10 software on a password-protected computer. Recordings were deleted from 
recording devices once the transcriptions had been completed. My supervisory team 
reviewed a sample of transcripts to provide guidance and some assurance of my interview 
and focus group techniques and analysis.  
 
3.3 Methodological approach and my perspective 
There are two main paradigms in research, the positivist or deductive and the interpretivist or 
constructive. Methodology is a term used to describe an outline of the broad principles and 
philosophies governing research, associated to a paradigm (Broom and Willis, 2007) and is a 
way of discovering knowledge in a systematic way (Killam, 2013). Associated methods are 
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only one component of an overall methodology but determine how the research will be 
conducted.  
 
Pharmacists have been traditionally trained to take a scientific approach to their work. In my 
clinical role, this usually meant searching for definitive answers to clinical questions in the 
evidence-base. This often involved looking at experimental drug trials that adopted a realist, 
also known as positivist or deductive, ontological belief about reality. The assumption is that 
is that there is one reality to be discovered and that this reality is context-free and does not 
change (Broom and Willis, 2007; Killam, 2013). Typically, an experimental study would 
involve an attempt at removing all variables apart from the ones under study. An example 
would be comparing drug to drug or drug to no drug in a highly-controlled environment, the 
clinical trial. The aim is to provide high-quality evidence and reproducible results that can be 
reliably applied to a wider population. The relationship between the researcher and the 
research (epistemology) is driven by the realist approach (Guba and Lincoln, 1994; Killam, 
2013). The view is that because reality is fixed and measurable, researchers are therefore 
external to the experiment or observation and should strive for objectivity; researchers adopt 
an etic or outsiders perspective (Killam, 2013). The researcher strives to be an impassionate 
observer and to have no effect on the outcome of the experiment. 
 
Positivist methodology and methods have been criticised (Guba and Lincoln, 1994). For 
example, experimental studies remove bias by controlling variables within the study, typically 
excluding any patient with co-morbidities. This controlling makes it difficult to apply the study 
results and expected outcomes to the general population which often have common co-
morbidities. Experimental studies measure probability within a population, and so individual 
outcomes cannot be predicted from the study alone. Also, positivist methods cannot assess 
a person’s experience and social life (Broom and Willis, 2007). Experimental studies do not 
include any assessment of patients’ feelings about the intervention and so cannot predict 
how patients will react when the intervention is applied more widely in the population, e.g. 
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compliance with medication. 
 
While this has been the case for most my working-life, once I embarked on the IS, I had my 
mind opened to the constructivist view of the world. A relativist, also known as inductive or 
constructive ontological view, is that there are multiple perspectives of reality that evolve 
from culture and experience. Context cannot be separated from reality because it does not 
exist outside the individual (Killam, 2013). The inductive view is that, because reality is based 
on the perceptions of individuals, the researcher and the project participants co-create 
findings, so knowledge will be maximised by increasing the proximity between the researcher 
and the researched; an emic or insiders perspective is adopted (Killam, 2013).  
Interpretive approaches in healthcare also have issues at the paradigm and methods levels 
(Broom and Willis, 2007). There is no consensus on data collection and analysis, and studies 
often use small samples that cannot be realistically used to provide data that can be 
generalised. Sample selection is potentially biased because it is not randomised, and 
researchers can unconsciously (or consciously) influence the respondent. Respondents and 
researchers may confuse real-world events with those constructed from memory within the 
focus group or interview, for example. 
 
The realist and relativist ontological views are the two dominant paradigms used in 
healthcare research. The distinction between paradigms has been debated for many years 
(Guba and Lincoln, 1994; Bowling, 2009; Killam, 2013), but the division between them is not 
fixed or unchanging. Guba and Lincoln (1994) suggest that dialogue between the proponents 
is required for resolution. However, Killiam (2013) described a more modern viewpoint, 
based on the work of Kuhn, where a paradigm is described as “basic sets of viewpoints and 
practices that scientists agree on at a particular point in time” (Kuhn and Hacking, 2012). 
Despite the fact that the two approaches to healthcare research appear to be in opposition, 
the reality is that no one paradigm is superior or better than another, (Broom and Willis, 
2007; Killam, 2013) and each has their strengths and weaknesses. 
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I have adopted a pragmatic approach and have matched the methods I used to the questions 
being answered, as has been suggested in the literature (Broom and Willis, 2007). The 
quantitative and qualitative paradigms are considered complementary, especially in 
healthcare research, that starts with a practical question rather than an ideological stance. 
Qualitative methods can be used in complex situations or as a precursor to, or support for, 
quantitative work (Pope and Mays, 1995). 
A realistic approach is that the research question should dictate the correct methodology to 
use (Broom and Willis, 2007; Killam, 2013). Where there are quantifiable results that can be 
measured, a positivist approach is more suitable. Where the thoughts and perceptions of 
individuals are being investigated, then a relativist approach is likely to be more suitable, 
especially where little is known about a topic.  
 
Despite positivist roots, I now realise that there is another way of looking at the world that 
provides insights into the human condition where a positivist approach is impractical. Neither 
paradigm is perfect and can be potentially influenced by the human observer. Witnesses very 
rarely give the same account of what happened and recreate memories rather than playing 
them back as a recording (Arkowitz and Lilienfeld, 2010). Humans see what they want and 
ignore what they do not want to see; one cannot be impartial without conscious effort, and 
even then, biases and preferences will still be there in the subconscious making the “truth” 
relative to perspective. Broome and Willis (2007) stated that “all knowledge produced by 
research is subjective, interpreted, political and partly ideological, regardless of the 
paradigm”. Bowling (2009) agrees by saying that “investigators cannot be divorced from the 
cultural, social and political context of their topics”. Therefore, if true objectivity is elusive, 
researchers must be open about their biases and subjectivity regardless of underlying 
ontology. The researcher must be clear about their beliefs and try to avoid bias and to 
generate theory from the data rather than their preconceptions. My experience tells me that 
the PP’s role positively contributes to patient care. I have this preconception in mind, so it will 
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undoubtedly affect every aspect of my thesis project, from the initial idea to setting the aims 
and objectives to the conclusions. I cannot avoid it, but I can acknowledge it and attempt to 
be reflexive by constantly checking that I am not being biased and being open to the opinions 
of others and not promote my thoughts and feelings over theirs (Pillow, 2003). 
 
3.4 Discussion of methods used  
3.4.1 Quantitative methods 
The research question involving the background, educational and employment status of 
primary care pharmacists working in CCGs involved gathering information that could be 
analysed and represented in numerical terms, for example, the percentage of PPs with a 
diploma. Descriptive studies have been used in the evaluation of service development and 
have been used for hypothesis testing, but exploratory analysis of the data can also be 
hypothesis generating (Smith, 1999a; Bowling, 2009;). A quantitative methodology such as 
cross-sectional studies, surveys, structured interviews or structured questionnaires were 
possible choices of methods for this project. Descriptive cross-sectional surveys can be used 
to describe phenomena and obtain information about prevalence at a point in time (Bowling, 
2009). They have also been used to document professional practice where they can be 
repeated over time in the same individuals as a longitudinal study, or in different individuals 
as a repeated cross-sectional study (Calnan, 2007; Smith, 1997). A quantitative, descriptive, 
cross-sectional survey was, therefore, chosen as an appropriate method to collect data on 
the background, educational and employment status of PPs at a point in time (Bowling, 
2009). There is was no need to repeat it to collect data over time for analysis for this project, 
although it could be used to measure changes in employment and levels of educational 
achievement over time. Surveys are not experimental or likely to adversely affect the PPs, 
but permission needed to be obtained from the pharmacists and data was anonymised to 
ensure confidentiality. 
 
The descriptive survey had several potential limitations. A one-off descriptive survey cannot 
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describe trends or explore reasons behind the data ( Calnan, 2007; Bowling, 2009). The 
survey questions were structured to effectively obtain specific information about the 
pharmacist respondents without allowing for any elaboration or explanation of the answers. 
This is unlikely to be a problem with simple factual questions about age and gender but can 
lead to ambiguity where there are potentially more answers than options given in the 
questionnaire. 
The descriptive survey was not validated. It was not tested for reliability (reproducibility), 
although the results from the survey were subsequently found to be like those in other 
previously published studies. The survey questions were also framed, I believe, in an 
appropriate language for the intended respondents (Calnan, 2007). No attempt was made to 
go further than gathering simple descriptive statistics for the survey data since it was 
intended to inform further research and not to confirm or deny a hypothesis.  
 
3.4.2 Qualitative Methods 
Qualitative methods include the use of interviews, questionnaires, focus groups and 
observations (Smith, 2010). Because the views and experiences of HCPs and patients were 
being sought, for example in research questions two to five, interviews and focus groups 
were considered suitable for gaining the relevant information. They also had the advantage 
of allowing follow up questions if necessary. Other methods were rejected, for example, 
unstructured interviews since it has been suggested that these are less effective in gathering 
data on what people do, and that data is retrospective (Low, 2007). Structured and semi-
structured questionnaires can be a useful method of obtaining large amounts of information 
relatively quickly, but they were also rejected since they have limitations over interviews in as 
much as it is not usually possible to follow up ambiguous or particularly interesting answers 
from a questionnaire.  
 
Validity and reliability are different concepts in qualitative methods, relating to the richness of 
data and method respectively. Qualitative methodologies have their strengths and 
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weaknesses (Smith, 1999b), and it is usual to attempt to gather data by at least two other 
methods and to compare these in a bid to corroborate the initial findings (Bowling, 2009). 
This triangulation of data provides content validity, the extent to which all available data on 
relevant issues has been collected (Smith, 1999b). Possible triangulation methods could 
have included participant or non-participant observation e.g. of the PPs in practice. But these 
methods may have possibly limited the data that could be collected, as the consultation with 
the patient must take precedence. Also, participant or non-participant observation may have 
affected the consultation (Bowling, 2009; Hughes, 2007) and introduced additional (observer) 
bias thereby affecting the validity of the data (Smith, 1998b; Bowling 2009). Observation of 
PPs face-to-face encounters with patients would have required consent from each PP, 
patient, and the relevant GP practice because of issues of patient confidentiality and was 
considered too impractical and intrusive in a time and resource-limited project.  
 
The methods that I selected for my study were chosen as suitable based on my 
understanding of those available and my analysis of their compatibility to answering my 
research questions.  
 
3.4.3 Sample selection  
Sampling in qualitative studies is non-random and usually involves small numbers of 
respondents; the aim is to understand complex relationships and to generate theory 
(Bowling, 2009). Respondents are likely to be unrepresentative of the population as a whole, 
and this restricts generalisability (Low, 2007; Bowling, 2009). There are four qualitative 
sampling (non-random) methods (Bowling, 2009). The intention of the thesis project was to 
use purposive sampling to ensure that the selected participants had the experience and 
characteristics to be able to answer the relevant research questions and enhance the 
richness of the data. Convenience or opportunistic sampling, using individuals who were 
easy to recruit or likely to respond, was not chosen because this would not necessarily select 
suitable respondents with the required experience. Snowballing can be used where there is 
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no understanding of the size of the population under study where respondents recruit other 
respondents within the same study characteristics. While this was, theoretically, a potential 
method for recruiting patients, as they are a hard to reach group, it was felt that the social 
networks required to make snowballing work were not established for patients that had a 
consultation with a PP. The fourth method, theoretical sampling, is discussed in section 
3.4.4. 
 
3.4.4 Qualitative data analysis 
Qualitative research is undertaken in the real-world, i.e. the research setting is not controlled, 
as it is in quantitative studies, and data analysis involves identifying key themes and 
concepts from the transcripts related to the respondents’ perceptions of their social reality 
(Bowling, 2009). The analysis of the data from the interviews and focus groups utilised the 
principles of grounded theory, first proposed by Glaser and Strauss (Corbin and Strauss, 
1990), that is an inductive method producing theory from systematic research using 
qualitative data (Silverman, 2011). In its purest form, the researcher starts with no 
preconceived ideas, research questions or literature review of the topic or area under study 
and allows analysis of the data to create themes and concepts (Allan, 2003). The continuous 
comparison of new data with emerging themes and concepts ensures that the data and 
concepts remain closely aligned. In this way, any resulting theory is grounded in, or justified 
by, the data (Bowling, 2009; Silverman, 2011). In the analysis of the data in the thesis 
project, several principles of grounded theory were used. There were no preconceived 
hypotheses, the data was coded and re-coded as more data became available, and 
emerging themes and concepts were continuously related back to the data. Memos were 
used to support the analysis along with the recognition of categories from within the code 
lists; categories were linked to developing concepts. 
There are several recognised problems with grounded theory that are relevant to the project 
reported here. It is difficult to resolve the principle of no preconceptions or a neutral approach 
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to research with the benefits that being an insider or emic researcher have on understanding 
the context of the research.  A focus must be applied in advance to provide a project protocol 
and topic guides both necessary for research governance and to set up initial interviews and 
focus groups. Theoretical sampling of participants to strengthen or pursue emerging themes 
(Low, 2007; Silverman, 2011) is technically difficult in a project that is time and resource 
limited and that must pre-define respondent numbers for governance purposes. There were 
project specific issues of recruiting busy healthcare professionals at a time of profound 
change within the context of recently formed CCGs. These difficulties also potentially 
challenged the ability of any project to pursue respondent validation and theoretical data 
saturation.  
 
The thesis project, therefore, used the principles of grounded theory, within the constraints of 
research governance and resources available, to objectively build a model of integration from 
social reality (Silverman, 2011), i.e. the models of CCG commissioning of PP teams. The 
data were analysed systematically to ensure rigour (Smith, 1998b); this specifically requires 
that there is consistency in the results using the same method and that there is uniformity of 
results across a range of methods (triangulation) (Smith, 1999b). 
 
3.4.5 Case studies 
Differing models of commissioning presented an opportunity to treat each CCG as an 
individual case in an attempt to detect any common features by applying the same research 
tools to each (Bowling, 2009). At the start of the project it was not clear if the differing models 
of commissioning affected the PP role and their relationship with stakeholders, so a case 
study approach was considered appropriate. In this context it fits the definition of a case 
study proffered by Yin 2003, Stake 2005 and Johnson and Christensen 2008.  
Case studies are considered qualitative in their nature, not being able to prove cause and 
effect (Runeson and Höst, 2009), but can be designed to incorporate a survey or to be 
supported by survey acquired quantitative data (Yin, 2003; Runeson and Höst, 2009; Bell, 
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2010; Smith, 2010). Case studies have been further qualified by Stake (2005) as intrinsic, 
instrumental and collective. Intrinsic case and instrumental studies look at individual cases, 
but collective case studies look at multiple cases simultaneously or sequentially to further 
increase understanding (Crowe et al., 2011). Case studies have also been categorised as 
positivist, critical and interpretive (Klein and Myers, 1999). A positivist case study can 
measure variables and use representative samples to generalise the results to a wider 
population. Critical case studies look at social situations to challenge inequality, and 
interpretive case studies are based on the inductive/constructive ontological paradigm 
seeking meaning from respondents’ perceptions of the situation within a context. Thus, the 
thesis project case study could be described as collective and interpretive. 
Case studies also have their strengths and weaknesses (Runeson and Höst, 2009); they are 
carried out in a real-world situation and therefore are realistic and can provide a deep 
understanding of a situation. They have the same limitations as qualitative studies in that 
they cannot prove cause and effect and may be compromised by the researcher’s personal 
feelings and stance (Runeson and Höst, 2009; Crowe et al., 2011). The strength of the case 
study can be improved by using theoretical sampling and respondent validation and being 
clear about the steps involved in the research protocol, the methods used and interpretation 
of the results (Crowe et al., 2011). The problems of theoretical sampling in the context of the 
thesis project have been discussed in section 3.4.4. Triangulation of data in case studies 
increases the precision of the data and can be achieved by collecting data at different times, 
by different methods or by different observers and by considering alternative theories and 
viewpoints (Runeson and Höst, 2009). The thesis project achieved some degree of 
triangulation by asking similar questions to different groups of respondents. (See Table 3.2 
page 77) 
 
3.4.6 Focus groups 
Focus groups are an alternative to face to face interviews (Smith, 1998a) and are appropriate 
methods to capture the views of both PPs and GPs. Focus groups normally involve 6-12 
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individuals and one or more facilitators; this range allows group members more freedom to 
talk about their views and also to discuss these views with others in the group, broadening 
overall discussion (Green, 2007; Bowling, 2009).  
Focus groups should be representative of the population being studied so purposive 
sampling is helpful. Homogeneous focus groups, those with participants with similar 
backgrounds, appear to be more productive but this can limit generalisability. Conversely, 
having members with differing perspectives (heterogeneous groups) will improve content 
validity possibly at the expense of productivity, that in this context refers to the participation 
of all group members and the depth of discussion achieved (Smith, 1998a). The thesis study 
was exploratory, and so a heterogeneous focus group was appropriate at this stage. Further 
study with homogenous focus groups could be used in the future to investigate issues in 
more depth. Confidentiality is not possible within a focus group (Bowling, 2009), but 
permission was sought to record the groups’ conversations (Smith, 1998a), and comments 
from the transcripts were not be attributed in the report to any individuals. The group itself 
should be the unit of analysis and the discussions rather than individual ideas, should be 
reported (Green, 2007; Bowling, 2009).  
Focus Groups allow for examination of what people think, how they think and why they think 
that way (Bowling, 2009) and can be useful in an exploratory and descriptive context to 
generate a wide range of ideas and issues (Smith, 1998a). The optimal size for a focus 
group has been debated in the literature with numbers of participants of between 5-10 
(Huston and Hobson, 2008), 6-9 (Smith, 1998a) and 6-12 (Green, 2007; Bowling, 2009). In 
the IS it was difficult to get more than six PPs to attend an evening focus group, so a target 
of six PPs was adopted for each of the project focus groups. The number of interviews or 
focus groups required depends on a theoretical estimate of the number needed to reach data 
saturation. Saturation is reached when no new data emerges and where categories of data 
have depth, and the relationships between concepts are defined (Corbin and Strauss, 1990). 
The IS indicated that a focus group size of 4-6 allowed for free, in-depth discussion and that 
all themes were identified within one to two hours. 
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3.4.7 Semi-structured interviews 
Semi or unstructured interviews, arguably obtain richer data than semi-structured 
questionnaires, but they are difficult and more time-consuming to undertake and analyse 
(Bowling, 2009) and require more commitment from the respondent. Semi-structured 
interviews were chosen for the HoMMs and GPs because complex questions needed to be 
asked and detailed responses encouraged and clarified (Bowling, 2009). In addition, the 
numbers of respondents involved made interviewing the individual HoMMs and GPs at a time 
and place convenient to them, relatively easy. Focus groups were rejected because of 
practical difficulties of arranging agreeable times and venues for these busy individuals. The 
numbers of HoMMs was fixed for the study. The GP sample size of twelve was based on 
experience in the IS where no new topics were identified after three interviews. The IS 
indicated that GP interviews of 30 to 45 minutes were acceptable to the respondents and 
allowed for in-depth discussion with all themes identified in this time frame. This was 
expanded to the four CCGs to compare the GPs’ views over the four different commissioning 
models.  
 
3.4.8 Telephone interviews 
Telephone interviews are an alternative to face-to-face interviews where the topics are non-
controversial (Calnan, 2007; Bowling, 2009;). They also may be more economical to conduct 
(Bowling, 2009; Irvine et al., 2013). Telephone interviews were chosen as a practical solution 
for patients, and to encourage their participation since there was no need for them to travel to 
be interviewed and they could participate from their home. This also avoided cost and 
inconvenience of arranging multiple venues as they are a respondent group that could have 
been resident in any part of the four CCGs or surrounding areas. Face-to-face semi-
structured interviews may have allowed for a more in-depth dialogue, but this would have 
been more time consuming for the respondent and may have affected recruitment. 
Concerns have been expressed that use of the telephone does not allow the interviewer 
access to non-verbal communication, patient physical characteristics or the respondents 
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setting (Irvine et al., 2013). However, Holt supports the view that telephone interviews may 
give more “control” to patients, reduce feelings of intrusion into their social life and increase 
response rates (Holt, 2010). Naturally, the tone of voice and speech patterns were 
discernable over the telephone and allowed some assessment of the mood of the 
respondent and willingness to participate. The restrictions on translation excluded patients 
who could not converse in English. The views of some ethnic minority patients were, 
therefore, not fully represented and may be different in their evaluation of patient care, as 
has been suggested in the past (Mead and Roland, 2009). The patient sample size of thirty 
was manageable within the time frame for data collection because the interview guide was 
relatively simple, non-confrontational and did not require a long telephone conversation.  
 
3.5 Ethical approval 
The research was conducted in accordance with the ethics and research governance policies 
of Keele University. An application form (Appendix 3.15) for independent peer review was 
completed and then submitted, reviewed and approved by the Independent Review Panel in 
January 2014.  
Full ethical approval was sought via the Integrated Research Application System (IRAS) and 
was granted after a Proportionate Review (Appendix 3.16) by the NRES Committee South-
East-Surrey on the 8th May 2014.  
 
Local approval was sought and obtained from the four individual CCGs and two associated 
PP Provider Organisations between 13th May and the 26th June 2014. Despite there only 
being four CCGs, local ethical approval had also to be sought from one commissioning 
support unit and one acute trust, since two of the PP teams were employed by these other 
NHS organisations. 
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Chapter 4 The Case Study Participants 
4.1 Overview 
This chapter begins by describing the selection of the four thesis project CCGs. It goes 
on to introduce the case study project teams by respondent group and describes who 
they were. Descriptive data is reported for all the respondent groups, but in the case of 
the PPs this is more detailed and includes their professional background, levels of 
education and employment status within the CCG. Qualitative data are also included on 
the reasons why pharmacists take on the PP role and why some maintain a portfolio 
career. This overview of the PP participants, within the case CCGs, will indicate if they 
are typical of primary care pharmacists studied elsewhere.  
 
4.2 Research question 
1 What is the background, educational and employment status of primary care 
pharmacists working in CCGs? 
 
4.3 The Clinical Commissioning Groups 
The details of the four CCGs, which participated in this study are shown in table 4.1. Figures 
published in 2013 show that, at the time, the average CCG served 263,997 patients (Health 
and Social Care Information Centre, 2013).  The average population served by the four 
project CCG was 280,000 (range 260,000-300,000), and they commissioned an average of 
17.5 PPs (range 8-35) equating to a WTE average of 7 PPs (range 4.5-10). The average 
number of PP that were prescribers was 12.3 (range 5-20). Three CCGs employed an 
average of 2.3 pharmacy technicians (range 1-3). At the time of the project, all the HoMMs 
were considering employing more PPs and technicians. The funding for PP teams came from 
a variety of sources, and was different for each CCG, although the prescribing budget was a 
resource for two CCGs. All the CCG populations had similar demographics with areas of low 
to high levels of deprivation.  
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Despite similar populations and commissioning intentions, there was a wide variation in the 
numbers of PPs, WTE equivalents, and the proportion of pharmacist prescribers in each PP 
team.  
 
Table 4.1 Clinical Commissioning Group Practice Pharmacist Teams’ structure and funding  
CCG A B C D 
Population (1000) 270 260 300 290 
Number of PPs 35 8 17 10 
WTE PPs 10 4.5 8.5 5 
Independent prescribing PPs 20 8 16 5 
Technicians 1 3 0 3 
PP Team Provider CCG-via 
SLA 
Acute Trust Multiple CSU 
Funding A B C D 
Top Slice Prescribing Budget Yes - Yes - 
Programme Budget - Yes - - 
Transformation Budget - Yes - - 
Medicines Management Budget - - Yes Yes 
Central Management Budget - - - Yes 
Recruitment of more PPs and 
Technicians 
Possibly Possibly Possibly Possibly 
 
4.4 Heads of Medicines Management  
The average age of the four HoMMs interviewed was 48.3 years (range 39-53 years). They 
were all experienced pharmacists and had been registered for an average of 25.8 years 
(range 18-30 years). Three of the HoMMs were active prescribers and had worked as PPs 
for an average of 16 years (range 15-18). When asked about future PP recruitment, two of 
the HoMMs considered that this process would be relatively easy, with the remaining two 
stating that it could be “difficult” and “very difficult”. Three HoMMs had a preference to recruit 
a prescribing pharmacist over one without the qualification.  
 
4.5 Survey of Clinical Commissioning Group Practice Pharmacists 
Forty-nine PPs responded to the descriptive survey. The HoMMs reported the numbers of 
PPs in the four project CCGs as 70 (See Table 4.1), but two of the survey respondent PPs 
disclosed that they also worked for one of the other project CCGs, thereby reducing the 
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overall numbers of PPs to a maximum of 68. 
 
The response rate for the survey was therefore 72%, but this could be an overestimation as 
the CCG PPs that did not take part in the survey may also have been employed in more than 
one CCG. Respondents were asked to complete the survey with data from the CCG in which 
they spent the most time working. The four PPs who took part in the focus group for CCG D 
did not complete the descriptive survey despite reminders. 
 
4.5.1 Practice pharmacists’ demographic and personal information. 
Table 4.2 below shows the descriptive statistics for the study PPs. More male PPs took part 
in the survey (n=29) than females (n=20), with the majority (44.9%) of PPs in the 30-39 age 
group. The gender bias was affected by the largest PP team where most PPs were male. 
Combined male/female PP ages ranged from 26 to 61 years (range 35 years), with a median 
of 40 years and mode of 32 years. 
 
Table 4.2 Descriptive Statistics for PP Age, Registered Years and Years as a PP. 
 
The SD of 9.8 years is small about the mean showing that the spread of ages is close to the 
mean (all ages are within two SDs of the mean) and that the mean age of 42.3 years is 
representative of the project PPs as a group. The average age of the female PPs was higher 
than that of the male PPs by 2.9 years, but the lower SD and range age range, 31 years for 
(n=49) Mean Median Standard 
Deviation 
(SD) 
Range Minimum Maximum 
Age (M/F) 42.3 40 9.8 35 26 61 
Age (F) (n=20) 44.1 44 8.9 31 30 61 
Age (M) (n=29) 41.2 38 10.3 35 26 61 
Years as a PP (M/F) 8.4 9 4.8 17 1 18 
GPhC registered years 
(M/F) 
19 16 10.4 36 3 39 
Years as a PP (F) 9.5 11 5.4 17 1 18 
GPhC registered years (F) 21.3 22 9.8 31 7 38 
Years as a PP (M) 7.7 8 4.3 15  1 16 
GPhC registered years 
(M) 
17.4 15 10.7 36  3  39 
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females versus 35 years for males, shows that there was a smaller variation of ages in the 
female PP cohort.  
Female PPs had been qualified as pharmacists for longer (a mean of 2.9 years) with a 
smaller range of qualified years but a larger range of years as a PP, compared to the males. 
The average difference between the number of GPhC registered years and years as a PP 
was 11.8 years for the females and 9.7 years for the males.  
 
4.5.2 Professional background 
Figure 4.1 shows a cumulative total of the number of background roles in which the PPs had 
experience, so that some PPs will be included in more than one total. The majority, 46 
(93.8%) had experience in community pharmacy and 20 (40.8%) in hospital pharmacy. Five 
PPs (10%) had experience in postgraduate education, four in the pharmaceutical industry 
(8%) and nine in other pharmacy roles (10%) with four having experience in non-pharmacy 
related roles. Twenty-one (42.9%) had worked in one sector only, 28 (57.1%) in more than 
one sector and nine (18.4%) in more than two sectors.  
 
Figure 4.1 Cumulative Practice Pharmacist background roles  
(n=49) 
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The number of professional background roles tended to increase with age; nine PPs under 
the age of 41 had experience of more than one sector, but none had experience of more 
than two sectors. In contrast, PPs with experience in three or more sectors were all over the 
age of 41 with only three over the age of 50 years having single sector experience.  
 
4.5.3 Portfolio roles 
Figure 4.2 shows a cumulative total of the number of on-going roles undertaken, so some 
PPs will be included in more than one total. The majority, 36 (73.5%) of the PPs said that 
they continued to combine the PP role with other roles, but 13 (26.5%) had no other role. 
Twenty-four (48.9%) continued to work in community pharmacy, five (10.2%) in hospital 
pharmacy, 12 (24.5%) in another pharmacy related role, and eight (16.3%) in postgraduate 
education. Non-pharmacy related continuing roles were reported by four, and one PP 
reported having an on-going role in the pharmaceutical industry. Regarding multiple other 
roles, 11 (22.4%) reported two or more other roles and four reported more than three other 
roles in addition to the PP role. 
 
Figure 4.2 Cumulative Practice Pharmacist on-going roles in other sectors  
(n=49) 
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4.5.4 Education and training 
The numbers of PPs with various qualifications are shown in Figure 4.3 with some PPs 
having more than one postgraduate qualification, so they appear more than once. Only two 
of the respondents did not have formal postgraduate qualifications.  The most common 
qualifications were supplementary or independent prescribing and a postgraduate diploma, 
39 PPs (79.6%) and 34 PPs (69.4%) respectively. Twelve PPs (24.5%) had higher degrees, 
17 (34.7%) had postgraduate certificates and ten PPs (20%) had completed postgraduate 
accredited units. The length of experience and levels of postgraduate education were 
possibly related to the established nature of the CCG teams before the NHS changes. 
 
Figure 4.3 Cumulative Practice Pharmacist postgraduate qualifications  
(n=49) 
 
 
4.5.5 Prescribing  
Thirty-nine (79.6%) PPs were prescribers, but there were proportionately more male PPs 
with the qualification (24, 82.8%) than females (15, 75%). Prescribers were on average 
seven years older than the non-prescribers (See Table 4.3) and had been registered and 
worked as PPs for longer than non-prescribing pharmacists. Mills (2016) also found that 
more senior pharmacists were more likely to have prescribing qualifications. There was a 
broad range in the number of prescription items (individual drugs and devices) prescribed by 
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prescribing PPs. The majority reported that they wrote 50 or fewer items a month, with only 
three writing over one hundred items a month. 
 
Table 4.3 Descriptive statistics for prescribing and non-prescribing Practice Pharmacists 
 
Figure 4.4 shows prescribing activity in the independent prescribing qualified PP 
respondents. The most active prescriber was female, but male prescribers wrote more items 
each month than their female counterparts. Younger prescribing pharmacists (< 40 years) in 
the project prescribed more often than older pharmacists. 
 
Figure 4.4 Number of prescription items written per month and Practice Pharmacist by 
gender  
(n=39) 
 
  
Age Prescriber (n=39) Non-prescriber (n=10) 
Mean 
 
43.8 36.8 
Median 41 34.5 
Std. Deviation 9.9 58.4 
Minimum 30 26 
Maximum 61 50 
Range 31 24 
15
7
1 1
0
12
2
0
1
0
2
4
6
8
10
12
14
16
0-50 51-100 101-150 151-200  201 or more
N
u
m
b
e
r 
o
f 
P
P
s
Items per month
Male
Female
 95 
4.5.6 Current Employment in the PP Role 
The majority, (40, 81.6%) of PPs worked part-time in the role; there was a small difference 
between the genders in that 17 (85%) females worked part-time compared with 23 (79.3%) 
males. The number of hours a week spent as a PP varied between 4 and 40 hours with nine 
(18.4%) pharmacists stating that they worked full-time as a PP.  
 
4.5.7 Direct patient contact 
Figure 4.5 shows the percentage of time that PPs spent face-to-face with patients. Most PPs 
spent less than 20% of their time with patients, with only ten (20.4%) spending 41% or more 
of their time with patients. 
  
Figure 4.5 Percentage of time spent face-to-face with patients by Practice Pharmacists  
(n= 49) 
 
 
Table 4.4 shows the relationship between the total number of hours that pharmacists were 
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Table 4.4 Practice Pharmacist hours spent face-to-face with patients and employed hours 
(n=49) Time spent face-to-face with patients 
PP 
hours 
per 
week 
<20 (%) 21-40 (%) 41-60 (%) 61-80 (%) 81-100 (%) 
0-10 
(n=11) 
9 (81.8) 1 (9.1) 1 (9.1) 0 (0.0) 0 (0.0) 
11-20 
(n=15) 
8 (53.3) 5 (33.3) 2 (13.3) 0 (0.0) 0 (0.0) 
21-30 
(n=8) 
5 (62.5) 1 (12.5) 0 (0.0) 1 (12.5) 1 (12.5) 
>30 
(n=15) 
7 (46.7) 3 (20.0) 4 (26.7) 0 (0.0) 1 (6.7) 
 
Table 4.5 Practice Pharmacist hours spent face-to-face with patients and prescribing status 
 
Overall male prescribers appeared to spend more time with patients and wrote more 
prescriptions, although one female prescriber did prescribe over 201 prescription items a 
month. The data on prescriptions written was collected on bands starting with 0-50 items per 
month. This did not differentiate between the extremes of each band and did not differentiate 
prescribers that were inactive in the 0-50 band. 
 
4.5.8 Practice Pharmacists by Clinical Commissioning Group data summary 
Summary data for the PPs by CCG is shown in Table 4.6. Unfortunately, CCG D is only 
represented by one PP, so the data is unlikely to be representative of that CCG. 
Comparisons between the remaining CCGs show significant variation and that the PPs from 
CCG A had the lowest average age, the highest proportion of full-time employees and non-
prescribing pharmacists. It also had the lowest proportion of 0-50 prescription items a month 
and of 20% or less contact time with patients and the lowest average years as a PP.  
  
Prescriber <20 (%) 21-40 (%) 41-60 (%) 61-80 (%) 81-100 (%) 
No (n=10) 7 (70.0) 3 (30.0) 0 (0.0) 0 (0.0) (0) (0.0) 
Yes (n=39) 22 (56.4) 7 (17.9) 7 (17.9) 1 (2.6) 2 (5.1) 
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Table 4.6 Practice Pharmacist data by Clinical Commissioning Group 
 
CCG 
(no of PPs) 
PP Average 
age  
Employed 
full-time 
Salaried 
employee 
% Female 
PPs 
Average 
hours a 
week as a 
PP 
A 
(n=30) 
40.5 23.3% 13.3% 36.6% 20.6 
B 
(n=7) 
48.0 14.2% 100.0% 71.4% 26.9 
C 
(n=11) 
44.0 9% 0% 36.3% 21.8 
D 
(n=1) 
40.0 0% 100% 0% 9.0 
 
CCG 
(no of PPs) 
% of 0-50 Rx 
items a 
month 
% Non-
prescribing 
PPs 
% of PP with 
less <20% 
patient f-to-f 
contact time 
Av. years 
on register 
Av. years 
as a PP 
A 
(n=30) 
70.0 30% 50% 16.9 6.9 
B 
(n=7) 
100.0 0% 85.7% 25.7 11.4 
C 
(n=11) 
72.7 9% 63.6% 21.2 10.9 
D 
(n=1) 
100.0 0% 100% 9.0 5.0 
 
4.6 The focus group Practice Pharmacist participants 
The following data is based on the number of PPs that volunteered the information or where 
it could be determined visually. A total of eighteen PPs attended four focus groups held 
within their relevant CCG areas. The number of participants ranged from two to seven. The 
majority, (14, 77.8%) were female with an overall average age of 44.1 years (See Table 4.7). 
Females were over-represented in the focus group, based on the national percentages of 
registered pharmacists (60% female) and the subset of registered pharmacist prescribers, 
(70% female) (Phelps et al., 2014). 
 
The FG participants had an age range of 31 years. They had been registered with the GPhC 
for an average of 20.9 years and worked as a PP for an average of 9.4 years. These figures 
are similar to those PPs who completed the descriptive survey, where the average age was 
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42.3 years, the age range was 35 years, with an average of 19 GPhC registered years and 
8.4 years as a PP.  
 
Table 4.7 Focus Group descriptive statistics 
(n=15) Mean Median Mode Std. 
Deviation 
Range Minimum Maximum 
Age 
 
44 46 30 
(lowest) 
11.7 31 30 61 
Years 
on 
GPhC 
register 
20.9 22.5 25 10.9 33 5 38 
Year as 
a PP 
9.4 10.5 14 4.6 14 1 15 
 
4.7 Focus group themes related to the Practice Pharmacist role 
4.7.1 Why do pharmacists choose the Practice Pharmacist role? 
Focus group participants indicated that they chose to become PPs because of a desire to 
either move away from current roles or a need to find a new more challenging role. Those 
participants with a significant hospital background felt that there was a danger of becoming 
too specialised if they remained in hospital pharmacy and also that there were limited 
opportunities in obtaining promotion.  
 
“Me personally, there was an issue of career progression in secondary care, I think it's 
extremely difficult now … I know people that historically would have done a clinical diploma 
and automatically jump a band, that's no longer the case, that's saturated now …” PP B7 
 
Participants with a community pharmacy background identified some concerns that they had 
with the current community pharmacy model as among their reasons for seeking a new role; 
they felt that it was too centred in business aspects and was focused on income generation.  
 
“It's [community pharmacy] all to generate money, the script numbers as well. So that 
generates extra income for them [the employer], and I think it's driven by income...the model 
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is fundamentally geared towards quantity rather than quality… " PP A6 
 
Community pharmacy was also described as repetitive, boring, monotonous, and a 
“prescription factory”, as well as being stressful with high workloads and a poor career 
structure. For one respondent, this was a sufficient driver to leave the sector. 
 
“Mine [reason for leaving the sector] was more of a need to step away from community 
pharmacy as opposed to going into practice pharmacy…. I was finding community pharmacy 
a little bit mundane, so I thought I would try something different, something a bit more 
clinical, and I found that I quite enjoyed it...” PP A1  
 
The dispensing workload was also perceived as a barrier to the necessary integration of 
community pharmacy with practice in primary and secondary care. 
 
“The stumbling block here [to community pharmacy integration] is the community pharmacy 
model; that's got to change…I mean when some guys are doing five to seven hundred 
[prescription] items in a day they just haven't the time”. PP A6 
 
Lack of use of their skills was a key issue in encouraging a change in role, both regarding 
dissatisfaction with their current role and their desire to move on to a more clinical role.  
 
“So, I just wanted to go into a role where I could put my clinical skills to better use, and I've 
been doing it for ten years now. Really enjoy it.” PP D2 
 
Not all PPs were unhappy working in hospital or community pharmacy, as many continued in 
these roles part-time, some considered the PP role allowed them to be more decisive and 
effective. 
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“I think I enjoyed what I was doing, but I felt it was being wasted, I wasn't being used to my 
full capacity with what I could do as a community pharmacist, I just felt held back all of the 
time, and I just felt as a Practice Pharmacist you could make decisions and have an effect, 
get things done.” PP C2 
 
Some also perceived the PP role as an opportunity for professional development. 
 
“...so, there's different sort of things, you can develop yourself more and do the IP course, 
Masters or, most people have done the clinical diploma as well, so there's just a general 
development there.” PP A4 
 
Others wanted variety in their working hours and were curious about the PP role, and some 
early adopters felt that it was an opportunity to take part in the development of a new role. 
Patient contact, as well as the ability to effect changes, were other attractions of the PP role 
with some pharmacists giving this as a reason for moving into it 
 
“I also wanted more patient contact ‘cos I felt that, at the time, pharmacy for me was more 
about the checking of the prescription than actually speaking to the patient and improving 
their lives or helping them with their medicines.” PP B2 
 
Participants discussed their perceived hierarchy of pharmacy roles and felt that PPs were 
more highly respected than community pharmacists, certainly in the eyes of other HCPs and 
that this was probably because of their closer working relationship with GP practices. It was 
also felt that other pharmacists “looked up” to PPs 
 
“The role’s a bit higher than community pharmacy, in the pharmacy hierarchy it' s bit more-
the other pharmacists look up to you as well.” PP A3 
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One participant illustrated this difference in an example around the perceived value of advice 
given by the same pharmacist in different settings. They felt that advice from a PP was 
valued more by patients than the same advice from a community pharmacist. 
 
“I know if I'm the Practice Pharmacist and I'm working in the pharmacy my advice is not 
taken in the same way as in the surgery. I'm the same person, giving the same advice to the 
same people in the same way, but how they [patients] value that opinion is different.” PP A1 
 
At least one pharmacist in each focus group mentioned employment flexibility as an 
additional benefit that attracted them to the PP role. This was linked to family commitments, 
work-life balance, return to work after maternity leave. 
 
“I just wanted to try a new sector, really, and in all honesty, it fitted in better with family life. 
That's how I started - I have three children, and hospital pharmacy wasn't very flexible…” PP 
D2 
 
There was also flexibility related to the commitment required for the PP role.  
 
“The opportunity was there at that moment in time they were happy for you to do whatever 
you could do, so you did have that relative flexibility…” PP C1 
 
The variety of work available in the PP role, and also working with other HCPs, was 
mentioned in all four focus groups as a reason for starting and continuing in the PP role.  
 
“And the variety in primary care…looking back in hindsight, at the time I didn't know that the 
work was going to be so varied, but the work is varied, and you work with different teams…” 
PP B2 
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The variety of work in the PP role contrasts with the respondents perceived repetitive nature 
of community pharmacy and to becoming too specialized in hospital pharmacy. Similarly 
working with other HCPs contrasts with the potential professional isolation of community 
pharmacy. One respondent particularly acknowledged the time taken to become integrated 
into the GP practice, as a Primary Care Organisations (PCOs) pharmacist and that 
integration itself was a source of job satisfaction. 
 
“It's taken us many years in our practice is to get to the point where we are and become 
embedded in that practice, and you become part of that team… you may be part of the CCG 
or PCT or whatever you started off as you become integrated into those different teams and I 
think, you know, that gives me a lot of job satisfaction.” PP C1 
 
4.7.2 Portfolio working 
Portfolio working was commonplace amongst the focus group participants; pharmacists 
mentioned several reasons why they continued to work in more than one sector. Working in 
community pharmacy was perceived as useful to the PP role as it allowed “hands on” 
experience with new drugs and devices and allowed them to keep abreast of new 
medicines/devices and supply shortages.  
 
“I was doing my asthma clinics [in the GP surgery], but it's to maybe keep that hands-on [in] 
community - knowing what's going on in terms of new drugs and availability. So, it is useful.” 
PP D1 
 
Participants also used the knowledge that they gained in the PP role to improve their 
interventions in community pharmacy, so there was reciprocation.  
 
“Likewise, your practice pharmacy might, for example, increase your clinical knowledge, you 
might be doing an audit that you can then apply in your community pharmacy role.”  PP A1 
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In addition to portfolio roles complementing each other, maintaining a portfolio career also 
allowed PPs to understand issues in other roles. For example: 
 
“I mean I still do community work as well... and simply because …. you've got to appreciate 
and understand [their], the difficulties they have as well, [general agreement]...” PP B6 
 
“I can now see where all the problems in hospital are raised from, and vice versa.” PP D3 
 
Other participants recognised that their personality was the driver for choosing a portfolio 
career, in that they became bored easily and portfolio working meant that they were 
constantly being challenged, and this satisfied their nature.  
 
“I think it's probably like my personality, in that I get bored very quickly, I like to do lots of 
different things, and the current [CCG PP] role means you go to different practices, doing 
different roles, doing different things even within those practices….” PP C1 
 
The undergraduate course had raised one pharmacist’s expectation that working as a 
pharmacist would be diverse and varied; a portfolio career allowed them to achieve this and 
to apply more of what they had learned. 
 
“You don't get bored, do you, there's variety there, diversity so, when you're taught on your 
MPharm or BPharm programme…different placements, different experiences you can use 
different aspects of what you've learnt”. PP A3 
 
Some participants had roles outside traditional pharmacy sectors to increase the variety in 
their work, broaden their outlook and provide personal growth. 
 
 104 
“I look after one of the enhanced services on behalf of the LPC, that's a completely different 
kind of role, you talk to commissioners, and you get engagement with the other stakeholders 
in the service as well, so it kind of opens horizons a little bit more”. PP A6 
 
“Yes, I work for NHS Direct, I work for UKMI, some work for the prisons, so I'm always open 
to new opportunities to grow yourself as a person”. PP C1 
 
The changes in the NHS have led to a degree of uncertainty in the on-going viability of the 
PP role, and some pharmacists had responded by taking on other roles as income and 
employment “insurance” against this and any future NHS changes. Two PPs started working 
for a non-NHS hospital despite not having previously worked in a secondary care 
environment. They felt that the experience had broadened their horizons and given them an 
alternative career path in case they lost their PP role in this or any future NHS 
reorganisation. 
 
“I work at the [hospital name] as a bank-pharmacist too, it's another string to my bow…we 
knew that we had a job for the next X number of years, but we don't know what's going to 
happen after then, it was again another interest, another string.” PP B2 
 
Given the part-time nature of the PP role, it is not surprising that some pharmacists admitted 
that they continued to work in other roles for purely financial reasons. 
 
“I mean I still do community work as well, but that's on a weekend, and that's, well financially 
the reason I do it” PP B6 
 
4.8 The General Practitioner participants 
Eight GPs were interviewed, seven were male and one was female with an average age of 
48.1 years (range 34-63). They had been qualified as GPs for an average of 18.4 years 
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(range 4-31 years). They had been working at their current practice for an average of 18 
years (range 4-25 years) and had worked with a PP for an average of 11.9 years (range 4-17 
years). The average practice population was 6938 and ranged from 3000-11,000 patients 
(See Table 4.8). 
 
Table 4.8 GP and Practice Demographics 
CCG 
(GP) 
Age 
(Gender) 
Position in the 
practice 
Years as 
GP 
Years at 
current 
practice 
Practice Population 
(Nearest 1000) 
A (1) 54 (m) Senior partner 25 25 11,000 
A (2) 63 (m) GP Partner 31 31 4000 
A (3) 39 (m) Senior Partner 12 12 4000 
B (1) 34 (m) Sole Partner 4 4 3000 
B (2) 52 (m) GP Partner 26 26 8500 
C (1) 41 (f) GP Principle 
Partner 
15 13 7000 
C (2) 57 (m) GP Partner 15 15 9000 
D (1) 45 (m) Partner 19 19 9000 
 
When asked about their position within their practices, six described themselves as Partners 
and the remaining two considered themselves to be Senior Partners. Regarding their 
engagement with the CCG Board four were Board members, two of the non-board members 
sat on CCG committees, but the remaining two had no formal committee function within their 
respective CCGs (See Table 4.9). The GP respondents, therefore, came from a range of 
practice size, were all partners, had significant experience of working with PPs, with the 
majority being engaged with the management of their respective CCGs at some level. 
 
Most of the GPs interviewed had ten or more years of experience of working with PPs, and 
most were able to identify which organisation funded their individual PP. Regarding the 
weekly hours of GP practice contact time with their PP, this averaged to 7.9 hours. But there 
was a wide variation of between 2 to 17 hours, with the average figure influenced by two 
practices in CCG A. The GPs reported that six of their practices pharmacists were employed 
by the CCG to which the practice belonged.  
The views of female GPs were under-represented, and no salaried GPs participated in the 
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project despite the increase in the numbers of GPs employed in this way. 
 
Table 4.9 GP Engagement with the Practice Pharmacists and Clinical Commissioning Group.   
CCG 
(GP) 
CCG 
Board 
Member 
CCG Committees Years 
worked 
with PP 
PP Hours 
per week 
PPs work 
directly for the 
CCG 
A (1) Yes Diabetes STaR* GpwSI# 17 12 Yes 
A (2) Yes Clinical Chair 17 8 Yes 
A (3) Yes Chair of Finance, 
Commissioning, and Quality, 
Lead for IT 
10 17 Yes 
B (1) No Pathways Sub-committee 4 4 Yes 
B (2) Yes Governing Body Member 17 4 No 
C (1) No Clinical Lead 10 8 Yes 
C (2) No No 10 8 Yes 
D (1) No No 10 2 No 
*Strategic Transformation and Redesign                #GP with Special Interest 
 
4.9 The patient participants 
A total of twelve patients agreed to the telephone interview after being identified as per the 
protocol. There were eight males and four females with an average age of 66.4 years (range 
21-77 years). The demographic profile of their postal town is shown below in Table 4.10, 
based on the patient’s postcode and provides some indication that the patients came from a 
variety of areas with differing levels of affluence. Four patients, A1-A4 came from relatively 
affluent areas with >50% of the local population from the upper-middle-class, intermediate 
middle and lower-middle-class segments. Five patients, C1-C5 came from less affluent areas 
with >50% of the population from lower-middle-class and skilled working-class. Three 
patients, A5, B1, and B2 came from the least affluent areas represented by the patients in 
the project. No patients from CCG D were recruited.  
 
The thesis study patient participants were largely male, with an average age of 70 years 
(range 54-78 years). The female patient respondents had a lower average age of 59.3 years 
(range 21-77 years). The overall average age was 66.4 years (range 21-78).  
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Table 4.10 Patient Participants and Demographic Profile of their Postal Town 
   Demographic composition of patients’ postal 
towns 
Patient 
 
Age Gender AB C1 C2 DE 
A1 64 Male 23.6 31.9 23.4 21.1 
A2 >75 Male 23.6 31.9 23.4 21.1 
A3 77 Female 23.6 31.9 23.4 21.1 
A4 78 Male 23.6 31.9 23.4 21.1 
A5 77 Male 6.1 19.1 27 47.9 
B1 77 Male 10.1 24.8 29.1 36.1 
B2 62 Male 8.5 27.2 17.6 46.7 
C1 67 Female 12.5 27.9 27.1 32.5 
C2 73 Male 13.4 27.2 29.5 30 
C3 21 Female 13.4 27.2 29.5 30 
C4 72 Female 13.4 27.2 29.5 30 
C5 54 Male 15.8 27.3 24.3 32.6 
Population codes Available from http://www.postcodearea.co.uk/postaltowns/ <accessed on 
19.7.14> 
A - Upper Middle-Class Higher administrative, managerial or professional 
B – Middle-Class Intermediate managerial, administrative or professional 
C1 - Lower Middle-Class Supervisory or clerical and junior management, administrative or 
professional 
C2 - Skilled Working-Class Skilled manual workers 
D – Working-Class Semi and unskilled manual workers 
E – Non-Working Casual or lowest grade workers, pensioners, and others who may rely on 
the welfare state for their income, including students. 
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Chapter 5 NHS Changes and the Commissioning of Practice Pharmacists 
5.1 Overview 
 
5.2 Research Question 
2 What is the impact of the recent NHS changes on primary care Practice Pharmacist 
teams? 
 
5.3 Results 
5.3.1 The structure and commissioned functions of the project Practice Pharmacist teams. 
Despite a desire to continue to employ their PP teams after April 2013, there were insufficient 
funds in the CCG management budget for this and CCGs were commissioning organisations, 
so alternative methods for commissioning the teams had to be found. For example, GP B1 
revealed: 
 
“…the budget that the CCG had to fulfil management costs was not sufficient for us to 
employ the team, which is what I would like to do, and the only way to do it is to purchase it 
as a delivery team through the wider commissioning budget, rather than the management 
budget…” GP B1 
This chapter describes the effects of the NHS change from the stakeholders as PCTs 
transitioned to CCGs in 2013. It begins by outlining why the PP Teams could no longer 
be directly employed by the CCGs and then goes on to describe the structure and 
commissioned functions of the CCG PP teams and how these functions were 
perceived by the stakeholders. There follows a brief discussion on how the PP role was 
assessed by the commissioners and the stakeholders’ views on the work plans agreed 
by the commissioners. The chapter continues with the effects of the transition on the 
relationships between the professional stakeholders and how the PP role changed and 
concludes with a discussion on the current training of PPs.  
 109 
 
The CCGs addressed this issue in different ways, CCG A commissioned the PP team by 
indirect employment on service level agreements with effectively no provider organisation. 
Two CCGs commissioned PP teams from NHS provider organisations, such as acute trusts 
(CCG B) and the newly formed CSUs (CCG D). The remaining CCG (C) was moving towards 
the provider model. Funding for the PP teams came from a variety of sources with two CCGs 
using the prescribing budget and the remaining CCGs using a variety of sources as shown in 
Table 5.1. At the time of the project, all the HoMMs stated that they would possibly consider 
recruiting more PPs and pharmacy technicians in the future. 
 
Table 5.1 Commissioned functions of project Practice Pharmacist teams 
 
The HoMM were asked to select the PP Team commissioned roles from a list, developed 
from the pre-study survey (See Table 5.1). The common activities included medication 
review, audit, prescribing efficiencies, liaison with community pharmacy, medicines 
reconciliation and supporting the local incentive scheme. Only one CCG did not commission 
specific disease management and pharmacist prescribing, even though half of their 
commissioned pharmacists were prescribers. Three out of the four CCGs commissioned 
CCG Funding Activities 
A Top sliced from 
Prescribing Budget 
Specific disease management, Repeat prescription 
management, Medication Review, Therapeutic detailing, Audit, 
Prescribing and Prescribing efficiencies, Liaison with Community 
Pharmacy, Medication reconciliation, Supporting QoF and 
Incentive Scheme 
B Programme Budget 
& Transformation 
Budget 
Specific disease management, Medication Review, Therapeutic 
detailing. Audit, Prescribing, Prescribing efficiencies, Liaison with 
Community Pharmacy, Medicines reconciliation, Supporting 
Incentive scheme 
C Top sliced from 
Prescribing Budget 
Specific disease management, Repeat prescription 
management, Medication review, Therapeutic detailing, Audit, 
Prescribing and Prescribing Efficiencies, Liaison with Community 
Pharmacy, Medicines reconciliation, Supporting QoF and 
Incentive scheme 
D Medicines 
Management 
Budget & Central 
Management 
Budget 
Repeat prescription management, Medication review, Audit, 
Prescribing efficiencies, Liaison with Community Pharmacy, 
Medicines reconciliation, Supporting QoF and Incentive Scheme 
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repeat prescription management, and only one CCG did not specifically support the GP 
practices with QoF although this CCG did allow their pharmacists to undertake CDM that 
might ultimately support QoF.  
 
Table 5.2 compares commissioned PP roles with stakeholder observed PP roles. While there 
was a degree of agreement between the HoMM commissioned roles and the GP observed 
role, the patient observed roles were different, reflecting the operationalisation of the 
commissioned patient-facing roles and individual patient experiences. 
 
Table 5.2 Commissioned and observed roles by participant groups 
 
HoMM (Commissioned) GP (Observed) Patients (Observed) 
Audit Audit - 
Specific disease 
management 
Chronic disease management COPD, Asthma & 
anticoagulation management 
  Deals with minor ailments 
Therapeutic detailing Clinical information resource Medicines queries 
Corrects media hype 
Drug information 
Explains disease 
Reassures patients 
 Drug safety Drug monitoring 
Identifies ADR and drug 
interactions 
 Facilitating electronic 
prescribing 
- 
 Facilitating medication issues Explains drug rationale 
Aligns medication 
Ensure Rx supplies are 
adequate 
Prescribing Efficiencies Financial control Stopping glucosamine 
Liaison with Community 
Pharmacy 
Liaison with Community 
Pharmacy 
Liaison with Community 
Pharmacy 
Medication Review Medication review Medication review 
Medication Reconciliation Medicines reconciliation - 
Supporting Incentive 
Scheme 
Prescribing incentive scheme - 
Repeat Prescription 
management 
Repeat prescribing 
management 
- 
Prescribing Prescribing for patients Prescribing 
Supporting QoF  - 
 
Patients recounted the medicines safety and information giving aspects of the PP role, along 
with liaising with community pharmacy, CDM, and prescribing. They also recognised a role in 
minor ailments as PPs dealt with these when in consultation with patients to assist in 
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managing the practice workload. 
 
5.3.2 Assessment of the role 
Only two CCGs (A and C) stated that they formally assessed the PP role. The CCG A 
evaluated types of interventions, efficiencies, and harm reduction, including Long Term 
Condition (LTC) Clinics where disease-specific outcomes were also monitored. Whereas 
CCG C used annual reporting and monthly analysis based on interventions made, work 
completed against their annual work plan and other interventions.  
 
The HoMMs were asked about this in their interviews, and all four took informal feedback 
from the GPs, for whom they commissioned the PPs; this was always positive.  
 
“Overall, the feedback is fairly positive… practices get quite sniffy if they think they're going 
to get reduced [PP] hours. It gives the feeling that they do value what is going on in their 
practices.” HoMM D 
 
One HoMM equated satisfaction with the PPs to an increasing demand for PP services. 
 
“I think our feedback has been very positive…I think the fact that the demand has increased 
tends to tell you that the GPs appreciate the advice.” HoMM A 
 
Another HoMM reinforced this by recounting the GP’s attitude to the temporary loss of PP 
services due to staff issues. 
 
“… if you're in a situation where the pharmacist has been on long-term sick or maternity, 
they've [GP practice] been without them for a while… they want to know when they are going 
to get a replacement and so on.” HoMM C 
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The fourth HoMM demonstrated the value of the role to practices by the support that GP s 
gave during the NHS changes and the expansive use of PPs in practice. 
 
“…PP always come out at the top of any list, and GPs will come up with no end of ways of 
using them… a five-star service, well valued, you know. If you go back to when all the [NHS] 
changes came out, a lot of the GPs were very supportive and helped us maintain PPs within 
[CCGB].” HoMM B 
 
The same CCG (B) had surveyed their practices and found that the service provided by their 
PPs was valued by their GPs. HoMM D thought that the provider organisation was 
considering carrying out an anonymous survey of the GP practices that they served. 
 
5.3.3 Work plans 
The PPs were given a work plan based on the commissioned functions, usually to address 
the incentive scheme, as directed by the individual HoMM and the CCG. The CCG priorities, 
described by the HoMMs, were around the management of medicines because medicines 
were the most common intervention in health care, and prescribing was a significant 
proportion of the overall CCG budget. The role of the PP team was to facilitate prescribers to 
get the best value for money from medicines and to show that this function could have a 
significant impact on the budget.  
 
“...so, it's [financial control of prescribing costs] very important now, it's one of the few areas 
where we're managing to control the costs.” HoMM B 
 
Another HoMM reinforced this by considering long-term funding for prescribing as the CCGs 
developed. 
 
“I also think it’s because of the pressure from NHS-top down, regarding financial pressures, 
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CCGs aren't getting [budgetary] uplifts…so, therefore, they are going to be under more 
financial pressure than perhaps PCTs.” HoMM A 
 
The HoMMs felt that there was a duty to patients to optimise the use of medicines for clinical 
reasons as well as financial. The commissioned functions included interventions that could 
support both patient care and cost-effectiveness, e.g. medicines reconciliation and repeat 
prescription management respectively. The CCGs work plans directed the PP team’s work 
but allowed some flexibility to deal with urgent items (recalls and safety alerts) and practice 
issues to be addressed. The PPs understood the importance of the work plan and accepted 
that their role included financial savings and patient safety issues and understood the need 
for flexibility. 
 
“The work plan is predominately driven by safety and cost, isn't it, and I think that's true of 
every team, cos that's our remit, as long as it fits with that then there's flexibility.” PP B5 
 
But there was some frustration at the monetary focus in the work plan.  
 
“We all get slightly frustrated that the focus is financial a lot of the time” PP D2 
 
Some PPs expressed a conflict between their primary commissioned role and the practice 
agenda, although some PPs were disposed to look at the practice issues first. For example: 
 
“I know my first question is OK then, what have you [the practice] got ready for me? And 
they'll be several queries waiting to do first before I start my proper job.” PPC2 
 
GPs also understood that this work plan was generated centrally to meet CCG goals and that 
the PP would try and combine this with practice-led tasks.  
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“Mostly it comes from his managers within the CCG… but he's very flexible, and if we've got 
things that we need her to do, he'll do that too”. GP C1 
 
Despite some negotiation between the PP and the GP practice to prioritise work to suit the 
needs of the practice, GPs from all CCGs felt that the CCG agenda was also important, and 
that PP time should include this work. Only one GP stated that they took a more practice-
centred approach and would consider blocking CCG work that they did not consider was in 
their interest. 
 
“So, if the CCG require her to do something that doesn't fit our mode, I will intervene to align 
their work with mine….” GP B2 
 
5.4.4 Transition of the Practice Pharmacist teams 
All four focus groups were asked about the transition of the team from the PCT to the CCG. 
The responses varied based on the levels of perceived disruption that the transition caused 
to the individuals and team. For example, CCG A’s team felt that the move had been almost 
without incident, largely because there had been little change in personnel and function.  
 
“I feel quite indifferent because I don't feel like there has been much change, haven't seen 
much change… you know we've got the same colleagues, doing the same kind of work.” PP 
A1 
 
Despite this, the focus group acknowledged that other teams had not fared so well. 
 
“… other CCGs got rid of pharmacists and they've left without jobs…” PP A3 
 
The situation in CCG C, which had a mixed model for the commissioning of the PP team, 
appeared to raise more issues, including uncertainty of on-going employment. These were 
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exacerbated by the fact that the transition was not complete at the time of the focus group. 
One focus group member was transferring from an acute trust to the CSU, that was itself 
reorganising at the time. This appeared to create a continual state of flux that was disruptive 
and time-consuming affecting the PPs core roles. 
 
“It's been pretty disruptive to our working because a lot of times we're taken up with various 
meetings and reading e-mails about changes to structures…We’ve just finished going 
through a second consultation period with the CSU because it's merged with another CSU...It 
just takes a lot of time and energy really, to deal with the day to day changes to your actual 
employment status...” PP C1 
 
The PP team in CCG B perceived more disruption and job uncertainty and were affected 
more deeply, especially one respondent that felt that they had a vocational and personal 
attachment to the role that was being threatened. 
 
“That is why I got so sad when it was about, you know, all the changes happening because 
we didn't know if we would have jobs, and it's quite sad when you think, Oh I've found where 
I am happy in my working career, and you could potentially take all this away from me…”  
PP B2 
 
This team had little information about the transition due to the difficulties in understanding 
which organisation would host them.  
 
“I think initially lack of direction, we just didn't have a clue what was going on.” PP B4 
 
This uncertainty finally resulted in the team being hosted by the local Acute Trust close to the 
date that PCTs were disbanded. 
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“It all happened very quickly and at the last minute.” PP B2 
 
Despite the perceived threat of job loss during the transition, one focus group member felt 
that now there was more job security working for the Acute Trust. Although this was not 
necessarily in the PP role, they were happy in the knowledge that they were pharmacists 
within an organisation that employed pharmacists in other capacities, and content that the 
PPs might cover other roles.  
 
“I just thought our jobs are safer now because we're employed by an acute trust whereas you 
don't know what's going to happen to the CCGs…it may not necessarily be this [PP] job and I 
think that there is a possibility that they could say...we need some volunteers...to come and 
do…sessions at the (Acute Trust).” PP B1 
 
The HoMM that commissioned PP Team B confirmed that their Team had had a bad 
experience during the transition. The HoMM felt that this was reflected in their feelings about 
the move that were centred around the demise and loss of their previous affiliation. This 
HoMM arranged social events to address the feelings of loss. 
 
“There's almost like a bereavement feeling… some people reacted badly to that, angrily to 
that, and we had to sort of manage it with…, you know, exit-type meetings and nights out, 
you know what I mean? Almost like ‘goodbye, I'm leaving…” HoMM B 
 
One of the GPs in the same CCG noted changes resulting from the new structure and the 
purchaser/provider split. There was an extra layer of management that subtly changed the 
dynamic, potentially affecting shared goals. 
 
“…because the team at (Acute Trust) are responsible to the Chief Pharmacist and she is 
responsible for the service delivery and what we ask her to do, and that's just put an extra 
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different dimension to it…I know I'm the commissioner, but actually we're all in this together 
aren't we.”  GP B1 
 
The same GP considered this further and felt that it was a relationship change that might 
affect team working. 
 
“I know it's a very subtle change, but it alters relationships, and a lot of the time we are 
working as part of a team, it's actually the relationships that make the difference…” GP B1 
 
Relative changes in relationships with the provider organisation, the CCG, and the GP 
practice were highlighted by one of the PPs from the same CCG. Basic PP work had not 
significantly changed, so the GP/PP relationship was less affected, but the PPs and their 
new employer’s relationship was perceived to be based on little understanding of the PP role 
and the PP team that they now employed. Within this, the description of GPs as “our 
customers”, suggests a formal change in the way that PPs perceived, or had been told to 
perceive, the GPs for whom they work.  
 
“…the work in practices is unchanged…what has changed is…our employers [Acute Trust] 
don't understand what we do, and so we just carry on every day doing what we do [and] try 
to explain to everybody what it is that we do, but our customers the GPs, understand… and 
values our job.” PP B5 
 
The conflict between the CCG and practice work, the new relationships and mode of 
employment had left one member feeling additionally conflicted between the needs of the 
three organisations.  
 
“…because of the way, we are funded and the way we are employed… you are kind of 
"piggy in the middle" aren't you…” PP B6 
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When considering the benefits and drawbacks of the provider-hosted model, two HoMMs 
described a more business-like relationship with the PP team and the provider. The benefits 
included, not having to manage the PP team, and having a pre-determined work plan, but 
this meant that any change had to be negotiated within the agreed package of measures. 
 
“…if they [the CCG] want us to do something that's not on the work plan, we ask them what 
we are going to drop, so that we can make sure that we deliver…it's a more business to 
business relationship…” HoMM C 
 
A third HoMM stated that they were at “arms-length” from the PP team with contact via an 
intermediary, suggesting that they no longer felt part of the PP Team.  
 
“We’re not as closely involved as we used to be and then we have a contract review meeting 
with [Provider Manager] around the service they provide, and I get regular monthly reports on 
progress from her…So it’s more ‘arms-length’ sort of thing now.” HoMM B 
 
Another HoMM identified the relationship change and the dynamic with the PP team 
concurring with HoMM B.  Again, the term “customer” suggests the business-like relationship 
with the provider.  
 
“…I am no longer the direct line manager of the practice base pharmacists. I'm employed by 
the CCG, but everybody else in our medicines optimisation team is provided by our local 
CSU. So that has changed the dynamics …I am a customer [of the CSU] rather than just part 
of the team and a line manager.” HoMM D 
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5.3.5 Changes to role  
The professional respondents were asked if the PP role had changed since the transfer to 
the CCG. Two HoMMs identified only minor changes at a GP practice level. HoMM (C) 
stated that the mechanism for reporting outcomes had changed because of the new 
structure.  
 
"Has the role changed? I think fundamentally the work they do hasn't changed, but the 
reporting upwards did change.” HoMM C 
 
The PP role had not changed, according HoMM A, but they considered that cost-
effectiveness had become a greater focus due to changes in the CCG financial 
responsibilities. 
 
“I don't think it has changed locally significantly; I think perhaps there may be more of a focus 
around the financial savings since we became a CCG and I think that part of the driver for 
that is the fact that CCGs have to break even on their overall budget that they manage…” 
HoMM A 
 
HoMM (B) had a strict commissioner/provider relationship with their PP Team, hosted by 
another NHS provider, where the CCG had stipulated that the PPs should focus on broader 
patient-related outcomes rather than savings and reporting pathways. 
 
“The focus has got to be now about interaction with patients, recording outcomes, clinical 
intervention …” HoMM B 
 
HoMM (D) also had a strict commissioner/provider relationship with their PP Team but was 
interviewed last and had the advantage of having had more time to see how the PCT-CCG 
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change was affecting the PP team. This HoMM also had strict commissioner/provider 
relationship with their PP Team, but when asked about changes to the pharmacist role, 
indicated a change in the way that PPs were perceived by GPs rather than changes to the 
role although this did relate back to the PP role. 
  
“I think GPs more so than ever do regard the practice pharmacist as their resource, rather 
than something parachuted in from outside than most. They definitely start to look at those 
pharmacists as part of the team and looking at other ways of involving them.” HoMM D 
 
The GPs interviewed also had a range of opinions about the PP role related to each CCG. 
The GPs in CCGs (B) and (C) did not identify any changes in the PP role. However, one GP 
in CCG (D) identified a move towards quality issues. 
 
“I don't think the role has changed a huge amount…I think when they started it seemed to be 
more about money - saving money… So, I think the quality issue has come in a bit more, 
recently, in the last year or so.” GP D1 
 
In CCG (A), the GPs indicated that any change in focus was organic, part of a natural 
progression to a more patient-facing role for the PPs and that the development of the PP role 
was overdue. 
 
“It's going to be a matter of natural progression. Practice-based pharmacy will become a 
bigger and bigger role-I think it's shocking that it isn't already.” GP A1 
 
“I think that the change is more in the sense of what roles can the pharmacist do more and 
more.” GP A2 
 
 “I think it seems to have changed, I think they do seem to be doing more face-to-face work, 
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and I think also they seem to [be] more looking at prescribing for residential homes and 
patient who are on vast amounts of medication.” GP A3 
 
The PPs in the focus groups were divided between no real change and a move towards 
more financial savings. One PP felt that the focus on cost savings was a cyclical step 
reminiscent of the early days of PPs. 
 
“I feel like it started off with the cost pressures, you know years ago, then it kind of drifted 
towards...clinical things and it kind of feels, not like we are going backwards but that we have 
almost come full circle…” PP A1 
 
Where there was a perceived move towards cost-savings, over other PP work, this was seen 
as partly generated by another NHS organisation. 
 
“More financially driven, but that's NHS England, (general agreement) that's the goals now.” 
PP B6 
 
Financial pressures were not necessarily a result of the change from PCT to CCG, but more 
likely due to the poor overall financial situation.  
 
“I am not saying it is the change to the CCG that has caused it; I think it's the general climate 
[general agreement].”  PP A2 
 
They felt that there was a problem in that the financial savings were harder to achieve now 
than they had been in the past, for example, switching from expensive branded drugs where 
generic alternative medicines were available. 
 
“There isn't the money to be saved that there was years ago when we were ahead of the 
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game using simvastatin instead of atorvastatin.” PP A2 
 
Despite the cost agenda, some PPs thought there was an increase in the variety of work that 
they were asked to do confirming the GPs aspirations to expand the PP role. 
 
“The variety of the work has gone up as well; we're getting involved with different things now-
that might not have been the same as before...” PP B3 
 
5.3.6 Practice Pharmacist training 
The training of Practice Pharmacists is included in this Chapter as it was affected by the NHS 
changes when the NPC was absorbed into NICE, and a significant source of training for PPs 
was withdrawn. Provider organisations offered some training for their PP staff such as IT, 
and other training relevant to the work plans and some PPs obtained information training 
from the CCG Medicines Management Team as part of the support for the PPs working in 
practice.  
 
Two HoMMs thought that the provider organisation should fund some basic training.  
 
“…we’ve written into the contract that the [provider] should be providing all of their basic 
training needs...” HoMM B 
 
“That's one of those areas that's a bit grey and where I potentially think that the [Provider] 
should be at least contributing to that because obviously that training and those skills - 
although are embedded in GP practices…some of them do central work for the [Provider] 
and work in other areas too.” HoMM D 
 
One CCG used their lead pharmacists to identify training needs from the PP Team and were 
considering using local specialists to deliver this, particularly where this met CCG priorities. 
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“Well locally what we have done is to ask our Lead Pharmacists to manage the practice-
based pharmacists … requests are around IT and improving their knowledge of chronic 
disease…[What] we are hoping to do is to use local specialists to try and deliver some of 
that. I am trying to link it to some of the CCG priorities.” HoMM A 
 
The other HoMM encouraged self and group learning with the use of national training 
sources that were provided free to all pharmacists. 
 
“Yes, so we have a meeting every two months…which do have an educational input, we offer 
professional development sessions on top of that, like Learning@ Lunch, and we take it in 
turns at hosting those…” HoMM C 
 
One CCG had begun to use a competency framework for identification of training needs and 
subsequent continuing professional development (CPD). 
 
“Not formally [using competency frameworks] until recently when we all started going through 
the Royal Pharmaceutical Society [Faculty] Portfolio… They [PPs] all have contract service 
reviews, annually and six monthly; we do set clear key performance indicators that they have 
to achieve, some of which are CPD related.” HoMM C 
 
The other CCG used the Practice Pharmacist Competency Framework and an additional one 
for its prescribing PPs but were uncertain how to use this to confirm prescribing competency 
in new areas of practice. 
 
“Yes, we've got a Practice Pharmacist Competency Framework, and the prescribers will 
need to have additional competencies around [prescribing]. What will be interesting is if our 
[pharmacist] prescribers start working in new areas is how we as a commissioning 
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organisation can make sure that they are competent in those areas.” HoMM A 
 
The HoMMs in CCG (B) and (D) were not aware if their PP provider organisation used any 
competency framework, but HoMM B was assured that their commissioned PPs had 
adequate training. The PPs in focus groups B, C and D thought that they were either already 
using a competency framework or were going to be soon. Only one of the three focus groups 
(B) mentioned using the RPS Faculty Framework; the Competency Framework for all 
Prescribers (Royal Pharmaceutical Society, 2016). 
 
“We will be moving in that direction. There is one but because we have had to move into a 
new organisation we've had to use their competency framework first, but we will be using the 
Independent Prescribing one” PP B5 
 
All the HoMMs identified gaps in the provision of training, and some were considering or 
using private providers. Funding appeared to be a limiting factor, but the HoMM with the 
biggest PP team was also concerned about the logistics of providing training for the whole 
team.  
 
“I think the other daunting task with that is, with a team of 30+ pharmacists, to release them 
for a full day would probably be… quite expensive and two, backfill-issues would arise.” 
HoMM A 
 
Overall GPs thought that PPs were adequately trained for their role, with perhaps some 
provisos. 
 
“They're all very well trained… they come up with a scheme of work, come with all the right 
tools to do the job … So, I think from that point of view it works well, and I don't see there's a 
massive training issue or need really.” GP B1 
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“I would think that they are probably adequately trained for the basic stuff that we ask them to 
do, so in other words medication checking, budget and looking at our prescribing data and 
doing the searches, I think they are probably OK with that.” GP A2 
 
Two GPs did have some concerns about PPs’ consultation skills and ability to deal with 
CDM; this was despite not having had any patient complaints or any detailed understanding 
of pharmacists training. 
 
“I don't know how much training they get in actually seeing patients, counselling patients.” 
GP C1 
 
“…like hypertension, I think they would have to have special training, so I think whatever you 
do about increasing their skill base then they will need more training. I suspect that they have 
a good understanding of patient medication…I haven't had any complaints from patients…” 
GP A2 
 
One GP did consider that good training on the IP course imparted more clinical skills to the 
PP and that such skills were necessary for the management of chronic disease.  
 
“I think the [IP] training … gives them that insight into the clinical scenario. I don't think 
chronic disease management works as well unless you've got that kind of clinical approach.” 
GP C1 
 
Another GP felt that the PPs they had were all “good pharmacists” and therefore they were 
not so aware of any training issues. They also raised an important issue, that the success of 
the integration of PPs into GP practice was dependent on training. 
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“…I would say that I have been spoilt a little bit with good pharmacists, and the whole 
introduction of pharmacists into primary care does depend on their training…” GP A1 
 
The PPs were resourceful when seeking out training opportunities and mentioned. For 
example, attending training designed for GPs, and assessing the Medicines & Healthcare 
products Regulatory Agency (MHRA) education website. 
 
“I go to the [local] Medical Institute, they do GP based kind of lectures, and I find this most 
useful for my clinical side, it's just because that CPD is more relevant for where I am coming 
from as a prescriber…” PP A3 
 
“I've been trying to log onto the MHRA education site which is fairly new… hopefully, as an 
older person's pharmacist, there's loads and loads going on now around dementia.”  
PP C2 
 
The National Prescribing Centre used to run therapeutic training sessions for PPs and were 
also important for networking between PP teams. These were highly regarded by PPs but 
have been discontinued since the organisation was merged with NICE. The Midlands HEI 
study days were considered as somewhat “filling” this gap, particularly around networking. 
 
“[The Midlands HEI] are filling the gap of the NPC [general agreement].” PP B3 
 
“…the NPC was just therapeutic subjects, on rotation, the networking was brilliant, with other, 
you know, prescribing advisers, other Practice Pharmacists, you saw what they did…share 
ideas...” PP B1 
 
Responses from the focus group pharmacists also provided information about their training 
needs. Three focus groups (A, B and D) wanted more IT training including training on 
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practice computer systems, ePACT, electronic transfer of prescriptions, mail-merging and 
spreadsheets. Focus group B pharmacists were particularly concerned about the lack of staff 
induction for PPs new to their organisation. Communication and clinical topics were 
mentioned, such as influencing skills, interpreting blood results, health assessment and 
CDM. One PP felt that current sources of education and training were too focused on 
community pharmacists but acknowledged that this was appropriate given the number of 
pharmacists in that role. 
 
“Nearly all pharmacist training is geared towards the community pharmacist, if you look at 
pharmacy training, and I do appreciate that the large majority [of] pharmacists are community 
pharmacists?” PP C1 
 
Patients did not often question the PPs competencies related to medicines use and 
considered that the pharmacist competencies were inherent in their training. Two patients  
(P A2 and P C3) felt that “any good [GP] practice” would consider the pharmacist’s ability to 
carry out the role before employing them. Thus the practice validated the PP’s competency in 
the patient’s mind. 
 
 “Obviously, she knows the tablets. She’s learned and knows what they do, and apart from 
anything else, I don't think that a good practice would not have a pharmacist to do these 
things for them, to be honest.” P A2 
 
“I … just assumed, because obviously he's located in my GP surgery, that he could be 
trusted. So, that was fine. P C3 
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Chapter 6 – Stakeholders’ Views of the Practice Pharmacist’s Role and its Future. 
 
6.1 Overview 
This Chapter begins with the importance of the PP role, including the value of PP 
prescribing, from the stakeholders’ point of view. The stakeholders’ aspirations for the 
future of the pharmacist’s role within general practice are then described. The Chapter 
continues by defining the drivers for the integration of pharmacists into primary care that 
have been identified during the thesis project and draws attention to some remaining 
perceived obstacles.  
 
 6.2 Research questions 
3 What are the key stakeholders’ perceptions of the current practice pharmacist role 
and its future, including prescribing? 
4 What are the personal and career aspirations of primary care practice 
pharmacists and the perceived opportunities and barriers to achieving these? 
 
6.3 Results 
6.3.1 Importance of the practice pharmacist’s role 
The current roles of the practice pharmacists and the perceived importance of these roles in 
the four CCGs were discussed with the patients, GPs and HoMMs. The management of 
medicines was particularly important to all the HoMMs because of the financial and clinical 
outcomes that it delivered. For example, HoMM D said: 
 
“I think managing and optimising medicines is very important in all CCGs... From the point of 
view both financial and clinical probity and making the most of how we treat our patients and 
how we use resources.” HoMM D 
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The HoMMs considered PPs to be essential to medicines management as they were not only 
able to carry out work at a practice level but could help practitioners change their behavior. 
One HoMM, whose PP team was commissioned from another NHS provider, saw their PPs 
as a conduit for the flow of medicines related information between the CCG and their GPs as 
well as delivering CCG priorities. 
 
“…it’s [PPs] my only outlet into other practices other than…top-level communications, 
newsletters, that sort of thing…so they’re meant to act as a two-way communication…to 
make sure that medicines’ safety alerts are implemented and…our means to deliver the … 
Quality Innovation Prevention & Productivity (QIPP) work within practices and the team 
themselves on the ground, talk to GPs...” HoMM B 
 
The GPs also felt that the PP role was important for the flow of information between 
themselves and the CCG related to cost savings and patient safety. The GPs were all aware 
of the overall cost of medicines and how their prescribing could be improved by liaising with 
their PP on the appropriate use of medicinal products, although there sometimes was a 
tension between these two.  
 
“Prescribing appropriately regarding costs, so we don’t spend too much, and sometimes 
those go together, sometimes not.” GP D1 
 
One GP picked up on the two-way communication theme where the practice was trying to be 
cost-effective but could not get other providers to support this. The PP contacted the CCG 
and the CCG, in their commissioning role, liaised with the provider to negotiate the change. 
 
“…recently we had an issue with quetiapine modified-release versus immediate release cost, 
trying to get the psychiatrist to prescribe the cheap stuff, there was no real reason not to, and 
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getting [the PP] to kind of feedback to [the psychiatrist] about that.” GP C1  
 
Several of the GPs considered that PPs saved the GP time or undertook things that the GPs 
should do but did not have time to do. Medicines reconciliation and audit were examples of 
tasks that required a certain level of training to complete safely and were identified as time-
saving functions that PPs could safely undertake on behalf of GPs. 
  
“[medicines reconciliation] It's more complex that we would expect even a fairly senior 
receptionist to do, particularly where there is a change of medication, a change of doses, 
trying to tally up different amounts of medication, so I think it does need someone with a 
professional background to do that…I would suspect that it probably saves each doctor, 
maybe an hour or two a week.” GP A3 
 
Moreover, some functions devolved to PPs would not otherwise take place. For example: 
 
“Going through a list of patients and auditing things... So, it's something that saves us a lot of 
time. Well, the stuff that we just don't have time to do.” GP D1 
 
“[the PP functions] are very important, because the stuff that [the PP] does is clearly stuff we 
could do, but it's the stuff we often don't have time to do.” GP C1 
 
Patients identified a significant number of benefits in dealing with a PP. Saving GP time was 
identified by patients as a function of the PP role. Moreover, it was felt that PPs could reduce 
waiting times, and absorb some of the practice workloads.  
 
“Well, maybe you would not have to wait so long to see, you know, someone. It probably 
would be a bit quicker [to see a PP] because …I think it would be a little pressure off doctors, 
does that make sense?” P C1 
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Patients also considered that PPs were more approachable than doctors for issues that they 
felt were not sufficiently concerning to bother a GP with.   
 
“…you wouldn't go and waste a doctor's appointment time just to say, "Look, my legs are 
dry." But [named PP] gave me some cream. Now I'm using that cream, and I use it every 
day, and now I've improved and my legs aren’t as dry as they were.” P A3 
 
Increased consultation time was a recurring theme related to PP consultations, with patients 
equating this to a more informative and personal experience.  
 
“They [PPs] seem to give more information than a GP does, they can take that extra time… 
but they just seem to take their time to get to know you…” P C3 
 
Patients did appreciate that there was an inherent benefit in seeing a pharmacist rather than 
a doctor. This benefit was not only related to the “more time” theme but also to the fact that 
PPs were non-medical, and they could answer different questions and were focused on 
medicines use, benefits and harms. In the case of PPs managing chronic disease, there was 
also a recognition of expertise and, in some cases, even specialism. 
 
“I felt he [PP] seemed to have a specialist interest in that particular aspect of health. When 
you get older, you've got lots of things wrong with you [chuckles],…It's nicer to have 
someone who focuses on one of those and gives you his undivided interest in that, and 
obviously his expertise.” P C4 
 
The same pharmacist was acknowledged by their GP as a specialist pharmacist that 
provided a service to patients and acted as a resource on respiratory matters. 
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“He is an experienced pharmacist. He is a pharmacist with a special interest, respiratory and 
is an information source for this and other conditions when necessary.” GP C2 
 
6.3.2 Benefits of pharmacist prescribing 
The value of PP prescribing to the stakeholders was sought in the interviews and focus 
groups. Pharmacist prescribing was generally seen as advantageous by the HoMMs, but in 
one CCG (D) is was not a current priority because of limited capacity and funding. 
 
“…[pharmacist prescribing] it's not part of a standard work that we expect them to do. I 
strongly hope that as we go forward, it will become part of the work that we commission. But 
now, I don't think we have the finance or the resource to make it an equitable and viable 
thing.” HoMM D 
 
Two of the other CCGs (C and A) had a high proportion of pharmacist prescribers who were 
thought by the HoMMs to be actively prescribing in repeat prescription management, post 
discharge-medicine reconciliation, and CDM. 
 
“Well 16/17 of the Team are non-medical prescribers, all of them use it…” HoMM C 
 
“I think in [CCG A] I am pretty certain that most of our pharmacists prescribe regularly if we 
look at the definition of regularly as someone who has prescribed in the last two or three 
months; I suspect that most of our pharmacists are doing that.” HoMM A 
 
The benefits of pharmacist prescribing were summarised by one of the HoMM who echoed 
the overall benefits of non-medical prescribing that are published by the DoH, i.e. increased 
patient access to medicines, freeing up doctors’ time and utilising the skills of other HCPs 
(Department of Health, 2008).  A fourth benefit was around patient safety but related to the 
perception that pharmacists had a cautious approach to prescribing. 
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“I think there are also benefits in terms of safety as I suspect that pharmacist prescribers 
generally are quite careful prescribers ...” HoMM A 
 
Other HoMMs identified further benefits that included the PP delivering a more complete and 
efficient service that did not require any consultation with the GP  
 
“The added value is that they can give a more rounded service and not always have to then 
go and give a whole wodge of stuff for the GP to then look at and sign off, and then wait, and 
then action.” HoMM D 
 
Functions like pharmaceutical care would be supported by increasing numbers of prescribing 
pharmacists; there was an assumption that a prescribing qualification would be more 
common in the future. 
 
“… the availability of more prescribing pharmacists… in future means that we can actually 
move forward into this pharmaceutical care model because we have the staff there to start 
doing that.” HoMM D 
 
“I would expect that they would all be prescribers…” HoMM C 
 
Two GPs also identified that completing the consultation independently was a valuable 
benefit. This function was linked to making changes to the patient’s medication and the 
“responsibility” of completing the consultation by prescribing.  
 
“… it gives them [PPs] more responsibility- enables them to do the job right through to the 
completion of doing the script and changing the patient.” GP D1 
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“I think a pharmacist with a prescribing qualification who can take that responsibility and 
complete the task, I think is invaluable.” GP A1 
 
Another GP considered that by not being able to prescribe at the end of a consultation 
somehow reduced patient confidence in the PP.  
 
“…and I think that the act of prescribing at the end of a consultation gives the patient 
confidence in the clinician (pharmacist), having to get another to sign the prescription 
somehow reduces the patient’s confidence.” GP C2 
 
While another GP saw pharmacists prescribing as a learning tool and that the experience 
and responsibility of being a PP prescriber was a benefit to the PP. 
 
“…when you are a prescriber, your own prescribing, you then see the results of that, that 
experience then gives you an added edge…as you see how that goes [with the patient], I 
think that is worth something…” GP A2 
 
Some areas of pharmacist prescribing were acknowledged as cost-saving. Managing the 
repeat prescription requests from those acting on behalf of patients (third party requests) was 
something that GPs felt required the scrutiny of a PP to avoid waste.  
 
“where we have had complex requests for medications say from District Nurses-I think they 
[prescribing PPs] seem to be quite good in teasing out what's needed in terms of dressings. 
They also tend to, take responsibility … for managing prescriptions for catheters, bags and 
appliances and things, which I think has shown huge cost benefits.”  
GP A1 
 
Prescribing PPs also echoed the views of GPs around the use of non-medical prescribing to 
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improve patient access to medicines.  
 
“It's got to be better for patients hasn't it cos they can get the prescription straight away 
rather than waiting?” PP B4 
 
Pharmacist prescribing was also felt to reduce GP workload by addressing aspects of CDM 
which freed up GP time to manage more complex patients. 
 
“And I also think that if you follow it all through… we should be reducing the work load of the 
GP… they could be dealing with more complicated acute illnesses…” PP B6 
 
One PP considered that prescribing equates to autonomy and that this improves both the 
perception of the patient and their relationship with the pharmacist. 
 
“I think it gives them [patients] a more complete consultation. The autonomy definitely helps 
improve your working relationship, and it changes the perception of the patient [positively] as 
well to a certain degree.” PP C1 
 
Among patient respondents who were asked about pharmacist prescribing, there was a 
range of level of awareness. Some were completely unaware. 
 
“I didn't know actually. I didn't know about them [being able to prescribe]. Completely new to 
me.” P C5 
 
Another had experience of nurse prescribing in an urgent care setting and also dental 
prescribing and was not surprised to find that pharmacists could also prescribe. 
 
“Yes. I have been to a "Walk in" clinic, and the nurses there sometimes prescribe…I didn't 
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find it strange [PP prescribing] because sometimes the dentist will prescribe for you, as well.” 
P C4 
 
Other patients were fully aware and indicated that pharmacist prescribers prescribed a range 
of medicines for minor ailments and also for chronic diseases to good effect. For example:  
 
“Well, he's changed my medication… the one for asthma. He's actually prescribed a better 
inhaler…” P C5 
 
Not all HoMMs were convinced that pharmacist prescribing was an essential skill for a PP. 
Their previous experiences of difficulties around recruitment of PPs, and also issues with 
finding funding for the non-medical prescribing (NMP) course, seemed to contribute to the 
view that these factors may be a barrier to the expansion of pharmacists prescribing. 
 
“The downside is funding for NMP, with the loss of training monies I think CCGs will struggle 
to find funding for NMP, so, therefore, it may mean that pharmacists themselves might have 
to self-fund which could be a barrier [to increase the number of pharmacist prescribers]” 
HoMM A 
 
Further issues with pharmacist prescribing for CCG commissioned PPs were linked to how 
they are deployed and where their funding should come from. HoMM B considered that non-
medical prescribing was more applicable to a directly employed role. 
 
…we've struggled a little bit strategically to identify an area where they would best use those 
[PP] prescribing skills…the NMP role to me more fits more with someone who's regularly 
employed by the practice…” HoMM B 
 
HoMM A felt that PPs should be integrated into primary care to address long-term conditions 
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and was unclear how the PP funding could be allocated to make this happen.  
 
“I think the next step is getting the pharmacists integrated into primary care around long-term 
conditions and other roles that they have the expertise for…I think the crucial question is will 
that be funded by GP practices or will it be, as at the moment, through the CCG-so 
somehow, we need to have a shift of funding towards practices...” HoMM A 
 
Two GPs considered that pharmacist prescribing was essential to the PP role, others saw it 
as desirable. One GP went further and identified the underutilisation of the prescribing 
pharmacist’s skills in CDM, and the potential for improved patient care, despite not being 
clear about how this could work in the current situation.  
 
“You know we have highly qualified independent prescribing pharmacists, and we're not 
using their skills to the full…we should be using them to deliver all kinds of chronic disease 
management… so we're going to have to find out where that role sits.” GP B1 
 
The GPs felt that the lack confidence among some prescribing PPs meant that they were not 
utilising the skill. For example: 
 
 “…it's the confidence to use the qualification, so I have got some with the qualification who 
won't use it, where they are of no more benefit as someone without it.” GP A1 
 
The PP prescribers identified some issues that they had encountered when they were 
actively prescribing in practice. For example, there was some pressure to prescribe for 
patients when there was no GP available.  
 
“I mean the staff sometimes if there are no GPs in the building, it's like can you sign this 
prescription? “PP C1 
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This was associated with a perceived lack of understanding of the prescribing pharmacists’ 
role and the need for them to prescribe within their areas of therapeutic competence. 
 
“But I think it's important to say no, I think it's important that the reception staff understand 
your role…” PP A2 
 
The reluctance to sign ad-hoc prescriptions was linked by the PPs to the perception that 
pharmacists were much more cautious prescribers than GPs and that a pharmacist 
prescriber would want more detail before considering prescribing.  
 
“Whereas [compared to a GP] I think as a pharmacist, I would like to think that we are all 
much more careful about what we sign, and we think about what we are going to sign and 
what we are not going to sign.” PP A2 
 
This cautious approach may be due to a lack of experience or limited areas of competence, 
whereas GPs were much more accustomed to prescribing and had wider areas of 
competence. It was also felt that over time experience would make pharmacists less 
cautious. 
 
“I think…[GPs] they're more relaxed [about prescribing] they do it all of the time, and possibly 
if you did it every single day we wouldn't [be so cautious].” PP C1 
 
Other prescribing PPs specifically mentioned being limited by competency when considering 
signing prescriptions for patients.  
 
“There are certain things that like… there was an example today… growth hormone. I'd got 
the letter from the hospital, but I still didn't feel it was in my competency to sign this 
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prescription for the growth hormone.” PP A2 
 
Other PPs assessed risks, rather than just competency, to set parameters around their 
prescribing and to determine if they would sign a prescription. 
 
“I've done [prescribed] methotrexate…in another CCG simply because if the bloods are 
done, and you're happy… and you're confident, and they're on repeat. I wouldn't initiate it 
obviously, but I'd sign a repeat.” PP B6 
 
Another prescribing PP thought that the difference in perception of risk between doctors and 
prescribing pharmacists was a result of differences in medical and pharmacy training.  
 
“They're [doctors] trained to be autonomous [prescribers]…and we are encouraged to work 
more as a team; we take less individual, we share our responsibility…” PP B5 
 
Another limiting factor for PP prescribing was the working relationship with other practitioners 
in the practices. Not all wanted to reduce their workload or felt the need to let the PP see 
patients with chronic disease. 
 
“…where I do the hypertension clinics; there's a couple of GPs who won't refer patients to 
me, they just see their own patients and the same with one of the nurses…she's an IP and 
she prefers to see her own patients…” PP A3 
 
Patients were largely happy for pharmacists to prescribe for them, although some were only 
comfortable for a prescribing pharmacist to prescribe repeat medications against the 
diagnosis of a doctor.  
 
“No, I had seen doctors about that in the past, so I think it was a diagnosis made actually by 
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a hospital, consultant at the hospital, followed up by the GP, and then carried on by the 
pharmacist, so I felt that was okay.” P C4 
 
This feeling was echoed by another patient who also included situations where the patient 
might have a new condition or felt ill.  
 
“I don't know whether you would want to see the pharmacist if you have a condition if you 
were looking for help with a new problem. If you have a new condition if you felt ill… I don't 
think that you would want to go and see the pharmacist then.” P A1 
 
For another patient, it was the type of medication that was important. 
 
“Where blood pressure or statins are concerned, that's different, but I take epilepsy 
medication, I wouldn't like them [PP] to change that.” P B2 
 
Other limitations to the PP prescribing role were identified by individual patients. For 
example, some patients noted that the PP prescriber would not always prescribe all their 
medication and were not autonomous.  
 
“I wanted other tablets, and he couldn't do it…. he couldn't prescribe my other tablets.”  
P B2 
 
  “During the consultation, something arose which required them to speak to a doctor, which 
is what they did. That was done quickly, and it was resolved there and then.” P A1 
 
Others specifically noted restrictions on the availability of the PP. 
 
“…not in the case of the condition that I've got because I know he's a specialist, and he's 
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there a certain time each week.” P C2 
 
6.3.3 Heads of Medicines Managements view of the practice pharmacist role in the future 
Two HoMMs had considered the move towards direct employment of pharmacists by GP 
practices and were supportive of this, despite the likelihood that PPs could be drawn from 
existing CCG teams being attracted to more patient-facing roles.  
 
“They are now part of the CCG. But I see them ideally becoming part of the individual 
practice teams, same as the practice nurse and the health care assistant (HCA) are, fully 
joined up members that are more aligned to the practice than to any outside body.”  
HoMM D 
 
“…if pharmacists become employed by GP practices, that potentially could have an impact 
on commissioning organisations…I suspect that pharmacists will become attracted by the 
option of doing long-term conditions work rather than what they might see as more 
commissioning type roles.” HoMM A 
 
Another HoMM identified that one of the drivers for this was the desire of GPs to direct the 
work PPs were doing in practice. 
 
“The GPs that I have spoken to so far want more control over what the practice pharmacists 
do.” HoMM C 
 
There was an understanding that the integration into practice teams would provide benefits 
regarding patient facing activities such as clinical medication review and medicines 
optimisation. 
 
“And where their skills are slotted in with the practice nurses and the other NMPs and HCAs 
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and GPs, to provide the patients of that practice with a fuller service. And be able to feed in 
proper clinical pharmacist medication review, as a normal part of NHS provision...” HoMM D 
 
One HoMM wanted PPs to work more closely with community and hospital pharmacists. 
They saw the PP as a conduit between these two sectors of the profession.  
 
“As the role develops I think… there needs to be better working with your local community 
pharmacists and also with the hospital pharmacists team because at the end of the day the 
[PP] is a pharmacist within the health economy and it’s about better integration of those 
groups of pharmacists”. HoMM A 
 
They went on to suggest that patient care would be enhanced, regarding interface issues, if 
this could be achieved. 
 
“…So, for example, could community pharmacists refer patients to a practice pharmacist and 
vice-versus or could hospital pharmacists refer to a community pharmacist directly…that's 
something we need to develop as well because I think at the moment there is a dotted line 
instead of a bold line in terms of continuity for patients etc.…” HoMM A 
 
The HoMMs also identified the need for a better career structure for PPs role related to the 
expected growth in the numbers of PPs and the likelihood that many would be embarking on 
the role for the first time. One suggestion was that there should be an entry level with a clear 
career path to more senior level(s)  
 
“Because whilst there are going to be more pharmacists…a lot of those pharmacists are 
going to have very little experience. So, we really do need a proper employment framework 
with potential for stepping up through the grades - a proper career progression model”. 
HoMM D 
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6.3.4 General Practitioners’ view of the practice pharmacist role in the future 
All the GP respondents agreed that the future role of PPs should include patient facing roles 
that would address the workforce issues in primary care. CDM was frequently mentioned, for 
example, COPD, diabetes, thyroid disease, asthma and chronic pain, where they felt PP 
could have an impact. 
 
“I think [PPs] can have a huge role, a bigger role in chronic disease management where that 
would be structured so that if…a HbA1c is above target; they could work on getting it into 
target… these things are set out, and most work in algorithms”. GP B2 
 
This respondent wanted to limit the role to those conditions where treatment was defined by 
existing algorithms and was kept broadly within these parameters. Not all GPs agreed with 
this, and two considered that PPs could get involved in the triage of patients presenting for 
treatment where a precedent had been set by nurse practitioners.  
 
“…I think it's more about saying how best to use pharmacists in different roles and even to 
take on, for example, urgent care work…pharmacy triage, for example, nurse practitioners do 
triage why not pharmacists?” GP A2 
 
One GP went further to suggest that all PPs should be considered for all of the above roles 
and more, stating that PPs were only limited by access to training, and that specialisation in 
one area was one outcome that training could deliver.  
 
“But I think they could go into a million and one different roles. They could triage, they could 
do other chronic disease management, they could help us with the clinical audits, with QoF 
the over 75s that we are looking at. I don't think there is anything that a GP does that they 
couldn't do with training and I think particularly a focus on particular specialty.” GP A1 
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Another felt that pharmacists should not only advise on medicines use but also focus on the 
quality of life issues within treatment protocols. 
 
“An interesting report out earlier this month with diabetes saying actually although the pills 
that we prescribe for diabetes make the magic numbers for HbA1C, cholesterol and blood 
pressure, are we actually improving the patients’ quality of life? And I think that a pharmacist 
may be involved to actually look at those quality of life issues.” GP A3 
 
6.3.5 Patients’ views of the practice pharmacist role in the future 
 
All patient respondents thought that there should be a PP in every GP practice often because 
they extrapolated the benefit to themselves in the wider population, but some did consider 
that the need for pharmacists would depend on how much demand there was for their 
services. For example: 
 
“Well, it's just because he has helped me in so many ways, so I don't see why other people 
wouldn't want that facility… It kind of depends on their popularity. You know when he is there 
any you know when to book for him, but I suppose [it] depends if they're needed full time”. P 
C3 
 
“I don't know what the demand is [for PPs]. I suppose it's like all things. It's money, isn't it? 
It's whether the demand is there for them.” P C4 
 
Patients also felt that the PP could be used to extend the GP consultation where information 
was required about a new or current medicine.  
 
“… if you're going on to a new treatment, it might have side effects and whatever. And if you 
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could ring her/him up, or get in touch with her/him quicker…” P C5 
 
“It's nice to talk to someone [like a PP] about their medication. Cos [with] the doctor, all I do 
now is phone up, and he gives me a repeat prescription, whether it’s the right medication for 
my health at the moment, I don't know.” P B1 
 
Also, the PP was a useful contact if the information given by a GP had been forgotten or was 
required again later.  
 
“…sometimes you've come away from the doctor and thought, "Oh, blast, I never mentioned 
that." Well, with [PP name], you've got the opportunity.” P A3 
 
Saving GP time emerged as a key benefit that patients perceived could be exploited further 
in the future. 
 
“I think it would take some of the pressure off and spread it around a little bit, and that 
hopefully will allow people with conditions that needed to see a GP, could see them more 
easily because there'd be less pressure.” P C4 
 
“[PP name] will listen to you, advise you, and she can prescribe. So, that means you don't 
have to waste doctor's time.” P A5 
 
When asked about potential future roles, patients did not have any strong ideas regarding 
the future role of PPs. They recounted their experiences of PPs current roles in their 
narratives as they perceived them. For example, medication side effects, minor ailment 
prescribing, ease of access for further information, community pharmacy interface issues 
regarding the supply of medicines, interactions, pharmacist prescribing within competence, 
medicines advice and medication review.  
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6.3.6 Practice pharmacists’ aspirations for their future role 
Pharmacists, particularly those commissioned from the CSU, wanted to spend more time at 
each practice. This model of PP provision lacked quality and the kind of patient focus that the 
PPs desired.  
 
“Personally, I think going back to what other focus group members said, it would be really 
nice to be able to spend quality time in a practice…for most of us at the moment, we've got 
eight or nine practices that you're trying to juggle over two weeks…” PP D1 
 
Some PPs had specific aspirations for the time they wanted to spend in each practice. For 
example: 
 
“I would like to be doing a day a week in a practice so that you could do the safety issues 
and see patients and do the long-term conditions…rather than this flitting in and out.” PP B2 
 
“But if you were in a practice where if you had maybe only two or three practices and worked 
in those a couple of days a week in each, that would be the perfect scenario for me.” PP D1 
 
This PP summed up for many a general desire for more face-to-face time in any future PP 
role. 
 
“I'd like to have more patient contact.” PP D2 
 
Another PP thought that there was a future role in addressing interface issues. They went on 
to quote an example in another CCG where this was being tried but were unsure of the 
outcome. 
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“We still haven't talked about the interface between primary and secondary care…[other 
CCG] has got an interface pharmacist…that's definitely somewhere where there's a lot more 
potential to work.” PP D2 
 
The integration of the pharmacy sectors, so that the divisions between secondary care and 
primary care pharmacy were less well defined, were felt to be important. Community 
pharmacy was perceived as a block due to the nature of the current model. 
 
“The integration of primary care and secondary care and community pharmacy really is vital, 
but where it's going to happen or not, I have reservations…The stumbling block here is the 
community pharmacy model… When that changes, I think you can start to integrate the three 
services together.” PP A6 
 
Integration within the practice was also felt to be important, and it was agreed that this was a 
way forward. It was suggested that PPs should be directly employed by the practice rather 
than the CCG.  
 
“What I would like to see in the future… is more integration into the practice, being able to 
run the practice in combination with other healthcare professionals… actually be part of the 
practice rather than being a part of the CCG.” PP C1 
 
At the time of the thesis project, this was beginning to happen as practices had started 
advertising for PPs.  
 
“You see practices now openly advertising for full-time pharmacists, there's one near where I 
live...” PP A1 
 
Another PP had a friend who was employed in this way.  
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“I know somebody who is directly employed by a practice; it works well for them.” PP D2 
 
Some PPs went further and suggested that PP should be involved with the management of 
the practice. This was a former community pharmacist who would have had managerial 
experience in this role. 
 
“In one of our practices we have got an advanced nurse practitioner that's a partner in 
exactly the same way, and there's no reason why we could not be more integrated into the 
management.” PP C1 
 
The prospect of becoming a partner in the practice was discussed again by another former 
community pharmacist. 
 
“I think a pharmacist should be a partner in the GP practice…I think in that case it could 
work.” PP A2 
 
One pharmacist went on to suggest that they aspired to become a Partner in the practice to 
improving patient care and income. 
 
“I don't see why a pharmacist can't be a partner in a practice, like you're looking at everything 
they need to do, and they need to do it efficiently, and I need to get it done then there's no 
reason why large majority of their QoF and meeting their targets couldn't be done outside the 
consulting room.” PP C1 
 
6.4 Drivers for the integration of pharmacists into general practice 
Given the developments in the role of pharmacists in general practice, and the desire from 
the thesis project to be integrated into general practice, it is important to define the drivers for 
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the integration of pharmacists into GP practices. These are summarised in Table 6.1 below. 
 
Table 6.1 Drivers for the increase in the numbers of pharmacists working in general practice 
Drivers for change Leading to current issues Potential solutions 
delivered by pharmacists 
Workforce deficiencies Shortage of HCPs especially doctors Take on workloads e.g. 
CDM 
Appropriate use of NHS 
funds 
The need to ensure that medicine use is 
appropriate. 
Pharmacists prescribing 
and medication review, 
medicines optimisation. 
The need to improve 
prescribing 
Inappropriate prescribing, ADRs and 
medicines related issues. 
Pharmacists-led 
medication review, 
medicines optimisation. 
Clinical information 
overload 
More complex and costly treatment, 
ageing population living with multiple 
LTCs, increased patient expectation, 
expanding evidence-base, Increasing 
national and local guidance. 
Pharmacist as manager of 
clinical information and a 
conduit for dissemination. 
Provision of PPs by 
CCG (funding and 
management) 
Dissatisfaction with the current service 
provision via CCGs by GPs and PPs. 
Direct employment or 
CCG/CSS/Acute trust PP 
budget devolved to 
practices. 
Changing culture Acceptance of the need for collaborative 
working. Pharmacists desire for a more 
clinical role. 
Collaborative working. 
 
6.4.1 Workforce deficiencies 
All the HCPs interviewed, individually or in the focus groups, identified a shortage of GPs as 
a potential driver for the inclusion of practice pharmacists into general practice teams as a 
way of absorbing some of the GP workload. The background to the current shortage of GPs 
has been outlined in 1.5.1. 
There was an awareness of GP shortages and recruitment issues amongst pharmacists who 
felt that doctors were disillusioned with the GP role and that GP practices were frustrated 
with the situation and the cost of employing GP locums. Pharmacists reported having seen 
advertisements for full-time pharmacist posts to work for GPs as employees. 
 “Yes, but they hired about 4-5 different GPs, and not had much success with any of them, 
and now they know the situation is going to get worse, they’re just frustrated because there's 
nothing they can do, and they pay locums a considerable rate”. PP C1 
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There was a general acceptance that the workload in primary care was increasing, due to the 
ageing population and the concomitant increase in chronic disease as well as emerging 
treatments and technologies. Direct employment of pharmacists was seen by GPs as a way 
of supporting the practice in managing workload. There was a general acceptance that 
practice pharmacists were adequately trained for their current role (with caveats about 
consultation skills) and moreover that they could easily be trained, where necessary, to take 
on more clinical roles. 
“I would be looking for expanding the role of the practice pharmacist as time goes on and 
give her/him more of a clinical role… we could quite easily up-skill and if you think the 
pharmacist has all this knowledge about medications, done a lot of pharmacology and a little 
bit of clinical work as well, you know, in their course, and then you just up-skill them 
clinically…”. GP A2 
 
GPs, pharmacists, and HoMMs also identified the contribution that PPs could make in CDM 
as a solution to workload problems in general practice.  
“…the bottom line is that he helps us … with the chronic disease management which is 
essential, because we'd have to do it if he wasn't doing that…” GP C1 
Despite the above, not all GPs saw the need to increase their practice pharmacist hours. 
However, the recent introduction of an Enhanced Service providing funding for over 75s care 
planning (NHS England, 2014c) had stimulated discussion at practice level about increasing 
practice pharmacist hours. In some cases, this had led to direct employment of pharmacists 
to support the programme.  
 
6.4.2 Appropriate use of NHS funds 
Heads of Medicines Management focused on the need to save money on prescribing within 
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the NHS as a driver. Medicines were the most common intervention and generated 
significant cost pressures and drug budgets, they felt, were unlikely to significantly increase 
in the next few years. Practice pharmacists were considered as one of the ways that drug 
spending could be controlled through medicines optimisation. 
“I think managing and optimising medicines is very important in all CCGs, to be honest… 
from the point of view both financial and clinical probity and making the most of how we treat 
our patients and how we use resources.” HoMM D 
The focus group pharmacists saw themselves as responsible for financial savings and 
understood that their individual savings would be quantified, and their effectiveness would be 
monitored. 
“We've got set amount of money to save which ultimately that is what it comes back to you - 
we've got to save this money.” PP D1 
 
Efficiencies were also identified by GPs as a key function of the practice pharmacist both 
concerning the pharmacists’ responsibility to the CCG and the individual practice. Practice 
pharmacists were considered cost-effective in this role by GPs, saving more than they cost.  
“It seems the amount that pharmacists can save us completely out-ways the cost [of PPs].” 
GP D1 
The benefit to patients from more PP contact was felt to be potentially very high, and 
pharmacists themselves wanted to work more closely with patients to make this happen. 
“actually, conversations with patients really helps you to understand where the gaps are [in 
understanding medicines] and how complicated some of these medicines are, maybe 
simplify them in some case.” PP D2 
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6.4.3 The need to improving prescribing 
GPs also identified a pressing need to improve prescribing and reduce hospital admissions 
due to medication issues. 
“There is so much scope for just improving prescribing of medications and reducing 
prescribing errors which contribute to admissions and these sorts of things, and even just 
patients not quite understanding how to take things…” GP A2  
 
Practice pharmacists recognised their role in medicines safety as well and linked this to 
medication review (MR). They felt that regular MR was a key factor in medication safety and, 
that now GP practice compliance with MR was monitored by the Care Quality Commission 
(Care Quality Commission, 2016). The focus group pharmacists did not think that GPs 
carried out MR in sufficient depth and felt that MR by a pharmacist could help reduce hospital 
admissions, improve prescribing and also save money.  
6.4.4 Clinical information overload 
GPs and practice pharmacists identified a role in providing information, training and updates 
to GPs and their staff. GPs felt that they were being overloaded with information related to 
medicines and that a pharmacist was ideally placed to help with controlling this and providing 
relevant information to practitioners, including training new staff such as registrars and 
medical students, especially around rational prescribing. 
 
“We are a training practice, and we have registrars and medical students, and we have 
asked our pharmacist to do a session, when the registrars start, on sensible prescribing in 
general practice, because so many junior doctors coming out of hospital training, really 
haven't a clue, in terms of what's an appropriate amount of pain-killer to prescribe, what dose 
of antibiotic, oh -what antibiotics do we actually prescribe in primary care as opposed to in 
the hospital.” GP A3 
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6.4.5 CCG provision of practice pharmacists 
The CCG provision of the PP service was considered to be a driver because of the 
restrictions it placed on the GPs and PPs. The pharmacists in the focus groups raised issues 
around the time that they worked in practices under their current commissioning model. None 
of the practice pharmacists in this project were directly employed by their GP practices. 
Pharmacists spent their time at some practices within their CCG visiting each practice once a 
week or less, usually for less than 8 hours per practice, so there was an inevitable delay at 
the beginning of each session as the pharmacist picked up the threads of work not 
completed at the last session.  
 “I'll be doing something at one practice, and if I'm not back there then next week, it takes me 
an hour to get back to where I was when I finished off. I think that lack of continuity is really 
difficult.” PP D1 
 
Working with GPs had shown the PPs that they could demonstrate the worth of the practice 
pharmacist role and to begin to define the place of the pharmacist within the practice. 
“I think the more time you spend there, the more they can see your worth and the more they 
can appreciate the variety of things you can actually manage or change.” PP D3 
 
Sessional working (one or two 4-hour sessions a week per practice) combined with a work 
plan meant that practice pharmacists had little opportunity to take on any work that was 
requested by, or that might be more relevant to the individual practices. One PP expressed 
the view that engagement with the practice agenda might overwhelm them and they would 
not be able to complete the work plan that had been commissioned. 
“Like when we said we can't get involved in some of these areas because if you say, "Oh I 
can do that for you" you're going to be flooded aren't you but when you only go for half a day 
per week you just can't offer that service.” PP B1 
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One GP stated that they did not always understand what the PPs were doing in their practice 
and that the external management of the PP meant that the GP did not have the authority to 
question their work. This GP also raised another team specific issue related to having more 
than one practice pharmacist working at their practice and described the service as 
“piecemeal” and wanted to have one practice pharmacist to undertake in all the work in their 
practice to ensure continuity and the completion of work from one session to the next.  
“I think we have some difficulty with having a piecemeal service, because you've got different 
pharmacists, and we've been trying to push for having a single pharmacist rather than having 
different people because you will find that pharmacists will leave work for the other 
pharmacists tomorrow and you'll find it can be "pass the buck" in some ways. Whereas if 
there was one pharmacist responsible for all the work, they'll get on and do it and that might 
mean they'll do it today or tomorrow but it’s still their job.” GP A1 
 
GPs also expressed a desire to have more control over the work that practice pharmacists 
undertook. External employers like the CCG, Acute Trust and CSU, were a barrier as they 
imposed the work plan on the practice. Some GPs felt that changing the commissioning 
pathway would mean they could be more creative by having more control and the ability to 
direct the PPs work to meet the individual practice situation and needs. One way to achieve 
this would be to devolve the practice pharmacist budget to individual practices so that they 
could manage pharmacists more effectively; this would give the practice ownership of the 
pharmacist’s work and provide greater involvement in the practice team and a wider role in 
CDM.  
“As mentioned before I think there is undoubtedly a role for pharmacists in conditions like 
diabetes, hypertension management, anticoagulation-there is lots of things which I think a 
pharmacist could do very effectively but it is a case of trying to work out what the priorities 
are and ultimately it comes back to who is employing the pharmacist, who is paying for their 
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time.” GP A3 
6.4.6 Changing culture 
Changing culture within the professions was linked to increasing workload and 
familiarisation. GPs, pharmacists and HoMM all recognised that both sets of HCP, doctors 
and pharmacists, possessed an inbuilt reluctance to change. GPs considered that, as a 
group, they could be protective of their role and to be reluctant to admit that another person 
could do aspects of their job well, or even better than they could. While this was felt to be a 
barrier to greater pharmacist involvement, the increasing workload pressures in the NHS 
were now so great that this reticence was no longer the barrier it once might have been. 
“GPs were protective of their job and role, but the pressure of work in primary care is so 
great now that we will accept help from anyone qualified to help.” GP C2 
 
Some GPs, who had worked in primary care for many years, did refer to a concern that had 
been a barrier in the past but that had now apparently ceased to be an issue. When 
pharmacists were first introduced into GP practices, there was a suspicion that they were 
there to effectively “spy” on the practice and report back to the Primary Care Organisation 
(PCGs and then PCTs at the time). This historic view of the CCG employed practice 
pharmacist was no longer held, but the fact that it was mentioned at all might indicate that 
this view is not entirely historical.  
“At first when pharmacists started to work in surgeries we though they were PCT spies.” GP 
C2 
 
“I think the initial barrier where GPs were suspicious-I think that has gone now-I don't think 
any GP is particularly concerned with "they should not be there.” GP A2 
 
Pharmacists also echoed the GP’s protective attitude towards their role, although this was 
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only felt to be a concern in a minority of GPs who generally appeared to be disengaged with 
the changes in the NHS. Most GPs were accepting of the pharmacist’s role in general 
practice and were “pharmacist friendly”. Pharmacists did feel that the opportunities for 
greater involvement in primary care were dependent upon the GP’s positive attitude.   
Pharmacist resistance to change was identified in both the focus groups and the HoMM 
interviews. Pharmacists considered that, as a group, they were reluctant to promote 
themselves or the roles that they could potentially deliver.  They also felt that this might 
change as pharmacists, new to the role, were recruited.  
“I think the only other rate-limiting step, as people have said, is - although, hopefully, it won't 
be such an issue with newer pharmacists - is pharmacist's reluctance to change what they're 
doing.” HoMM D 
 
6.5 Perceived obstacles to the integration of pharmacists into primary care 
Participants identified several potential obstacles that need to be surmounted or removed to 
facilitate the integration of pharmacists into GP practices.  
 
6.5.1 Funding and resources 
Practice pharmacists, GPs and HoMM all considered that funding was a major barrier to 
increasing the time that pharmacists worked in practices. All practice pharmacists in this 
project were funded directly or indirectly by the CCG (usually from the drugs or management 
budget), so there was no direct payment from the GPs for the services provided by the 
pharmacists. The focus group pharmacists felt that GPs, therefore, had little idea of the cost 
of providing the current PP service and that this made pharmacists nervous about the future. 
 “I am employed by one of the practice again to help with the repeat prescribing, and when 
asked what my salary rate was, they almost fell over and said I don't suppose you accept any 
less would you.” PP C2 
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Many of the GPs interviewed had strategic input to the CCG, so they theoretically had 
access to the cost of the current practice pharmacist service, but two GPs described practice 
pharmacists as “expensive”. One went on to suggest that practice pharmacists were a 
“luxury item” and thought that the commissioner of the service might question the value of a 
pharmacist compared to that of a nurse practitioner, although the GP did not know how the 
salaries compared. 
 
“I suppose they're [PPs] still fairly expensive aren't they as well, as professionals go, the 
CCG might not see the value of them... I don't know whether a nurse prescriber and a 
practice pharmacist prescriber earn a similar salary or not?” GP C1 
 
One other GP was more pragmatic and felt that the choice between a nurse and a 
pharmacist depended on the needs of the practice at the time. He also felt that GPs did not 
invest in sufficient practice nurses and that this had to be addressed before they could 
consider a PP. The PPs were more direct about this issue and sceptical because nurse 
salaries were lower than those of pharmacists; nurses would be employed preferentially in 
the current financial climate.  
Changes to GP funding streams via QoF (National Institute for Health and Care Excellence, 
2016) were thought to be a threat to the future possibility of pharmacists being directly 
employed by GPs (independently of any CCG funding); the potential loss of GP income 
would make it less likely for GPs to be able to invest in a pharmacist to make savings. 
Physical space within GP surgeries was also identified as a barrier limiting access to 
practices. 
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6.5.2 Value of practice pharmacists based on cost-savings 
Another issue related to resources was the current focus on savings; the CCG emphasis was 
currently on cost saving through the QIPP agenda (Department of Health, 2010) and PPs felt 
that this was unsustainable given that savings were becoming harder to realise. GPs also 
considered this unsustainability as a risk.  
“I would hope that they [PPs] would be maintained I think there's been a danger that they're 
seen as one of those luxury items that potentially is cut.” GP C1 
The threat of removal of the current service provision was considered a backwards step by 
GPs in general. One GP was prepared to outline the potential impact on their practice of the 
loss of their practice pharmacist, including the likely cost implications. 
“… my biggest fear is that my practice pharmacists will be taken away-not funded…which 
would be a large detriment… to general practice…I wouldn't be surprised if they were taken 
away-which would be paradoxical, I think it would end up- to save £50 an hour you'd lose 
£100.” GP B2 
6.5.3 Medical education and training 
One of the GPs felt that their undergraduate training did not cover the role of pharmacists in 
primary care and so there was a lack of basic understanding of the benefits of having a 
pharmacist on their teams when they went into general practice. Practice pharmacists 
themselves felt that their role was poorly defined, not always related to a relevant 
competency framework and that, although training opportunities were available, the training 
was not always relevant to the role. This view may have been exacerbated because of the 
withdrawal of centrally funded training for PPs, delivered by the NPC.  
One HoMM suggested that confusion between the different sectors of the profession was a 
barrier, particularly where practice pharmacists were confused with community pharmacists. 
Practice pharmacists and HoMM considered that practice pharmacists are significantly 
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different from community pharmacists, regarding their training and experience, to be 
differentiated as a separate group.  
 “The difference between the different strands of pharmacy: primary care, practice-based, 
community pharmacy. Every so often, I'll still see a paper that someone's written without 
talking to me that talks about community pharmacists, and I like to put my hand up and say, 
"They're not community pharmacists. They're clinical pharmacists, and they're working in 
practice.” HoMM D 
6.5.4 Salaried doctors 
Salaried doctors have been replacing many retiring partners in GP practices, and this was 
considered a potential barrier to engagement with the PP and CCG because it was felt that a 
salaried doctor’s relationship with the business aspects of the practice was potentially 
different to that of a partner. Salaried GPs might not be so likely to care about cost savings or 
act on the advice of a practice pharmacist, thereby reducing the value of the pharmacist to 
the practice. This was identified as an issue by both GPs and HoMM but interestingly not by 
pharmacists themselves. 
“Because there's an issue from the practice’s point of view and there's also an issue from the 
engagement with the CCG … you've got salaried doctors who don't necessarily want to 
follow the formulary...” HoMM B 
 
6.5.5 Practice pharmacists’ professional isolation 
There was a sense of isolation from the rest of the pharmacy profession, in as much as the 
number of practice pharmacists was small. It was felt that there was little recognition of the 
role in the undergraduate course and, arguably until recently, within the professional body.  
Since these views were expressed, the professional bodies for medicine and pharmacy and 
NHSE have increased the number of clinical pharmacists (PPs) and raised the profile of the 
role, both inside and outside the pharmacy profession. The NHSE pilot has addressed some 
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issues related to training and funding of pharmacists working with GPs. Health Education 
England is working to develop pharmacist clinical assessment and consultation skills (Health 
Education England, 2015a), and has funded independent prescribing courses for 
pharmacists (Health Education England, 2017). 
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Chapter 7 Discussion 
 
7.1 Overview 
 
7.2 What is the background, educational and employment status of primary care 
pharmacists working in Clinical Commissioning Groups? 
 
7.2.1 Clinical Commissioning Groups’ practice pharmacists background  
As far as can be ascertained this project is unique in that it is the first in-depth study of CCG 
commissioned PPs that has been undertaken since the NHS changes in April 2013. The PP 
respondents were experienced in the role and where comparisons can be made with 
previously published UK studies reporting a similar range of variables, the respondents in the 
thesis project were like those studied elsewhere (Blenkinsopp et al., 2001; Martin et al., 
1998; Mullen et al., 2005; Mills, 2016). The PP respondents’ similarity to other PPs studied 
provides some assurance of the validity and reliability of the thesis study data. The project 
PPs were of a similar age (Blenkinsopp et al., 2001; Mullen et al., 2005; Mills, 2016), 
professional background, and spent about the same time face-to-face with patients as PP 
studied elsewhere. Those PPs qualified to prescribe reported similar levels of prescribing to 
the PPs in the study by Mills (2016). Like other PPs, many of the thesis project PPs 
continued to work in community pharmacy and could do so because they were not employed 
This Chapter discusses the results of the thesis project related to thesis project 
research questions numbers two-four. It includes the background of the PPs, their 
attributes and the effects of the 2013 NHS changes on them and their teams. The 
stakeholder perceptions of the PP role are discussed, including the value of the PP 
including pharmacist prescribing. These perceptions followed by a discussion about 
the future of the role PP role and the opportunities and perceived barriers. The 
chapter concludes by discussing the transferability and limitations of the thesis 
project. 
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full time in the PP role. The PPs gave similar reasons for becoming PPs to those given by 
PPs studied elsewhere and in the IS, related to dissatisfaction with traditional roles 
(Blenkinsopp et al., 2001; Boardman et al., 2001; Mullen et al., 2005).  
 
The pharmacy profession has largely lost its prime historical function, the technical skills 
required to acquire, store and manufacture medicines, other than in an industrial or specialist 
manufacturing unit. According to Elvey et al. 2013 pharmacists do not have a clear self-
identity and still cling to the idea of medicines maker and possibly see themselves as 
unremarkable. This may go some way to explain why pharmacists in the thesis project 
considered themselves to be diffident and lack self-promotion. While pharmacy 
undergraduate courses prepare pharmacists to work in any pharmacy sector, the reality is 
that most pharmacists work in community pharmacy which remains dispensing focused 
(Davies et al., 2014). Consequently, many of the taught skills are not needed or fully utilised 
affecting personal satisfaction and self-image (Boardman et al., 2001). The thesis PP 
respondents, in common with others studied, suggested community pharmacy did not use 
their skills, was business focused, created a “shopkeeper image” and lacked autonomy. 
These were given as reasons for seeking other roles that did use their skills more fully. 
Mullen et al. (2005) showed that pharmacists, especially community pharmacists, moved into 
the PP role full-time to make better use of their knowledge. In the PP role they had 
undergone reprofessionalisation that moved them away from technical skills (knowing what) 
towards knowing how and using judgment, using their knowledge to problem solve 
medication-related problems, that has been suggested by Waterfield (2010) as a way of 
improving patient expectations of pharmacists. The thesis project PPs thought that 
community pharmacy was less respected than the PP role by HCPs and provided some 
evidence for this by recounting instances of when patients accepted the advice of a PP more 
readily than that of a community pharmacist. 
 
Many PPs adopted a portfolio career and some had added new roles because of a perceived 
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uncertainty about future employment as a PP that was related to the timing of the thesis 
study. Several benefits were identified for portfolio working such as information and skill 
transfer between portfolio roles that improved the pharmacist’s contribution and allowed for a 
greater variety and range of the pharmacist’s skills to be used. Portfolio working continually 
challenged them to grow professionally. Blenkinsopp et al. (2001) had previously implied that 
there was a synergistic relationship between the PP role and community pharmacy. The PP 
respondents agreed that the PP role was enhanced by concomitantly working in community 
pharmacy and also stated that the PP role supported their community pharmacy role. The PP 
respondents in the thesis study felt that portfolio working was also an opportunity for 
personal growth and improved their understanding of the perspective of other pharmacists 
and challenges in other sectors helping them to facilitate the resolution of interface issues. 
Liaising with other pharmacy sectors was identified in the thesis project as a long-term role 
for pharmacists in general practice, that has been suggested by Williams et al. (2000) in the 
past. The thesis project respondents thought that a community pharmacist’s business skills 
are useful in understanding the motivation and commercial drivers behind some prescription 
requests from third parties. These skills could, therefore, be usefully employed by 
pharmacists in general practice. Moreover, some PPs in the thesis study expressed their 
desire to utilise their business skills in practice management. 
 
Flexible working itself was identified by the respondents as one benefit of the PP role also 
found by the past by Mullen et al. (2005). Only a small number of PPs mentioned the need to 
have a portfolio career that was related the financial constraints of the part-time nature of the 
CCG role or the threat of loss of the PP role. It is, therefore, conceivable that the professional 
benefits of cross-sector working, flexibility and a desire to have variety in one’s work, may be 
significant to some pharmacists and prevent them from committing to a full-time role in GP 
practices.  
 
Most of the project PPs had a prescribing qualification (79.6%), and a postgraduate diploma 
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(69.4%) and many had higher degrees (24.5%). The respondent GPs felt that the PPs were 
adequately trained for their CCG PP role, thus providing some evidence that the 
postgraduate education undertaken was fit-for-purpose for the PP role. Some GPs did have 
concerns about pharmacists' consultation skills, but none provided evidence to support this. 
Indeed, most PPs were qualified prescribers and would have had their consultation skills 
assessed, to address the current competency framework for prescribers (Royal 
Pharmaceutical Society, 2016), during their prescribing course. The training for non-medical 
prescribing has been previously reported as fit for purpose (Latter et al., 2010). 
 
My research concurs with that of Blenkinsopp et al. (2001) confirming that CCG PPs have 
high levels of job satisfaction and perceive the role to have autonomy, responsibility, and to 
be interesting and clinically challenging. The motivations of the project PPs to achieve 
postgraduate qualifications were likely to be due, in part, to recruitment requirements for the 
PP role, as has been suggested by Thomas (2003) and personal aspirations to improve in 
the role. The latter view was also expressed by pharmacists in an earlier study of PPs by 
Blenkinsop at al. (2001) where all the PPs had completed further training and some 
respondents identified the need to keep up to date with the evidence base, with some 
suggestion of formal education to diploma level as a standard level for the role. Other studies 
have subsequently identified the potential benefit of a postgraduate diploma and a 
prescribing qualification to the PP role. (Mills, 2016; General Pharmaceutical Council, 2016) 
The 2013 Registrant Survey, also showed that prescribing pharmacists are more likely than 
the general pharmacist population, to be trained to a postgraduate level (Phelps et al., 2014) 
so the prescribing course itself may be a driver for further education. The thesis project PPs 
were mostly experienced pharmacists who had been in the CCG PP role for an average of 
eight years. They thought the PP role was developmental and identified that they were 
personally driven to be high achievers. It is perhaps not surprising, therefore, that they had 
high levels of postgraduate training.  
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7.2.2 Pharmacists’ attributes 
The project PPs were motivated to obtain high levels of professional and job satisfaction that 
drove some into new or multiple roles to meet this need. Some of the portfolio roles were not 
pharmacy related, suggesting that PPs are adaptable and have transferrable skills and were 
not afraid to look outside the profession for remuneration or job satisfaction. The PP role 
provided a more patient-facing clinical role and was valued by PPs as being developmental 
requiring the application of more of their skills and providing variety. These factors appear to 
be attractive to PPs with many wanting even more patient contact. Even so for some 
boredom was identified as a driver to continually look for personal growth opportunities, so 
the PP role must remain attractive to highly motivated pharmacists, with high expectations of 
themselves and their role, to promote recruitment into, and retention in, the role. Jorgenson 
et al. (2014) have reported that motivated pharmacists integrate more effectively into primary 
care teams.  
The PPs in the IS demonstrated the ability to adapt to different GP attitudes and practice 
agendas. Some PPs, affected by the NHS changes in this thesis study, demonstrated 
adaptability, in the face of change to maintain employability. Adaptability, identified by Tan et 
al. (2013) as an attribute that supports integration, combined with the need for continual 
challenge, are potentially positive attributes. But, this may mean that pharmacists with these 
attributes could be tempted by other roles in pursuit of this kind of stimulation if the PP role 
does not continue to deliver the necessary challenges in the future. The thesis study found 
that, in keeping with the latest study by Mills (2016), that the number of portfolio roles 
increased with seniority. It is not clear if this is driven by personality, opportunity, or a general 
dissatisfaction with pharmacy as a profession, and needs further study.  
 
Once in the GP practice role some of the thesis study PPs exhibited other traits that have 
been identified in the literature as part of pharmacists’ self-perceptions. Pharmacists also 
identify themselves as scientists (Elvey et al., 2013), but this equates to avoiding risk and a 
cautious approach to patient care. While this is laudable and encourages patient safety, it 
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may be a negative trait when related to prescribing that usually involves an element of risk. 
 
7.3 What is the impact of the recent National Health Service changes on primary care 
practice pharmacist teams? 
The NHS changes in April 2013 appear to have had a negative effect on the established PP 
teams and on individual members, as they transitioned from the PCTs to CCG. The effect 
was felt a both at a personal and operational level, and some PPs were concerned about the 
loss of their PP role. The situation created both operational and behavioural barriers to 
change, similar to those described by Pettinger (2002) about managing change in a business 
environment and led to demoralisation of the individuals involved. There was evidence of 
inadequate change management during the transition resulting in a lack of information from 
the shadow CCGs to the PPs. Moving PPs to a new provider organisation introduced an 
additional layer of management, effectively creating additional barriers and changing the 
relationship between the commissioning organisation and the PP team. This extra layer of 
management exacerbated tension over the prioritisation of work, that already existed 
between the CCG and practices as identified in both the Initial Study and thesis project.  
 
Axelsson and Axelsson (2006) have reported that integration, within a public health context, 
occurs when there is co-ordination within a hierarchy of organisations. The thesis study is 
unique in applying this theory to the hierarchy, in which the thesis study PP worked. The 
hierarchy formed by the provider, the GP practices and CCG suffered from poor 
coordination, with the CCG work plans not always matching the practice needs. This resulted 
in conflict in the role with some GPs becoming dissatisfied with the CCG PP service.  
 
Regarding integration, the CCG/provider commissioned model appears to have limited the 
ability of PPs to integrate into primary care and possibly to have contributed to the desire for 
direct employment of pharmacists by GPs.  The thesis project suggests that Axelsson and 
Axelsson’s theory may be applicable outside a public health context.  
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The focus on saving money, related to the current NHS funding problems, was seen by PPs 
as a retrograde step back to the early days of PPs, that conflicted with more patient-focused 
interventions and engagement in the practice agenda. The GPs echoed the PP’s view  
because their agenda was to develop the role of the PP to help address the workforce crisis, 
but CCG financial priorities were seen as a barrier to this. Even so, the PPs and GPs 
acknowledged the need to promote efficiencies due to the current financial situation. Some 
GPs were also unhappy where more than one commissioned PP was delivering the service, 
as this caused issues related to accountability and responsibility for the work. The ability to 
be proactive and accept responsibility for care have been identified by (Jorgenson et al., 
2013) as positive attributes for integration of pharmacists into primary care.  
 
All the professional respondents (GPs, HoMMs and PPs) saw the direct employment of a 
pharmacist as a way of overcoming most of these shortcomings by gearing the PP and their 
workload directly to the practice management. The HoMMs also saw the benefits of the 
direct employment of a pharmacist, despite considering that their PP teams would likely be 
depleted as a result of GPs taking on pharmacists from the teams, with whom they were 
familiar and trusted. The 2013 NHS changes appear to have effectively supported direct 
pharmacist employment by emphasising the shortcomings of the CCG commissioned models 
to both PPs and GPs as discussed in 6.4.5. 
 
Primary care organisations have been the main supporters of the PP role over the last 25 
years, and their contribution to the role has been invaluable and must be acknowledged. The 
CCGs and GPs still valued the PP role in cost-effective prescribing, patient care and safety. 
Nevertheless, this thesis project has identified several issues with the CCG models for 
commissioning PPs that suggests that the development of the PP role may be restricted 
within CCGs. Both the GP and PP respondents wanted more control over the work that the 
PPs did, but this was constricted by central control of PPs work by the CCG. All the 
organisations involved will need to co-ordinate their agendas if commissioned PPs are to 
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develop and fully integrate into GP practices in the CCG models.  
 
There appeared to be difficulties in obtaining relevant training for the PP role. The lack of the 
formal application of competency frameworks to the PP teams at the time of the study meant 
that training needs were not necessarily identified methodically. The decommissioning of the 
NPC (News Team, 2010) had removed a valued training resource, and although PPs were 
resourceful, this resulted in ad hoc training with materials that were not specifically related to 
the PP role. Although valued, the NPC delivered training to local CCG PP teams in an all-day 
face-to-face session, which was a major disadvantage identified by a HoMM, as it disrupted 
the CCG PP service to GPs. The respondent GPs understood that PPs might need further 
training to expand their capacity to treat chronic disease, but the source of such training and 
how the PP would demonstrate competency in that area was unclear.  
 
7.4 What are the key stakeholders’ perceptions of the current practice pharmacist role 
and its future, including prescribing? 
7.4.1 Based in trust 
The IS and thesis project identified that the PP/GP relationship had evolved from uncertainty, 
through acknowledgement of the role and skills required, to mutual respect and now 
increasing dependence on the PPs to manage the primary care workload. The PP role was 
complex and built on trust, based on evidence of the benefit of their actions, decision-making 
and behaviours over time. Mutual trust and respect have previously been identified as key 
components of integration in models of community pharmacist integration (Bradley et al., 
2012; McDonough and Doucette, 2001; Van et al., 2013), and of primary care pharmacist 
integration (Jorgenson et al., 2014). Trust and respect take time to develop (Bradley et al., 
2012; McDonough and Doucette, 2001); this view was supported by the thesis project GPs 
who voiced a preference for a long-term relationship with their PP. McDonough and 
Douchette (2001) considered that trust was likely to be facilitated by socialisation of the 
individuals and having coterminous patients which was the case with the thesis project PPs 
 169 
and GPs. The PPs and GP did achieve a level of interdependence and had a shared goal to 
improve patient care (Bradley et al., 2012). Trust and interdependence (Bardet et al., 2015) 
and collaborative working (McDonough and Douchette, 2001) appear to be indicators of the 
integration of pharmacists into primary care.  
 
Patients saw the employing practice as validating their pharmacist’s clinical skills and trusted 
the practice to only employ PPs of sufficient caliber, effectively making the practice 
responsible for both the recruitment and training of the pharmacist. It is not known if patients 
understood that they were engaging with a commissioned PP, or if this might affect their 
opinion. Validation of the pharmacist’s competence by the practice has implications for 
pharmacist engagement/employment and the credibility of the practice if it does not employ 
and integrate an adequately qualified and experienced pharmacist.  
 
7.4.2 Benefit to the practice 
The benefits to the GP practice of having a practice pharmacist were identified in both the IS 
and the thesis project. The IS GPs were aware of the roles that the PPs performed, as 
described in the literature, and identified a new role around monitoring repeat prescription 
requests from third parties and ensuring the suitability of sip feeds when they were 
requested. Repeat prescription management by pharmacists appears to be practical and 
cost-effective (Walsall Clinical Commissioning Group, 2014). Other benefits to the GP 
practice, described in the thesis project, included the facilitation of two-way communication 
with the CCG and other Trusts. The GPs thought that PPs could be used in different ways to 
save GP time by taking over tasks currently being undertaken by the GPs and undertake 
other tasks that GPs did not have time to do at all, e.g. audit.   
 
Overall the GPs felt that PPs could make a significant contribution to CDM and that this was 
an obvious next step in the growth of the role. One GP felt some frustration that this next 
step in the role had not already become mainstream. The study GPs believed that 
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pharmacists’ professional attributes make them suitable for undertaking both medicine 
reconciliation and medication review. Patients identified that PPs improved their access to a 
HCPs, allocated more time to individual patients and could provide more information about 
medication and disease. Informal feedback to the commissioners indicated that the PP 
service was also valued by GPs, and this was further evidenced by the support that GPs had 
given the PP teams during the transition to the CCGs. Overall PPs were increasingly 
perceived by GPs as a practice resource, rather than a commissioned one, indicating the 
level of need and the desire to direct their work. The thesis study PPs felt integrated into the 
practices that they served and believed that they were appreciated by the GPs. This has also 
been reported for PP studied elsewhere (Blenkinsopp et al., 2001; Hemsley, 2017). 
 
The HoMMs saw the PP role as a way of implementing change at the practice level and 
related this to the need to meet the financial targets set for the CCGs. This was also 
acknowledged by the GPs and PPs. There was some informal assessment of the PP role by 
the commissioners, although there was a lack of clarity around who was responsible for this 
in one CCG, the CCG or Provider. The informal assessments were always encouraging and 
supported the value of the PP to the GPs and practices. It is surprising that there was no 
formal evaluation of the PP Teams given the numbers of PPs commissioned by the CCGs, 
the inevitable cost, and the importance of the PPs to the CCGs and GPs. Formal evaluation 
and reporting of the cost-effectiveness of the PP role, within CCGs and their GP practices, 
should be a requirement to ensure the best use of NHS resources.   
 
Patients liked the extra time that PPs gave them in consultations to discuss their medicines 
and diseases, which has been identified previously by Jamieson et al. (2010). Patients 
wanted more information on drugs and disease, and in some cases treatment for minor 
conditions. The latter was related to a perceived hierarchy of value in practitioners’ time 
where a PP’s time was perceived differently to that of a GP. Patients were comfortable with 
asking a prescribing PP to treat conditions that they considered were “too trivial to bother the 
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GP”. While this perceived hierarchy may be related to patient perceptions of the higher status 
of the medical profession over other health professions (McDonald et al., 2010), in practice it 
supports the value of the pharmacist as another clinician for patients to access. Not all the 
patients who participated in the thesis study were aware that their practices had a pharmacist 
attached or that the pharmacist could potentially prescribe which may have limited 
patient/pharmacist contact. Kolodziejak et al. (2010) suggest that pharmacists’ services 
should be advertised to help address this and integrate pharmacists into a GP practice. 
 
7.4.3 Pharmacist prescribing 
Pharmacist prescribing was commissioned by three CCGs, but not all HoMMs were 
convinced of the value of pharmacist prescribing despite suggesting that all their prescribing 
PPs were actively prescribing. The individual CCG PP teams had grown independently of 
each other to meet the needs of each organisation, reflecting the lack of direction on how 
CCGs themselves should be structured as indicated by Checkland et al. (2016). Therefore, 
different models were to be expected, but there was no clear strategy or aspiration for the 
inclusion of prescribing into any CCG PP role, indicating that prescribing was driven 
elswhere, probably by the PPs and GPs. Nevertheless, the value of PP prescribing was 
acknowledged by commissioners. 
Some HoMMs saw a prescribing qualification as improving patient access to medicines, 
contributing to seamless care, reducing GP workloads and enhancing PP skills around CDM. 
These benefits have been previously identified in the literature (Lloyd et al., 2010; Smalley, 
2006; Stewart et al., 2009a), and support the aims of non-medical prescribing to improve 
access to medicines and to support the GP role. 
 
Levels of prescribing by qualified PPs in the thesis study were variable and in line with levels 
of prescribing published by Phelps et al. (2014) and Mills (2016). It is of note that the thesis 
study PPs had higher levels of educational achievement and levels of experience compared 
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with those PPs studied by Mills but were not more active prescribers. Conversely, some of 
the PPs studied by Mills were directly employed by the GP practices in which they 
prescribed, but this had little effect on the overall levels of prescribing in that study. However, 
the PPs on SLAs reported being more active regarding face-to-face time with patients and 
prescribing compared with the PPs from the two other CCGs with provider-based models. 
Levels of prescribing in the thesis study appear to be due to the way the PPs are employed 
within CCGs and the strategic intentions of the CCGs. Several factors are known to affect the 
extent of non-medical prescribing, besides the employer, such as PPs’ pre-prescribing levels 
of experience, governance and support (Courtenay et al., 2012), so it is difficult to draw any 
firm conclusions because of the number of variables. This is an important area for further 
research, especially if prescribing is limited by pharmacists’ personality traits, education and 
culture as described by Rosenthal et al. (2010). Since the thesis project and the survey by 
Phelps et al. (2014), more encouraging national levels of pharmacist prescribing have been 
reported (General Pharmaceutical Council, 2016). 
 
The PPs in the IS saw the lack of a prescribing qualification as a limiting factor with regard to 
the effectiveness and the range of activities in the PP role, and most of the thesis project 
respondents saw the benefits of a PP having a prescribing qualification. The GPs thought 
that PP prescribing avoided the GP becoming unnecessarily involved in the consultation just 
to write the prescription. Prescribing allowed the PP to complete the consultation and make 
changes to the patient’s medication. This was felt to increase patient confidence in the 
pharmacist and allow the pharmacist prescriber to take responsibility for their actions. The 
overall effect, they felt, was to improve patients access to medicines, reduce the GP 
workload and allow GPs more time to see more complex patients. The PPs echoed the GPs’ 
perceptions of completing a consultation, giving the PP prescriber more autonomy, and 
changing the pharmacist/patient relationship. The PPs thought that pharmacist prescribing 
also supported them to undertake CDM, repeat prescribing and medication review. It is now 
known that NMPs are as good at CDM as medical prescribers for surrogate outcomes, 
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patient satisfaction and adherence (Weeks et al., 2016).  
 
Not all patients in the thesis study were aware of pharmacist prescribing, but there was an 
overall acceptance that the role was appropriate and avoided the patient bothering the GP 
for what they considered to be minor concerns. Where the patients understood that the 
prescribing PP had a specialist interest, such as asthma or COPD, patients appreciated a 
focused discussion around the specific condition and felt that there would be improved 
outcomes from interventions made by a “specialist” PP. The PP’s expertise in a specific area 
was seen as an information resource for the practice. Given all the benefits of pharmacist 
prescribing in general practice, that were identified by the participants, it is surprising and 
disappointing, that there is no coherent policy for implementation within the CCGs and that 
low levels of prescribing by qualified pharmacists were commonplace.  
 
Several issues with pharmacist prescribing were identified by participants that may limit the 
contribution that prescribing PPs can make within CCGs and also may be significant in 
addressing the primary care workforce issues. The HoMMs were concerned about the 
funding for training pharmacists to become prescribers, as it was not included in the NHSE 
Pilot monies. One solution proposed was that funding for pharmacists prescribing should 
come from the practice that would ultimately benefit from it. As prescribing was considered 
important for the PP role, funding issues may, arguably, restrict the rate at which pharmacists 
can be trained and therefore their contribution to the practice workload.  
 
The PPs and HoMMs considered that pharmacists were careful prescribers, with prescribing 
PPs risk assessing their prescribing before deciding to sign the prescription. While patient 
safety is paramount, there is also a need for prescribers (and their patients) to accept some 
level of risk and uncertainty as it is not always possible to predict the outcomes from 
prescribing. One GP was more critical and suggested that some pharmacist prescribers were 
not confident to use the qualification to the full or even not at all. This criticism was echoed 
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by the PPs who felt that the confidence to use the qualification was partly related to their 
prescribing training, where they were encouraged to only prescribe within their areas of 
competency. Differences in the training of doctors and pharmacists, where doctors were 
trained to be more autonomous in their prescribing and less cautious than pharmacists, had 
been alluded to in the study. It was suggested that over time pharmacists would become 
more confident in their prescribing abilities. Cordina et al. (2015) suggested that pharmacy 
students exhibit a character trait profile with high levels of cautiousness that is maintained 
throughout the pharmacy undergraduate course, so it may be that more cautious people are 
attracted to the pharmacy profession and that they struggle in roles where a cautious 
approach can be a barrier. This view is supported by previous non-UK studies into 
pharmacist personality traits where pharmacists were identified as being risk-averse 
(Rosenthal et al., 2010). It is of note that small numbers of PP prescribers have much higher 
rates of prescribing suggesting that some PPs, by circumstance or personality, are less 
inhibited about prescribing risks. In my thesis study, some prescribing PPs did stay within 
their original competency areas while others prescribed more widely. Some PPs used an 
internal risk management assessment when they signed prescriptions for drugs that they 
would not initiate but were happy to repeat prescribe with the necessary supporting 
information. Prescribing PPs remained cautious about diagnosing and, rightly, limited this to 
where they felt confident and competent but were much more confident in prescribing in pre-
diagnosed conditions. 
 
Another issue that participants identified with PP prescribing was related to an apparent lack 
of understanding of the PP role by the practice staff resulting in inappropriate requests to 
sign prescriptions, for the convenience of the practice, that were outside the PP’s 
competence. Prescribing PPs sometimes used prescribing within competence to “protect” 
themselves from such requests to sign prescriptions. The IS indicated that the PP’s ability to 
positively interact with the practice staff was important. While data on the importance of the 
pharmacist’s relationship with practice staff appears sparse, Tan et al. (2013) found that a 
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rapport between practice staff and pharmacists helps staff to understand the pharmacist’s 
role and to view the pharmacist as part of the team.  
 
Some GPs and nurses were protective of their patients and workload and did not want to use 
the PP to support them with their patients. This suggests a need to explain the prescribing 
pharmacist’s role and function to the practice more clearly as suggested by Jorgenson et al. 
(2013) and Kolodziejak et al. (2010), to possibly to allay encroachment fears. 
 
As found by Latter et al. (2010), patient respondents accepted prescribing by pharmacists 
but identified that prescribing PPs were limited to prescribing within their competencies. 
Patients found that prescribing PPs had to refer to the GP on occasions and that PPs were 
not necessarily always available at the practice. Some patients were concerned with PP 
prescribing in new conditions or prescribing certain drugs but were more comfortable when 
this was limited to modifying repeat medications for existing conditions or initiating 
medications for minor ailments. There is evidence that this is not an isolated finding and that 
some patients see some medicines as “stronger” or some diseases as “more rare” (Stewart 
et al., 2009b). My study adds to the sparse knowledge in this area. 
 
7.5 What are the personal and career aspirations of primary care practice pharmacists 
and the perceived opportunities and barriers to achieving these? 
 
7.5.1 Practice pharmacists’ future role 
The future of the PP role was discussed with all respondents in the thesis project. The GPs 
were keen to expand the PPs’ existing roles to meet the increasing workload and considered 
that this would include both CDM and acute disease. The GPs also wanted more control over 
the workload of their PPs. The GPs felt that current PP roles would continue, such as audit 
and supporting QoF. A new PP role was identified by the GPs to help manage information 
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overload and to address the training of new practice staff.  
 
The PP role was expected to naturally progress, but there was feeling that this was not 
happening quickly enough. The HoMMs were supportive of the direct employment of PPs 
and understood the desire of PPs to have more patient contact. They were also aware of 
some GP’s aspirations to directly employ their PPs. The HoMMs, three of whom continued to 
work as PPs, saw the potential benefits to patients from PP roles such as clinical medication 
review and medicines optimisation, supported by increasing numbers of pharmacist 
prescribers. An additional role that they suggested for the PPs was to address interface 
issues between the practice, hospital (previously suggested by Williams et al. (2000)) and 
community pharmacy. Dealing with interface issues was also identified as a role by the thesis 
project PPs.  
 
Patients did not provide any particular insights into the future role of PPs, although they did 
identify the current need to take pressure off GPs and suggested ways in which PPs already 
facilitated this. Patients understood the personal benefit of having a PP in their GP practice 
and wanted to extend this to other patients but were mindful of the cost and demand for PP 
services. Despite this, patients wanted access to a PP to discuss medication, receive further 
information and to be treated for minor ailments, and linked these functions to their 
convenience and saving GP time. Many of the functions appear to have been carried out by 
at least some of the more experienced NHSE Pilot pharmacists (Primary Care 
Commissioning, 2017).  
 
The lack of patient-orientated outcomes and proven reductions in disease and morbidity, due 
to pharmacist interventions in primary care is a concern. High-quality RCTs are lacking, 
partly because of difficulties in blinding and also funding since trials would have to be run for 
several years to be able to detect this level of evidence. Fortunately, since the thesis study 
data was collected, the evidence that non-medical prescribing delivers similar surrogate 
 177 
outcomes, levels of adherence and patient satisfaction as medical care, has been 
strengthened (Weeks et al., 2016), supporting the value of PP taking on some of the roles of 
GPs. There is also growing evidence of the value of pharmacists working with GP practice. 
Specific interventions are pharmacists supporting repeat prescription management (Walsall 
Clinical Commissioning Group, 2014) or delivering specific education and following up over 
time, in patient safety (Avery et al., 2012) and effecting change (Lowrie et al., 2014). These 
studies support the thesis project finding that pharmacists can act as agents for change 
when working within the GP Team and add to the value of pharmacists and pharmacist 
prescribers working within GP practices.  
The evaluation of the NHSE Pilot is will hopefully, add to the existing body of evidence in this 
respect.  
 
7.5.2 Pharmacists’ problematic attributes 
The PPs in the study recognised that they could be diffident and reluctant to promote 
themselves or their role within the practice and felt somewhat isolated from the rest of the 
pharmacy profession. These attributes reflect those found by Rosenthal et al. (2010) a lack 
of confidence, fear of new responsibilities and risk aversion. Modesty and lack of self-
confidence are potentially negative traits, and opposite to the trait of assertiveness that is 
thought to help pharmacists cope with barriers to integration (Jorgenson et al., 2014). More 
work is needed to explore and address any underlying cause for pharmacists’ diffidence and 
risk aversion. The earlier introduction of undergraduate and pre-registration pharmacists to 
primary care may improve their confidence to make autonomous decisions (Malson, 2016). 
 
7.5.3 Professional culture 
The Medical and Pharmacy professions seem to have a built-in reluctance to changing the 
way that they work. The respondent GPs initial suspicion of PCO pharmacists seems to have 
largely been overridden by years of familiarisation and the need to collaborate to address the 
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workload. The PPs in the thesis study found that there were still some GPs that would not 
engage with pharmacists, for example, some GPs (and nurses) were protective of their 
patients despite increasing workloads. Wilcock and Hughes (2015) also detected negative 
perceptions around the PP role, for example, funding and prescribing that were also 
identified in other pharmacist integration studies. Tan et al. (2014a) have proposed that GPs 
may feel threatened by the PP role. Pettinger (2001) somewhat supports this view and 
suggests that a protective attitude towards an individual’s workload may be a result of fear of 
change, role loss or control. Other researchers have proposed that these issues can be 
alleviated by better communication of the pharmacist’s role within the practice (Jorgenson et 
al., 2013; Kolodziejak et al., 2010). Nevertheless, the PP respondents stated that most GPs 
were accepting of the PPs role in primary care, but that the opportunities for greater 
involvement were dependent upon the GP’s positive attitude to the PPs. This thesis study 
also found that there is a need to ensure that the whole practice supports the PP to facilitate 
integration and that better communication of the pharmacist’s role in the practice is key. 
(Jorgenson et al., 2013; Kolodziejak et al., 2010) also published this view. 
The lack of the recognition of the PP role within the Pharmacy profession was identified by 
the thesis project pharmacist respondents and was linked to a perceived lack of training 
available specifically for PPs along with any necessary funding. A coherent application of 
competency frameworks within the thesis project PP teams would, it was felt, have helped 
identify gaps in skills and knowledge that would have aided the identification of training 
needs. Furthermore, the pharmacist respondents felt that an employment framework within 
primary care for PPs is required if they wanted to progress within this sector. It was felt that 
this would also generate learning needs as a means of career progression. Many of the 
points previously discussed could be addressed by the introduction of a recognised career 
pathway for primary care pharmacists, linked to experience and appropriate competency 
frameworks with related training pathways.  
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7.5.4 Practice pharmacist recruitment 
The HoMMs were divided over the availability of suitably qualified pharmacists to take on the 
CCG PP role, possibly reflecting the difficulties they found with recruitment in the recent past. 
The HoMMs were concerned that inexperienced pharmacists might be recruited to the PP 
role, a view that has been partly supported in one recent study (Mills, 2016). An 
inexperienced pharmacist may only be able to provide a low level of support to the practice 
initially, not being able to make a full contribution. While this will provide an opportunity for 
the pharmacists to be trained by the practice, which arguably, could support better 
integration, it may increase rather than reduce the practice workload significantly in the early 
days. Practices need to be aware of this and tailor their PPs role to their current level of 
experience and competency and be open to the need to invest in the future training and 
development of their PP. A formal training pathway would be helpful here. 
 
7.5.5 Funding 
Funding is a key issue for the development of the PP role as it is directly related to 
recruitment, employment, training and role definition. The NHSE pilot (Sukkar, 2016) is 
providing significant levels of funding for training and salary, but this is limited to the pilot 
pharmacists. The thesis project GP respondents were asked about the direct employment of 
pharmacists, and some had begun to think about this. The negativity around the NHS 
changes, the commissioning problems, increasing workload and change of focus are all likely 
to have been significant factors in the growing interest among the PPs and GPs for a direct 
employment model. Another factor was that project GPs were unsure of future funding for the 
existing practice pharmacist teams and they did not want the service withdrawn. Despite all 
this, and even though they believed, as other studies have suggested that practice 
pharmacists are cost-effective (Patel and Afghan, 2009; Westerlund and Marklund, 2009; 
Desborough et al., 2012), they remained reticent about employing a pharmacist directly. 
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Several GPs referred to their falling income from the NHS as a barrier to directly employing a 
pharmacist, but the introduction of extra NHS funding for the over 75s at the time of the 
thesis project had provided a short-term solution. Some GPs had considered employing a 
pharmacist, but there was a perception that a pharmacist’s time was “expensive” and that a 
nurse would cost less. The PPs were also concerned about the salary differential between 
nurses and pharmacists being a barrier to pharmacist employment that was subsequently 
raised in the GPhC Prescribers Survey Report (General Pharmaceutical Council, 2016). 
There is now a shortage of nurses in primary care (NHS Alliance and Royal Pharmaceutical 
Society, 2014) that may make the salary argument less compelling, if not redundant.  
 
The commissioning of PPs by CCGs may be another barrier to direct employment because 
the CCG PPs were effectively a “free” resource. Wilcox and Hughes (2015) found that while 
the PP service was being supplied by the CCG, the practices were getting the benefits of 
having a pharmacist, reducing the overall need for them to have a directly employed 
pharmacist. Funding issues have been shown to be a barrier to primary care pharmacist 
integration in other countries, for example, Jorgenson et al. (2014) and Tan et al. (2014a). In 
the UK, NHS England has provided tapering salary support for Pilot GP practices to employ 
a pharmacist that may have helped drive interest in the scheme. But practices outside the 
Pilot will have to fund a pharmacist from within the practice wages envelope. In either case, 
the salary cost is, arguably, easily offset by substantial savings to the GP practice wages bill 
because of the doctors that cannot be recruited to the practice due to workforce shortages, 
and “replaced” by pharmacists at lower salaries. Further research is required to understand 
the financial pressures and perception inside general practice in relation employing a 
pharmacist. 
 
7.5.6 Initial and ongoing training 
The thesis study respondents suggest that recruitment, integration and role development are 
 181 
dependent on training. Unfortunately, competency frameworks for PPs were not universally 
used and, where they were used, the PPs were not always aware of this. This, combined 
with a lack of formal feedback on service provision, made the identification of training needs 
difficult. It was suggested by GPs that PPs may require extra training in consultation skills 
and further training to take on more CDM. Although the respondent GPs were mostly happy 
with their PP’s training, the GPs also acknowledged that they were probably influenced by 
the high calibre of the PPs that they had dealt with so far. This may not be the case if 
inexperienced, and less qualified pharmacists are recruited in the future and is crucial since 
the GPs thought that successful integration was based on the quality and suitability of the 
PPs training.  
The PPs identified other training needs that consisted of both clinical and communication 
topics similar to those found by Mills (2016). The PPs felt that the training currently available 
was not tailored to the PP role, also identified by Campbell et al. (2016), and so PPs had 
become resourceful in finding training to suit their needs. The lack of suitable initial training 
has been somewhat addressed by the NHSE Pilot, but not all new PPs will be recruited via 
the pilot. Ongoing training for the PP role also remains an issue although, recently, Higher 
Education Institutions and CPPE have begun to address this (Centre for Pharmacy 
Postgraduate Education, 2015). If PPs are to take on the role of medicines and therapeutic 
expert within the practice, then more intensive therapeutic training will be required, like that 
provided by the National Prescribing Centre in the past. The PPs identified two positive 
elements to the former NPC training, namely networking (that has been addressed locally to 
a degree by the HEI) and high-quality therapeutic training that was not currently available. 
Commissioners were not only concerned about access to training but also the time away 
from practice that was sometimes required for training to take place. Distance learning may 
be a practical alternative to study days for the therapeutic training element. The respondent 
GPs felt that it would be easy to train pharmacists to take on more roles as necessary. When 
training programmes are being designed for PPs, they should take into account the range of 
topics required and the means of delivery, being mindful of the need to include networking 
 182 
and to minimise time away from practice. The use of online courses with access to secure 
discussion areas may be one solution. 
 
7.5.7 Role definition 
A clear definition of the PP role is, arguably, a prerequisite for integration of PPs into GP 
practices. The PP role appeared to be poorly defined and was linked to a perception of a lack 
of awareness-raising of the work of PPs in undergraduate pharmacy courses. One GP felt 
that doctors were also unaware of the benefits and role of pharmacists in primary care due to 
a lack of exposure to pharmacists during medical and GP training. This lack of awareness of 
the PP role was also seen in the dealings of the commissioning and provider organisations 
where the PPs role was confused with the community pharmacy role. The need for a primary 
care pharmacist to have a well-defined role to support integration has been identified in 
primary care studies in Canada (Jorgenson et al., 2014, 2013; Kolodziejak et al., 2010). In 
the UK several professional bodies have begun to collaborate to support GP practices to 
employ a pharmacist and to define the PP role (Primary Care Pharmacists Association, 
2015). They have produced support pack that includes job descriptions for both junior and 
senior PPs and sample business cases for their employment. 
  
This Chapter has discussed the themes from the thesis study related to the research 
questions and has demonstrated the value of pharmacists and pharmacist prescribing to 
general practice and the training required for the role. The thesis project has also identified 
potential long-term roles in general practice that pharmacists are particularly suited to, such 
as, repeat prescription management, medication review and reconciliation, CDM and liaison 
across interfaces. The pharmacist’s role in general practice has, and continues to, develop 
while still rooted in medicines cost-effectiveness safety. However, an opportunity for an 
“evolutionary jump” in the role into increasingly patient-facing roles beckons, but not without 
pitfalls or risks. In Chapter Eight, I go on to propose a Model for the Successful Integration of 
Pharmacists into General Practice that draws on this discussion, and the evidence gathered 
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in previous chapters. 
 
7.7 Transferability and limitations 
The transferability of the thesis project findings is supported by the similarity of the profiles of 
respondent pharmacists to those studied elsewhere and the degree of similarity of the 
findings with other studies looking at the integration of pharmacists into general practice 
teams. The qualitative elements of the thesis project are bound by the general limitations of 
inductive studies regarding small sample sizes and non-randomised samples. 
 
The project was conducted in CCGs only one year after their inception. The professional 
respondents had all been through the transition and for some, particularly a sub-group of 
PPs, this had been traumatic. The results from the professional interviews and focus groups 
may have reflected the trauma and proximity of the change and resulted in more negative 
views being expressed. 
 
The descriptive survey asked about the number of prescriptions written per month by 
prescribers but only allowed answers to be expressed in bands, 0-50, 51-100 and so on. 
Similarly, the “time spent with patients” question also used banding. The use of bandings, to 
avoid a wide range of answers, is a blunt instrument that may not give an accurate picture of 
activity, for example, the lowest band did not differentiate those pharmacists that were 
inactive and those with very low levels of activity, thereby potentially overestimating activity 
here. The descriptive survey was not validated or tested for reliability (reproducibility) and 
only had a degree of face validity. This limits its value and application to a wider population of 
PPs. The descriptive survey data was biased towards both male respondents and to one 
CCG with a large PP team. The CCG with the large team may have been atypical, and this 
may have affected the data. Most of the data does, however, reflect the national picture, 
giving some reassurance. The focus groups were biased towards female respondents, but 
again there were some similarities in the responses in topics where these had been studied 
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elsewhere.  
 
Another potential limitation of the thesis project was that the PPs were all experienced, highly 
trained and in one CCG the GPs stated that they had always had “good pharmacists”. This 
raised the GPs’ expectations of their PPs that may not be realised with less experienced and 
less well-trained pharmacists. It does, however, set the bar at an appropriately high level. 
 
There was a degree of triangulation of data in the study, but I conducted all the interviews 
and focus groups, and so the results are potentially biased by my assumptions both in the 
interviews, focus groups, and in the analysis. I have tried to be objective in all aspects of the 
study, but I may also have introduced bias in some aspects of respondent selection, also 
using respondents to identify other individual respondents may have been influenced by the 
personal biases of others as well. Using HoMMs to identify GPs and PPs and PPs to identify 
patients may have led to more compliant respondents as it is likely that “user-friendly” 
respondents would be recruited to avoid repercussions and to subconsciously provide more 
positive results. This may be particularly significant in the patient respondent selection by 
PPs, who want to ensure their role is seen positively. The patient respondents could not be 
said to represent the demographics of the West Midland population; they were largely 
elderly, and data on ethnicity was not collected. The views of patients whose first language 
was not English were not represented and therefore the patients’ views may not reflect those 
of the wider UK population. 
 
There were recruitment difficulties for both the GP and patient respondent groups with only 
one GP recruited from CCG D. Two focus groups did not recruit sufficient respondents, and 
although most of the themes discussed in this group were similar, this may have limited the 
dialogue and the depth of the interaction between respondents in these two groups. Semi-
structured interviews might have been a better option if recruitment had been identified early 
on as an issue. Interviews may have also allowed respondents to be more open (two focus 
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groups included line managers), and because confidentiality is impossible between focus 
group respondents, these factors may have limited the discussion on sensitive topics. One of 
the CCG based focus groups had fewer participants than the other three, so the respondents 
may be less likely to be representative of that CCG. 
 
This project used a pragmatic approach driven by time constraints; that may not have been 
ideal, but there was a degree of similarity of results from other PP studies conducted in the 
UK giving limited assurance. The pharmacist respondents were all commissioned by NHS 
organisations and may not be representative of the pharmacists that are, or will be, working 
with GPs in the future. The interviews and focus groups inevitably used relatively small 
numbers of respondents from one area in the UK, further limiting the generalisability of the 
results. 
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Chapter 8 A Model for the Successful Integration of Pharmacists into General Practice 
Teams. 
8.1 Overview
 
8.2 Research question 
5 What recommendations can be made to support the successful integration of 
pharmacists into GP practice teams  
 
8.3 Introduction to the Model for the Successful Integration of Pharmacists into 
General Practice 
The integration of pharmacists into existing teams, in the context of general practice, is more 
complex than simply employing a pharmacist, as the published literature relating to 
pharmacists’ integration in the UK and elsewhere demonstrates. This thesis project and the 
Initial Study support some of the findings in published studies, but also describe additional 
unique findings. The synergy between published studies and my study provides some 
assurance that my findings are relevant to primary care in the UK and can be used to support 
a model for pharmacist integration into GP practices. A summary infographic of the proposed 
model is presented in Figure 8.1. The model consists of three main elements, National 
Support, Practice Level Facilitation and the Pharmacist’s Skills and Attributes that together 
support the integration of pharmacists into UK general practice. The model is shown as 
stacked concentric circles to emphasise the hierarchical support the pharmacists need and 
that they are central to the model. I explain and argue my case for their inclusion in the text 
This Chapter summarises the results related to integration and postulates a model for the 
successful integration of pharmacists into general practice based on my findings from the 
Initial Study and the thesis project. I present a unique conceptual model, the elements of 
which may be generalisable to facilitate the integration of clinical pharmacists into general 
practice in a UK setting.  
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that follows. 
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Figure 8.1 A Model for the Successful Integration of Pharmacists into General Practice 
Teams 
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Figure 8.1 A Model for the Successful Integration of Pharmacists into General Practice 
Teams 
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• Training plans 
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8.4 Pharmacist skills and attributes 
Several personal attributes of pharmacists themselves appear to support the integration of 
pharmacists into UK GP practice teams. The first element of the model are the skills and 
attributes of the pharmacist which consists of three areas. 
 
8.4.1 Professional background 
A background in community pharmacy has been consistently identified in the Initial and 
thesis studies as beneficial to the PP role. It is thought to help the pharmacists understand 
the motivations behind prescription requests and would be a useful attribute for those 
pharmacists working on repeat prescription requests and systems.  
 
8.4.2 Postgraduate level education and prescribing qualification 
The level of pharmacist postgraduate education for recruitment to the PP role has yet to be 
established. Most of the thesis study PPs were trained to postgraduate diploma level or 
higher and were considered by their GPs to be trained to an adequate level for the PP role. 
The respondent GPs also wanted their pharmacists to be responsible for training and 
updating other healthcare professionals on the evidence-base. Ongoing training and CPD 
are essential to keep up with changes in the evidence-base, not only for the pharmacist’s 
clinical and prescribing role in the practice but also for the proposed information and training 
role. The thesis study supports the suggestion of Mills (2016), that education and training to 
a postgraduate diploma level with, or incorporating, a prescribing qualification facilitates 
pharmacists working in general practice. A prescribing qualification was felt by the thesis 
study respondents to be a useful enhancement for PPs to have. Prescribing allowed them to 
complete a consultation without unnecessarily involving a GP, was convenient for patients, 
and improved the pharmacist/patient relationship. Pharmacist prescribing was also 
acceptable to the thesis study patients, concurring with Latter et al. (2010). Reassuringly, 
Weeks et al. (2016), have confirmed that non-medical prescribing delivers comparable 
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surrogate outcomes to medical prescribing in acute and CDM. Given the growing body of 
evidence for the benefits of non-medical prescribing per se and pharmacist prescribing, 
together with the findings from my study, I agree with Campbell et al. (2016), that a 
prescribing qualification should be a pre-requisite for pharmacists working in primary care. 
 
 
Also, pharmacy students in the UK have called for a prescribing qualification to be included 
in the pharmacy undergraduate course in the future (British Pharmaceutical Students’ 
Association, 2017). This view is supported by the Professional Body for Pharmacy, related to 
the taught elements of prescribing (The Royal Pharmaceutical Society, 2017). When 
implemented, this will further establish pharmacists as prescribers and facilitate their role in 
supporting patient care. 
 
8.4.3. Social and communication skills 
Thesis and Initial Study participants felt that good communication and social skills 
respectively were important for integration into the practice teams. A rapport with practice 
staff has been shown to be important in understanding the PP’s role (Tan et al., 2013). The 
PPs who took part in my study showed that they were adaptable and proactive because 
many chose a portfolio career, had to adapt to different practice settings, and some sought 
alternative employment in the face of job loss. Tan et al. (2013) have suggested that 
adaptability and proactivity are positive characteristics that facilitate pharmacist integration 
into Australian general practice. 
 
8.4.4 Motivational attributes 
The thesis study pharmacists were highly motivated to achieve in the PP role and found the 
role itself to be developmental. Their motivation was further demonstrated by their ability to 
access opportunities for training, specific to their needs, despite targeted training not being 
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available at the time. Jorgenson et al. (2014) found that motivated, confident and assertive 
pharmacists found it easier to forge new roles in primary care teams in Canada. Self-
motivation and adaptability have also been recognised as essential attributes for pharmacists 
working in primary care in the UK (Primary Care Pharmacists Association, 2015). Motivation, 
adaptability and proactivity appear to be positive attributes to look for in pharmacists working 
in primary care and are, therefore, included in my Model.  
 
8.5 Practice level facilitation 
The Initial Study and thesis project have identified several areas that the GP practice itself 
can address to help support a pharmacist to integrate into their team. The second element of 
the model consists of four areas. 
 
8.5.1 Mode of employment. 
I recommend that pharmacists should be directly employed by practices. The commissioning 
of PPs by CCGs induced a conflict of interest in the PPs related to a mismatch in the needs 
of the CCG and the practice that was further exacerbated if there was a provider organisation 
involved. The PPs and HoMM saw the direct employment of pharmacists by practices as a 
way of removing any such conflict, as the PP would be responsible directly to practice 
management. The HoMMs saw the desire of GPs to employ pharmacists directly, and the 
GPs themselves wanted more control over the PP’s workload.  
If recruitment from a provider is inevitable, management of the pharmacist must be achieved 
by co-operation (vertical integration) between the practice and the provider so that all parties 
are clear about the pharmacist’s remit and workload prioritisation. This is what Axelsson and 
Axelsson, (2006) proposed for Public Health and can, I argue, be extrapolated to PPs in 
primary care. The thesis study GPs were unhappy with multiple PPs providing the service. I 
recommend that job-sharing should be avoided unless there is good communication between 
the pharmacists to ensure joint responsibility for decisions and any actions. 
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8.5.2 Role specification 
The thesis project PP roles included many that had been identified in the literature but also 
identified new roles related to the management of repeat prescriptions and addressing 
interface issues. The management of repeat prescriptions was related to both patient safety 
and efficiencies. There is a historical, current and future value in managing the cost of 
medicines while maintaining patient care and safety. The PPs respondents were concerned 
that efficiencies were diverting them from clinical aspects of their role which caused some 
dissatisfaction. I, therefore, support the view that pharmacists should lead on the 
identification of efficiencies, but that achieving these should be a shared responsibility across 
all practice staff as part of the medicines optimisation agenda (Picton and Wright, 2013). 
Pharmacists were considered to be well situated to act as a conduit for information and 
problem solving between sectors and organisations which was facilitated by experience in 
other sectors. This interface role should be included in the remit of pharmacists working in 
general practice. Pharmacist prescribing (discussed in 8.4.2) should also be part of the role 
specification, including specialisation in a disease or body system, as this provides an extra 
resource for the practice. Being qualified to prescribe will improve patient access to a 
healthcare professional, make better use of pharmacists’ skills and reduce GP workloads. 
The thesis study pharmacists and patients wanted the pharmacist’s time at the practice to be 
maximised to improve the accessibility of the pharmacist to staff and patients which has been 
suggested to have a positive effect on integration (Jorgenson et al., 2013). I recommend that 
pharmacists are employed for the maximum number of hours a week that the practice can 
manage within its staffing budget to facilitate integration and maximize their value to the 
practice. 
 
Pragmatically, the pharmacist’s initial role within the practice should be defined in advance to 
reflect the needs of the practice and the individual pharmacist’s current knowledge-base, 
skills and competencies. The roles specified, however, should also be developmental. The 
role should remain interesting, challenging and professionally satisfying to ensure the 
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recruitment and retention of motivated pharmacists, like those in the thesis study. 
 
The thesis study indicated that patients perceive the practice as validating the pharmacist’s 
skills and expertise. Employing practices should, therefore, ensure that they have employed 
a pharmacist of the correct calibre as they may be seen by patients as responsible for any 
failings in the pharmacist’s input to patient care. 
 
8.5.3 Training Plans 
The study GPs thought that their PPs could easily be trained for new roles and also that GPs 
should be involved in any training of their pharmacists. The latter was felt to support 
integration and directed training to the needs of the practice. The study CCGs were 
inconsistent in assessing the training needs of their PPs and providing training. The 
employing practice should develop a training plan based on the pharmacist’s current 
competencies and what is required of the pharmacist to meet the current and future clinical 
needs of the practice, with GPs involved in the training. Tailored training provision, to meet 
the needs of individual pharmacist and role, has also been recommended by Campbell et al. 
(2016). Base-line competencies should be ascertained by using existing competency 
frameworks, for example, the RPS Advanced Pharmacy Framework and the Competency 
Framework for All Prescribers, as appropriate (Royal Pharmaceutical Society, 2016; The 
Royal Pharmaceutical Society and CoDEG, 2013). Time away from practice for training was 
raised as a concern in the thesis study; appropriate distance learning may be a potential 
solution as suggested by Mills (2016). It is not clear, at the time of writing, where targeted 
training resources can be accessed or how they can be funded, but the current CPPE GP 
Pharmacist Training Pathway may be a good starting point if this aspect of the NHSE pilot 
evaluates well. Mentorship, as described in the NHS England pilot, seems to have some 
merit and should help avoid professional isolation particularly at the junior level. 
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8.5.4 Briefing of practice staff and patients 
In the thesis study, HCPs were reported to be possessive about their patients and workload 
which was related to concerns about role encroachment. Not all of the patient respondents 
were aware that practices had a pharmacist, or that suitably qualified pharmacists could 
prescribe. Where patient respondents were aware that pharmacists could prescribe, they 
were not always clear about the scope of the pharmacist’s prescribing competencies. The PP 
respondents also reported pressure from practice staff to sign prescriptions outside the 
prescribing pharmacist’s areas of competence. These issues may be reduced, or even 
eliminated if the role of the pharmacist and scope of practice was explained to all the practice 
staff and patients before they started work at the practice. This should address the barriers to 
change identified by Pettinger (2001). 
 
Arguably, the most important aspect of the integration of pharmacists is that of building trust 
with the GP(s). Trust as a prerequisite for integration was identified in both the Initial and 
thesis studies and was based on evidence of their benefit and a positive track record of 
behaviours, built up over time. This view is supported by the literature as a key determinant 
of integration (Bardet et al., 2015; Jorgenson et al., 2014; Kolodziejak et al., 2010).  
Employing GP practices should recognise that, unless there has been a prior positive 
working relationship with the pharmacist, it may take time to develop the necessary trust with 
the GP(s), and possibly with other practice staff, to achieve integration.  
 
8.6 National support 
The Initial Study and thesis project has identified several areas that require a response at a 
national level to support the integration of pharmacists. The third element of the model 
relates to the support required at a national level and consists of five areas. 
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8.6.1 Formal role recognition 
The thesis study PP respondents felt isolated from the rest of the profession when working in 
primary care. They related this to the need for formal recognition of the pharmacist’s role in a 
GP practice and felt that this role should be a mainstream alternative to hospital and 
community pharmacy roles. Currently only the latter two options are considered as patient-
facing for pre-registration training, and pharmacy graduates must spend at least half of their 
pre-registration study year in either of these sectors. A pharmacist working in a GP practice 
will also spend time seeing patients and interacting with them, providing a valuable learning 
experience for pre-registration pharmacists that should count towards the patient-facing time. 
I recommend, therefore, that the regulatory body for pharmacy (GPhC) should, in the near 
future, require that work-based experiential learning in primary care is a core element in the 
undergraduate MPharm course. Pre-registration pharmacists should also be able to 
complete their pre-registration year solely in primary care. It is encouraging to note that in 
some areas pre-registration placements are already provided in conjunction with hospital or 
community pharmacy (Malson, 2016). Campbell et al. (2016) have called for a review of 
undergraduate and pre-registration training to meet the challenges in primary care. If these 
changes are instigated, then this will support pre-registration training, widen the experience 
of pre-registration pharmacists and increase the profile of the pharmacist’s role in GP 
practices beyond that generated by the NHS pilot. Given that pharmacists are part of the 
Government’s policy to address workforce shortages, it is illogical to provide initial training 
without provision for maintaining and widening competencies in the future to allow 
pharmacists to progress and take on more of the workload as appropriate.   
 
There remains some confusion in the minds of thesis project GPs as to the relative merits of 
employing a nurse or a pharmacist, that appears to be incorrectly based solely on the cost to 
the practice. Prescribing pharmacists, in a recent survey, also felt that the relative 
employment costs were a potential barrier to pharmacist employment (General 
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Pharmaceutical Council, 2016).  I argue that cost is an unreasonable way of differentiating 
between two professions with inherent strengths and weaknesses and different skill sets. 
The specific expertise that pharmacists bring to general practice should be openly discussed 
at the national level, as suggested by Campbell et al. (2016), so that GPs and practices can 
make informed decisions about which HCP fits their needs at the time. 
 
8.6.2 Career structure 
The thesis study HoMMs felt there should be a clear career pathway for pharmacists in 
primary care. To properly recognise the pharmacist’s role in GP practices, a nationally 
approved and recognised career structure should be developed, with appropriate input from 
the Medical profession, that differentiates between levels of experience and managerial 
responsibility. A need for a clear career progression pathway for pharmacists in general 
practice in the UK has also been recommended by Campbell et al. (2016) 
 
 
8.6.3 Secure national funding 
Sustained national funding will be required to support increasing the numbers of pharmacists 
required to address the workforce issues in primary care. If the shortage of GPs (and 
possibly practice nurses) is not going to be addressed in the next ten years, then significant 
numbers of suitably qualified pharmacists are going to be required, to meet the need in 
primary care. Recurring funding for initial training of PPs, prescribing courses and ongoing 
development will be needed. A lack of funding has been identified as a barrier to increasing 
the numbers of pharmacists in general practice in the literature  
(Freeman et al., 2012b; Tan et al., 2014b), and in the thesis study by the GPs, HoMMs and 
PPs. A lack of funding for training pharmacist prescribers was also felt to be a barrier to 
increasing the numbers of prescribing pharmacists by HoMMs in the thesis study; this view 
was supported in a recent survey of UK pharmacist prescribers (General Pharmaceutical 
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Council, 2016).  
 
8.6.4 Education and training strategy 
The Pharmacy and Medical professions need to agree on a competency framework for 
pharmacists working in GP practices to use to ascertain their current and future training 
needs. Campbell et al. (2016) also called for a definition of competencies. The RPS 
Advanced Pharmacy Framework and the Competency Framework for All Prescribers are 
validated and were used to a degree by the PP studied by Mills (2016). They still need to be 
confirmed as suitable for pharmacists working with GPs. An education and training strategy 
to maintain current, and develop additional competencies, must form part of the National 
Support element as shown in my proposed Model so that service gaps left by the workforce 
shortage in primary care can be filled by suitably trained pharmacists.  
 
8.6.5 Healthcare professionals’ initial education and training 
A longer-term solution to the socialisation of doctors, nurses and pharmacists and their inter-
professional understanding of each other’s strengths and weaknesses would be to ensure 
that they are trained together. A Cochrane review (Reeves et al., 2013) of inter-professional 
education (IPE) studies on patient outcomes or healthcare process found that only seven out 
of fifteen studies reported positive outcomes. Since 1988, IPE of HCPs has been introduced 
into undergraduate training courses, and while it appears to be feasible and effective, the 
best method of delivery is currently unclear (Olson and Bialocerkowski, 2014). The 
continuation of IPE into early years as practitioners should be considered to consolidate the 
collaborative nature of their roles in practice. A study of Scottish GPs and pharmacists 
suggests that both professions learn from IPE and that professional socialization occurred. 
Recently qualified GPs were more open to the pharmacist’s input, suggesting that early 
years GPs would be more open to IPE with pharmacists (Cunningham et al., 2016). 
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The elements and areas that I have presented in this Chapter make up my proposed Model 
for the Successful Integration of Pharmacists into GP practices. Not every element will be 
necessary or available to individual pharmacists and practices at the time of the pharmacist’s 
initial appointment to the role. For example, if there is a prior relationship with the pharmacist, 
then the time required for trust to build between colleagues and patients may be reduced. 
Utilising my proposed Model will, I argue, benefit the NHS, GP practices and patients by 
expediting the pharmacist’s integration and maximising their anticipated input to patient care. 
  
 199 
Chapter 9 Conclusion and further research 
 
9.1 Conclusion 
My thesis project has studied PPs working in CCGs in 2014 and their relationship with 
stakeholders. It is unique in this respect and was designed to address the original research 
questions related to my research, but also appropriately refocussed due to contemporary 
developments in primary care. The PPs studied were similar to those studied elsewhere, and 
many of the thesis study findings related to integration have been identified in other studies.  
These similarities provide some assurance that the thesis study results apply to pharmacists 
working in general practice in the rest of the UK. The commissioners, GPs, patients and PP 
respondents saw the value of the pharmacist to general practice including pharmacist 
prescribing. The commissioners and pharmacists felt that direct employment by GPs was 
advantageous as it directly linked the pharmacist’s workload to the needs of the practice. 
General practitioners were clear about the time that pharmacists saved them and wanted 
more involvement in CDM and saw prescribing as integral to this. Patients indicated that they 
appreciated the extra time and information that PPs were able to give and were largely 
happy for pharmacists to prescribe. The PPs wanted more patient contact and to be more 
involved in LTC management. The thesis project also adds to the growing body of evidence 
that suggests that UK clinical pharmacists should be trained to postgraduate diploma level 
with, or incorporating, a prescribing qualification. It has also provided further evidence of the 
value of a pharmacist to general practice, identified abiding roles that they are specifically 
suited to, and promulgated a unique Model for the integration of pharmacists into general 
practice in the UK. 
 
The workforce crisis in primary care has driven the need for more pharmacists to work with 
GPs to address the shortage of GPs and practice nurses. Significant finance and training 
have been provided to facilitate this, but it is a high-risk strategy because the Pilot has not 
been evaluated, yet a second and third wave of recruitment is going ahead. Some integration 
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issues have already been identified. This is a concern because the failure of this strategy will 
be significant to the taxpayer, the NHS, and the Medical and Pharmacy professions, and 
more importantly, patients. The Model which has emerged from this thesis study can be used 
to specifically address integration issues raised in the Pilot, such as encroachment, role 
definition and training requirements. It can also be used to support the wider integration of 
pharmacists into general practice in the UK.  
 
The proposed Model for the integration of pharmacists into general practice teams has three 
elements that are interrelated. Each element is sub-divided into a number of areas. The 
pharmacist’s skills and attributes that support integration are experience in community 
pharmacy, a prescribing qualification and training to a postgraduate diploma level.  An ability 
to build a rapport with the practice staff and to be adaptable, proactive and motivated are 
also key personal attributes that support integration. At the practice level, direct employment 
by the practice is the preferred method with a clear role definition that has been explained to 
practice staff and patients in advance. An individual training plan needs to be agreed to 
address gaps in the skills and knowledge of the pharmacists to meet the needs of the 
practice. National support underpins the other elements of the Model providing strategic 
structure and funding. More needs to be done to recognise the pharmacist’s role in general 
practice and to raise the profile within and outside the profession. The role of the pharmacist 
within general practice should be recognised as a patient-facing role suitable for inclusion in 
pre-registration training and have a nationally recognized career structure. Secure national 
funding is required for pharmacist prescribing and the initial and ongoing training of 
pharmacists for the general practice role. This training should be part of an education and 
training strategy that includes the joint training of healthcare professionals. 
 
The Model for integration detailed in this thesis should be implemented within and outside 
the NHSE Pilot to minimise the risk of integration failure and maximise the value of 
pharmacists to the NHS when they are embedded in general practice. It will not be possible 
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to apply all these factors to support pharmacist integration in every case as many, especially 
at the national level, are not in place at the time of writing, and the numbers of pharmacists 
with all the preferred attributes may be limited. The assumption is that the greater number of 
factors that are in place when the pharmacist is recruited, the easier it will be for the 
pharmacist to integrate. Unfortunately, it is not clear if some factors are more effective in 
supporting integration than others, so the proposed Model will require testing to provide 
assurance and possibly apportion weight to its recommendations. In the interim, any GP 
practice considering employing a pharmacist to take on some if its workload should consider 
the elements and areas of the Model that they can control or influence and act on these.  
 
9.2 Further research 
Further research is needed to ensure that the integration of pharmacists into primary care is 
cost-effective, safe and fulfils a sustainable role that utilises a pharmacist’s unique skill set to 
improve patient care rather than just a stopgap for poor workforce planning that may be 
addressed in the future. Further study into the relative importance of the factors described in 
the Model could help prioritise those that are essential and provide a clearer focus for the 
national and local recruitment of pharmacists. 
 
More research is needed on the role, and therefore training required, for pharmacists 
undertaking the PP role in any capacity as this is a key element of integration. This project 
identified GP concerns around consultation skills in a largely experienced and highly trained 
PP respondent group. Despite this concern not being substantiated by any GP or patient, it is 
worthy of further study. It is not clear how this perceived apprehension around consultation 
skills relates to the relatively low levels of patient contact that PPs had in this and other 
studies. The range of levels of prescribing by qualified pharmacist prescribers should also be 
investigated in the UK to ascertain if this is due to the circumstances of employment, is a 
function of perceived risk, training or the personal attributes of individual pharmacists.  
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A concerted effort is required to ensure that practices understand the differences between 
the skill sets of nurses and pharmacists so that informed decisions can be made by 
employers.  This may require re-evaluation of the role of both professions in primary care in 
the light of the current workforce issues and changing population demographics. 
 
Patient views of non-medical prescribing need to be more clearly understood as some 
patients see some diseases and diagnosis of new conditions as not suitable for pharmacist 
prescribers. More research is needed to understand the issues that facilitate pharmacist 
prescribing in a wider range of conditions. Prescribing in a wider range of conditions was a 
way forward identified by the commissioners, GPs and PPs who took part in this study, and 
is essential if pharmacists are to take an increasing role in the management of long-term 
conditions.  
 
  
 203 
References 
Agomo, C.O., 2012. Why UK pharmacy must adapt to the increasing demands of 
professionalism in practice: How UK pharmacists must adapt. Int. J. Pharm. Pract. 
20, 320–323. https://doi.org/10.1111/j.2042-7174.2012.00200.x 
 
Alaszewski, A., 2007. Using Documents in Health Research, in: Saks, M., Allsop, J. (Eds.), 
Researching Health: Qualitative, Quantitative and Mixed Methods. Los Angeles: 
SAGE Publications Ltd, pp 57-73 
 
Alex Broom, Evan Willis, 2007. Competing Paradigms and Health Research, in: Mike Saks, 
Judith Allsop (Eds.), Researching Health: Qualitative, Quantitative and Mixed 
Methods. London: SAGE Publications Ltd, pp. 16–31. 
 
Allan, G., 2003. A critique of using grounded theory as a research method. Electron. J. Bus. 
Res. Methods 2, 1–10. 
 
Arkowitz, H., Lilienfeld, S.O., 2010. Do the “Eyes” Have It? Sci. Am. Mind 20, 68–69. 
 
Austin, Z., Gregory, P.A.M., Martin, J.C., 2007. Negotiation of interprofessional culture shock: 
The experiences of pharmacists who become physicians. J. Interprof. Care 21, 83–
93. https://doi.org/10.1080/13561820600874817 
 
Avery, A.J., Rodgers, S., Cantrill, J.A., Armstrong, S., Cresswell, K., Eden, M., Elliott, R.A., 
Howard, R., Kendrick, D., Morris, C.J., others, 2012. A pharmacist-led information 
technology intervention for medication errors (PINCER): a multicentre, cluster 
randomised, controlled trial and cost-effectiveness analysis. The Lancet 379, 1310–
1319. 
 
Avery, A.J., Sheikh, A., Hurwitz, B., Smeaton, L., Chen, Y.-F., Howard, R., Cantrill, J., Royal, 
S., 2002. Safer medicines management in primary care. Br. J. Gen. Pract. 52, S17–
S21. 
 
Avorn, J., Soumerai, S.B., 1983. Improving Drug-Therapy Decisions through Educational 
Outreach: A Randomized Controlled Trial of Academically Based Detailing. N. Engl. 
J. Med. 308, 1457–1463. https://doi.org/10.1056/NEJM198306163082406 
 
Avorn, J., Soumerai, S.B., Everitt, D., Rose-Degnan, D., Beers, M., Sherman, D., Salem-
Schatz, S., Fieds, D., 1992. A randomized trial of a program to reduce the use of 
psychoactive drugs in nursing homes. N. Engl. J. Med. 327, 168–73. 
 
Axelsson, R., Axelsson, S.B., 2006. Integration and collaboration in public health—a 
conceptual framework. Int. J. Health Plann. Manage. 21, 75–88. 
https://doi.org/10.1002/hpm.826 
 
 204 
Bapen, 2016. MUST Online Calculator - Malnutrition Universal Screening Tool [pdf]. URL 
http://www.bapen.org.uk/screening-and-must/must-calculator (accessed 21.11.16). 
 
Bardet, J.D., Vo, T.H., Bedouch, P., Allenet, B., 2015. Physicians and community 
pharmacists’ collaboration in primary care: A review of specific models. Res. Soc. 
Adm. Pharm. 11, 602–622. https://doi.org/10.1016/j.sapharm.2014.12.003 
 
Bell, J., 2010. Doing Your Research Project, 5th ed. Maidenhead: Open University Press. 
 
Bereznicki, B., Peterson, G., Jackson, S., Haydn Walters, E., DeBoos, I., Hintz, P., 2011. 
Perceived feasibility of a community pharmacy-based asthma intervention: a 
qualitative follow-up study: Feasibility of a pharmacy asthma intervention. J. Clin. 
Pharm. Ther. 36, 348–355. https://doi.org/10.1111/j.1365-2710.2010.01187.x 
 
Bhanbhro, S., Drennan, V.M., Grant, R., Harris, R., 2011. Assessing the contribution of 
prescribing in primary care by nurses and professionals allied to medicine: a 
systematic review of literature. BMC Health Serv. Res. 11, 1–10. 
 
Bindman, A.B., Weiner, J.P., Majeed, A., 2001. Primary Care Groups In The United 
Kingdom: Quality And Accountability. Health Aff. (Millwood) 20, 132–145. 
https://doi.org/10.1377/hlthaff.20.3.132 
 
Blenkinsopp, A., Boardman, H., Jesson, J., Wilson, K., 2001. A pharmacy workforce survey 
in the West Midlands:(3) Primary care pharmacists. Pharm. J. 266, 684–687. 
 
Blenkinsopp, A., Boardman, H., Jesson, J., Wilson, K., 1999. A pharmacy workforce survey 
in the West Midlands: (1) Current work profiles and patterns. Pharm. J. 263, 909–913. 
 
Blenkinsopp, A., Bond, C., Raynor, D.K., 2012. Medication reviews: Medication reviews. Br. 
J. Clin. Pharmacol. 74, 573–580. https://doi.org/10.1111/j.1365-2125.2012.04331.x 
 
Boardman, H., Blenkinsopp, A., Jesson, J., Wilson, K., 2001. A pharmacy workforce survey 
in the West Midlands: (4) Morale and motivation. Pharm. J. 267, 685–690. 
 
Boardman, H., Blenkinsopp, A., Jesson, J., Wilson, K., 2000. A pharmacy workforce survey 
in the West Midlands: (2) Changes made and planned for the future. Pharm. J. 264, 
105–108. 
 
Bojke, C., Gravelle, H., Wilkin, D., 2001. Is bigger better for primary care groups? BMJ 322, 
599–602. 
 
Bowling, A., 2009. Research Methods in Health: Investigating Health and Health Services, 
Second edition. ed. Buckingham: Open University Press. 
 205 
 
Bradley, F., Ashcroft, D.M., Noyce, P.R., 2012. Integration and differentiation: A conceptual 
model of general practitioner and community pharmacist collaboration. Res. Soc. 
Adm. Pharm. 8, 36–46. https://doi.org/10.1016/j.sapharm.2010.12.005 
 
Bradley, F., Wagner, A.C., Elvey, R., Noyce, P.R., Ashcroft, D.M., 2008. Determinants of the 
uptake of medicines use reviews (MURs) by community pharmacies in England: A 
multi-method study. Health Policy 88, 258–268. 
https://doi.org/10.1016/j.healthpol.2008.03.013 
 
British Pharmaceutical Students’ Association, 2017. Aspirations and Expectations of 
Pharmacy Students: A View to the Future. London: The Royal Pharmaceutical 
Society 
 
Britten, N., 2001. Prescribing and the defence of clinical autonomy. Sociol. Health Illn. 23, 
478–496. 
 
Bruhn, H., Blyth, A., Elliott, A., Hannaford, P., Holland, R., Lee, A., MacNamee, P., Smith, B., 
Watson, M., Wright, D., Bond, C., 2011. Pharmacist-led management of chronic pain 
in primary care: The PIPPC study. J. Epidemiol. Community Health 65, A13–A14. 
https://doi.org/10.1136/jech.2011.143586.30 
 
Bruhn, H., Bond, C.M., Elliott, A.M., Hannaford, P.C., Lee, A.J., McNamee, P., Smith, B.H., 
Watson, M.C., Holland, R., Wright, D., 2013. Pharmacist-led management of chronic 
pain in primary care: results from a randomised controlled exploratory trial. BMJ Open 
3, e002361. 
 
Bryant, L., Coster, G., McCormick, R., 2010. General practitioner perceptions of clinical 
medication reviews undertaken by community pharmacists. J Prim. Health Care 2, 
225–33. 
 
Bush, J., Langley, C.A., Wilson, K.A., 2009. The corporatization of community pharmacy: 
Implications for service provision, the public health function, and pharmacy’s claims to 
professional status in the United Kingdom. Res. Soc. Adm. Pharm. 5, 305–318. 
https://doi.org/10.1016/j.sapharm.2009.01.003 
 
Calnan, M., 2007. Quantitative Survey Methods in Health Research, in: Saks, M., Allsop, J. 
(Eds.), Researching Health: Qualitative, Quantitative and Mixed Methods. London: 
SAGE Publications Ltd, pp. 174–196. 
 
Campbell, J., Healey, M., Sims, L., Sansom, A., Butterworth, J., 2016. The Pharmacist in 
Primary Care–An Introduction Project Report. [pdf] 
https://hee.nhs.uk/sites/default/files/documents/Pharmacy%20In%20Primary%20Car
e%20Report%20%20-%20FULL.pdf (accessed 3.6.17} 
 
 206 
Care Quality Commission, 2016. Care Quality Commission-Home Page [pdf]. URL 
http://www.cqc.org.uk/ (accessed 4.9.16). 
 
Centre for Pharmacy Postgraduate Education, 2016. Developing clinical pharmacists in 
general practice. [pdf] https://www.cppe.ac.uk/wizard/files/developing_career/cppe-
hee-general-practice-pharmacist-learning-pathway-current-edition.pdf (accessed 
1.5.17) 
 
Centre for Pharmacy Postgraduate Education, 2015. General practice - the fundamentals of 
working with GPs (tutor supported): CPPE [pdf]. Learn. Programme Assess. URL 
https://www.cppe.ac.uk/programmes/l/fundament-ec-01/ (accessed 3.7.17). 
 
Centre for Workforce Intelligence, 2013. A strategic review of the future pharmacist 
workforce: Informing pharmacist student intake. The Centre for Workforce 
Intelligence. [pdf] URL https://www.gov.uk/government/publications/strategic-review-
of-the-future-pharmacist-workforce (accessed 4.5.16) 
 
Checkland, K., Coleman, A., McDermott, I., Segar, J., Miller, R., Petsoulas, C., Wallace, A., 
Harrison, S., Peckham, S., 2013. Primary care-led commissioning: applying lessons 
from the past to the early development of clinical commissioning groups in England. 
Br. J. Gen. Pract. 63, 611–619. https://doi.org/10.3399/bjgp13X671597 
 
Checkland, K., McDermott, I., Coleman, A., Perkins, N., 2016. Complexity in the new NHS: 
longitudinal case studies of CCGs in England. BMJ Open 6, e010199. 
 
Chen, J., Britten, N., 2000. ‘Strong medicine’: an analysis of pharmacist consultations in 
primary care. Fam. Pract. 17, 480–483. 
 
Child, A., Clarke, A., Fox, C., Maidment, I., 2012. A pharmacy led program to review anti-
psychotic prescribing for people with dementia. BMC Psychiatry 12, 155. 
 
Cooper, R.J., Bissell, P., Ward, P., Murphy, E., Anderson, C., Avery, T., James, V., Lymn, J., 
Guillaume, L., Hutchinson, A., Ratcliffe, J., 2012. Further challenges to medical 
dominance? The case of nurse and pharmacist supplementary prescribing. Health 
Interdiscip. J. Soc. Study Health Illn. Med. 16, 115–133. 
https://doi.org/10.1177/1363459310364159 
 
Corbin, J.M., Strauss, A., 1990. Basics of Qualitative Research: Grounded Theory 
Procedures and Techniques, Third edition. Los Angeles, Calif: SAGE Publications, 
Inc.  
 
Cordina, M., Lauri, M., Buttigieg, R., Lauri, J., 2015. Personality traits of pharmacy and 
medical students throughout their course of studies. Pharm. Pract. 13, 640–640. 
https://doi.org/10.18549/PharmPract.2015.04.640 
 
 207 
Coulter, A., 1995. Shifting the balance from secondary to primary care. BMJ 311, 1447. 
 
Courtenay, M., Carey, N., Stenner, K., 2012. An overview of non-medical prescribing across 
one strategic health authority: a questionnaire survey. BMC Health Serv. Res. 12, 
138. 
 
Cresswell, K.M., Sadler, S., Rodgers, S., Avery, A., Cantrill, J., Murray, S.A., Sheikh, A., On 
behalf of the PINCER Evaluation Team, 2012. An embedded longitudinal multi-
faceted qualitative evaluation of a complex cluster randomized controlled trial aiming 
to reduce clinically important errors in medicines management in general practice. 
Trials 13, 78. https://doi.org/10.1186/1745-6215-13-78 
 
Crowe, S., Cresswell, K., Robertson, A., Huby, G., Avery, A., Sheikh, A., 2011. The case 
study approach. BMC Med. Res. Methodol. 11, 1. 
 
Cunningham, D.E., Ferguson, J., Wakeling, J., Zlotos, L., Power, A., 2016. GP and 
pharmacist inter-professional learning – a grounded theory study. Educ. Prim. Care 
27, 188–195. https://doi.org/10.1080/14739879.2016.1163645 
 
Davies, J.E., Barber, N., Taylor, D., 2014. What do community pharmacists do?: results from 
a work sampling study in London: Results from a work sampling study in London. Int. 
J. Pharm. Pract. 22, 309–318. https://doi.org/10.1111/ijpp.12083 
 
Dayan, M., Arora, S., Rosen, R., Curry, N., 2014. Is general practice in crisis? [pdf] URL 
https://www.nuffieldtrust.org.uk/files/2017-01/general-practice-in-crisis-web-final.pdf 
(accessed 3.5.15) 
 
Department of Health, 2008. Improving Patients’ Access to Medicines: A Guide to 
Implementing Nurse and Pharmacist Independent Prescribing within the NHS in 
England (No. Gateway reference: 6429). London: Department of Health. [pdf] URL 
webarchive.nationalarchives.gov.uk/20130107105354/...uk/.../dh_4133747.pdf. 
(accessed 13.5.15) 
 
Department of Health, 2015. NHS Constitution for England [pdf]. URL 
https://www.gov.uk/government/publications/the-nhs-constitution-for-england 
(accessed 11.14.16). 
 
Department of Health, 2010. QIPP: Quality, Innovation, Productivity and Prevention [pdf]. 
URL 
http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/en/Aboutus/Chiefprofessi
onalofficers/Chiefnursingofficer/Energiseforexcellence/DH_121229 (accessed 
4.9.16). 
 
Department of Health, 2000. The NHS Plan. A plan for investment. A plan for reform. [pdf] 
URL http://1nj5ms2lli5hdggbe3mm7ms5.wpengine.netdna-
cdn.com/files/2010/03/pnsuk1.pdf (accessed 15.3.15) 
 208 
 
Department of Health, 1997. The New NHS modern. dependable [pdf]. URL 
https://www.gov.uk/government/publications/the-new-nhs (accessed 10.17.15). 
 
Desborough, J.A., Sach, T., Bhattacharya, D., Holland, R.C., Wright, D.J., 2012. A cost-
consequences analysis of an adherence focused pharmacist-led medication review 
service: Medication review cost-consequences analysis. Int. J. Pharm. Pract. 20, 41–
49. https://doi.org/10.1111/j.2042-7174.2011.00161.x 
 
Drake, P., 2010. Practitioner Research at Doctoral Level: Developing Coherent Research 
Methodologies. Oxford: Routledge. 
 
Eccles, M.P., Steen, I.N., Whitty, P.M., Hall, L., 2007. Is untargeted educational outreach 
visiting delivered by pharmaceutical advisers effective in primary care? A pragmatic 
randomized controlled trial. Implement. Sci. 2, 23. https://doi.org/10.1186/1748-5908-
2-23 
 
Eden, M., Schafheutle, E.I., Hassell, K., 2009. Workload pressure among recently qualified 
pharmacists: an exploratory study of intentions to leave the profession. Int. J. Pharm. 
Pract. 17, 181–187. https://doi.org/10.1211/ijpp/17.03.0009 
 
Edmunds, J., Calnan, M.W., 2001. The reprofessionalisation of community pharmacy? An 
exploration of attitudes to extended roles for community pharmacists amongst 
pharmacists and General Practioners in the United Kingdom. Soc. Sci. Med. 53, 943–
955. 
 
Elvey, R., Hassell, K., Hall, J., 2013. Who do you think you are? Pharmacists’ perceptions of 
their professional identity. Int. J. Pharm. Pract. 21, 322–332. 
https://doi.org/10.1111/ijpp.12019 
 
Ferguson, J., Ashcroft, D., Hassell, K., 2011. Qualitative insights into job satisfaction and 
dissatisfaction with management among community and hospital pharmacists. Res. 
Soc. Adm. Pharm. 7, 306–316. https://doi.org/10.1016/j.sapharm.2010.06.001 
 
Fish, A., Antonazzo, E., Reid, J.P., Bond, C., Porteous, T.H., Scott, T., 2001. A randomised, 
controlled study to quantify the benefits of community pharmacist interventions on the 
prescribing of cardiovascular drugs in general practice. Int. J. Pharm. Pract. R26. 
 
Fish, A., Watson, M.C., Bond, C.M., 2002. Practice-based pharmaceutical services: a 
systematic review. Int. J. Pharm. Pract. 10, 225–233. 
 
Frankel, G.E.C., Austin, Z., 2013. Responsibility and confidence: Identifying barriers to 
advanced pharmacy practice. Can. Pharm. J. Rev. Pharm. Can. 146, 155–161. 
https://doi.org/10.1177/1715163513487309 
 209 
 
Freeman, C., Cottrell, N., Rigby, D., Williams, I.D., Nissen, L., 2014. The Australian practice 
pharmacist. J. Pharm. Pract. Res. 44, 240–248. https://doi.org/10.1002/jppr.1027 
 
Freeman, C., Cottrell, W.N., Kyle, G., Williams, I., Nissen, L., 2012a. Does a primary care 
practice pharmacist improve the timeliness and completion of medication 
management reviews? Int. J. Pharm. Pract. 20, 395–401. 
https://doi.org/10.1111/j.2042-7174.2012.00213.x 
 
Freeman, C., Cottrell, W.N., Kyle, G., Williams, I., Nissen, L., 2012b. Integrating a pharmacist 
into the general practice environment: opinions of pharmacist’s, general practitioner’s, 
health care consumer’s, and practice manager’s. BMC Health Serv. Res. 12, 229. 
 
Freeman, C.R., Cottrell, W.N., Kyle, G., Williams, I.D., Nissen, L., 2013. An evaluation of 
medication review reports across different settings. Int. J. Clin. Pharm. 35, 5–13. 
https://doi.org/10.1007/s11096-012-9701-8 
 
Freemantle, N., Nazareth, I., Eccles, M., Wood, J., Haines, A., others, 2002. A randomised 
controlled trial of the effect of educational outreach by community pharmacists on 
prescribing in UK general practice. Br. J. Gen. Pract. 52, 290–295. 
 
Furniss, L., 2000. Effects of a pharmacist’s medication review in nursing homes: 
Randomised controlled trial. Br. J. Psychiatry 176, 563–567. 
https://doi.org/10.1192/bjp.176.6.563 
 
General Pharmaceutical Council, 2017. Number of Pharmacist Prescribers in the UK. 
Information requests (foi@pharmacyregulation.org,16.10.2017). Numbers of 
pharmacist prescribers. email to Robert Saunders (r.e.saunders@keele.ac.uk). 
 
General Pharmaceutical Council, 2016. Prescribers Survey Report. [pdf] URL 
https://www.pharmacyregulation.org/sites/default/files/gphc_prescribers_survey_repo
rt.pdf 
 
Gerada, C., 2013. What should clinical commissioning groups do on 1 April 2013? BMJ 346, 
f1977–f1977. https://doi.org/10.1136/bmj.f1977 
 
Gerard, K., Tinelli, M., Latter, S., Blenkinsopp, A., Smith, A., 2012. Valuing the Extended 
Role of Prescribing Pharmacist in General Practice: Results from a Discrete Choice 
Experiment. Value Health 15, 699–707. https://doi.org/10.1016/j.jval.2012.02.006 
 
Gidman, W., 2011. Increasing community pharmacy workloads in England: causes and 
consequences. Int. J. Clin. Pharm. 33, 512–520. https://doi.org/10.1007/s11096-011-
9498-x 
 210 
 
Gray, S., Urwin, M., Woolfrey, S., Harrington, B., Cox, J., 2008. Copying hospital discharge 
summaries to practice pharmacists: does this help implement treatment plans? Qual. 
Prim. Care 16, 327–334. 
 
Green, J., 2007. The use of focus groups in research into health, in: Saks, M., Allsop, J. 
(Eds.), Researching Health: Qualitative, Quantitative and Mixed Methods. London: 
SAGE Publications Ltd, pp. 112–132. 
 
Green, P.E., 1985. The general practice formulary—its role in rational therapeutics. Br. J. 
Gen. Pract. 35, 570–572. 
 
Grimes, T., Duggan, C., Gallagher, P., Strawbridge, J., 2009. Care of the stroke patient—
communication between the community pharmacist and prescribers in the Republic of 
Ireland. Pharm. World Sci. 31, 648–655. https://doi.org/10.1007/s11096-009-9322-z 
 
Guba, E., Lincoln, Y., 1994. Competeing Paradigms in Qualitative Research, in: Denzin, 
N.K., Lincoln, Y.S. (Eds.), Handbook of Qualitative Research. London: SAGE 
Publications Ltd. pp. 105–117. 
 
Guillaume, L., Cooper, R., Avery, A., Mitchell, S., Ward, P., Anderson, C., Bissell, P., 
Hutchinson, A., James, V., Lymn, J., others, 2008. Supplementary prescribing by 
community and primary care pharmacists: an analysis of PACT data, 2004–2006. J. 
Clin. Pharm. Ther. 33, 11–16. 
 
Hall, L., Eccles, M., Barton, R., Steen, N., Campbell, M., 2001. Is untargeted outreach visiting 
in primary care effective? A pragmatic randomized controlled trial. J. Public Health 
23, 109–113. 
 
Ham, C., 2012. The management of the NHS in England. BMJ 344, e928–e928. 
https://doi.org/10.1136/bmj.e928 
 
Hamley, J.H., MacGregor, S.H., Dunbar, J.A., Cromarty, J.A., 1997. Integrating Clinical 
Pharmacists into the Primary Health Care Team: A Framework for Rational and Cost-
Effective Prescribing. Scott. Med. J. 42, 4–7. 
https://doi.org/10.1177/003693309704200102 
 
Harding, G., Taylor, K., 1997. Responding to change: the case of community pharmacy in 
Great Britain. Sociol. Health Illn. 19, 547–560. 
 
Harris, C.M., Dajda, R., 1996. The scale of repeat prescribing. Br. J. Gen. Pract. 46, 649–
653. 
 
 211 
Hassell, K., 2012. CPWS Briefing Paper GPhC Register Analysis 2011. Centre for Pharmacy 
Workforce Studies School of Pharmacy University of Manchester. [pdf] URL 
https://www.pharmacyregulation.org/sites/default/files/Analysis%20of%20GPhC%20P
harmacist%20Register%202011.pdf (accessed 10.5.15) 
 
Hassell, K., 2000. The impact of social change on professions—gender and pharmacy in the 
UK: an agenda for action. Int. J. Pharm. Pract. 8, 1–9. 
 
Hassell, K., Royal Pharmaceutical Society of Great Britain, University of Manchester, 
Medicines & People, 2004. Pharmacy workforce census 2003: main findings. London: 
Royal Pharmaceutical Society of Great Britain. [pdf] URL  
faculty.ksu.edu.sa/hisham/Documents/RPSGB_Files_/1/census0309.pdf (accessed 
13.5 15) 
 
Hassell, K., Seston, E.M., Schafheutle, E.I., Wagner, A., Eden, M., 2011. Workload in 
community pharmacies in the UK and its impact on patient safety and pharmacists’ 
well-being: a review of the evidence: A review of workload in community pharmacies. 
Health Soc. Care Community 19, 561–575. https://doi.org/10.1111/j.1365-
2524.2011.00997.x 
 
Hassell, K., Seston, L., Eden, M., 2006. Pharmacy workforce census 2005: main findings. 
London: Royal Pharmaceutical Society of Great Britain. [pdf] URL 
http://faculty.ksu.edu.sa/hisham/Documents/StudentsAll4/1/2/1a%20(89).pdf. 
(accessed 13.5.15) 
 
Health and Social Care Information Centre, 2013. CCG Outcomes Indicator Set: General 
Practice registered patient counts. [pdf] URL https://digital.nhs.uk/media/22902/CCG-
Outcomes-Indicators-June-2013-release-GP-registered-patient-
counts/Any/CCG_Ind_TOI_Jun_13_V3_final 
 
Health Education England, 2015a. Pharmacy education and training. [pdf] URL 
https://hee.nhs.uk/our-work/developing-our-workforce/pharmacy-education-training 
(accessed 10.4.17). 
 
Health Education England, 2015b. Primary Care [pdf] URL Health Educ. Engl.-Prim. Care. 
URL https://www.hee.nhs.uk/hee-your-area/west-midlands/our-work/attracting-
developing-our-workforce/primary-care (accessed 5.7.16). 
 
Health Education England 2017. Pharmacy Independent Prescribing [pdf] URL 
https://www.tenderlake.com/home/tender/f7b8b63c-2858-437e-a1c8-
211de27669c1/health-education-england-pharmacy-independent-prescribing 
(accessed 10.4.17). 
 
Hemsley, S., 2017. Pharmacists in GP practices: role of the medicines management team. 
Pharm. J. 299, 172–3. 
 
 212 
Holland, R., 2005. Does home-based medication review keep older people out of hospital? 
The HOMER randomised controlled trial. BMJ 330, 293–0. 
https://doi.org/10.1136/bmj.38338.674583.AE 
 
Holland, R., Desborough, J., Goodyer, L., Hall, S., Wright, D., Loke, Y.K., 2008. Does 
pharmacist-led medication review help to reduce hospital admissions and deaths in 
older people? A systematic review and meta-analysis. Br. J. Clin. Pharmacol. 65, 
303–316. https://doi.org/10.1111/j.1365-2125.2007.03071.x 
 
Holland, R., Smith, R., Harvey, I., 2006. Where now for pharmacist led medication review? J. 
Epidemiol. Community Health 60, 92–93. 
 
Holt, A., 2010. Using the telephone for narrative interviewing: a research note. Qual. Res. 10, 
113–121. https://doi.org/10.1177/1468794109348686 
 
Hughes, C.A., Makowsky, M., Sadowski, C.A., Schindel, T.J., Yuksel, N., Guirguis, L.M., 
2014. What prescribing means to pharmacists: a qualitative exploration of practising 
pharmacists in Alberta: What prescribing means to pharmacists. Int. J. Pharm. Pract. 
22, 283–291. https://doi.org/10.1111/ijpp.12079 
 
Hughes, C.M., McCann, S., 2003. Perceived interprofessional barriers between community 
pharmacists and general practitioners: a qualitative assessment. Br. J. Gen. Pract. 
53, 600–606. 
 
Hughes, D., 2007. Participant Observation in Health Research, in: Saks, M., Allsop, J. (Eds.), 
Researching Health: Qualitative, Quantitative and Mixed Methods. SAGE 
Publications Ltd, London, pp. 92–111. 
 
Huston, S.A., Hobson, E.H., 2008. Using focus groups to inform pharmacy research. Res. 
Soc. Adm. Pharm. 4, 186–205. https://doi.org/10.1016/j.sapharm.2007.09.001 
 
Irish, B., Purvis, M., 2012. Not just another primary care workforce crisis…. Br J Gen Pr. 62, 
178–179. 
 
Irvine, A., Drew, P., Sainsbury, R., 2013. “Am I not answering your questions properly?” 
Clarification, adequacy and responsiveness in semi-structured telephone and face-to-
face interviews. Qual. Res. 13, 87–106. https://doi.org/10.1177/1468794112439086 
 
Jacobs, S., Ashcroft, D., Hassell, K., 2011. Culture in community pharmacy organisations: 
what can we glean from the literature? J. Health Organ. Manag. 25, 420–454. 
https://doi.org/10.1108/14777261111155047 
 
Jamieson, L.H., Scally, A.J., Chrystyn, H., 2010. A randomised comparison of practice 
pharmacist-managed hypertension providing Level 3 Medication Review versus usual 
 213 
care in general practice. J. Appl. Ther. Res. 7, 77–86. 
 
Jesson, J., 2001. Cross-sectional studies in prescribing research. J. Clin. Pharm. Ther. 26, 
397–403. 
 
Johnson, R.B., Christensen, L.B., 2008. Educational Research: Quantitative, Qualitative, and 
Mixed Approaches, Third Edition. Los Angeles: SAGE Publications, Inc.  
 
Jokanovic, N., Tan, E.C., Sudhakaran, S., Kirkpatrick, C.M., Dooley, M.J., Ryan-Atwood, T., 
Bell, J.S., 2016. Pharmacist-led medication review in community settings: an 
overview of systematic reviews. Res. Soc. Adm. Pharm. 
https://doi.org/10.1016/j.sapharm.2016.08.005 
 
Jones, L., Fisher, T., 2006. Workforce trends in general practice in the UK: results from a 
longitudinal study of doctors’ careers. Br. J. Gen. Pract. 134–6. 
 
Jorgenson, D., Dalton, D., Farrell, B., Tsuyuki, R.T., Dolovich, L., 2013. Guidelines for 
pharmacists integrating into primary care teams. Can. Pharm. J. Rev. Pharm. Can. 
146, 342–352. https://doi.org/10.1177/1715163513504528 
 
Jorgenson, D., Laubscher, T., Lyons, B., Palmer, R., 2014. Integrating pharmacists into 
primary care teams: barriers and facilitators: Primary care team pharmacist 
integration. Int. J. Pharm. Pract. 22, 292–299. https://doi.org/10.1111/ijpp.12080 
 
Kay, A., 2002. The abolition of the GP fundholding scheme: a lesson in evidence-based 
policy making. Br. J. Gen. Pract. 52, 141–144. 
 
Kay, A., 2001. Beyond Policy Community—the Case of the GP Fundholding Scheme. Public 
Adm. 79, 561–577. 
 
Killam, L., 2013. Research terminology simplified: Paradigms, axiology, ontology, 
epistemology and methodology. Published online by L. Killiam 
 
Klein, H.K., Myers, M.D., 1999. A set of principles for conducting and evaluating interpretive 
field studies in information systems. MIS Q. 23(1), pp. 67–93. 
 
Kolodziejak, L., Rémillard, A., Neubauer, S., 2010. Integration of a primary healthcare 
pharmacist. J. Interprof. Care 24, 274–284. 
https://doi.org/10.3109/13561820903130149 
 
Krska, J., Cromarty, J.A., Arris, F., Jamieson, D., Hansford, D., Duff, P.R.S., Downie, G., 
Gwyn Seymour, D., 2001. Pharmacist-led medication review in patients over 65: a 
randomised controlled trial in primary care. Age Ageing 30, 205–211. 
 214 
 
Krska, J., Gill, D., Hansford, D., 2006. Pharmacist-supported medication review training for 
general practitioners: feasibility and acceptability. Med. Educ. 40, 1217–1225. 
https://doi.org/10.1111/j.1365-2929.2006.02633.x 
 
Krska, J., Hansford, D., Seymour, D.G., Farquharson, J., 2007. Is hospital admission a 
sufficiently sensitive outcome measure for evaluating medication review services? A 
descriptive analysis of admissions within a randomised controlled trial. Int. J. Pharm. 
Pract. 15, 85–91. https://doi.org/10.1211/ijpp.15.2.0002 
 
Krska, J., Ross, S., 2002. Medication review: whose job it is? Int. J. Pharm. Pract. 10, R86–
R86. 
 
Kuhn, T.S., Hacking, I., 2012. The Structure of Scientific Revolutions: 50th Anniversary 
Edition, 50th anniversary ed. Chicago: University of Chicago Press. 
 
Lakasing, E., 2009. The rise of the medical McJob: why we should turn the clock back. Br. J. 
Gen. Pract. 59, 380–382. 
 
Lambert, B., 1996. Face and Politeness in pharmacist physician interaction. Soc. Sci. Med. 
43, 1189–1198. 
 
Latter, S., Blenkinsopp, A., Smith, A., Chapman, S., Tinelli, M., Gerard, K., Little, P., Celino, 
N., Granby, T., Nicholls, P., others, 2010. Evaluation of nurse and pharmacist 
independent prescribing. University of Southampton; Keele University. 
 
Lea, V.M., Corlett, S.A., Rodgers, R.M., 2012. Workload and its impact on community 
pharmacists’ job satisfaction and stress: a review of the literature: Community 
pharmacists and workload. Int. J. Pharm. Pract. 20, 259–271. 
https://doi.org/10.1111/j.2042-7174.2012.00192.x 
 
Lloyd, F., Parsons, C., Hughes, C.M., 2010. ‘It’s showed me the skills that he has’: 
pharmacists’ and mentors’ views on pharmacist supplementary prescribing. Int. J. 
Pharm. Pract. 18, 29–36. 
 
Low, J., 2007. Unstructured Interviews and Health Research, in: Saks, M., Allsop, J. (Eds.), 
Researching Health: Qualitative, Quantitative and Mixed Methods. London: SAGE 
Publications Ltd, pp. 74–91. 
 
Lowe, C.J., Petty, D.R., Zermansky, A.G., Raynor, D.K., 2000. Development of a method for 
clinical medication review by a pharmacist in general practice. Pharm. World Sci. 22, 
121–126. 
 
 215 
Lowrie, R., Lloyd, S.M., McConnachie, A., Morrison, J., 2014. A Cluster Randomised 
Controlled Trial of a Pharmacist-Led Collaborative Intervention to Improve Statin 
Prescribing and Attainment of Cholesterol Targets in Primary Care. PLoS ONE 9, 
e113370. https://doi.org/10.1371/journal.pone.0113370 
 
Lowrie, R., Mair, F.S., Greenlaw, N., Forsyth, P., Jhund, P.S., McConnachie, A., Rae, B., 
McMurray, J.J.V., on behalf of the Heart Failure Optimal Outcomes from Pharmacy 
Study (HOOPS) Investigators, 2012. Pharmacist intervention in primary care to 
improve outcomes in patients with left ventricular systolic dysfunction. Eur. Heart J. 
33, 314–324. https://doi.org/10.1093/eurheartj/ehr433 
 
Lytle, S., Zeni, J., 2001. Ethical Issues in Practitioner Research. New York: Teachers’ 
College Press. 
 
Macgregor, S.H., Hamley, J.G., Dunbar, J.A., Dodd, T.R., Cromarty, J.A., 1996. Evaluation of 
a primary care anticoagulant clinic managed by a pharmacist. BMJ 312, 560. 
 
Majeed, A., Evans, N., Head, P., 1997. What can PACT tell us about prescribing in general 
practice? BMJ 315, 1515–16. 
 
Malson, G., 2016. Placements for pharmacy students and trainees in GP practices and 
primary care. Pharm. J. 297. [pdf] URL http://www.pharmaceutical-
journal.com/careers-and-jobs/career-feature/placements-for-pharmacy-students-and-
trainees-in-gp-practices-and-primary-care/20201630.article (accessed12.3.17) 
 
Marinker M, Reilly P, 1994. Judging rational prescribing., in: Marshall Marinker (Ed.), 
Controversies in Health Care Policies: Challenges to Practice. London: Wiley-
Blackwell.  
 
Martin, R., Lunec, S., Rink, E., 1998. UK postal survey of pharmacists working with general 
practices on prescribing issues: characteristics, roles and working arrangements. Int. 
J. Pharm. Pract. 133–139. 
 
McCann, L., Adair, C.G., Hughes, C.M., 2009a. An exploration of work-related stress in 
Northern Ireland community pharmacy: a qualitative study. Int. J. Pharm. Pract. 17, 
261–267. https://doi.org/10.1211/ijpp/17.05.0002 
 
McCann, L., Hughes, C.M., Adair, C.G., Cardwell, C., 2009b. Assessing job satisfaction and 
stress among pharmacists in Northern Ireland. Pharm. World Sci. 31, 188–194. 
https://doi.org/10.1007/s11096-008-9277-5 
 
McCann, L., Lloyd, F., Parsons, C., Gormley, G., Haughey, S., Crealey, G., Hughes, C., 
2012. “They come with multiple morbidities”: A qualitative assessment of pharmacist 
prescribing. J. Interprof. Care 26, 127–133. 
https://doi.org/10.3109/13561820.2011.642425 
 216 
 
McDermott, M.E., 2005. The use of medication for chronic pain in primary care, and the 
potential for intervention by a practice-based pharmacist. Fam. Pract. 23, 46–52. 
https://doi.org/10.1093/fampra/cmi068 
 
McDonald, R., Cheraghi-Sohi, S., Sanders, C., Ashcroft, D., 2010. Professional status in a 
changing world: The case of medicines use reviews in English community pharmacy. 
Soc. Sci. Med. 71, 451–458. https://doi.org/10.1016/j.socscimed.2010.04.021 
 
McDonough, R.P., Doucette, W.R., 2001. Dynamics of Pharmaceutical Care: Developing 
Collaborative Working Relationships Between Pharmacists and Physicians. J. Am. 
Pharm. Assoc. 41(5), 628–692. 
 
Mead, N., Roland, M., 2009. Understanding why some ethnic minority patients evaluate 
medical care more negatively than white patients: a cross sectional analysis of a 
routine patient survey in English general practices. BMJ 339, b3450–b3450. 
https://doi.org/10.1136/bmj.b3450 
 
Mills, E., 2016. A Training Needs Analysis of Clinical Pharmacists in General Practice. 
Commissioned by the London and Southeast Local Teams of Health Education 
England. [pdf] URL 
https://www.lasepharmacy.hee.nhs.uk/dyn/_assets/_folder4/community-
pharmacy/pharmacists-in-
gp/TrainingNeedsofClinicalPharmacistsinGeneralPracticeFINAL.pdf (accessed 
1.12.17) 
 
Motulsky, A., Winslade, N., Tamblyn, R., Sicotte, C., 2008. The impact of electronic 
prescribing on the professionalization of community pharmacists: a qualitative study 
of pharmacists’ perception. J. Pharm. Pharm. Sci. 11, 131–146. 
 
Mullen, R., 2003. Clarity of nomenclature is needed for pharmacists who work in primary 
care. Pharm. J. 271, 772–5. 
 
Mullen, R., Hassell, K., Noyce, P., 2005. Primary care pharmacist workforce mobility: why do 
pharmacists want to work in primary care and how do these reasons differ for 
community and hospital pharmacists? Int. J. Pharm. Pract. 13, 281–288. 
https://doi.org/10.1211/ijpp.13.4.0007 
 
National Health Service and Community Care Act 1990. [pdf] URL 
http://www.legislation.gov.uk/ukpga/1990/19/contents (accessed 10.16.15). 
 
National Health Service Reorganization Act 1973 [pdf], 1973. URL 
http://www.legislation.gov.uk/ukpga/1973/32/enacted (accessed 10.16.15). 
 
 217 
National Institute for Health and Care Excellence, 2016. NICE Quality and Outcomes 
Framework indicator [pdf]. URL https://www.nice.org.uk/standards-and-
indicators/qofindicators (accessed 12.5.16). 
 
National Institute for Health and Care Excellence, 2011. NICE-BUSINESS PLAN 2011/12 to 
2014/15. [pdf] URL https://www.nice.org.uk/Media/Default/About/Who-we-
are/Corporate-publications/Corporate-and-business-plans/NICE-business-plan-2011-
2015.pdf (accessed 12.8.2017) 
 
National Prescribing Centre, NHS Executive, 2000. A Core Competency Framework for 
Primary Care Pharmacists. National Prescribing Centre. 
 
National Prescribing Centre, NHS Executive, 1998. GP Prescribing Support: a resource 
document and guide for the New NHS. National Prescribing Centre. 
 
News Team, 2010. National Prescribing Centre to merge with NICE. Pharm. J. [pdf] URL 
http://www.pharmaceutical-journal.com/news-and-analysis/national-prescribing-
centre-to-merge-with-nice/11037165.article (accessed 3.28.16). 
 
NHS Alliance, Royal Pharmaceutical Society, 2014. Pharmacists and general practice: A 
practical and timely part of solving the primary care workload and workforce crisis. 
[pdf] URL http://www.nhsalliance.org/wp-content/uploads/2014/12/NHS-Alliance-
Pharmacists-in-general-practice.pdf (accessed 1.12.16) 
 
NHS Choices, 2013. NHS England » CCG directory [pdf]. URL 
https://www.england.nhs.uk/resources/ccg-directory/ (accessed 3.19.17). 
 
NHS England, 2017. NHS England » Clinical Pharmacists in General Practice [pdf]. URL 
https://www.england.nhs.uk/gp/gpfv/workforce/building-the-general-practice-
workforce/cp-gp/ (accessed 6.5.17). 
 
NHS England, 2016a. General Practice Forward View. NHS England. [pdf] URL 
https://www.england.nhs.uk/wp-content/uploads/2016/04/gpfv.pdf (accessed 14.8.16) 
 
NHS England, 2016b. BMA Agree New GP Contract 201617. [pdf] URL 
https://www.england.nhs.uk/2016/02/gp-contract-16-17/ (accessed 5.7.16). 
 
NHS England, 2015a. Clinical Pharmacists in General Practice Pilot. [pdf] URL 
https://www.england.nhs.uk/commissioning/primary-care-comm/gp-action-plan/cp-gp-
pilot/ (accessed 10.28.15). 
 
NHS England, 2015b. The structure of the NHS in England - NHS Choices. [pdf] URL 
http://www.nhs.uk/NHSEngland/thenhs/about/Pages/nhsstructure.aspx (accessed 
10.24.15). 
 218 
 
NHS England, 2014a. Understanding the New NHS. A guide to everyone working and 
training in the NHS. [pdf] URL https://www.england.nhs.uk/wp-
content/uploads/2014/06/simple-nhs-guide.pdf (accessed 12.7.14) 
 
NHS England, 2014b. Five Year Forward View. [pdf] URL https://www.england.nhs.uk/wp-
content/uploads/2014/10/5yfv-web.pdf (accessed 3.3.15) 
 
NHS England, 2014c. Enhanced service specification Avoiding unplanned admissions: 
proactive case finding and patient review for vulnerable people. [pdf] URL  
https://www.england.nhs.uk/wp-content/uploads/.../avoid-unplanned-admissions.pdf 
(accessed 11.10.14) 
 
NHS Improvement, 2017. Sustainability model and guide | NHS Improvement [pdf] URL 
https://improvement.nhs.uk/resources/Sustainability-model-and-guide/ (accessed 
7.10.17). 
 
Nørgaard, L.S., Colberg, L., Niemann, M.R., 2001. The role of the Danish community 
pharmacist: perceptions and future scenarios. Pharm. World Sci. 23, 159–164. 
 
O’Brien, M., Oxman, A., Davis, D., Haynes, R., Freemantle, N., Harvey, E., 1997.  
Educational outreach visits: effects on professional practice and health care 
outcomes, in: The Cochrane Collaboration (Ed.), Cochrane Database of Systematic 
Reviews. John Wiley & Sons, Ltd, Chichester, UK. 
 
O’Dowd, A., 2015. Recruiting 5000 more GPs will be tough, NHS chief tells MPs. BMJ 
h3993. https://doi.org/10.1136/bmj.h3993 
 
Olson, R., Bialocerkowski, A., 2014. Interprofessional education in allied health: a systematic 
review. Med. Educ. 48, 236–246. https://doi.org/10.1111/medu.12290 
 
Panton, R., Fitzpatrick, R., 1996. The involvement of pharmacists in professional and clinical 
audit in the UK: a review and assessment of their potential role. J. Eval. Clin. Pract. 2, 
193–98. 
 
Patel, B., Afghan, S., 2009. Effects of an educational outreach campaign (IMPACT) on 
depression management delivered to general practitioners in one primary care trust. 
Ment. Health Fam. Med. 6, 155. 
 
Peile, E., 2013. General practice careers: choices and judgements. Br. J. Gen. Pract. 565–
566. 
 
Petchey, R., 1995. General practitioner fundholding: weighing the evidence. The Lancet 346, 
1139–1142. 
 219 
 
Pettinger, R., 2002. Introduction to Management, 3rd ed. New York: Palgrave Macmillan. 
 
Petty, D., 2003. Drugs and professional interactions: the modern-day pharmacist. Heart 89, 
ii31–ii32. 
 
Petty, D.R., Zermansky, A.G., Alldred, D.P., 2014. The scale of repeat prescribing-time for an 
update. BMC Health Serv. Res. 14, 76. 
 
Phelps, A., Agur, M., Nass, L., Blake, M., 2014. GPhC Registrant Survey 2013. London: 
General Pharmaceutical Council. [pdf] URL 
https://www.pharmacyregulation.org/sites/default/files/gphc_registrant_survey_2013_
main_report_by_natcen.pdf  (accessed 4.8.14) 
 
Picton, C., Wright, H., 2013. Medicines Optimisation: Helping patients to make the most of 
medicines Good practice guidance for healthcare professionals in England. Royal 
Pharmaceutical Society. [pdf] URL 
https://www.rpharms.com/Portals/0/RPS%20document%20library/Open%20access/P
olicy/helping-patients-make-the-most-of-their-medicines.pdf (accessed 3.7.14) 
 
Pillow, W., 2003. Confession, catharsis, or cure? Rethinking the uses of reflexivity as 
methodological power in qualitative research. Int. J. Qual. Stud. Educ. 16, 175–196. 
https://doi.org/10.1080/0951839032000060635 
 
Pollock, A.M., Price, D., Viebrock, E., Miller, E., Watt, G., 2007. Health Policy: The market in 
primary care. BMJ 335, 475. 
 
Pope, C., Mays, N., 1995. Reaching the parts other methods cannot reach: an introduction to 
qualitative methods in health and health services research. BMJ 311, 42. 
 
Primary Care Commissioning, 2017. Clinical Pharmacists in General Practice. A prescription 
for better general practice. Primary Care Commissioning. [pdf] URL https://www.pcc-
cic.org.uk/sites/default/files/articles/attachments/clinical_pharmacist_july_2017_web.p
df (accessed 14.9.17) 
 
Primary Care Commissioning, 2016. PCC supports scheme to embed clinical pharmacists in 
general practice. Prim. Care Comm. [pdf[ URL https://www.pcc-cic.org.uk/article/pcc-
supports-scheme-embed-clinical-pharmacists-general-practice (accessed 7.9.17). 
 
Primary Care Pharmacists Association, 2015. A guide for GPs considering employing a 
pharmacist. [pdf] URL https://www.pcpa.org.uk/assets/documents/PDF-guide-for-
GPs-considering-employing-pharmacist.pdf (accessed 14.10.17) 
 
 220 
Ragubeer, R., Patel, H.J., 2011. Pilot to improve the appropriate prescription of oral 
nutritional supplements within the Walsall area. Proc. Nutr. Soc. 70. 
https://doi.org/10.1017/S0029665111003570 
 
Rajah, T., Bates, I., Davies, J.G., Webb, D.., Flemming, G., 2001. An occupational survey of 
hospital pharmacists in the South of England. Pharm. J. 266, 723–26. 
 
RCGP, BMA, NHSE, HEE, 2015a. Building the Workforce – the New Deal for General 
Practice. [pdf] URL https://www.england.nhs.uk/commissioning/wp-
content/uploads/sites/12/2015/01/building-the-workforce-new-deal-gp.pdf (accessed 
3.4.16) 
 
RCGP, BMA, NHSE, HEE, 2015b. Clinical Pharmacists in General Practice Pilot. NHS 
England. [pdf] URL https://www.england.nhs.uk/commissioning/wp-
content/uploads/sites/12/2015/07/clinical-pharmacists-gp-pilot.pdf (accessed 
7.9.2016) 
 
RCGP, RPS, 2015. RCGP and RPS Policy Statement on GP Practice Based Pharmacists. 
Royal College of General Practitioners & The Royal Pharmaceutical Society. [pdf] 
URL 
https://www.rpharms.com/Portals/0/RPS%20document%20library/Open%20access/P
olicy%20statements/rcgp-joint-statement-for-pharmacists-in-gp-surgeries.pdf 
(accessed 12.4.16) 
 
Reeves, S., Perrier, L., Goldman, J., Freeth, D., Zwarenstein, M., 2013. Interprofessional 
education: effects on professional practice and healthcare outcomes (update), in: The 
Cochrane Collaboration (Ed.), Cochrane Database of Systematic Reviews. 
Chichester, UK: John Wiley & Sons, Ltd. 
https://doi.org/10.1002/14651858.CD002213.pub3 
 
Reid, F., Murray, P., Storrie, M., 2005. Implementation of a pharmacist-led clinic for 
hypertensive patients in primary care–a pilot study. Pharm. World Sci. 27, 202–207. 
 
Rimmer, A., 2015. It will take up to 31 years to deliver number of GPs promised by political 
parties, says RCGP. BMJ 350, h2472–h2472. https://doi.org/10.1136/bmj.h2472 
 
Rodgers, S., Avery, A.J., Meechan, D., Briant, S., Geraghty, M., Doran, K., Whynes, D.K., 
1999. Controlled trial of pharmacist intervention in general practice: the effect on 
prescribing costs. Br. J. Gen. Pract. 49, 717–720. 
 
Rosenthal, M., Austin, Z., Tsuyuki, R.T., 2010. Are pharmacists the ultimate barrier to 
pharmacy practice change? Can. Pharm. JournalRevue Pharm. Can. 143, 37–42. 
 
Royal Pharmaceutical Society, 2016. A Competency Framework for all Prescribers. [pdf URL 
https://www.rpharms.com/Portals/0/RPS%20document%20library/Open%20access/P
 221 
rofessional%20standards/Prescribing%20competency%20framework/prescribing-
competency-framework.pdf (accessed 4.8.2016) 
 
Royal, S., 2006. Interventions in primary care to reduce medication related adverse events 
and hospital admissions: systematic review and meta-analysis. Qual. Saf. Health 
Care 15, 23–31. https://doi.org/10.1136/qshc.2004.012153 
 
Rubio-Valera, M., Jové, A.M., Hughes, C.M., Guillen-Solà, M., Rovira, M., Fernández, A., 
2012. Factors affecting collaboration between general practitioners and community 
pharmacists: a qualitative study. BMC Health Serv. Res. 12, 188. 
 
Runeson, P., Höst, M., 2009. Guidelines for conducting and reporting case study research in 
software engineering. Empir. Softw. Eng. 14, 131–164. 
https://doi.org/10.1007/s10664-008-9102-8 
 
Rutter, P.R., Hunt, A.J., Jones, I.F., 2000. Exploring the gap: community pharmacists’ 
perceptions of their current role compared with their aspirations. Int. J. Pharm. Pract. 
8, 204–208. 
 
Salim, A., Elgizoli, B., 2016. Exploring self-perception of community pharmacists of their 
professional identity, capabilities, and role expansion. J. Res. Pharm. Pract. 5, 116. 
https://doi.org/10.4103/2279-042X.179574 
 
Seston, E., Hassell, K., Ferguson, J., Hann, M., 2009. Exploring the relationship between 
pharmacists’ job satisfaction, intention to quit the profession, and actual quitting. Res. 
Soc. Adm. Pharm. 5, 121–132. https://doi.org/10.1016/j.sapharm.2008.08.002 
 
Seston, L., Hassell, K., 2009. Pharmacy workforce census 2008: Main findings. London: 
Pharmaceutical Society of Great Britain. [pdf] URL 
http://www.rpsgb.org.uk/pdfs/census08.pdf (accessed 12.6.14) 
 
Shann, P., Hassell, K., 2006. Flexible working: Understanding the locum pharmacist in Great 
Britain. Res. Soc. Adm. Pharm. 2, 388–407. 
https://doi.org/10.1016/j.sapharm.2006.03.002 
 
Shortt, S.E.D., 2003. General practice fundholding in the United Kingdom. Can. Fam. 
Physician 49, 279. 
 
Shulman, J.I., Shulman, S., Haines, A.P., 1981. The prevention of adverse drug reactions—a 
potential role for pharmacists in the primary care team? J. R. Coll. Gen. Pract. 31, 
429–434. 
 
Sibbald, B., Enzer, I., Cooper, C., Rout, U., Sutherland, V., 2000. GP job satisfaction in 1987, 
1990 and 1998: lessons for the future? Fam. Pract. 17, 364–371. 
 222 
 
Silcock, J., Petty, D., 2008. Pharmacist-led medication review: comment on Holland et al.  
2008. Br. J. Clin. Pharmacol. 66, 575–575. https://doi.org/10.1111/j.1365-
2125.2008.03226.x 
 
Silverman, D., 2011. Interpreting Qualitative Data, fourth. ed. Los Angeles: SAGE 
Publications Ltd 
 
Smalley, L., 2006. Patients’ experience of pharmacist-led supplementary prescribing in 
primary care. Pharm. J. Vol 276. 
 
Smith, F., 1999a. Evaluation of pharmaceutical services: (1) Objectives,designs and 
frameworks. Int. J. Pharm. Pract. 113–127. 
 
Smith, F., 1999b. Health services research methods in pharmacy: triangulation. Int. J. 
Pharm. Pract. 7, 60–68. 
 
Smith, F., 1998a. Health services research methods in pharmacy: focus groups and 
observation studies. Int. J. Pharm. Pract. 6, 229–242. 
 
Smith, F., 1998b. Health services research methods in pharmacy: Qualitative interviews. Int. 
J. Pharm. Pract. 6, 97–108. 
 
Smith, F., 1997. Health Services Research Methods in Pharmacy: Survey research:(1) 
Design, samples and response. Int. J. Pharm. Pract. 5, 152–166. 
 
Smith, F.J., 2010. Conducting Your Pharmacy Practice Research Project: A Step-by-step 
Guide, 2nd Revised edition. London: Pharmaceutical Press. 
 
Smith, G., Sukkar, E., 2014. Boots Benchmark pharmacist salaries in 2015 pay review. 
Pharm. J. 293. https://doi.org/10.1211/PJ.2014.20067281 
 
Smith, J., Curry, N., Mays, N., Dixon, J., 2010. Where next for commissioning in the English 
NHS? Nuffield Trust London. 
 
Smith, J., Mays, N., 2005. Primary care trusts: do they have a future? 331, 1156–1157. 
 
Smith, J., Regen, E., Shapiro, J., Baines, D., 2000. National evaluation of general practitioner 
commissioning pilots: lessons for primary care groups. Br. J. Gen. Pract. 50, 469–
472. 
 
 223 
Socialist Health Association, 2015. Reform of the National Health Service Chronology. 
Social. Health Assoc. [pdf] URL http://www.sochealth.co.uk/national-health-
service/reform-of-the-national-health-service/ (accessed 10.5.15). 
 
Stake, R.E., 2005. Multiple Case Study Analysis, New Ed edition. ed. Guilford Press, New 
York. 
 
Stewart, D., George, J., Bond, C., Diack, L., Cleland, J., McCaig, D., Cunningham, S., 
MacLure, K., Harkness, S., 2010. Developing and validating a tool for assessment of 
pharmacist prescribers’ consultations. Fam. Pract. 27, 520–526. 
https://doi.org/10.1093/fampra/cmq034 
 
Stewart, D., George, J., Bond, C.M., Diack, H.L., McCaig, D.J., Cunningham, S., 2009a. 
Views of pharmacist prescribers, doctors and patients on pharmacist prescribing 
implementation. Int. J. Pharm. Pract. 17, 89–94. 
 
Stewart, D., George, J., Diack, H.L., Bond, C.M., McCaig, D.J., Cunningham, I.S., Munro, K., 
Pfleger, D., 2009b. Cross Sectional Survey of the Scottish General Public’s 
Awareness of, Views on, and Attitudes Toward Nonmedical Prescribing. Ann. 
Pharmacother. 43, 1115–1121. https://doi.org/10.1345/aph.1L609 
 
Stewart, D.C., MacLure, K., Bond, C.M., Cunningham, S., Diack, L., George, J., McCaig, 
D.J., 2011. Pharmacist prescribing in primary care: the views of patients across Great 
Britain who had experienced the service: Pharmacist prescribing in primary care. Int. 
J. Pharm. Pract. 19, 328–332. https://doi.org/10.1111/j.2042-7174.2011.00130.x 
 
Sukkar, E., 2016. GP surgeries could employ an extra 1,500 pharmacists with £112m 
investment. Pharm. J. 296. https://doi.org/10.1211/PJ.2016.20201055 
 
Tan, E.C., Stewart, K., Elliott, R.A., George, J., 2013. Stakeholder experiences with general 
practice pharmacist services: a qualitative study. BMJ Open 3, e003214. 
 
Tan, E.C.K., Stewart, K., Elliott, R.A., George, J., 2014a. Integration of pharmacists into 
general practice clinics in Australia: the views of general practitioners and 
pharmacists: Pharmacist integration into general practice. Int. J. Pharm. Pract. 22, 
28–37. https://doi.org/10.1111/ijpp.12047 
 
Tan, E.C.K., Stewart, K., Elliott, R.A., George, J., 2014b. Pharmacist services provided in 
general practice clinics: A systematic review and meta-analysis. Res. Soc. Adm. 
Pharm. 10, 608–622. https://doi.org/10.1016/j.sapharm.2013.08.006 
 
Teal, S., Ricketts, L., Belton, A., Allsopp, G., Silcox, J., Wright, D.J., 2002. How effective are 
pharmacists who work with medical practitioners? A study of interventions intended to 
influence prescribing. Int. J. Pharm. Pract. 185–190. 
 
 224 
The Royal Pharmaceutical Society, 2017. Workforce Development Handbook: Transforming 
the Pharmacy Workforce in Great Britain. [pdf] URL 
https://www.rpharms.com/Portals/0/RPS%20document%20library/Open%20access/S
upport/Workforce%20and%20Education/Workforce%20Development%20Handbook
%20Update%20April%202017.pdf (accessed 2.7.17) 
 
The Royal Pharmaceutical Society, CoDEG, 2013. The RPS Advanced Pharmacy 
Framework. [pdf] URL 
https://www.rpharms.com/Portals/0/RPS%20document%20library/Open%20access/F
rameworks/RPS%20Advanced%20Pharmacy%20Framework.pdf (accessed 4.10.16) 
 
Thomas, T., 2003. Careers in Pharmacy. Tomorrows Pharm. 16, 47–50. 
 
Traulsen, J.M., Bissell, P., 2004. (9) Theories of professions and the pharmacist. Int. J. 
Pharm. Pract. 12, 107–114. https://doi.org/10.1211/0022357023727 
 
Travis, A., 2010. Coalition agreement - the full deal at a glance. [online] 
URLhttp://www.theguardian.com/politics/2010/may/20/conservative-liberal-democrat-
coalition-agreement-analysis (accessed 3.5.15) 
 
Van, C., Costa, D., Abbott, P., Mitchell, B., Krass, I., 2012. Community pharmacist attitudes 
towards collaboration with general practitioners: development and validation of a 
measure and a model. BMC Health Serv. Res. 12, 1. 
 
Van, C., Costa, D., Mitchell, B., Abbott, P., Krass, I., 2013. Development and validation of a 
measure and a model of general practitioner attitudes toward collaboration with 
pharmacists. Res. Soc. Adm. Pharm. 9, 688–699. 
https://doi.org/10.1016/j.sapharm.2012.12.005 
 
Walley, T., 1993. Rational prescribing in primary care-a new role for clinical pharmacology? 
Br. J. Clin. Pharmacol. 36, 11–12. 
 
Walsall Clinical Commissioning Group, 2014. Pharmacist-led repeat prescription 
management. Qual. Product. Proven Case Study. [pdf] URL 
https://www.nice.org.uk/savingsandproductivityandlocalpracticeresource?ci=http%3A
%2F%2Farms.evidence.nhs.uk%2Fresources%2FQIPP%2F1040169%3Fniceorg%3
Dtrue (accessed 5.21.15). 
 
Walshe, K., 2010. Reorganisation of the NHS in England. BMJ 341, c3843–c3843. 
https://doi.org/10.1136/bmj.c3843 
 
Walshe, K., Smith, J., Dixon, J., Edwards, N., Hunter, D.J., Mays, N., Normand, C., 
Robinson, R., 2004. Primary care trusts. Premature reorganisation, with mergers, 
may be harmful. BMJ 329, 871–2. 
 
 225 
Waterfield, J., 2010. Is pharmacy a knowledge-based profession? Am. J. Pharm. Educ. 74(3) 
Article 50, pp. 1-6. 
 
Watson, M., Gunnell, D., Peters, T., Brookes, S., Sharp, D., 2001. Guidelines and 
educational outreach visits from community pharmacists to improve prescribing in 
general practice: a randomised controlled trial. J. Health Serv. Res. Policy 6, 207–
213. 
 
Weeks, G., George, J., Maclure, K., Stewart, D., 2016. Non-medical prescribing versus 
medical prescribing for acute and chronic disease management in primary and 
secondary care, in: The Cochrane Collaboration (Ed.), Cochrane Database of 
Systematic Reviews. John Wiley & Sons, Ltd, Chichester, UK. 
 
Weiss, M.C., Sutton, J., 2009. The changing nature of prescribing: pharmacists as 
prescribers and challenges to medical dominance. Sociol. Health Illn. 31, 406–421. 
https://doi.org/10.1111/j.1467-9566.2008.01142.x 
 
Wells, D., 1997. Pharmacists are key members of primary health care teams. Br. Med. J. 
314, 1486. 
 
Westerlund, T., Marklund, B., 2009. Assessment of the clinical and economic outcomes of 
pharmacy interventions in drug-related problems. J. Clin. Pharm. Ther. 34, 319–327. 
https://doi.org/10.1111/j.1365-2710.2008.01017.x 
 
Wilcock, M., Hughes, P., 2015. GPs’ perceptions of pharmacists working in surgeries. 
Prescriber 26, 29–31. 
 
Wilkin, D., 2002. Primary care budget holding in the United Kingdom National Health Service: 
learning from a decade of health service reform. Med. J. Aust. 176, 539–542. 
 
Williams, S.E., Bond, C.M., Menzies, C., 2000. A pharmaceutical needs assessment in a 
primary care setting. Br. J. Gen. Pract. 50, 95–99. 
 
Wright, M., 2013. How many pharmacists is too many? Pharm. J. 291, 177. 
 
Yin, R.K., 2003. Case Study Research: Design and Methods: (Applied Social Research 
Methods, Volume 5): Third Edition. Thousand Oaks, Calif: SAGE Publications. 
  
Young, R., Leese, B., 1999. Recruitment and retention of general practitioners in the UK: 
what are the problems and solutions? Br J Gen Pr. 49, 829–833. 
 
Zermansky, A.G., 1996. Who controls repeats? Br. J. Gen. Pract. 46, 643–647. 
 
 226 
Zermansky, A.G., Alldred, D.P., Petty, D.R., Raynor, D.K., Freemantle, N., Eastaugh, J., 
Bowie, P., 2006. Clinical medication review by a pharmacist of elderly people living in 
care homes--randomised controlled trial. Age Ageing 35, 586–591. 
https://doi.org/10.1093/ageing/afl075 
 
Zermansky, A.G., Petty, D.R., Raynor, D.K., Freemantle, N., Vail, A., Lowe, C.J., 2001. 
Randomised controlled trial of clinical medication review by a pharmacist of elderly 
patients receiving repeat prescriptions in general practice. BMJ 323, 1340. 
 
Zermansky, A.G., Petty, D.R., Raynor, D.K., Lowe, C.J., Freemantle, N., Vail, A., 2002. 
Clinical medication review by a pharmacist of patients on repeat prescriptions in 
general practice: a randomised controlled trial. National Coordinating Centre for 
Health Technology Assessment. 6(20), pp.1-86. 
 
Zwarenstein, M., Bheekie, A., Lombard, C., Swingler, G., Ehrlich, R., Eccles, M., Sladden, 
M., Pather, S., Grimshaw, J., Oxman, A.D., 2007. Educational outreach to general 
practitioners reduces children’s asthma symptoms: a cluster randomised controlled 
trial. Implement. Sci. 2. https://doi.org/10.1186/1748-5908-2-30 
 
 
  
 227 
Bibliography 
Jesson, J, Matheson, L., Lacey, F M., 2012 Doing Your Literature Review: Traditional and 
Systematic Techniques. London: SAGE Publications Ltd. 
 
Bell, J., 2010 Doing Your Research Project: A Guide for First-Time Researchers in 
Education, Health and Social Science (Open Up Study Skills) 5th ed. Maidenhead: 
McGraw Hill. 
 
Drake, P., 2010. Practitioner Research at Doctoral Level, 1st ed. Oxford, England: Routledge 
 
Stephens, M., 2003. Hospital pharmacy within the National Health Service, in: Stephens, M. 
(Ed.), Hospital Pharmacy. London: Pharmaceutical Press. 
 
 
 
  
 228 
Appendices 
Appendix 1.1 Permission to use NHS structure diagram  
 
From: Felicity Taylor felicityjanetaylor@gmail.com Subject: Use of diagram  
Date: 31 August 2016 at 10:11 To: r.e.saunders@keele.ac.uk  
Dear Robert  
Thank you for your letter, which was forwarded to me. Please do feel free to use the referenced diagram.  
All the best  
Felicity  
Dr Felicity Taylor  
m: 07951461323  
e: felicityjanetaylor@gmail.com  
t: @FelicityJTaylor  
 
  
Dr. Felicity Taylor  
National Medical Director's Clinical Fellow,  
Medical Directorate  
Skipton House  
80 London Road  
SE1 6LH 
 
Robert Saunders 
20 Oakfield Road 
Bilbrook 
Codsall 
Wolverhampton 
WV8 1LA 
07970340843 
 
16.8.16 
 
Dear Dr. Taylor,  
 
I am writing to ask permission to use the diagram below in my thesis to illustrate the 
structure of the NHS in 2014. It is published in the leaflet Understanding the New NHS. A 
guide to everyone working and training in the NHS from 2014. It will naturally be fully 
referenced. I am investigating the role of the practice pharmacists within CCGs in 2014 and 
this diagram will be part of the chapter on NHS reforms and the effect on practice pharmacist 
teams. 
 
 
 
 
Yours faithfully, 
 
Robert Saunders 
 
Teaching Fellow-Prescribing Studies 
Keele University 
r.e.saunders@keele.ac.uk 
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Appendix 3.1 Pre-project questionnaire to prospective Clinical Commissioning Groups 
 
  
1 What is the size of the patient population covered by your CCG? 
2 How many (whole time equivalent) practice-based pharmacists do you have in 
your team? 
3 How many (whole time equivalent) pharmacy technicians do you have in your 
team? 
4 How many of your practice-based pharmacists are independent prescribers? 
5 Who are your practice-based pharmacists employed by: 
6 
 
Have you any plans to increase the size of your practice-based team- 
practice-based pharmacists? 
practice-based technicians?  
7 If you were to recruit more practice-based pharmacists, how difficult do you 
think it would be to find pharmacists with the necessary competencies? 
8 Which of the following roles do your practice-based pharmacist currently 
undertake: 
Specific chronic disease management clinics? 
Repeat prescription management? 
Medication review? 
Education to practice staff and patients? 
Audit? 
Prescribing (if qualified)? 
Prescribing efficiencies? 
Liaison with community pharmacy? 
Medicines reconciliation? 
Supporting QoF? 
Supporting GP incentive scheme? 
9  
 
Would you consider taking part in a future study into the role of the practice-
based pharmacist? (if yes please give a contact e-mail) 
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Appendix 3.2 Head of Medicines Management and CCG data collection tool 
  
1.  Please state the name of the CCG that you work for?   
2.  Please state your gender   
3.  Please state your age   
4.  How many years have you been on the pharmaceutical register?    
5.  How many years, in total, have you worked as a practice pharmacist?    
6.  Do you still work in a GP practice as a practice pharmacist?   
7.  Are you a qualified independent pharmacist prescriber?   
8.  What is the size of the population covered by your CCG?    
9.  How many practice pharmacists do you commission to work with GPs?   
10.  How many whole-time equivalents does this equate to?   
11.  How many of the practice pharmacists that you commission are qualified 
prescribers?   
12.  Would you prefer to commission practice pharmacists that are qualified 
prescribers?   
13.  How many pharmacy technicians do you commission to work in the CCG?   
14.  How many whole-time equivalents does this equate to?   
15.  Who employs the practice pharmacists that you commission?   
16.  How do you fund the practice pharmacist (and technicians if applicable)?   
17.  Do you plan to commission more practice pharmacists in the next 12 months?   
18.  Do you plan to commission more pharmacy technicians in the next 12 months?  
19.  In your opinion, how hard is it to find suitable pharmacists to recruit to the 
practice pharmacist role?   
20.  Which of the following roles do you commission your practice pharmacist team 
to carry out?  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Specific chronic disease management clinics   
Repeat prescription management   
Medication review   
Therapeutic detailing (practice education)   
Audit   
Prescribing   
Prescribing efficiencies   
Liaison with community pharmacy   
Medicines reconciliation  
Supporting QoF   
Supporting incentive scheme   
Other 
21.  Have you evaluated the practice pharmacists’ role?   
22. How did you evaluate practice pharmacist’s role?  
23. What was the result of your evaluation?  
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Appendix 3.3 Generic consent form 
 
 
 
 
 
 
CONSENT FORM 
 
Title of Project:  The Primary Care Pharmacist’s Role – a study of current and future models 
 
Name and contact details of Principal Investigator: Robert Saunders 07970 340843 
r.e.saunders1@keele.ac.uk 
 
Please tick box if you agree with the statement 
 
1 I confirm that I have read and understand the information sheet for the above study and 
have had the opportunity to ask questions. 
 
□ 
2 I understand that my participation is voluntary and that I am free to withdraw at any time. □ 
3 I agree to take part in this study. □ 
4 I understand that data collected about me during this study will be anonymised before it 
is submitted for publication. 
 
□ 
5 I agree to the focus group or interview being audio recorded □ 
6 I agree to allow the dataset collected to be used for future research projects □ 
7 I agree to be contacted about possible participation in future research projects □ 
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_______________________ 
Name of participant 
___________________ 
Date 
_____________________ 
Signature 
________________________  
Researcher 
___________________ 
Date 
_____________________ 
Signature 
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CONSENT FORM 
(for use of quotes) 
 
Title of Project:  The Primary Care Pharmacist’s Role – a study of current and future models 
Name and contact details of Principal Investigator: Robert Saunders 07970 340843 
r.e.saunders1@keele.ac.uk  
 
Please tick box if you agree with the statement 
 
 
 
1 I agree for any quotes to be used 
 
 
   
2 I do not agree for any quotes to be used 
 
 
3 I consent to being audio recorded  
 
 
________________________ 
 
___________________ 
 
_____________________ 
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Name of participant Date Signature 
 
_______________________  
Researcher 
 
__________________ 
Date 
 
____________________ 
Signature 
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Appendix 3.4 Head of Medicines Management interview topic guide 
Introduction 
Interviewer 
Introduction  
My name is Robert Saunders and I am a postgraduate student at Keele 
University and I am interested in the practice pharmacist role and how this is 
perceived by those the work in the role and those that commission them. I 
have extensive experience as a practice pharmacist. 
Study introduction This interview is part of my Doctorate in Pharmacy to answer the following 
research question: 
The Primary Care Pharmacist’s Role – a study of current and future models 
Description of the 
Interview 
Methodology 
A semi-structured interview is a qualitative research technique used to obtain 
opinions on complex topics. 
Rules of a Focus 
Group 
 
• Reasons for audio tape (Meeting is being recorded to help write the report) 
• Promise of anonymity (Your name will not be associated with your 
comments) 
• Sensitivity of recording (No tapping on the table etc.) 
• Honest, open opinions 
• Stay on topic (Avoid moving off topic) 
• Role of the interviewer 
• Questions? 
• Reaffirm agreement to take part 
Introductory 
Exercise 
 
• Name and job title? 
• Name of your employing organisation? 
• Number of years on register? 
Discussion 
Exploratory 
questions 
• What do you think about the current practice pharmacists’ role? 
o How important is the management of medicines to your CCG? 
o How important is the role of the practice pharmacist to your CCG? 
o Has the practice pharmacist role appreciably changed with the 
move to GP Commissioning?  
o How have the recent NHS changes affected your practice 
pharmacist team? 
o Have the changes affected your relationship with the practice 
pharmacist team?  
o Do you feel that you have the resources to commission enough 
practice pharmacists to deliver prescribing support across your 
CCGs? 
o Who determines the work plan for the practice pharmacists and 
how flexible is this? 
o What are the benefits of your commissioning model for practice 
pharmacist support? 
o What are the drawbacks of this model? 
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• What is the importance of a non-medical prescribing qualification to 
the practice pharmacists’ role? 
o In what ways do your practice pharmacists use NMP in the role? 
o What is the added value of their ability to prescribe? 
• Do you provide training and updates for your practice pharmacists? 
o How do you assess the training needs of your practice 
pharmacists? 
o Do you use a competency framework for practice pharmacists? 
o If so which one? 
o Where do you source training? 
o Are these sources adequate-If no, what do you need? 
• What do you think is the future of the practice pharmacists’ role? 
o What are the barriers to practice pharmacists becoming more 
integrated into primary care? 
o What feedback do you get from GPs regarding the practice 
pharmacists and how does this influence the future role and levels 
of support 
o How do you see the practice pharmacist role developing over the 
next 5 to10 years? 
o In your opinion, how will the increasing numbers of pharmacists 
affect medicines management teams? 
Final question Are there any other issues, that we have not covered, that you feel are 
important? 
Ending 
Closing Thank all for your help. The information you've shared has been extremely 
useful. You will receive a written summary of the initial findings in the future. 
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Appendix 3.5 Head of Medicines Management interview information sheet 
Information Sheet  
Study Title: The Primary Care Pharmacist’s Role – a study of current and future models 
 
Aims of the Research 
The overall aim of the project is to develop an understanding of the perceived value of the 
practice pharmacist role to stakeholders-practice pharmacists themselves, commissioners 
and patients. 
 
Invitation 
You are being invited to consider taking part in the research study-What is the perceived value 
of the practice pharmacists’ role?   
 
This project is being undertaken by Robert Saunders. Robert Saunders is a University student 
conducting this study as part of educational requirements. 
 
Before you decide whether or not you wish to take part, it is important for you to understand 
why this research is being done and what it will involve. Please take time to read this 
information carefully and discuss it with colleagues if you wish. Ask us if there is anything that 
is unclear or if you would like more information.  
 
Why have I been chosen? 
You have been chosen because you are a Head of Medicines Management in a Clinical 
Commissioning Group that is part of the study-Up to four Heads of Medicines Management 
like you will be selected for interview. 
 
Do I have to take part? 
You are free to decide whether you wish to take part or not. You are free to withdraw from this 
study at any time and without giving reasons.  
 
What will happen if I take part? 
If you decide to take part you will be contacted with a list of alternative dates, times and 
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venues so that you can choose a time and place that is convenient for you to be interviewed. 
Before the interview you will be asked to sign two consent forms, one is for you to keep and 
the other is for our records. 
 
If I take part, what do I have to do? 
The interview will be digitally recorded and then transcribed for further analysis. This is likely 
to take about 30 minutes. The key topic will be your perceptions of the value of the practice 
pharmacist’s role to commissioners. 
 
What are the benefits (if any) of taking part? 
We are not aware of any obvious benefits to you as an individual in taking part in this study. 
 
What are the risks (if any) of taking part? 
We are not aware of any disadvantages or risks to you in taking part in the study.  
 
How will information about me be used? 
The results (including anonymised short direct quotes) will be included in a research report as 
part of my Doctorate in Pharmacy at Keele University, and may subsequently be published as 
research papers in academic journals and presented at conferences. No individual person will 
be identifiable in any direct quotes, reports, papers, presentations or summaries. The results 
of the study might also be used for additional or subsequent research. 
 
Who will have access to information about me? 
All the information that I collect about you during the course of the research will be kept strictly 
confidential and no one outside the project will be allowed access to it. Electronic data 
containing personally identifiable information about you will only be stored on password-
protected media that only I and my Supervisors will have access to. Tapes will be erased once 
they have been transcribed. Hardcopies of data and other documentation containing 
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personally identifiable information about you will be kept secure in a locked cupboard. At the 
end of the study all data and documents containing personally identifiable information about 
you will be destroyed. You will not be able to be identified in any reports or publications. 
 
I do however have to work within the confines of current legislation over such matters as 
privacy and confidentiality, data protection and human rights and so offers of confidentiality 
may sometimes be overridden by law. For example, in circumstances whereby I am made 
aware of future criminal activity, abuse either to yourself or another (i.e. child or sexual abuse) 
or suicidal tendencies. I must pass this information to the relevant authorities. 
 
Who is funding and organising the research? 
The study is being organised and funded by the School of Pharmacy at Keele University. 
 
What if there is a problem? 
 
If you have a concern about any aspect of this study, you may wish to speak to the 
researcher(s) who will do their best to answer your questions.  You should contact Robert 
Saunders on r.e.saunders1@keele.ac.uk Alternatively, if you do not wish to contact the 
researcher you may contact Professor Patricia Black p.e.black@keele.ac.uk  
 
If you remain unhappy about the research and/or wish to raise a complaint about any aspect 
of the way that you have been approached or treated during the course of the study, please 
write to Nicola Leighton who is the University’s contact for complaints regarding research at 
the following address: - 
 
Nicola Leighton 
Research Governance Officer 
Research & Enterprise Services 
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Dorothy Hodgkin Building 
Keele University  
ST5 5BG 
E-mail: n.leighton@uso.keele.ac.uk 
Tel: 01782 733306 
 
Contact for further information 
If you have any questions or require any further information, either now or at any time during 
the study, please contact me Robert Saunders at r.e.saunders1@keele.ac.uk. Alternatively, 
you can contact me in writing at the School of Pharmacy, Keele University, Staffordshire ST5 
5BG. 
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Appendix 3.6 Practice Pharmacist survey 
 
 
This survey is designed to collect some basic information about you and your current role as a 
practice pharmacist. It is part of a research project that is being conducted as outlined in the 
accompanying study information sheet. By completing this survey, you are consenting to the 
use of the information provided in the study. The information that you provide will be not be 
attributed to you in any future report or publication. Please click on submit at the bottom of the 
page when you are happy with your answers.   
No Question and supportive text Answer (options as stated) 
1 Please state your name Free text 
2 What is your e-mail address? Free text 
3 Please state your age 
To the nearest year 
Free text 
4 Please state your gender Female 
Male 
5 How many years have you been on the Pharmaceutical 
Register? 
To the nearest year 
Free text 
6 What is your work background?  
Please tick all the sectors that you have worked in before 
you became a practice pharmacist? 
Community Pharmacy 
Hospital Pharmacy 
Postgraduate education 
Pharmaceutical industry 
Other pharmacy related role 
Other non-pharmacy role 
7 Apart from any practice work do you continue to work 
in other sectors?  
What other roles do you continue to work in? 
Community Pharmacy 
Hospital Pharmacy 
Postgraduate education 
Pharmaceutical industry 
Other pharmacy related role 
Other non-pharmacy role 
8 What postgraduate qualifications do you have Please Postgraduate unit(s) 
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tick all the PG qualifications you have Certificate(s) 
Prescribing (SP or IP or both) 
Diploma 
MSc 
MBA 
Doctorate 
Other: 
9 How many years have you been a practice pharmacist?  
Round up to the nearest year 
Free text 
10 How many hours a week, on average, do you work as a 
practice pharmacist?  
Total of all hours worked as a practice pharmacist in all GP 
practices. 
Free text 
11 What proportion of your practice pharmacist time is 
spent face-to-face with patients?   
 Please give your best estimate 
 
less than 20% 
21%-40% 
41%-60% 
61%-80% 
81%-100% 
12 Are you a qualified pharmacist prescriber?     
Only answer yes if you are on the GPhC register as a 
prescriber 
 
Yes 
No 
13 If you are a qualified prescriber, what on average is the 
total number of items that you prescribe each month? 
Please give your best estimate 
0-50 
51-100 
101-150 
151-200 
201 or more 
14 Which CCG(s) do the GP practices that you work for 
belong to? 
Please list all   
Six named CCG options plus 
“other” 
15 Which CCG do the majority of the practices that you 
work for belong to? 
Free text 
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Choose one CCG only as your principal CCG  
16 How long have you worked for the practice(s) in this 
principal CCG? 
 Include time working for the PCT/PCG before if appropriate 
 
17 Are you employed full time or part time in your 
principle CCG? 
Part time is less than 37.5 hours a week. Full time is 37.5 
hours or more  
Full time 
Part time 
18 Are you self-employed or a salaried employee in your 
principal CCG?  
A salaried employee will have PAYE deducted from their 
wages  
Self-employed  
 
Salaried employee  
 
19 What organisation pays you for your work in your 
principle CCG?  
This will be the organisation that you have an employment 
contract with  
 
 
CCG 
CSU 
Acute or other trust 
GP Practice 
Not known 
Other 
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Appendix 3.7 Practice Pharmacists survey information sheet 
Information Sheet  
Study Title: The Primary Care Pharmacist’s Role – a study of current and future model 
 
Aims of the Research 
The overall aim of the project is to develop an understanding of the perceived value of the 
practice pharmacist role to stakeholders-practice pharmacists themselves, commissioners 
and patients. 
 
Invitation 
You are being invited to consider taking part in the research study-What is the perceived value 
of the practice pharmacists’ role?   
 
This project is being undertaken by Robert Saunders. Robert Saunders is a University student 
conducting this study as part of educational requirements. 
 
Before you decide whether or not you wish to take part, it is important for you to understand 
why this research is being done and what it will involve. Please take time to read this 
information carefully and discuss it with colleagues if you wish. Ask us if there is anything that 
is unclear or if you would like more information.  
 
Why have I been chosen? 
You have been chosen because you are a practice pharmacist working in a Clinical 
Commissioning Group that is part of the study-Up to 60 pharmacists like you will be asked to 
complete the questionnaire. 
 
Do I have to take part? 
You are free to decide whether you wish to take part or not. If you do not wish to take part, 
please just ignore this e-mail 
 
What will happen if I take part? 
If you do decide to take part, you will be asked to complete an online survey. By completing 
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the online survey, you are agreeing to take part in the study and to your dataset to be 
used in future projects 
 
If I take part, what do I have to do? 
Following the link will take you to the online questionnaire. It will only take you 10 minutes to 
complete. You will be asked to give some details about your career as a pharmacist so far, 
your postgraduate qualifications and your current employment. No data will be collected that 
can be traced back to you as an individual. 
 
What are the benefits (if any) of taking part? 
We are not aware of any obvious benefits to you as an individual in taking part in this study. 
 
What are the risks (if any) of taking part? 
We are not aware of any disadvantages or risks to you in taking part in the study.  
 
How will information about me be used? 
The results will be included in a research report as part of my Doctorate in Pharmacy at Keele 
University, and may subsequently be published as research papers in academic journals and 
presented at conferences. No individual person will be identifiable in any reports, papers, 
presentations or summaries. The results of the study might also be used for additional or 
subsequent research. 
 
Who will have access to information about me? 
All the information that I collect about you during the course of the research will be kept strictly 
confidential and no one outside the project will be allowed access to it. At the end of the study 
the electronic questionnaire will be removed from the internet. You will not be able to be 
identified in any reports or publications. 
 
 247 
Who is funding and organising the research? 
The study is being organised and funded by the School of Pharmacy at Keele University. 
 
What if there is a problem? 
If you have a concern about any aspect of this study, you may wish to speak to the researcher 
who will do their best to answer your questions.  You should contact Robert Saunders on 
r.e.saunders1@keele.sc.uk Alternatively, if you do not wish to contact the researcher you may 
contact Professor Patricia Black p.e.balck@keele.ac.uk  
 
If you remain unhappy about the research and/or wish to raise a complaint about any aspect 
of the way that you have been approached or treated during the course of the study please 
write to Nicola Leighton who is the University’s contact for complaints regarding research at 
the following address: - 
 
Nicola Leighton 
Research Governance Officer 
Research & Enterprise Services 
Dorothy Hodgkin Building 
Keele University  
ST5 5BG 
E-mail:  
 
Tel: 01782 733306 
 
Contact for further information 
If you have any questions or require any further information, either now or at any time during 
the study, please contact me Robert Saunders at r.e.saunders1@keele.ac.uk  Alternatively, 
you can contact me in writing at the School of Pharmacy, Keele University, Staffordshire ST5 
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5BG. 
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Appendix 3.8 Practice Pharmacist focus group topic guide 
 
 
Introduction 
Moderator (and scribe) 
Introduction  
Housekeeping: Fire exits and alarms, toilets, refreshments, expected finishing 
time.  
Study introduction This Focus Group is part of my Doctorate in Pharmacy answer the following 
research question: 
What is the value of the practice pharmacist’s role? 
Description of the Focus 
Group Methodology 
A focus group is a qualitative research technique used to generate ideas 
Rules of a Focus Group 
 
• Informality, but group discussion is an important work session in which 
everyone should participate 
• Reasons for audio tape (Meeting is being recorded to help write the report) 
• Promise of anonymity (Your name will not be associated with your 
comments) 
• Sensitivity of recording (No side conversations, no tapping on the table 
etc.) 
• Everyone's opinion needs to be included 
• Honest, open opinions 
• Agree to disagree (Not striving for consensus) 
• Stay on topic (Avoid moving off topic) 
• Role of the moderator  
• Questions? 
• Reaffirm agreement to take part 
Introductory Exercise 
 
• Name  
• Number of years qualified 
• Number of years as a practice pharmacist 
Discussion 
Exploratory questions • What do you think about current practice pharmacists’ role? 
o Why did you choose the practice pharmacists’ role? 
o If you have other roles (or work as a practice pharmacist in other 
CCGS), why do you choose a portfolio career? 
o Has the role changed with the move to GP Commissioning? 
o Who determines your work plan? 
o How do you feel about the move to your new organisation? 
o What are the “pros and cons” of being an employee or self 
employed 
• What is the importance of a non-medical prescribing qualification to 
the practice pharmacists’ role? 
o In what ways do you use NMP in your role? 
o Do you actively diagnose or mostly treat patient with a diagnosis? 
o What is the added value of your ability to prescribe in terms of: 
▪ patients,  
▪ GPs  
▪ practices? 
o Do you think other health care professions recognise the added 
value of your ability to prescribe? 
• What do you think about training and education in the practice 
pharmacist’s role? 
o Do you use a competency framework? 
o If yes-which one? 
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o Does your employer provide educational support? 
o Where do you source (other) training and education for your 
practice pharmacist role? 
o If the sources are inadequate, what do you need? 
• What do you think is the future of the practice pharmacists’ role? 
o What are the barriers to practice pharmacists becoming more 
integrated into primary care? 
o How do you see the role developing over the next 5 to10 years?  
o Where do you want to be professionally in 5 years?  
o How will the increasing numbers of pharmacists affect you? 
Final Question • Are there any other issues, that we have not covered, that you feel are 
important? 
Ending 
Closing Thank all for your help. The information you've shared has been extremely 
useful. You will be notified when a summary of the findings are available. 
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Appendix 3.9 Practice Pharmacists focus group information sheet 
Information Sheet  
Study Title: The Primary Care Pharmacist’s Role – a study of current and future models 
 
Aims of the Research 
The overall aim of the project is to develop an understanding of the perceived value of the 
practice pharmacist role to stakeholders-practice pharmacists themselves, commissioners 
and patients. 
 
Invitation 
You are being invited to consider taking part in the research study-What is the perceived value 
of the practice pharmacists’ role?   
 
This project is being undertaken by Robert Saunders. Robert Saunders is a University 
student conducting this study as part of educational requirements. 
 
Before you decide whether or not you wish to take part, it is important for you to understand 
why this research is being done and what it will involve. Please take time to read this 
information carefully and discuss it with colleagues if you wish. Ask us if there is anything that 
is unclear or if you would like more information.  
 
Why have I been chosen? 
You have been chosen because you are a practice pharmacist working in a Clinical 
Commissioning Group that is part of the study-Up to twenty-four pharmacists like you will be 
selected for four focus groups 
 
Do I have to take part? 
You are free to decide whether you wish to take part or not. You are free to withdraw from this 
study at any time and without giving reasons.  
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What will happen if I take part? 
If you decide to take part you will be contacted with a list of alternative dates, times and 
venues so that you can choose a time and place that is convenient for you to attend one of 
the focus groups. When you attend the focus group you will be asked to sign two consent 
forms, one is for you to keep and the other is for our records. 
 
If I take part, what do I have to do? 
You will be invited to join in one focus group, of up to 6 other practice pharmacists, where the 
groups’ comments will be digitally recorded and then transcribed for further analysis. This is 
likely to take about 90 minutes. The key topic will be your perceptions of the value of the 
practice pharmacist’s role in general practice. 
 
What are the benefits (if any) of taking part? 
We are not aware of any obvious benefits to you as an individual in taking part in this study. 
 
What are the risks (if any) of taking part? 
We are not aware of any disadvantages or risks to you in taking part in the study.  
 
How will information about me be used? 
The results (including anonymised short direct quotes) will be included in a research report as 
part of my Doctorate in Pharmacy at Keele University, and may subsequently be published as 
research papers in academic journals and presented at conferences. No individual person will 
be identifiable in any direct quotes, reports, papers, presentations or summaries. The results 
of the study might also be used for additional or subsequent research. 
 
Who will have access to information about me? 
All the information that I collect about you during the course of the research will be kept strictly 
 253 
confidential and no one outside the project will be allowed access to it. Electronic data 
containing personally identifiable information about you will only be stored on password-
protected media that only I and my Supervisors will have access to. Tapes will be erased once 
they have been transcribed. Hardcopies of data and other documentation containing 
personally identifiable information about you will be kept secure in a locked cupboard that only 
I have access to. At the end of the study all data and documents containing personally 
identifiable information about you will be destroyed. You will not be able to be identified in any 
reports or publications. 
 
I do however have to work within the confines of current legislation over such matters as 
privacy and confidentiality, data protection and human rights and so offers of confidentiality 
may sometimes be overridden by law. For example, in circumstances whereby I am made 
aware of future criminal activity, abuse either to yourself or another (i.e. child or sexual abuse) 
or suicidal tendencies. I must pass this information to the relevant authorities. 
 
Who is funding and organising the research? 
The study is being organised and funded by the School of Pharmacy at Keele University. 
 
What if there is a problem? 
 
If you have a concern about any aspect of this study, you may wish to speak to the 
researcher(s) who will do their best to answer your questions.  You should contact Robert 
Saunders on r.e.saunders1@keele.sc.uk Alternatively, if you do not wish to contact the 
researcher you may contact Professor Patricia Black p.e.balck@keele.ac.uk  
 
If you remain unhappy about the research and/or wish to raise a complaint about any aspect 
of the way that you have been approached or treated during the course of the study please 
write to Nicola Leighton who is the University’s contact for complaints regarding research at 
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the following address: - 
 
Nicola Leighton 
Research Governance Officer 
Research & Enterprise Services 
Dorothy Hodgkin Building 
Keele University  
ST5 5BG 
E-mail: n.leighton@uso.keele.ac.uk 
Tel: 01782 733306 
 
Contact for further information 
If you have any questions or require any further information, either now or at any time during 
the study, please contact me Robert Saunders at r.e.saunders1@keele.ac.uk  Alternatively, 
you can contact me in writing at the School of Pharmacy, Keele University, Staffordshire ST5 
5BG 
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Appendix 3.10 General Practitioner interview guide 
Introduction 
Interviewer 
Introduction  
My name is Robert Saunders and I am a postgraduate student at Keele 
University and I am interested in the practice pharmacist role and how this is 
perceived by those the work in the role and those that commission them. 
Study introduction This interview is part of my Doctorate in Pharmacy to answer the following 
research question: The Primary Care Pharmacist’s Role – a study of current 
and future models. 
Description of the 
Interview 
Methodology 
An unstructured interview is a qualitative research technique used to obtain 
opinions on complex topics. 
Rules of a Focus 
Group 
 
• Reasons for audio tape (Meeting is being recorded to help write the 
report) 
• Promise of anonymity (Your name will not be associated with your 
comments) 
• Sensitivity of recording (No tapping on the table etc.) 
• Honest, open opinions 
• Stay on topic (Avoid moving off topic) 
• Role of the interviewer 
• Questions? 
• Reaffirm agreement to take part 
Introductory 
Exercise 
• Name 
• Number of years qualified 
• Number of years working with a practice pharmacist 
Discussion 
Exploratory 
questions 
• What do you think about the current practice pharmacists’ role? 
o What is the role of your practice pharmacist? 
o How important is their role to you as a GP and to your practice? 
o Has the role changed with the move to GP Commissioning? 
o Has your relationship with your practice pharmacist changed 
since the move to GP Commissioning? 
o Who now determines the practice pharmacist work plan? 
o Is there a need to increase your practice pharmacist hours? 
o Would you consider directly employing a pharmacist? 
• Do you feel that practice pharmacists are adequately trained for 
their role? 
o If not, what new or current skills, knowledge and behaviour(s) are 
required or need upgrading?   
o Can you suggest any new role(s) for practice pharmacists and 
any training required for this? 
• What is the importance of a non-medical prescribing qualification to 
the practice pharmacists’ role? 
o In what ways does your practice pharmacist use their NMP 
qualification in the role? 
o What is the added value to you and the practice of their ability to 
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prescribe? 
o Have you more respect for a practice pharmacist with a 
prescribing qualification? 
•  What do you think is the future of the practice pharmacists’ role? 
o What are the barriers to practice pharmacists becoming more 
integrated into primary care? 
o How do you see the practice pharmacist role developing over the 
next 5 to10 years? 
Final question • Are there any other issues, that we have not covered, that you feel 
are important? 
Ending 
Closing Thank all for your help. The information you've shared has been extremely 
useful. You will receive a written summary of the initial findings in the future. 
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Appendix 3.11 General Practitioner information sheet 
Information Sheet  
Study Title: The Primary Care Pharmacist’s Role – a study of current and future model 
Aims of the Research 
The overall aim of the project is to develop an understanding of the perceived value of the 
practice pharmacist role to stakeholders-practice pharmacists themselves, commissioners 
and patients. 
Invitation 
You are being invited to consider taking part in the research study-What is the perceived value 
of the practice pharmacists’ role?   
 
This project is being undertaken by Robert Saunders.  Robert Saunders is a University student 
conducting this study as part of educational requirements. 
 
Before you decide whether or not you wish to take part, it is important for you to understand 
why this research is being done and what it will involve. Please take time to read this 
information carefully and discuss it with colleagues if you wish. Ask us if there is anything that 
is unclear or if you would like more information.  
 
Why have I been chosen? 
You have been chosen because you are a GP working in a Clinical Commissioning Group 
that is part of the study-Up to twelve GPs like you will be selected for interview. 
 
Do I have to take part? 
You are free to decide whether you wish to take part or not. You are free to withdraw from this 
study at any time and without giving reasons.  
 
What will happen if I take part? 
If you decide to take part you will be contacted with a list of alternative dates, times and 
venues so that you can choose a time and place that is convenient for you to be interviewed. 
Before the interview you will be asked to sign two consent forms, one is for you to keep and 
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the other is for our records. 
 
If I take part, what do I have to do? 
The interview will be digitally recorded and then transcribed for further analysis. This is likely 
to take about 30 minutes. The key topic will be your perceptions of the value of the practice 
pharmacist’s role in general practice. 
 
What are the benefits (if any) of taking part? 
We are not aware of any obvious benefits to you as an individual in taking part in this study. 
 
What are the risks (if any) of taking part? 
We are not aware of any disadvantages or risks to you in taking part in the study.  
 
How will information about me be used? 
The results (including anonymised short direct quotes) will be included in a research report as 
part of my Doctorate in Pharmacy at Keele University, and may subsequently be published as 
research papers in academic journals and presented at conferences. No individual person will 
be identifiable in any direct quotes, reports, papers, presentations or summaries. The results 
of the study might also be used for additional or subsequent research. 
 
Who will have access to information about me? 
All the information that I collect about you during the course of the research will be kept strictly 
confidential and no one outside the project will be allowed access to it. Electronic data 
containing personally identifiable information about you will only be stored on password-
protected media that only I and my Supervisors will have access to. Tapes will be erased once 
they have been transcribed. Hardcopies of data and other documentation containing 
personally identifiable information about you will be kept secure in a locked cupboard. At the 
end of the study all data and documents containing personally identifiable information about 
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you will be destroyed. You will not be able to be identified in any reports or publications. 
 
I do however have to work within the confines of current legislation over such matters as 
privacy and confidentiality, data protection and human rights and so offers of confidentiality 
may sometimes be overridden by law. For example, in circumstances whereby I am made 
aware of future criminal activity, abuse either to yourself or another (i.e. child or sexual abuse) 
or suicidal tendencies. I must pass this information to the relevant authorities. 
 
Who is funding and organising the research? 
The study is being organised and funded by the School of Pharmacy at Keele University. 
 
What if there is a problem? 
 
If you have a concern about any aspect of this study, you may wish to speak to the 
researcher(s) who will do their best to answer your questions.  You should contact Robert 
Saunders on r.e.saunders1@keele.ac.uk Alternatively, if you do not wish to contact the 
researcher you may contact Professor Patricia Black p.e.black@keele.ac.uk  
 
If you remain unhappy about the research and/or wish to raise a complaint about any aspect 
of the way that you have been approached or treated during the course of the study, please 
write to Nicola Leighton who is the University’s contact for complaints regarding research at 
the following address: - 
 
Nicola Leighton 
Research Governance Officer 
Research & Enterprise Services 
Dorothy Hodgkin Building 
Keele University  
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ST5 5BG 
E-mail: n.leighton@uso.keele.ac.uk 
Tel: 01782 733306 
 
Contact for further information 
If you have any questions or require any further information, either now or at any time during 
the study, please contact me Robert Saunders at r.e.saunders1@keele.ac.uk. Alternatively, 
you can contact me in writing at the School of Pharmacy, Keele University, Staffordshire ST5 
5BG. 
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Appendix 3.12 General Practitioner Pre-Interview questionnaire 
Your name  Today’s date  
 
Please state your age? 
 
 
How many years in total have you worked as 
a GP? 
 
 
How long have you worked in this practice? 
 
 
What is the list size to the nearest 1000 
patients? 
 
 
Do you serve on the CCG Board or any of its 
sub-committees? 
1 
2 
3 
If so in what position? 1 
2 
3 
What is your position in the practice?  
How long (in years) have you worked with a 
practice pharmacist? 
 
How many hours a week does a practice 
pharmacist work at this practice? 
 
Who employs your practice pharmacist?  
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Appendix 3.13 Patient interview guide and verbal consent 
Introduction 
Patient ID   Date of contact  Male Female 
Moderator 
(and scribe) 
Introduction  
Hello, I am Robert Saunders and I am a pharmacist interested in the views of 
patients, like you, that have been seen by practice pharmacists-these are 
pharmacists that work with GPs in their surgeries rather than in a 
pharmacy. Thank you for agreeing to let me contact you. Is it convenient to talk 
to you now? 
Can you hear me clearly? 
Study 
introduction 
I am interested in finding out about what patient’s think about the role that 
practice pharmacists have in the GP surgery and how they value that role.  
This is part of my Doctoral Studies and I will also be speaking to other patients, 
doctors, and pharmacists as part of my studies.  
Description of 
the telephone 
interview 
I would like to ask you some questions over the phone as it is a convenient way 
to gather your views and opinions. It should take no more than 15 minutes.  Do 
you have any questions so far?  
Telephone 
interview pre-
amble 
 
Before we start can I just check that you are fully informed of what will happen-
did you receive an information sheet? (If no I will read it out or suspend the 
interview and send one to the participant and re-schedule) 
• Please speak freely and give your honest opinions. Your name will not be 
associated with your comments. No one, including your doctor or the 
pharmacist you saw will know what you have said. 
• The interview is being recorded to help me write the report as it would be 
difficult to write down everything that you say during the interview. 
• Your name will not be included in the report. 
• I will be asking you the same questions that I will be asking other patients 
who have agreed to take part.  
• You can decide not to answer any individual question 
• If you would like to stop for any reason, then please just let me know.  
• If you wish to withdraw from the study, then you can do so at any time   
• If you want me to stop recording at any time, or if, after the interview, you 
would rather I did not use the recording please let me know.  
• Do you have any further questions? 
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Reaffirm 
agreement to 
take part and 
consent 
 
 
Please can you confirm that: 
• You have read and understand the information sheet for the above 
study and have had the opportunity to ask questions. 
• You understand that your participation is voluntary and that you are free 
to withdraw at any time. 
• You agree to take part in this study. 
• You understand that data collected about you during this study will be 
anonymised before it is submitted for publication. 
• You agree to the telephone interview being audio recorded 
• You agree to allow for the information collected to be used for future 
research projects 
Verbal agreement to take part 
 
Yes  No STOP 
 Verbal agreement for quotes to be 
used 
Yes  No  
Initial questions 
Can you remember back to the consultation that you had with your practice 
pharmacist where you were asked to take part in this interview  
• Did you know that there was practice pharmacist working at your GP surgery?  
o If yes, had you ever seen a pharmacist at your GP surgery before this 
consultation? 
• Were you expecting to be seen by a pharmacist when you went to the doctors on this 
occasion?  
o If no-who did you think you were going to see? 
o How did you feel when you found out it was a pharmacist?  
• What did the pharmacist do for you at this visit?  
o How did this help you?  
• Were there any advantages in seeing a pharmacist rather than a GP or nurse? 
• Were there any disadvantages to seeing a pharmacist? 
• Would you recommend a consultation with a practice pharmacist to your friends and 
family?  
o What are your reasons for this answer? 
• Can you think of any other useful things that a pharmacist could do for you whilst working 
at your doctors? 
• Some practice pharmacists are qualified to prescribe. This means they could write a 
prescription for your medication.  
o Did you know this?  
o Did the pharmacist write a prescription for you on this occasion? 
o What do you think about this? 
o Does this worry you in any way? 
o How might this be important to you and other patients?  
• Should all GPs have a pharmacist working in their surgeries in this role?  
o What are your reasons for this answer? 
o If yes –Should the practice pharmacist be available to patients during all surgery 
hours   
• Would you mind telling me your age?  
• And the first half of your postcode?  
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Have you any further questions? 
Thank you for your help. The information you've shared has been extremely useful. I 
would be happy to send you a copy of the report of this interview or any eventual 
publication arising from this work 
If interested take contact e-mail or address 
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Appendix 3.14 Patient information sheet and initial consent 
Information Sheet 
Study Title: The Primary Care Pharmacist’s Role – a study of current and future models 
Aims of the Research 
The overall aim of the project is to develop an understanding of the perceived value of the 
practice pharmacist role to stakeholders-practice pharmacists themselves, those that employ 
them and patients. 
 
Invitation 
You are being invited to consider taking part in the research study-What is the value of the 
practice pharmacist’s role?   
 
This project is being undertaken by Robert Saunders who is also a pharmacist. 
 
Before you decide whether or not you wish to take part, it is important for you to understand 
why this research is being done and what it will involve. Please take time to read this 
information carefully and discuss it with friends and relatives if you wish. Ask us if there is 
anything that is unclear or if you would like more information.  
 
Why have I been chosen? 
You have been chosen because you are a patient that has recently had a consultation with a 
pharmacist that works at your doctor’s surgery. Up to 30 patients like you will complete a 
telephone questionnaire. 
 
Do I have to take part? 
You are free to decide whether you wish to take part or not. You can withdraw from the study 
at any time. 
 
What will happen if I take part? 
If you do decide to take part please write your contact details on the tear off slip below and 
hand the slip to your practice pharmacist or to reception staff. Robert Saunders will contact 
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you to arrange a convenient time to contact you to conduct an interview on the telephone. 
 
If I take part, what do I have to do? 
It will take about 15 minutes to complete the telephone questionnaire. You will be asked to 
give your age and gender, and answer some simple questions about your consultation with 
the practice pharmacist. The data collected will not be traced back to you as an individual.  
 
What are the benefits (if any) of taking part? 
We are not aware of any obvious benefits to you as an individual in taking part in this study. 
 
What are the risks (if any) of taking part? 
We are not aware of any disadvantages or risks to you in taking part in the study.  
 
How will information about me be used? 
The results will be included in a research report as part of my Doctorate in Pharmacy at Keele 
University, and may subsequently be published as research papers in academic journals and 
presented at conferences. No individual person will be identifiable in any reports, papers, 
presentations or summaries. The results of the study might also be used for additional or 
subsequent research. 
 
Who will have access to information about me? 
All the information that I collect about you during the course of the research will be kept strictly 
confidential and no one outside the project will be allowed access to it. You will not be able to 
be identified in any reports or publications. 
 
Who is funding and organising the research? 
The study is being organised and funded by the School of Pharmacy at Keele University. 
 
 267 
What if there is a problem? 
 
If you have a concern about any aspect of this study, you may wish to speak to the 
researcher(s) who will do their best to answer your questions.  You should contact Robert 
Saunders on r.e.saunders1@keele.ac.uk Alternatively, if you do not wish to contact the 
researcher you may contact Professor Patricia Black p.e.black@keele.ac.uk  
 
If you remain unhappy about the research and/or wish to raise a complaint about any aspect 
of the way that you have been approached or treated during the course of the study please 
write to Nicola Leighton who is the University’s contact for complaints regarding research at 
the following address:- 
 
Nicola Leighton 
Research Governance Officer 
Research & Enterprise Services 
Dorothy Hodgkin Building 
Keele University  
ST5 5BG 
E-mail: n.leighton@uso.keele.ac.uk 
Tel: 01782 733306 
 
Contact for further information 
If you have any questions or require any further information, either now or at any time during 
the study, please contact me Robert Saunders at r.e.saunders1@keele.ac.uk Alternatively, 
you can contact me in writing at the School of Pharmacy, Keele University, Staffordshire ST5 
5BG. 
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Tear off section-please complete and give to the practice pharmacist if you are considering taking part  
Please complete your preferred method of contact below hand this slip to your 
practice pharmacist or to the surgery reception. 
 
I have been given the attached information sheet and I am happy to be contacted to take part 
in a telephone interview about my consultation with my practice pharmacist today.  
 
I understand that I will be contacted by Robert Saunders to arrange a convenient date and 
time for my telephone interview and that this interview will be recorded to help write up the 
report. 
 
I understand that nothing I say during the interview will be attributed to me at any time. 
 
I understand that I can decide not to take part in the telephone interview at a later date. 
 
I would prefer to be contacted initially by phone……………………………………………… 
 
I would prefer to be contacted initially by e-mail……………………………………………… 
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Appendix 3.15 Keele University independent peer review 
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